U.S. patent application number 17/303494 was filed with the patent office on 2021-12-02 for novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases.
The applicant listed for this patent is Rhizen Pharmaceuticals SA. Invention is credited to Govindarajulu Babu, Prashant K. Bhavar, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam, Swaroop K. V. S. Vakkalanka, Srikant Viswanadha.
Application Number | 20210371416 17/303494 |
Document ID | / |
Family ID | 1000005756475 |
Filed Date | 2021-12-02 |
United States Patent
Application |
20210371416 |
Kind Code |
A1 |
Vakkalanka; Swaroop K. V. S. ;
et al. |
December 2, 2021 |
NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-
DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS
MODULATORS OF C-MET PROTEIN KINASES
Abstract
The present invention provides compounds useful as c-Met protein
kinase modulators, methods of preparing them, pharmaceutical
compositions containing them and methods of treatment, prevention
and/or amelioration of c-Met kinase mediated disease or disorders
with them.
Inventors: |
Vakkalanka; Swaroop K. V. S.;
(Basel, CH) ; Nagarathnam; Dhanapalan; (Bethany,
CT) ; Viswanadha; Srikant; (Basel, CH) ;
Muthuppalaniappan; Meyyappan; (Hyderabad, IN) ; Babu;
Govindarajulu; (Hyderabad, IN) ; Bhavar; Prashant
K.; (Hyderabad, IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Rhizen Pharmaceuticals SA |
Basel |
|
CH |
|
|
Family ID: |
1000005756475 |
Appl. No.: |
17/303494 |
Filed: |
May 30, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15705005 |
Sep 14, 2017 |
11066402 |
|
|
17303494 |
|
|
|
|
14389336 |
Sep 29, 2014 |
9815831 |
|
|
PCT/IB2013/051577 |
Feb 27, 2013 |
|
|
|
15705005 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 45/06 20130101;
C07D 471/04 20130101; A61K 31/437 20130101; A61K 31/4709
20130101 |
International
Class: |
C07D 471/04 20060101
C07D471/04; A61K 31/437 20060101 A61K031/437; A61K 31/4709 20060101
A61K031/4709; A61K 45/06 20060101 A61K045/06 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 30, 2012 |
IN |
1262/CHE/2012 |
Claims
1-45. (canceled)
46. A method for the treatment of a c-Met associated disease or
disorder, comprising the step of administering to a subject in need
thereof an effective amount of a compound of formula (IA-I)
##STR00215## or a tautomer, stereoisomer, enantiomer, diastereomer,
pharmaceutically acceptable salt, or N-oxide thereof, wherein X is
CR.sup.1 or N; D is monocyclic aryl, wherein D is substituted with
a group E which is selected from
--CONH--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x, and
--CONH--O--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p---
OR.sup.x; and further D can optionally be substituted with one or
more of R.sup.z; L.sub.2 is --(CR.sup.aR.sup.b)--; Cy.sup.2 is
substituted or unsubstituted heteroaryl; each occurrence of R.sup.1
and R.sup.2 may be same or different and is independently selected
from hydrogen, nitro, hydroxy, cyano, halogen, --OR.sup.a,
--S(.dbd.O).sub.q--R.sup.a, --NR.sup.aR.sup.b,
--C(.dbd.Y)--R.sup.a, --CR.sup.aR.sup.b--C(.dbd.Y)--R.sup.a,
--CR.sup.aR.sup.b--Y--CR.sup.aR.sup.bR.sup.b,
--C(.dbd.Y)--NR.sup.aR.sup.b,
--NR.sup.aR.sup.b--C(.dbd.Y)--NR.sup.aR.sup.b,
--S(.dbd.O).sub.q--NR.sup.aR.sup.b--,
--NR.sup.aR.sup.b--S(.dbd.O).sub.q--NR.sup.aR.sup.b,
--NR.sup.aR.sup.b--NR.sup.aR.sup.b, substituted or unsubstituted
C.sub.1-6 alkyl, substituted or unsubstituted C.sub.2-6 alkenyl,
substituted or unsubstituted C.sub.2-6 alkynyl, substituted or
unsubstituted C.sub.3-6 cycloalkyl, substituted or unsubstituted
C.sub.3-6 cycloalkylalkyl, and substituted or unsubstituted
C.sub.3-6 cycloalkenyl; each occurrence of Y is independently
selected from O, S, and NR.sup.a; each occurrence of R.sup.a and
R.sup.b may be same or different and are independently selected
from hydrogen, nitro, hydroxy, cyano, halogen, substituted or
unsubstituted C.sub.1-6 alkyl, substituted or unsubstituted
C.sub.2-6 alkenyl, substituted or unsubstituted C.sub.2-6 alkynyl,
substituted or unsubstituted C.sub.3-6 cycloalkyl, substituted or
unsubstituted C.sub.3-6 cycloalkylalkyl, and substituted or
unsubstituted C.sub.3-6 cycloalkenyl, or when two R.sup.a and/or
R.sup.b substituents are directly bound to a common atom, they may
be joined to form a substituted or unsubstituted, saturated or
unsaturated 3-10 member ring, which may optionally include one or
more heteroatoms which may be same or different and are selected
from O, NR.sup.c or S; each occurrence of R.sup.c is independently
selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted
or unsubstituted C.sub.1-6 alkyl, substituted or unsubstituted
C.sub.2-6 alkenyl, substituted or unsubstituted C.sub.2-6 alkynyl,
substituted or unsubstituted C.sub.3-6 cycloalkyl, substituted or
unsubstituted C.sub.3-6 cycloalkylalkyl, and substituted or
unsubstituted C.sub.3-6 cycloalkenyl; each occurrence of R.sup.x
and R.sup.y is independently selected from hydrogen, hydroxy,
halogen, carboxyl, cyano, nitro, oxo (.dbd.O), thio (.dbd.S),
substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or
unsubstituted alkynyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted cycloalkenyl, substituted or
unsubstituted cycloalkylalkyl, substituted or unsubstituted
cycloalkenylalkyl, substituted or unsubstituted heterocycyl,
substituted or unsubstituted heterocyclylalkyl, substituted or
unsubstituted aryl, substituted or unsubstituted arylalkyl,
substituted or unsubstituted heteroaryl, substituted or
unsubstituted heteroarylalkyl, --COOR.sup.z, --C(O)R.sup.z,
--C(S)R.sup.z, --C(O)NR.sup.zR.sup.z, --C(O)ONR.sup.zR.sup.z,
--NR.sup.zR.sup.z, --NR.sup.zCONR.sup.zR.sup.z,
--N(R.sup.z)SOR.sup.z, --N(R.sup.z)SO.sub.2R.sup.z,
--(.dbd.N--N(R.sup.z)R.sup.z), --NR.sup.zC(O)OR.sup.z,
--NR.sup.zC(O)R.sup.z--,
--NR.sup.xC(S)R.sup.y--NR.sup.zC(S)NR.sup.zR.sup.z,
--SONR.sup.zR.sup.z--, --SO.sub.2NR.sup.zR.sup.z--, --OR.sup.z,
--OR.sup.zC(O)NR.sup.zR.sup.z, --OR.sup.zC(O)OR.sup.z--,
--OC(O)R.sup.z, --OC(O)NR.sup.zR.sup.z,
--R.sup.zNR.sup.zC(O)R.sup.z, --R.sup.zOR.sup.z,
--R.sup.zC(O)OR.sup.z, --R.sup.zC(O)NR.sup.zR.sup.z,
--R.sup.zC(O)R.sup.z, --R.sup.zOC(O)R.sup.z, --SR.sup.z,
--SOR.sup.z, --SO.sub.2R.sup.z, and --ONO.sub.2, or any two of
R.sup.x and R.sup.y which are directly bound to a common atom may
be joined to form (i) a substituted or unsubstituted, saturated or
unsaturated 3-14 membered ring, which may optionally include one or
more heteroatoms which may be the same or different and are
selected from O, NR.sup.z or S, or (ii) an oxo (.dbd.O), thio
(.dbd.S) or imino (.dbd.NR.sup.z); wherein each occurrence of
R.sup.z is independently hydrogen, hydroxy, halogen, carboxyl,
cyano, nitro, oxo (.dbd.O), thio (.dbd.S), substituted or
unsubstituted alkyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted
cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl,
substituted or unsubstituted heterocycyl, substituted or
unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl,
substituted or unsubstituted arylalkyl, substituted or
unsubstituted heteroaryl, substituted or unsubstituted
heteroarylalkyl, and --ONO.sub.2, or any two of R.sup.z which are
directly bound to a common atom may be joined to form (i) a
substituted or unsubstituted, saturated or unsaturated 3-14
membered ring, which may optionally include one or more heteroatoms
which may be the same or different and are selected from O, NR'
(where R' is H or alkyl) or S, or (ii) an oxo (.dbd.O), thio
(.dbd.S) or imino (.dbd.NR.sup.z); each occurrence of p
independently represents 1, 2, 3, 4, 5, 6, 7 or 8; and each
occurrence of q independently represents 0, 1 or 2.
47. The method of claim 46, wherein the c-Met associated disease,
disorder or condition is an immune system-related disease, a
disease or disorder involving inflammation, cancer or other
proliferative disease, a hepatic disease or disorder, or a renal
disease or disorder.
48. The method of claim 46, wherein D is ##STR00216## and X.sup.1,
X.sup.2 and X.sup.3 are independently selected from --CR.sup.z and
--CR.sup.z.dbd.CR.sup.z.
49. The method of claim 46, wherein L.sub.2-Cy.sup.2 is
##STR00217## (where the squiggly line represents the bond to the
bicyclic core in formula (IA-I)); each occurrence of R.sup.a and
R.sup.b are independently selected from hydrogen, halogen, and
substituted or unsubstituted (C.sub.1-6) alkyl, or both together
with the carbon atom to which they are attached form a saturated 3
to 6 member cyclic ring which may optionally include one or more
heteroatoms which may be same or different and are selected from O,
NR.sup.e and S (where R.sup.e is R.sup.z); Z is selected from
CR.sup.c, S, O, NR.sup.c, R.sup.cC.dbd.CR.sup.c,
--N.dbd.CR.sup.c--, and --R.sup.cC.dbd.N--; Z.sub.1 is selected
from N, NR.sup.c and CR.sup.c; Z.sub.2 and Z.sub.3 are
independently selected from C and N; and R.sup.c is absent or
selected from hydrogen, hydroxy and halogen.
50. The method of claim 46, wherein D is ##STR00218##
L.sub.2-Cy.sup.2 is ##STR00219## (where the squiggly line
represents the bond to the bicyclic core in formula (IA-I));
X.sup.1, X.sup.2 and X.sup.3 are independently selected from
--CR.sup.z and --CR.sup.z.dbd.CR.sup.z; Z is selected from
CR.sup.c, S, O, NR.sup.c, R.sup.cC.dbd.CR.sup.c,
--N.dbd.CR.sup.c--, and --R.sup.cC.dbd.N--; Z.sub.1 is selected
from N, NR.sup.c and CR.sup.c; and Z.sub.2 and Z.sub.3 are
independently selected from C or N; with the proviso that when each
occurrence of R.sup.1 and R.sup.2 is hydrogen, and E is
--CONH--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x, then p is not 2.
51. The method of claim 46, wherein the compound of formula (IA-I)
is selected from
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide;
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl) benzamide hydrochloride;
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate;
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide hydrobromide; sodium
(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)benzoyl)(2-hydroxyethoxy)amide;
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide;
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride; sodium
(2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)benzoyl)(2-hydroxyethoxy)amide;
2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3-
]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide;
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide;
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide hydrochloride; sodium
(2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-
-5-yl)benzoyl)(2-hydroxyethoxy)amide;
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide;
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride; sodium
(2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-
-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide;
2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide;
2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide;
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2-chloro-N-(2-hydroxyethoxy)benzamide;
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2,6-difluoro-N-(2-hydroxyethoxy)benzamide; sodium
(4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-
-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide;
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2-fluoro-N-(2-hydroxyethoxy)benzamide;
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H--
[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide;
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H--
[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride;
N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)benzamide;
N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)-2-(trifluoromethyl)benzamide;
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide;
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide hydrochloride;
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide;
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide hydrochloride;
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide hydrobromide;
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate;
N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl-
)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide;
6-((5-(4-(2-hydroxyethoxycarbamoyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,-
5-b]pyridin-3-yl)methyl)quinoline 1-oxide;
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-methylbenzamide;
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride;
2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide;
2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride;
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl acetate,
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-5-yl)benzamidooxy)ethyl 2-(tert-butoxycarbonylamino)propanoate,
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-5-yl)benzamidooxy)ethyl 2-aminopropanoate,
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl pivalate,
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl isobutyrate,
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl 2-benzamidoacetate,
2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazo-
lo[4,5-b]pyridin-5-yl)benzamide, ethyl
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)acetate,
2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H--
[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-
-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl acetate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl isobutyrate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl pivalate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl benzoate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl furan-2-carboxylate, and pharmaceutically
acceptable salts thereof.
52. The method of claim 46, wherein the compound of formula (IA-I)
is selected from:
N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]p-
yridin-5-yl)-benzamide;
2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]p-
yridin-5-yl)-benzamide;
N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imida-
zo[4,5-b]pyridin-5-yl)-benzamide,
2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imida-
zo[4,5-b]pyridin-5-yl)-benzamide, and pharmaceutically acceptable
salts thereof.
53. A method of inhibiting the proliferative activity of a cell
comprising contacting said cell with a compound of formula (IA-I)
##STR00220## or a tautomer, stereoisomer, enantiomer, diastereomer,
pharmaceutically acceptable salt, or N-oxide thereof; wherein X is
CR.sup.1 or N; D is monocyclic aryl, wherein D is substituted with
a group E which is selected from
--CONH--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x, and
--CONH--O--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p---
OR.sup.x; and further D can optionally be substituted with one or
more of R.sup.z; L.sub.2 is --(CR.sup.aR.sup.b)--; Cy.sup.2 is
substituted or unsubstituted heteroaryl; each occurrence of R.sup.1
and R.sup.2 may be same or different and is independently selected
from hydrogen, nitro, hydroxy, cyano, halogen, --OR.sup.a,
--S(.dbd.O).sub.q--R.sup.a, --NR.sup.aR.sup.b,
--C(.dbd.Y)--R.sup.a, --CR.sup.aR.sup.b--C(.dbd.Y)--R.sup.a,
--CR.sup.aR.sup.b--Y--CR.sup.aR.sup.bR.sup.b,
--C(.dbd.Y)--NR.sup.aR.sup.b,
--NR.sup.aR.sup.b--C(.dbd.Y)--NR.sup.aR.sup.b,
--S(.dbd.O).sub.q--NR.sup.aR.sup.b--,
--NR.sup.aR.sup.b--S(.dbd.O).sub.q--NR.sup.aR.sup.b,
--NR.sup.aR.sup.b--NR.sup.aR.sup.b, substituted or unsubstituted
C.sub.1-6 alkyl, substituted or unsubstituted C.sub.2-6 alkenyl,
substituted or unsubstituted C.sub.2-6 alkynyl, substituted or
unsubstituted C.sub.3-6 cycloalkyl, substituted or unsubstituted
C.sub.3-6 cycloalkylalkyl, and substituted or unsubstituted
C.sub.3-6 cycloalkenyl; each occurrence of Y is independently
selected from O, S, and NR.sup.a; each occurrence of R.sup.a and
R.sup.b may be same or different and are independently selected
from hydrogen, nitro, hydroxy, cyano, halogen, substituted or
unsubstituted C.sub.1-6 alkyl, substituted or unsubstituted
C.sub.2-6 alkenyl, substituted or unsubstituted C.sub.2-6 alkynyl,
substituted or unsubstituted C.sub.3-6 cycloalkyl, substituted or
unsubstituted C.sub.3-6 cycloalkylalkyl, and substituted or
unsubstituted C.sub.3-6 cycloalkenyl, or when two R.sup.a and/or
R.sup.b substituents are directly bound to a common atom, they may
be joined to form a substituted or unsubstituted, saturated or
unsaturated 3-10 member ring, which may optionally include one or
more heteroatoms which may be same or different and are selected
from O, NR.sup.c or S; each occurrence of R.sup.c is independently
selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted
or unsubstituted C.sub.1-6 alkyl, substituted or unsubstituted
C.sub.2-6 alkenyl, substituted or unsubstituted C.sub.2-6 alkynyl,
substituted or unsubstituted C.sub.3-6 cycloalkyl, substituted or
unsubstituted C.sub.3-6 cycloalkylalkyl, and substituted or
unsubstituted C.sub.3-6 cycloalkenyl; each occurrence of R.sup.x
and R.sup.y is independently selected from hydrogen, hydroxy,
halogen, carboxyl, cyano, nitro, oxo (.dbd.O), thio (.dbd.S),
substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or
unsubstituted alkynyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted cycloalkenyl, substituted or
unsubstituted cycloalkylalkyl, substituted or unsubstituted
cycloalkenylalkyl, substituted or unsubstituted heterocycyl,
substituted or unsubstituted heterocyclylalkyl, substituted or
unsubstituted aryl, substituted or unsubstituted arylalkyl,
substituted or unsubstituted heteroaryl, substituted or
unsubstituted heteroarylalkyl, --COOR.sup.z, --C(O)R.sup.z,
--C(S)R.sup.z, --C(O)NR.sup.zR.sup.z, --C(O)ONR.sup.zR.sup.z,
--NR.sup.zR.sup.z, --NR.sup.zCONR.sup.zR.sup.z,
--N(R.sup.z)SOR.sup.z, --N(R.sup.z)SO.sub.2R.sup.z,
--(.dbd.N--N(R.sup.z)R.sup.z), --NR.sup.zC(O)OR.sup.z,
--NR.sup.zC(O)R.sup.z--,
--NR.sup.xC(S)R.sup.y--NR.sup.zC(S)NR.sup.zR.sup.z,
--SONR.sup.zR.sup.z--, --SO.sub.2NR.sup.zR.sup.z--, --OR.sup.z,
--OR.sup.zC(O)NR.sup.zR.sup.z, --OR.sup.zC(O)OR.sup.z--,
--OC(O)R.sup.z, --OC(O)NR.sup.zR.sup.z,
--R.sup.zNR.sup.zC(O)R.sup.z, --R.sup.zOR.sup.z,
--R.sup.zC(O)OR.sup.z, --R.sup.zC(O)NR.sup.zR.sup.z,
--R.sup.zC(O)R.sup.z, --R.sup.zOC(O)R.sup.z, --SR.sup.z,
--SOR.sup.z, --SO.sub.2R.sup.z, and --ONO.sub.2, or any two of
R.sup.x and R.sup.y which are directly bound to a common atom may
be joined to form (i) a substituted or unsubstituted, saturated or
unsaturated 3-14 membered ring, which may optionally include one or
more heteroatoms which may be the same or different and are
selected from O, NR.sup.z or S, or (ii) an oxo (.dbd.O), thio
(.dbd.S) or imino (.dbd.NR.sup.z); wherein each occurrence of
R.sup.z is independently hydrogen, hydroxy, halogen, carboxyl,
cyano, nitro, oxo (.dbd.O), thio (.dbd.S), substituted or
unsubstituted alkyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted
cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl,
substituted or unsubstituted heterocycyl, substituted or
unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl,
substituted or unsubstituted arylalkyl, substituted or
unsubstituted heteroaryl, substituted or unsubstituted
heteroarylalkyl, and --ONO.sub.2, or any two of R.sup.z which are
directly bound to a common atom may be joined to form (i) a
substituted or unsubstituted, saturated or unsaturated 3-14
membered ring, which may optionally include one or more heteroatoms
which may be the same or different and are selected from O, NR'
(where R' is H or alkyl) or S, or (ii) an oxo (.dbd.O), thio
(.dbd.S) or imino (.dbd.NR.sup.z); each occurrence of p
independently represents 1, 2, 3, 4, 5, 6, 7 or 8; and each
occurrence of q independently represents 0, 1 or 2, with the
proviso that when Cy.sup.2 is substituted or unsubstituted
heteroaryl, each occurrence of R.sup.1 and R.sup.2 is hydrogen, and
E is --CONH--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x, then p is not
2.
54. The method of claim 53, wherein D is ##STR00221## and X.sup.1,
X.sup.2 and X.sup.3 are independently selected from --CR.sup.z and
--CR.sup.z.dbd.CR.sup.z.
55. The method of claim 53, wherein L.sub.2-Cy.sup.2 is
##STR00222## (where the squiggly line represents the bond to the
bicyclic core in formula (IA-I)); each occurrence of R.sup.a and
R.sup.b are independently selected from hydrogen, halogen, and
substituted or unsubstituted (C.sub.1-6) alkyl, or both together
with the carbon atom to which they are attached form a saturated 3
to 6 member cyclic ring which may optionally include one or more
heteroatoms which may be same or different and are selected from O,
NR.sup.e and S (where R.sup.e is R.sup.z); Z is selected from
CR.sup.c, S, O, NR.sup.c, R.sup.cC.dbd.CR.sup.c,
--N.dbd.CR.sup.c--, and --R.sup.cC.dbd.N--; Z.sub.1 is selected
from N, NR.sup.c and CR.sup.c; Z.sub.2 and Z.sub.3 are
independently selected from C or N; and R.sup.c is absent or
selected from hydrogen, hydroxy and halogen.
56. The method of claim 53, D is E ##STR00223## L.sub.2-Cy.sup.2 is
##STR00224## (where the squiggly line represents the bond to the
bicyclic core in formula (IA-I)); X.sup.1, X.sup.2 and X.sup.3 are
independently selected from --CR.sup.z and --CR.sup.z.dbd.CR.sup.z;
Z is selected from CR.sup.c, S, O, NR.sup.c, R.sup.cC.dbd.CR.sup.c,
--N.dbd.CR.sup.c--, and --R.sup.cC.dbd.N--; Z.sub.1 is selected
from N, NR.sup.c and CR.sup.c; and Z.sub.2 and Z.sub.3 are
independently selected from C and N.
57. The method of claim 53, wherein the compound of formula (IA-I)
is selected from
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl acetate,
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-5-yl)benzamidooxy)ethyl 2-(tert-butoxycarbonylamino)propanoate,
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-5-yl)benzamidooxy)ethyl 2-aminopropanoate,
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl pivalate,
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl isobutyrate,
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl 2-benzamidoacetate,
2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazo-
lo[4,5-b]pyridin-5-yl)benzamide, ethyl
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)acetate,
2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H--
[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-
-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide,
N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide,
N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl acetate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl isobutyrate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl pivalate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl benzoate,
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl furan-2-carboxylate, and pharmaceutically
acceptable salts thereof.
58. The method of claim 53, wherein the compound of formula (IA-I)
is selected from:
N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imida-
zo[4,5-b]pyridin-5-yl)-benzamide,
2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imida-
zo[4,5-b]pyridin-5-yl)-benzamide, and pharmaceutically acceptable
salts thereof.
Description
[0001] This application claims the benefit of Indian Provisional
Patent Application No. 1262/CHE/2012 dated 30 Mar. 2012 all of
which is hereby incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention provides compounds useful as protein
kinase modulators, methods of preparing them, pharmaceutical
compositions containing them and methods of treatment, prevention
and/or amelioration of kinase mediated diseases or disorders with
them.
BACKGROUND OF THE INVENTION
[0003] In the recent past, immense research has been dedicated to
the discovery and understanding of the structure and functions of
enzymes and bio-molecules associated with various diseases. One
such important class of enzymes that has been the subject of
extensive research is protein kinase.
[0004] In general, protein kinases represent a set of structurally
related phosphoryl transferases having conserved structures and
catalytic functions. These enzymes modify proteins by chemically
adding phosphate groups (phosphorylation). Phosphorylation involves
the removal of a phosphate group from ATP and covalently attaching
it to amino acids that have a free hydroxyl group such as serine,
threonine or tyrosine. Phosphorylation usually results in a
functional change of the target protein (substrate) by altering
enzyme activity, cellular localization or association with other
proteins. Up to 30% of all proteins may be modified by kinase
activity.
[0005] This class of proteins are classified into subsets depending
upon the substrate they act upon, such as tyrosine kinase,
serine/theronine kinase, histidine kinase and the like. These
proteins can also be classified based on their localization into
receptor tyrosine kinases (RTKs) or non-receptor tyrosine
kinases.
[0006] Receptor tyrosine kinases (RTKs) have an extracellular
portion, a transmembrane domain, and an intracellular portion,
while non-receptor tyrosine kinases are entirely intracellular.
Receptor tyrosine kinase mediated signal transduction is typically
initiated by an extracellular interaction with a specific growth
factor (ligand), followed by receptor dimerization, stimulation of
the intrinsic protein tyrosine kinase activity, and phosphorylation
of amino acid residues. The ensuing conformational change leads to
the formation of complexes with a spectrum of cytoplasmic
signalling molecules and facilitates a myriad of responses such as
cell division, differentiation, metabolic effects, and changes in
the extracellular microenvironment.
[0007] At present, at least twenty (20) distinct RTK subfamilies
have been identified. One subfamily of the RTKs is designated as
the Met subfamily (c-Met, Ron and Sea). For a detailed discussion
of protein kinases, see, Plowman et al., DN&P 7(6): 334-339,
1994, Blume-Jensen, P. et al., Nature, 2001, 411(6835):355-365 and
Manning, G. et al., Science, 2002, 298(5600): 1912-1934.
[0008] Kinases have also been classified either based on the
pathway or the diseases in which they are involved (visit:
www.reactionbiology.com/pages/kinase.htm). c-Met has been
identified as involved in oncogenesis.
[0009] Protein kinases exert their physiological functions through
phosphorylation of proteins (or substrates) thereby modulating the
cellular activities of the substrate in various biological
contexts. Protein kinases are known to control a wide variety of
biological processes such as cell growth, survival and
differentiation, organ formation and morphogenesis,
neovascularisation, tissue repair and regeneration. In addition to
their functions in normal tissues/organs, many protein kinases also
play specialized roles in a host of human diseases including
cancer. A subset of protein kinases (also referred to as oncogenic
protein kinases), when dysregulated, can cause tumor formation and
growth and contribute to tumor maintenance and progression
(Blume-Jensen P et al, Nature, 2001, 411(6835):355-365). Thus far,
oncogenic protein kinases represent one of the largest and most
attractive groups of protein targets for therapeutic intervention
and drug development.
[0010] Both receptor and non-receptor protein kinases have been
found to be attractive targets for small molecule drug discovery
due to their impact on cell physiology and signalling.
Dysregulation of protein kinase activity thus leads to altered
cellular responses including uncontrolled cell growth associated
with cancer. In addition to oncological indications, altered kinase
signalling is implicated in numerous other pathological diseases.
These include, but are not limited to immunological disorders,
cardiovascular diseases, inflammatory diseases, and degenerative
diseases.
[0011] A significant number of tyrosine kinases (both receptor and
nonreceptor) are associated with cancer (see Madhusudan S, Ganesan
T S. Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem.,
2004, 37(7):618-35). Clinical studies suggest that over expression
or dysregulation of tyrosine kinases may also be of prognostic
value. For example, members of the HER family of RTKs have been
implicated in breast, colorectal, head and neck and lung cancer.
Mutation of c-Kit tyrosine kinase is associated with decreased
survival in gastrointestinal stromal tumors (GIST). In acute
myelogenous leukemia, Flt-3 mutation predicts shorter disease free
survival. VEGFR expression, which is important for tumor
angiogenesis, is associated with a lower survival rate in lung
cancer. Tie-1 kinase expression is inversely correlated to survival
in gastric cancer. BCR-AbI expression is an important predictor of
response in chronic myelogenous leukemia while Src tyrosine kinase
expression is co-related to the stage of colorectal cancer.
[0012] Modulation (particularly inhibition) of cell proliferation
and angiogenesis, the two key cellular processes needed for tumor
growth and survival is an attractive goal for development of
small-molecule drugs (Matter A. Drug Disc. Technol., 2001, 6,
1005-1024). Anti-angiogenic therapy represents a potentially
important approach for the treatment of solid tumors and other
diseases associated with dysregulated vascularisation including
ischemic coronary artery disease, diabetic retinopathy, psoriasis
and rheumatoid arthritis. Similarly, cell antiproliferative agents
are desirable to slow or inhibit the growth of tumors.
[0013] Some of the kinases implicated in cancer are c-Met, RON
(recepteur d'origine nantais) receptor, Vascular Endothelial Growth
Factor (VEGF) receptor, Epidermal growth factor receptor kinase
(EGF-R kinase), Eph receptors, c-Kit, and Flt-3.
[0014] A number of small molecule kinase modulators have found
their way into the clinic which either act selectively on either
one or multiple kinases. These include Gefitinib (AstraZeneca), a
EGFR kinase inhibitor; Gleevec (Novartis), a dual c-Kit and AbI
kinase inhibitor approved for the treatment of Chronic Myeloid
Leukemia (CML) and gastrointestinal stroma cancers; Dasatinib
(BMS), a dual BCR/ABL and Src family tyrosine kinases inhibitor,
and Sunitinib (Pfizer) a multi kinase inhibitor targeting PDGF-R,
VEGF-R, RET, KIT (CD117), CSF-1R and flt-3.
[0015] The kinase, c-Met, is the prototypic member of a subfamily
of heterodimeric receptor tyrosine kinases (RTKs) which include
Met, Ron and Sea (see Birchmeier, C. et al., Nat. Rev. Mol. Cell
Biol., 2003, 4(12):915-925; Christensen, J. G. et al., Cancer
Lett., 2005, 225(1): 1-26). Expression of c-Met occurs in a wide
variety of cell types including epithelial, endothelial and
mesenchymal cells where activation of the receptor induces cell
migration, invasion, proliferation and other biological activities
associated with "invasive cell growth." As such, signal
transduction through c-Met receptor activation is responsible for
many of the characteristics of tumor cells.
[0016] The only high affinity endogenous ligand for c-Met is the
hepatocyte growth factor (HGF), also known as scatter factor (SF).
Binding of HGF to c-Met induces activation of the receptor via
autophosphorylation resulting in an increase of receptor dependent
signalling, which promotes cell growth and invasion. Both c-Met and
HGF are widely expressed in a variety of organs, but their
expression is normally confined to cells of epithelial and
mesenchymal origin. Anti-HGF antibodies or HGF antagonists have
been shown to inhibit tumor metastasis in vivo (see, Maulik et al.,
Cytokine &Growth Factor Reviews, 2002, 13, 41-59). The
biological functions of c-Met (or c-Met signalling pathway) in
normal tissues and human malignancies such as cancer have been well
documented (Christensen, J. G. et al., Cancer Lett., 2005, 225(1):
1-26; Corso, S. et al., Trends in Mol. Med., 2005, 11
(6):284-292).
[0017] Tumor growth progression involves the recruitment of new
blood vessels into the tumor as well as invasion, adhesion and
proliferation of malignant cells. c-Met over expression has been
demonstrated on a wide variety of tumor types including breast,
colon, renal, lung, squamous cell myeloid leukemia, hemangiomas,
melanomas, astrocytomas, and glioblastomas. Additionally activating
mutations in the kinase domain of c-Met have been identified in
hereditary and sporadic renal papilloma and squamous cell
carcinoma. See Maulik et al Cytokine & growth Factor reviews
2002, 13, 41-59; Longati et al Curr Drug Targets 2001, 2, 41-55;
Funakoshi et al Clinica Chimica Acta 2003 1-23. Thus modulation of
c-Met offers an attractive opportunity to target key oncogenic
processes thus limiting cell proliferation, survival and
metastasis.
[0018] Dysregulated c-Met pathway is linked to tumor formation,
growth, maintenance and progression (Birchmeier, C. et al., Nat.
Rev. MoI. Cell. Biol. 2003, 4(12):915-925; Boccaccio, C. et al.,
Nat. Rev. Cancer 2006, 6(8):637-645; Christensen, J. G. et al.,
Cancer Lett. 2005, 225(1): 1-26). HGF and/or c-Met are over
expressed in significant portions of most human cancers, and are
often associated with poor clinical outcomes such as more
aggressive disease, disease progression, tumor metastasis and
shortened patient survival. Further, patients with high levels of
HGF/c-Met proteins are more resistant to chemotherapy and
radiotherapy. In addition to abnormal HGF/c-Met expression, the
c-Met receptor can also be activated in cancer patients through
genetic mutations (both germline and somatic) and gene
amplification. Although gene amplification and mutations are the
most common genetic alterations that have been reported in
patients, the receptor can also be activated by deletions,
truncations, and gene rearrangement, as well as abnormal receptor
processing and defective negative regulatory mechanisms.
[0019] The various cancers in which c-Met is implicated include but
are not limited to carcinomas (e.g., bladder, breast, cervical,
cholangiocarcinoma, colorectal, esophageal, gastric, head and neck,
kidney, liver, lung, nasopharygeal, ovarian, pancreas, prostate,
thyroid); musculoskeletal sarcomas (e.g., ostcosarcaoma, synovial
sarcoma, rhabdomyosarcoma); soft tissue sarcomas (e.g.,
MFH/fibrosarcoma, leiomyosarcoma, Kaposi's sarcoma); hematopoietic
malignancies (e.g., multiple myeloma, lymphomas, adult T cell
leukemia, acute myelogenous leukemia, chronic myeloid leukemia);
and other neoplasms (e.g., glioblastomas, astrocytomas, melanoma,
mesothelioma and Wilm's tumor (www.vai.org/met/; Christensen, J. G.
et al., Cancer Lett. 2005, 225(1): 1-26). c-Met inhibitors may also
be useful in preventative and adjuvant therapy settings. In
addition, certain cancers (e.g., papillary renal cell carcinoma,
and some gastric and lung cancers) may be treated with c-Met
inhibitors as they are believed to be driven by c-Met
mutation/genetic alteration and dependent on c-Met for growth and
survival. These cancers are expected to be sensitive to
treatment.
[0020] The notion that activated c-Met contributes to tumor
formation and progression and could therefore be a potential target
for effective cancer intervention has been further validated by
numerous preclinical studies (Birchmeier, C. et al., Nat. Rev. Mot.
Cell Biol. 2003, 4(12):915-925; Christensen, J. G. et al., Cancer
Lett. 2005, 225(1): 1-26; Corso, S. et al., Trends in Mol. Med.
2005, 11(6):284-292). For example, studies have demonstrated that
the tpr-met fusion gene, over expression of c-Met, and activated
c-Met mutations caused oncogenic transformation of various model
cell lines and resulted in tumor formation and metastasis in mice.
Conversely, significant anti-tumor and anti-metastasis activities
have been demonstrated in vitro and in vivo with agents that
specifically impair and/or block HGF/c-Met signalling. Those agents
include anti-HGF and anti-c-Met antibodies, HGF peptide
antagonists, decoy c-Met receptor, c-Met peptide antagonists,
dominant negative c-Met mutations, c-Met specific antisense
oligonucleotides and ribozymes, and selective small molecule c-Met
kinase inhibitors (Christensen, J. G. et al., Cancer Lett. 2005,
225(1): 1-26). In addition to its established role in cancer,
abnormal HGF/c-Met signalling is also implicated in
atherosclerosis, lung fibrosis, renal fibrosis and regeneration,
liver diseases, allergic disorders, inflammatory and autoimmune
disorders, cerebrovascular diseases, cardiovascular diseases, and
conditions associated with organ transplantation. See Ma, H. et
al., Atherosclerosis. 2002, 164(1):79-87; Crestani, B. et al., Lab.
Invest. 2002, 82(8): 1015-1022; Sequra-Flores, A. A. et al., Rev.
Gastroenterol. Mex. 2004, 69(4)243-250; Morishita, R. et al., Curr.
Gene Ther. 2004, 4(2)199-206; Morishita, R. et al., Endocr. J.
2002, 49(3)273-284; Liu, Y., Curr. Opin. Nephrol. Hypertens. 2002,
1 1 (1):23-30; Matsumoto, K. et al., Kidney Int. 2001,
59(6):2023-2038; Balkovetz, D. F. et al., Int. Rev. Cytol. 1999,
186:225-250; Miyazawa, T. et al., J. Cereb. Blood Flow Metab. 1998,
18(4)345-348; Koch, A. E. et al., Arthritis Rheum. 1996,
39(9):1566-1575; Futamatsu, H. et al., Cire. Res. 2005,
96(8)823-830; Eguchi, S. et al., Clin. Transplant. 1999,
13(6)536-544.
[0021] c-Met is thus an attractive target from a clinical
perspective mainly because of its upstream localisation which aids
in early detection and limiting metastasis and implications in the
growth and metastases of most types of cancers. These observations
suggest that c-Met kinase inhibitors would be an effective
treatment for tumors driven by c-Met, and also would prevent
disseminated micrometastases from further progression.
[0022] A family of novel compounds have been discovered which
exhibit c-Met modulating ability and have an ameliorating effect
against disorders related to abnormal c-Met activity such as
Johnson & Johnson's JNJ-38877605, Amgen's AMG-458, Eisai's
E-7050 and Pfizer's PF-04217903. However, to date, none of them
have been used in a clinical study.
##STR00001##
[0023] More recently Dussault et. al., Anti-Cancer Agents in
Medicinal Chemistry, 2009, 9(2), 221-229, have provided additional
insight about a receptor tyrosine kinase namely, RON (recepteur
d'origine nantais) which is closely related to c-Met. Both c-MET
and RON receptors upon activation can induce cell migration,
invasion, proliferation and survival. Moreover, both possess
oncogenic activity in vitro and in vivo and are often dysregulated
in human cancers.
[0024] While c-Met is now a well-accepted target for anti-cancer
treatment, less is known about the role of RON in cancer. Despite
their common attributes, c-Met and RON are activated by different
mechanisms in cancer cells. Due to a significant homology between
the two RTKs, some small molecule kinase inhibitors of c-Met have
inhibitory activity on RON suggesting that both receptors might be
involved in cancer progression. The review (Dussault et al., supra)
discusses the relevance of both c-Met and RON deregulation in human
cancers and the progress made in identifying small molecule kinase
inhibitors that can block the activity of these targets in vitro
and in animal models. One of the compounds discussed in the review,
AMG-458, inhibited c-Met and RON with IC.sub.50s of 4 and 9 nM
respectively.
[0025] Various research groups around the world such as Amgen,
Arquel, AstraZeneca, Bristol-Myers Squibb, Exelixis, Eisai, Incyte,
MethylGene, Pfizer, SGX Pharma, SmithKline Beecham, Schering,
Vertex, Xcovery, Novartis and others have been working on targeting
either single, dual or multiple kinase targets.
[0026] Patent literature belonging to some of these applicants
include the following patents and/or patent publications: U.S. Pat.
Nos. 7,446,199; 7,470,693; 7,459,562; 7,439,246; 7,432,373; U.S.
Pat. Nos. 7,348,325; 7,173,031; 7,314,885; 7,169,800; US
2010/0105656, US 2009/0012076; US 2008/0312232; US 2008/0161305; US
2007/0244116; US 2007/0225307; US 2007/0054928; US 2007/0179130; US
2007/0254868; US 2007/0191369; US 2006/0173055; US 2006/0135537; US
2005/0148574; US 2005/0137201; US 2005/0101650; WO 2009/002806; WO
2008/088881; WO 2008/051805; WO 2008/102870; WO 2008/078085; WO
2008/060866; WO 2008/54702; WO 2008/036272; WO 2007/111904; WO
2007/064797; WO 2006/052913; WO 2006/021881; WO 2006/021886; WO
2006/021884; WO 2006/108059; WO 2006/014325; WO 2006/052913; WO
2005/07891; WO 2005/030140; WO 2005/040345; WO 2005/028475; and WO
2005/016920.
[0027] International Publication Nos. WO 2009/058728, WO
2009/058729, WO 2009/058730 and WO 2009/058739 all assigned to
Schering Corporation disclose a series of thiazole carboxamide
compounds as protein kinase inhibitors and more specifically to be
inhibiting Aurora, MEK1 and/or CDK2 kinases.
[0028] Further review and literature disclosure on protein kinase
molecules have been given by Isabelle Dussault et. al., (see;
Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 221-229), Ted
L. Underiner et. al., (see; Anti-Cancer Agents in Medicinal
Chemistry, 2010, 10, 7-27) and Stephen Claridge et. al (see;
Bioorganic & Medicinal Chemistry Letters 18 (2008) 2793-2798).
All of these patents and/or patent applications and literature
disclosures are incorporated herein as reference in their entirety
for all purposes.
[0029] Despite the advances made in the area of kinases and in
particular the role that c-met, RON, EGFR or KDR pathway plays in
human diseases, challenges remain in term of the complexities of
the target involved, the protein structure of the kinases,
specificity issues for various kinase inhibitors, side effects and
desired clinical benefits expected form the small molecule
inhibitors. Accordingly, there still remains an unmet and dire need
for small molecule compounds having specificity towards either one,
two or multiple kinase inhibitors in order to regulate and/or
modulate transduction of kinases, particularly c-Met, RON, EGFR or
KDR for the treatment of diseases and disorders associated with
kinases-mediated events.
[0030] Further a reference is made herein to International Patent
Application No. PCT/IB2011/052120, filed May 13, 2011 and U.S.
patent application Ser. No. 13/108,642 filed May 16, 2011 which
generally disclose 3,5-Disubstituted-3H-Imidazo[4,5-b]Pyridine and
3,5-Disubstituted-3H-[1,2,3]Triazolo[4,5-b]Pyridine compounds as
modulators of Protein Kinases all of which are incorporated herein
by reference in their entirety for all purposes.
[0031] The c-Met pathway plays an important role in the above
described human diseases including cancer. There are no c-Met
inhibitors or antagonists that are currently available for treating
these human disorders that are characterized by abnormal HGF/c-Met
signaling. Therefore, there is a clear unmet medical need for
compounds which inhibit c-Met and other kinases. The compounds,
compositions, and pharmaceutical methods provided herein help meet
this need.
SUMMARY OF THE INVENTION
[0032] The present invention is directed to compounds useful as
protein kinase modulators and in particular as inhibitors of
c-Met.
[0033] In one embodiment, the compound of the present invention has
the formula I:
##STR00002##
or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g.,
pharmaceutically acceptable salt), prodrug (e.g., ester), or
N-oxide thereof, wherein
[0034] X is CR.sup.1 or N;
[0035] Cy.sup.1 and Cy.sup.2 may be same or different and are
independently selected from substituted or unsubstituted
cycloalkyl, substituted or unsubstituted heterocyclic group,
substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl;
[0036] L.sub.1 is absent or selected from --O--,
--S(.dbd.O).sub.q--, --NR.sup.a--, --(CR.sup.aR.sup.b).sub.n--,
--C(.dbd.Y)--, --C(.dbd.Y)--C(.dbd.Y)--,
--CR.sup.aR.sup.b--C(.dbd.Y)--CR.sup.aR.sup.b--,
--CR.sup.aR.sup.b--Y--CR.sup.aR.sup.b--, --C(.dbd.Y)--NR.sup.a--,
--NR.sup.a--C(.dbd.Y)--NR.sup.a--, --S(.dbd.O).sub.q--NR.sup.a--,
--NR.sup.a--S(.dbd.O).sub.q--NR.sup.a--, --NR.sup.a--NR.sup.a--,
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted cycloalkyl, and substituted or unsubstituted
heterocyclyl;
[0037] L.sub.2 is selected from --O--, --S(.dbd.O).sub.q--,
--NR.sup.a--, --(CR.sup.aR.sup.b)--, --C(.dbd.Y)--,
--C(.dbd.Y)--C(.dbd.Y)--,
--CR.sup.aR.sup.b--C(.dbd.Y)--CR.sup.aR.sup.b--,
--CR.sup.aR.sup.b--Y--CR.sup.aR.sup.b--, --C(.dbd.Y)--NR.sup.a--,
--NR.sup.a--C(.dbd.Y)--NR.sup.a--, --S(.dbd.O).sub.q--NR.sup.a,
--NR.sup.a--S(.dbd.O).sub.q--NR.sup.a--, --NR.sup.a--NR.sup.a--,
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted cycloalkyl, and substituted or unsubstituted
heterocyclyl;
[0038] each occurrence of R.sup.1 and R.sup.2 may be same or
different and is independently selected from hydrogen, nitro,
hydroxy, cyano, halogen, --OR.sup.a, --S(.dbd.O).sub.q--R.sup.a,
--NR.sup.aR.sup.b, --C(.dbd.Y)--R.sup.a,
--CR.sup.aR.sup.b--C(.dbd.Y)--R.sup.a,
--CR.sup.aR.sup.b--Y--CR.sup.aR.sup.bR.sup.b,
--C(.dbd.Y)--NR.sup.aR.sup.b,
--NR.sup.aR.sup.b--C(.dbd.Y)--NR.sup.aR.sup.b,
--S(.dbd.O).sub.q--NR.sup.aR.sup.b,
--NR.sup.a--S(.dbd.O).sub.q--NR.sup.aR.sup.b,
--NR.sup.aR.sup.b--NR.sup.aR.sup.b, substituted or unsubstituted
C.sub.1-6 alkyl, substituted or unsubstituted C.sub.2-6 alkenyl,
substituted or unsubstituted C.sub.2-6 alkynyl, substituted or
unsubstituted C.sub.3-6 cycloalkyl, substituted or unsubstituted
C.sub.3-6 cycloalkylalkyl, and substituted or unsubstituted
C.sub.3-6 cycloalkenyl;
[0039] each occurrence of R.sup.a and R.sup.b may be same or
different and are independently selected from hydrogen, nitro,
hydroxy, cyano, halogen, substituted or unsubstituted C.sub.1-6
alkyl, substituted or unsubstituted C.sub.2-6 alkenyl, substituted
or unsubstituted C.sub.2-6 alkynyl, substituted or unsubstituted
C.sub.3-6 cycloalkyl, substituted or unsubstituted C.sub.3-6
cycloalkylalkyl, and substituted or unsubstituted C.sub.3-6
cycloalkenyl, or when two R.sup.a and/or R.sup.b substituents are
directly bound to a common atom, they may be joined to form a
substituted or unsubstituted, saturated or unsaturated 3-10 member
ring, which may optionally include one or more heteroatons which
may be same or different and are selected from O, NR.sup.c or
S;
[0040] each occurrence of R.sup.c is independently selected from
hydrogen, nitro, hydroxy, cyano, halogen, substituted or
unsubstituted C.sub.1-6 alkyl, substituted or unsubstituted
C.sub.2-6 alkenyl, substituted or unsubstituted C.sub.2-6 alkynyl,
substituted or unsubstituted C.sub.3-6 cycloalkyl, substituted or
unsubstituted C.sub.3-6 cycloalkylalkyl, and substituted or
unsubstituted C.sub.3-6 cycloalkenyl;
[0041] each occurrence of Y is independently selected from O, S,
and NR.sup.a;
[0042] each occurrence of n independently represents 0, 1, 2, 3 or
4; and
[0043] each occurrence of q independently represents 0, 1 or 2.
[0044] Another embodiment is a compound of formula (IA):
##STR00003##
or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g.,
pharmaceutically acceptable salt), prodrug (e.g., ester), or
N-oxide thereof, wherein
[0045] each occurrence of R.sup.2 is independently hydrogen, nitro,
hydroxy, cyano, halogen, --OR.sup.a, --S(.dbd.O).sub.q--R.sup.a,
--NR.sup.aR.sup.b, or --C(.dbd.O)--R.sup.a, wherein R.sup.a and
R.sup.b in the R.sup.2 group are independently hydrogen, hydroxy,
or substituted or unsubstituted C.sub.1-6 alkyl; and all the other
variables (i.e., Cy.sup.1, Cy.sup.2 and L.sup.2) are as defined
above in relation to compound of formula (I).
[0046] Further preferred is a compound of formula (I) and (IA)
wherein Cy.sup.1 is selected from: (The line () in the structures
shown below represents the point of attachment of the structure to
the rest of the compound.)
##STR00004## ##STR00005## ##STR00006## ##STR00007## ##STR00008##
##STR00009## ##STR00010## ##STR00011## ##STR00012## ##STR00013##
##STR00014##
##STR00015## ##STR00016## ##STR00017## ##STR00018## ##STR00019##
##STR00020##
[0047] Yet another embodiment is a compound of formula (IA-I):
##STR00021##
or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g.,
pharmaceutically acceptable salt), prodrug (e.g., ester), or
N-oxide thereof, wherein
[0048] D is substituted or unsubstituted monocyclic aryl or
substituted or unsubstituted monocyclic heteroaryl;
[0049] wherein D is substituted with a group E which is selected
from --CONH--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x,
--CONH--(CR.sup.xR.sup.y).sub.p--OR.sup.x--,
--CONH--(CR.sup.xR.sup.y).sub.p--NR.sup.xR.sup.y,
--CONH--(CR.sup.xR.sup.y).sub.p--S(O).sub.qR.sup.x,
--CONH--O--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p---
OR.sup.x,
--CONH--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).s-
ub.p--OR.sup.x--,
--CONH--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p--NR.-
sup.xR.sup.y,
--CONH--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p--S(O-
).sub.qR.sup.x; and
[0050] D can be optionally be further substituted with one to four
substituents independently selected from R.sup.z;
[0051] each occurrence of R.sup.x and R.sup.y is independently
selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro,
oxo (.dbd.O), thio (.dbd.S), substituted or unsubstituted alkyl,
substituted or unsubstituted alkoxy, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted
cycloalkenyl, substituted or unsubstituted cycloalkylalkyl,
substituted or unsubstituted cycloalkenylalkyl, substituted or
unsubstituted heterocycyl, substituted or unsubstituted
heterocyclylalkyl, substituted or unsubstituted aryl, substituted
or unsubstituted arylalkyl, substituted or unsubstituted
heteroaryl, substituted or unsubstituted heteroarylalkyl,
--COOR.sup.z, --C(O)R.sup.z, --C(S)R.sup.z, --C(O)NR.sup.zR.sup.z,
--C(O)ONR.sup.zR.sup.z, --NR.sup.zR.sup.z,
--NR.sup.zCONR.sup.zR.sup.z, --N(R.sup.z)SOR.sup.z,
--N(R.sup.z)SO.sub.2R.sup.z, --(.dbd.N--N(R.sup.z)R.sup.z),
--NR.sup.zC(O)OR.sup.z, --NR.sup.zC(O)R.sup.z--,
--NR.sup.xC(S)R.sup.y--NR.sup.zC(S)NR.sup.zR.sup.z,
--SONR.sup.zR.sup.z--, --SO.sub.2NR.sup.zR.sup.z--, --OR.sup.z,
--OR.sup.zC(O)NR.sup.zR.sup.z, --OR.sup.zC(O)OR.sup.z--,
--OC(O)R.sup.z, --OC(O)NR.sup.zR.sup.z,
--R.sup.zNR.sup.zC(O)R.sup.z, --R.sup.zOR.sup.z,
--R.sup.zC(O)OR.sup.z, --R.sup.zC(O)NR.sup.zR.sup.z,
--R.sup.zC(O)R.sup.z, --R.sup.zOC(O)R.sup.z, --SR.sup.z,
--SOR.sup.z, --SO.sub.2R.sup.z, and --ONO.sub.2, or any two of
R.sup.x and R.sup.y which are directly bound to a common atom may
be joined to form (i) a substituted or unsubstituted, saturated or
unsaturated 3-14 membered ring, which may optionally include one or
more heteroatoms which may be the same or different and are
selected from O, NR.sup.z or S, or (ii) an oxo (.dbd.O), thio
(.dbd.S) or imino (.dbd.NR.sup.z), wherein
[0052] each occurrence of R.sup.z is independently hydrogen,
hydroxy, halogen, carboxyl, cyano, nitro, oxo (.dbd.O), thio
(.dbd.S), substituted or unsubstituted alkyl, substituted or
unsubstituted alkoxy, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted
or unsubstituted cycloalkylalkyl, substituted or unsubstituted
cycloalkenylalkyl, substituted or unsubstituted heterocycyl,
substituted or unsubstituted heterocyclcyalkyl, substituted or
unsubstituted aryl, substituted or unsubstituted arylalkyl,
substituted or unsubstituted heteroaryl, substituted or
unsubstituted heteroarylalkyl, and --ONO.sub.2, or any two of
R.sup.z which are directly bound to a common atom may be joined to
form (i) a substituted or unsubstituted, saturated or unsaturated
3-14 membered ring, which may optionally include one or more
heteroatoms which may be the same or different and are selected
from O, NR (where R' is II or alkyl) or S, or (ii) an oxo (.dbd.O),
thio (.dbd.S) or imino (.dbd.NR.sup.z);
[0053] each occurrence of p independently represents 0, 1-7 or 8;
[0054] q is an integer from 0, 1 or 2; [0055] each occurrence of
R.sup.2 is independently hydrogen, nitro, hydroxy, cyano, halogen,
--OR.sup.a, --S(.dbd.O).sub.q--R.sup.a, --NR.sup.aR.sup.a or
--C(.dbd.O)--R.sup.a wherein each occurrence of R.sup.a and R.sup.b
in group R.sup.2 is independently hydrogen, hydroxy, or substituted
or unsubstituted C.sub.1-6 alkyl; and
[0056] all other variables are the same as defined above with
respect to Formula I and (IA-I).
[0057] Yet another embodiment is a compound of formula (IA-I):
##STR00022##
or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g.,
pharmaceutically acceptable salt), prodrug (e.g., ester), or
N-oxide thereof, wherein
[0058] D is E
##STR00023##
[0059] X.sup.1, X.sup.2 and X.sup.3 are each independently selected
from --CR.sup.z, --CR.sup.z.dbd.CR.sup.z--, --CR.sup.z.dbd.N--,
--N.dbd.CR.sup.z--, --N.dbd.N--, --O--, --S-- or --N--;
[0060] and all the other variables (such as R.sup.2, R.sup.z, X,
L.sub.2' R.sup.x, R.sup.y, E, p, q and Cy.sup.2) are as defined
above with respect to Formula I and (IA-I).
[0061] Further preferred is a compound of formula (I-AI), wherein
Cy.sup.2 is substituted or unsubstituted aryl or substituted or
unsubstituted heteroaryl.
[0062] Further preferred is a compound of formula (I-AI), wherein
Cy.sup.2 is selected from
##STR00024## ##STR00025## ##STR00026##
[0063] Further preferred is a compound of formula (I-AI), wherein
Cy.sup.2 is selected from
##STR00027##
[0064] Further preferred is a compound of formula (IA-I) wherein E
is --CONH--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x,
--CONH--(CR.sup.xR.sup.y).sub.p--OR.sup.x or
--CONH--(CR.sup.xR.sup.y).sub.p--NR.sup.xR.sup.y; wherein all the
variables are as defined above.
[0065] Further preferred is a compound of formula (IA-I) wherein E
is
--CONH--O--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p---
OR.sup.x,
--CONII--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).-
sub.p--OR.sup.x--,
--CONII--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p--NR-
.sup.xR.sup.y, or
--CONH--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p--S(O-
).sub.qR.sup.x; wherein all the variables are as defined above.
[0066] Further preferred is a compound of formula (IA-I) wherein D
is substituted with one to four substituents selected from
hydrogen, halogen, substituted or unsubstituted alkyl, or
substituted or unsubstituted alkoxy.
[0067] Further preferred is a compound of formula (IA-I) wherein L2
is --CR.sup.aR.sup.b--.
[0068] Further preferred is a compound of formula (IA-I) wherein
L.sub.2 is --CH.sub.2--, --CH(OH)--, --CHF--, --CF.sub.2--,
--CH(CH.sub.3)-- or --C(CH).sub.2--.
[0069] Further preferred is a compound of formula (IA-I) wherein
L.sub.2 is --CH.sub.2
[0070] Yet another embodiment is a compound of formula (IA-I):
##STR00028##
or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g.,
pharmaceutically acceptable salt), prodrug (e.g., ester), or
N-oxide thereof, wherein
[0071] L.sub.2-Cy.sup.2 is
##STR00029##
[0072] each occurrence of R.sup.a and R.sup.b is independently
selected from hydrogen, halogen, and substituted or unsubstituted
(C.sub.1-6) alkyl, or both R.sup.a and R.sup.b, together with the
carbon atom to which they are attached, form a saturated 3 to 6
member cyclic ring which may optionally include one or more
heteroatoms which may be same or different and are selected from O,
NR.sup.e and S (where R.sup.e is R.sup.z);
[0073] Z is selected from CR.sup.c, S, O, NR.sup.c,
R.sup.cC.dbd.CR.sup.e, --N.dbd.CR.sup.c--, and
--R.sup.cC.dbd.N--;
[0074] Z.sub.1 is selected from N, NR.sup.c and CR.sup.c;
[0075] Z.sub.2 and Z.sub.3 are independently selected from C or
N;
[0076] R.sup.c is absent or selected from hydrogen, hydroxy and
halogen; and
[0077] all other variables are the same as defined above.
[0078] Yet another embodiment is a compound of formula (IA-I):
##STR00030##
or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g.,
pharmaceutically acceptable salt), prodrug (e.g., ester), or
N-oxide thereof, wherein
[0079] D is
##STR00031##
[0080] L.sub.2-Cy.sup.2 is
##STR00032##
and
[0081] all the variables are as defined above.
[0082] Further preferred is a compound of formula (IA-I) wherein
X.sup.1 and X.sup.2 is CR.sup.z and X.sup.3 is independently
selected from --CR.sup.z.dbd.CR.sup.z or --S--.
[0083] Further preferred is a compound of formula (IA-I) wherein
X.sup.1 is CH, X.sup.2 is CR.sup.z and X.sup.3 is
--CR.sup.z.dbd.CR.sup.z
[0084] Further preferred is a compound of formula (IA-I) wherein Rz
is Hydrogen, Halogen or substituted or unsubstituted C.sub.1-3
alkyl.
[0085] Further preferred is a compound of formula (IA-I) wherein
R.sup.z is hydrogen, chloro, fluoro, --CH.sub.3 or --CF.sub.3.
[0086] Further preferred is a compound of formula (IA-I) wherein D
is selected from
##STR00033## ##STR00034## ##STR00035## ##STR00036## ##STR00037##
##STR00038## ##STR00039## ##STR00040## ##STR00041## ##STR00042##
##STR00043## ##STR00044## ##STR00045## ##STR00046## ##STR00047##
##STR00048## ##STR00049## ##STR00050## ##STR00051##
##STR00052##
[0087] Further preferred is a compound of formula (IA-I) wherein D
is selected from
##STR00053## ##STR00054## ##STR00055## ##STR00056## ##STR00057##
##STR00058## ##STR00059##
[0088] Further preferred is a compound of formula (I), (IA) or
(IA-I) wherein X is N or CR.sup.1 and R.sup.1 is H, substituted or
unsubstituted C.sub.1-6 alkyl, NH.sub.2, OH, CN or CONH.sub.2.
[0089] Further preferred is a compound of formula (I), (IA) or
(IA-I) wherein R.sup.1 is H or C.sub.1-6 alkyl (e.g., methyl).
[0090] Further preferred is a compound of formula (I), (IA) or
(IA-I) wherein each of R.sup.2 is H.
[0091] Further preferred is a compound of formula (IA-I) wherein D
is
##STR00060##
[0092] E is selected from
--CONR.sup.x--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x,
--CONR.sup.x--(CR.sup.xR.sup.y).sub.p--OR.sup.x--,
--CONR.sup.x--(CR.sup.xR.sup.y), --NR.sup.xR.sup.y,
--CONR.sup.x--(CR.sup.xR.sup.y).sub.p--S(O).sub.qR.sup.x,
--CONR.sup.x--O--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).s-
ub.p--OR.sup.x,
--CONR.sup.x--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.-
p--OR.sup.x--,
--CONR.sup.x--(CR.sup.xR.sup.y).sub.p-[cycloalkyl]-(CR.sup.xR.sup.y).sub.-
p--NR.sup.xR.sup.y or
--CONR.sup.x--(CR.sup.xR.sup.y)-[cycloalkyl]-(CR.sup.xR.sup.y).sub.p--S(O-
).sub.qR.sup.x; and
[0093] R.sup.z is as defined above.
[0094] Further preferred is a compound of formula (IA-I) wherein E
is selected from
##STR00061##
[0095] Further preferred is a compound of formula (IA-I) wherein E
is selected from
##STR00062##
[0096] Further preferred is a compound of formula (IA-I) wherein
each occurrence of R.sup.z is selected from hydrogen, halogen or
substituted or unsubstituted alkyl,
[0097] Further preferred is a compound of formula (IA-I) wherein
each occurrence of R.sup.z is selected from hydrogen, fluoro,
chloro, methyl or CF.sub.3.
[0098] Further preferred is a compound of formula (IA-I) wherein X
is N, CR.sup.1 and R.sup.1 is H, substituted or unsubstituted
C.sub.1-6 alkyl, NH.sub.2, OH, CN or CONH.sub.2
[0099] Further preferred is a compound of formula (IA-I) wherein X
is N, CH or C--CH.sub.3.
[0100] Further preferred is a compound of formula (IA-I) wherein X
is N.
[0101] Further preferred is a compound of formula (IA-I) wherein
each occurrence of R.sup.2 is H.
[0102] Further preferred is a compound of formula (IA-I) wherein
each of R.sup.a and R.sup.b is hydrogen, alkyl or halogen.
[0103] Further preferred is a compound of formula (IA-I) wherein
R.sup.a and R.sup.b both are hydrogen.
[0104] Further preferred is a compound of formula (IA-I) wherein
R.sup.a methyl and R.sup.b is hydrogen.
[0105] Further preferred is a compound of formula (IA-I) wherein
R.sup.a is fluoro and R.sup.b is hydrogen.
[0106] Further preferred is a compound of formula (IA-T) wherein
R.sup.a and R.sup.b both are fluoro.
[0107] Further preferred is a compound of formula (IA-I) wherein
R.sup.a and R.sup.b both are methyl.
[0108] Further preferred is a compound of formula (IA-I) wherein Z
is CR.sup.c, N, S, O, HC.dbd.CH--, or --N.dbd.CH--.
[0109] Further preferred is a compound of formula (IA-I) wherein
Z.sub.1 is CH or N.
[0110] Further preferred is a compound of formula (IA-I) wherein
Z.sub.2 is CH or N.
[0111] Further preferred is a compound of formula (IA-I) wherein
Z.sub.3 is CH or N.
[0112] Further preferred is a compound of formula (IA-I) wherein Z
is --HC.dbd.CH--, --S-- or --O--, Z.sub.1 is CH, Z.sub.2 is C; and
Z.sub.3 is C or N.
[0113] Further preferred is a compound of formula (IA-I) wherein Z
is --HC.dbd.CH--, Z.sub.1 is CH, Z.sub.2 is C and Z.sub.3 is C.
[0114] Further preferred is a compound of formula (IA-I) wherein Z
is --CH--, Z.sub.1 is CH, Z.sub.2 is C and Z.sub.3 is N.
[0115] Further preferred is a compound of formula (IA-T) wherein Z
is --S--, Z.sub.1 is CH, Z.sub.2 is C and Z.sub.3 is C.
[0116] Further preferred is a compound of formula (IA-I) wherein Z
is --O--, Z.sub.1 is CH, Z.sub.2 is C and Z.sub.3 is C.
[0117] Further preferred is a compound of formula (IA-I) wherein Z
is --CH--, Z.sub.1 is NH, Z.sub.2 is C and Z.sub.3 is C.
[0118] Further preferred is a compound of formula (IA-I), wherein
each occurrence of R.sup.c is hydrogen or fluoro.
[0119] In one embodiment, in the compound of formula (IA-I), (a)
the bicyclic ring containing ring atoms Z, Z.sub.1, Z.sub.2 and
Z.sub.3 is quinoline, benzo[d]thiazol-6-yl, or an N-oxide thereof,
which is optionally substituted with one or two halogen (e.g., F),
(b) R.sup.a, R.sup.b, and each R.sup.c are hydrogen, (c) each
R.sup.2 is hydrogen, and (d) D is substituted phenyl.
[0120] For example, D may be N-(2-Hydroxy-ethoxy)-benzamide (i.e.,
Ph-CONH--O--CH.sub.2CH.sub.2--OH), where the phenyl group may
optionally be further substituted by one, two, or three
substituents selected from halogens (e.g., F, or Cl), alkyl (e.g.,
methyl or ethyl) and fluorinated methyl (e.g., --CF.sub.3). In one
preferred embodiment, the 2-hydroxy-ethoxy group
(--O--CH.sub.2--CH.sub.2--OH) is at the para-position (relative to
the phenyl group attachment to the bicyclic core). In another
preferred embodiment, the 2-hydroxy ethoxy group is at the
para-position (relative to the phenyl group attachment to the
bicyclic core), and the phenyl group is substituted at one or both
the 3- and 5-positions of the phenyl group with the substituents
independently selected from halogens (such as F or Cl) or alkyl
(such as methyl).
[0121] Alternatively, D can be
##STR00063## ##STR00064## ##STR00065## ##STR00066## ##STR00067##
##STR00068## ##STR00069##
[0122] In one embodiment, the bicyclic ring containing ring atoms Z
and Z.sub.1 in the compound of formula (I-IA) is quinoline or an
N-oxide thereof, which is optionally substituted with one or two
halogen (e.g., F).
[0123] In one embodiment, the bicyclic ring containing ring atoms Z
and Z.sub.1 in the compound of formula (I-IA) is
benzo[d]thiazol-6-yl or an N-oxide thereof, which is optionally
substituted with one or two halogen (e.g., F).
[0124] In one embodiment, the monocyclic ring D containing ring
atoms X, X.sup.1, X.sup.2 and X.sup.3 in the compound of formula
(I-IA) is N-(2-Hydroxy-ethoxy)-benzamide (i.e.,
Ph-CONH--O--CH.sub.2CH.sub.2--OH), where the phenyl group may
optionally be further substituted by one or two substituents
selected from halogens (e.g., F, or Cl), alkanes (e.g., methyl or
ethyl) and fluorinated methyl (e.g., --CF.sub.3).
[0125] In a preferred embodiment, each R.sup.2 is hydrogen.
[0126] In one embodiment the representative compounds of the
present invention include those specified below and
pharmaceutically acceptable salts thereof. The present invention
should not be construed to be limited to them. [0127] 1.
N-(2-amino-2-oxoethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)benzamide [0128] 2.
N-(2-(methylamino)-2-oxoethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triaz-
olo[4,5-b]pyridin-5-yl) benzamide: [0129] 3.
N-(3-amino-3-oxopropyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-
-b]pyridin-5-yl)benzamide: [0130] 4.
N-(3-(methylamino)-3-oxopropyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tria-
zolo[4,5-b]pyridin-5-yl)benzamide: [0131] 5.
2-chloro-N-(2-(pyrrolidin-1-yl)ethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,-
3]triazolo[4,5-b]pyridin-5-yl)benzamide: [0132] 6.
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide: [0133] 6a.
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl) benzamide hydrochloride: [0134] 6b.
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate [0135] 6c.
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[L1,2,3]triazo-
lo[4,5-b]pyridin-5-yl)benzamide hydrobromide: [0136] 6d. sodium
(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)benzoyl)(2-hydroxyethoxy)amide: [0137] 7.
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide: [0138] 7a.
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride: [0139] 7b.
sodium
(2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)benzoyl)(2-hydroxyethoxy)amide: [0140] 7c.
2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3-
]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide: [0141]
8.
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide: [0142] 8a.
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide hydrochloride: [0143] 8b. sodium
(2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-
-5-yl)benzoyl)(2-hydroxyethoxy)amide: [0144] 9.
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide [0145] 9a.
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride [0146]
9b. sodium
(2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triaz-
olo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide: [0147] 10.
2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide: [0148] 11.
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl acetate: [0149] 12.
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-5-yl)benzamidooxy)ethyl 2-(tert-butoxycarbonylamino)propanoate:
[0150] 13.
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)benzamidooxy)ethyl 2-aminopropanoate: [0151] 14.
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl pivalate: [0152] 15.
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl isobutyrate: [0153] 16.
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl 2-benzamidoacetate: [0154] 17.
2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide: [0155] 18.
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2-chloro-N-(2-hydroxyethoxy)benzamide: [0156] 19.
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2,6-difluoro-N-(2-hydroxyethoxy)benzamide: [0157] 19a. sodium
(4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-
-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide: [0158] 20.
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2-fluoro-N-(2-hydroxyethoxy)benzamide: [0159] 21.
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H--
[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [0160] 21a.
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H--
[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride: [0161]
22.
N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)benzamide: [0162] 23.
N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)-2-(trifluoromethyl)benzamide: [0163] 24.
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide: [0164] 24a.
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide hydrochloride:
[0165] 25.
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide: [0166] 25a.
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide hydrochloride: [0167] 25b.
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide hydrobromide: [0168] 25c.
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate: [0169]
25d.
N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl-
)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [0170] 25e.
6-((5-(4-(2-hydroxyethoxycarbamoyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,-
5-b]pyridin-3-yl)methyl)quinoline 1-oxide [0171] 26.
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-methylbenzamide: [0172] 26a.
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride: [0173] 27.
2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide: [0174] 27a.
2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride: [0175] 28.
2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazo-
lo[4,5-b]pyridin-5-yl)benzamide: [0176] 29. ethyl
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)acetate: [0177] 30.
2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide: [0178] 31.
(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide: [0179] 32.
(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide: [0180] 33.
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide: [0181] 34.
2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H--
[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide: [0182] 35.
2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2-
,3]triazolo[4,5-b]pyridin-5-yl)benzamide: [0183] 36.
(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide [0184] 37.
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-
-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [0185]
38.
(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tr-
iazolo[4,5-b]pyridin-5-yl)benzamide [0186] 39.
N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [0187] 40.
2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [0188] 41.
N-(2-hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)--
3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide [0189] 42.
N-hydroxy-2-methyl-4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyri-
din-5-yl)-benzamide [0190] 43.
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl acetate [0191] 44.
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl isobutyrate [0192] 45.
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl pivalate [0193] 46.
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl benzoate [0194] 47.
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamidooxy)ethyl furan-2-carboxylate [0195] 48.
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethanone [0196] 49.
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyl-
idene) hydrazinecarboxamide hydrochloride [0197] 50.
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyl-
idene) hydrazinecarbothioamide [0198] 51.
6-((5-(1-(2-(pyridin-2-yl)hydrazono)ethyl)-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-3-yl)methyl) quinoline [0199] 52.
2-(amino(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)me-
thylene) hydrazinecarboxamide: [0200] 53. tert-butyl
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyl-
idene) hydrazinecarboxylate: [0201] 54.
(E/Z)-1-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethylideneamino)imidazolidine-2,4-dione: [0202] 55.
N-ethyl-2-(1-(3-(quinolin-6-ylmethyl)-3II-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)ethylidene) hydrazinecarbothioamide: [0203] 56.
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyl-
idene) hydrazinecarbothioamide hydrochloride: [0204] 57.
2-(1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)ethylidene) hydrazinecarbothioamide: [0205] 58. Methyl
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyl-
idene) hydrazinecarboxylate: [0206] 59.
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethanone oxime: [0207] 60.
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethanone O-methyl oxime: [0208] 61.
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethanone O-2-hydroxyethyl oxime: [0209] 62.
1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
O-2-hydroxyethyl oxime: [0210] 63.
1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
O-2-aminoethyl oxime: [0211] 64.
1-(2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)
ethylideneaminooxy)ethyl)urea: [0212] 65.
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethanone O-methyl oxime hydrochloride: [0213] 66.
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethanone oxime hydrochloride: [0214] 67.
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethanone O-2-hydroxyethyl oxime hydrochloride: [0215] 68.
N-(3-Dimethylamino-propyl)-4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,-
5-b]pyridin-5-yl)-benzamide dihdrochloride
[0216] In another embodiment the representative compounds of the
present invention include those specified below and
pharmaceutically acceptable salts thereof. The present invention
should not be construed to be limited to them. [0217] 101.
2-chloro-N-(2-(dimethylamino)ethyl)-4-(3-(quinolin-6-ylmethyl)-3II-imidaz-
o[4,5-b]pyridin-5-yl)benzamide: [0218] 102.
2-chloro-N-(3-(dimethylamino)propyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidaz-
o[4,5-b]pyridin-5-yl)benzamide: [0219] 103.
2-chloro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5--
yl)benzamide: [0220] 104.
N-(2-(dimethylamino)ethyl)-2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imi-
dazo[4,5-b]pyridin-5-yl)benzamide: [0221] 105.
2,6-difluoro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridi-
n-5-yl) benzamide: [0222] 106.
1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethanone:
[0223] 107.
2-(1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethylide-
ne) hydrazinecarboxamide: [0224] 108.
2-(1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethylidene)
hydrazinecarbothioamide: [0225] 109.
(R)-2-fluoro-N-(2-hydroxypropyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,-
5-b]pyridin-5-yl)benzamide [0226] 110.
(S)-2-fluoro-N-(2-hydroxypropyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,-
5-b]pyridin-5-yl)benzamide [0227] 111.
N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]p-
yridin-5-yl)-benzamide [0228] 112.
N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3II-imid-
azo[4,5-b]pyridin-5-yl)-benzamide [0229] 113.
2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]p-
yridin-5-yl)-benzamide [0230] 114.
2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imida-
zo[4,5-b]pyridin-5-yl)-benzamide
[0231] In yet another embodiment the representative compounds of
the present invention include those specified below and
pharmaceutically acceptable salts thereof. The present invention
should not be construed to be limited to them. [0232] 1001.
6-((5-(4-carbamoyl-3,5-difluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-
-yl)methyl) quinoline 1-oxide [0233] 1002.
6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-
methyl)-7-fluoroquinoline 1-oxide: [0234] 1003.
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)benzamide 2,2,2-trifluoroacetate: [0235] 1004.
2-chloro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide: [0236] 1005.
2,6-difluoro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]tria-
zolo[4,5-b]pyridin-5-yl)benzamide: [0237] 1006.
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2,6-difluorobenzamide: [0238] 1007.
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl) benzamide: [0239] 1008.
2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzami-
de: [0240] 1009.
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzami-
de hydrochloride: [0241] 1010.
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3II-imidazo[4,5-b]pyridin-5-yl)be-
nzamide: [0242] 1011. Methyl
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoat-
e: [0243] 1012.
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoic
acid: [0244] 1013.
2-chloro-N-ethyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl-
)benzamide: [0245] 1014. Methyl
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ben-
zoate: [0246] 1015.
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ben-
zoic acid: [0247] 1016.
N-ethyl-2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin--
5-yl) benzamide: [0248] 1017.
2-chloro-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-y-
l) benzamide: [0249] 1018.
2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzami-
de: [0250] 1019.
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzami-
de 2,2,2-trifluoroacetate: [0251] 1020.
2-chloro-4-(2-methyl-3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-y-
l) benzamide: [0252] 1021.
2-chloro-4-(3-(1-(quinolin-6-yl)ethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benz-
amide: [0253] 1022.
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-imidazo[4,5-b]pyridin-5--
yl) benzamide: [0254] 1023.
2-chloro-4-(3-((5,7-difluoroquinolin-6-yl)methyl)-3H-imidazo[4,5-b]pyridi-
n-5-yl) benzamide: [0255] 1024.
4-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-2-trifluoromethyl-
-benzamide [0256] 1025.
4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-meth-
yl-benzamide [0257] 1026.
4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-trif-
luoromethyl-benzamide [0258] 1027.
4-[3-(5,7-Difluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2--
methyl-benzamide [0259] 1028.
4-[3-(5,7-Difluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2--
trifluoromethyl-benzamide [0260] 1029.
4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-meth-
yl-benzamide hydrochloride [0261] 1030.
2,N-Dimethyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benz-
amide methylamide [0262] 1031.
5-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-pyridine-2-carbox-
ylic acid [0263] 1032.
5-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,3-dihyd-
ro-isoindol-1-one [0264] 1033.
5-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-2,3-dihydro-isoin-
dol-1-one
TABLE-US-00001 [0264] TABLE 1 Ex. Structure Ex. Structure Ex.
Structure 1 ##STR00070## 7 ##STR00071## 10 ##STR00072## 2
##STR00073## 7a ##STR00074## 11 ##STR00075## 3 ##STR00076## 7b
##STR00077## 12 ##STR00078## 4 ##STR00079## 7c ##STR00080## 13
##STR00081## 5 ##STR00082## 8 ##STR00083## 14 ##STR00084## 6
##STR00085## 8a ##STR00086## 15 ##STR00087## 6a ##STR00088## 8b
##STR00089## 16 ##STR00090## 6b ##STR00091## 9 ##STR00092## 17
##STR00093## 6c ##STR00094## 9a ##STR00095## 18 ##STR00096## 6d
##STR00097## 9b ##STR00098## 19 ##STR00099## 19a ##STR00100## 25b
##STR00101## 30 ##STR00102## 20 ##STR00103## 25c ##STR00104## 31
##STR00105## 21 ##STR00106## 25d ##STR00107## 32 ##STR00108## 21a
##STR00109## 25e ##STR00110## 33 ##STR00111## 22 ##STR00112## 26
##STR00113## 34 ##STR00114## 23 ##STR00115## 26a ##STR00116## 35
##STR00117## 24 ##STR00118## 27 ##STR00119## 36 ##STR00120## 24a
##STR00121## 27a ##STR00122## 37 ##STR00123## 25 ##STR00124## 28
##STR00125## 38 ##STR00126## 25a ##STR00127## 29 ##STR00128## 39
##STR00129## 40 ##STR00130## 50 ##STR00131## 60 ##STR00132## 41
##STR00133## 51 ##STR00134## 61 ##STR00135## 42 ##STR00136## 52
##STR00137## 62 ##STR00138## 43 ##STR00139## 53 ##STR00140## 63
##STR00141## 44 ##STR00142## 54 ##STR00143## 64 ##STR00144## 45
##STR00145## 55 ##STR00146## 65 ##STR00147## 46 ##STR00148## 56
##STR00149## 66 ##STR00150## 47 ##STR00151## 57 ##STR00152## 67
##STR00153## 48 ##STR00154## 58 ##STR00155## 68 ##STR00156## 49
##STR00157## 59 ##STR00158##
TABLE-US-00002 TABLE 2 Ex Structure Ex Structure Ex Structure 101
##STR00159## 106 ##STR00160## 111 ##STR00161## 102 ##STR00162## 107
##STR00163## 112 ##STR00164## 103 ##STR00165## 108 ##STR00166## 113
##STR00167## 104 ##STR00168## 109 ##STR00169## 114 ##STR00170## 105
##STR00171## 110 ##STR00172##
TABLE-US-00003 TABLE 3 Ex Structure Ex Structure Ex Structure 1001
##STR00173## 1012 ##STR00174## 1023 ##STR00175## 1002 ##STR00176##
1013 ##STR00177## 1024 ##STR00178## 1003 ##STR00179## 1014
##STR00180## 1025 ##STR00181## 1004 ##STR00182## 1015 ##STR00183##
1026 ##STR00184## 1005 ##STR00185## 1016 ##STR00186## 1027
##STR00187## 1006 ##STR00188## 1017 ##STR00189## 1028 ##STR00190##
1007 ##STR00191## 1018 ##STR00192## 1029 ##STR00193## 1008
##STR00194## 1019 ##STR00195## 1030 ##STR00196## 1009 ##STR00197##
1020 ##STR00198## 1031 ##STR00199## 1010 ##STR00200## 1021
##STR00201## 1032 ##STR00202## 1011 ##STR00203## 1022 ##STR00204##
1033 ##STR00205##
[0265] Yet another embodiment of the present invention is a method
for treating a proliferative disease via modulation of a protein
kinase (such as c-Met) by administering to a patient in need of
such treatment an effective amount of at least one compound of
formula (I), (IA) or (IA-I) as defined above.
[0266] Yet another embodiment of the present invention is a method
for treating a proliferative disease via modulation of a protein
kinase (such as c-Met) by administering to a patient in need of
such treatment an effective amount of at least one compound of
formula (I), (IA) or (IA-I) as defined above, in combination
(simultaneously or sequentially) with at least one other
anti-cancer agent. In a preferred embodiment, the proliferative
disease is cancer.
[0267] More particularly, the compounds of formula (I), (IA) or
(IA-I) and pharmaceutically acceptable esters or salts thereof can
be administered for the treatment, prevention and/or amelioration
of c-Met, RON, EGFR or KDR kinase associated diseases or disorders,
including but not limited to, cancer and other proliferative
diseases or disorders.
[0268] The compounds of formula (I), (IA) or (IA-I) are useful in
the treatment of a variety of cancers, including, but not limited
to, the following: [0269] carcinoma, including that of the bladder,
breast, colon, kidney, liver, lung, including small cell lung
cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix,
thyroid, prostate, and skin, including squamous cell carcinoma;
[0270] hematopoietic tumors of lymphoid lineage, including
leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia,
B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins
lymphoma, hairy cell lymphoma and Burkett's lymphoma; [0271]
hematopoietic tumors of myeloid lineage, including acute and
chronic myelogenous leukemias, myelodysplastic syndrome and
promyelocytic leukemia; [0272] tumors of mesenchymal origin,
including fibrosarcoma and rhabdomyosarcoma; [0273] tumors of the
central and peripheral nervous system, including astrocytoma,
neuroblastoma, glioma and schwannomas; and [0274] other tumors,
including melanoma, seminoma, teratocarcinoma, osteosarcoma,
xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer
and Kaposi's sarcoma.
[0275] Due to the key role of protein kinases in the regulation of
cellular proliferation in general, inhibitors could act as
reversible cytostatic agents which may be useful in the treatment
of any disease process which features abnormal cellular
proliferation, e.g., benign prostatic hyperplasia, familial
adenomatosis polyposis, neuro-fibromatosis, atherosclerosis,
pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis,
restenosis following angioplasty or vascular surgery, hypertrophic
scar formation, inflammatory bowel disease, transplantation
rejection, endotoxic shock, and fungal infections.
[0276] The compounds of the present invention as modulators of
apoptosis, are useful in the treatment of cancer (including but not
limited to those types mentioned herein above), viral infections
(including but not limited to herpevirus, poxvirus, Epstein-Barr
virus, Sindbis virus and adenovirus), prevention of AIDS
development in HIV-infected individuals, autoimmune diseases
(including but not limited to systemic lupus, erythematosus,
autoimmune mediated glomerulonephritis, rheumatoid arthritis,
psoriasis, inflammatory bowel disease, and autoimmune diabetes
mellitus), neurodegenerative disorders (including but not limited
to Alzheimer's disease, AIDS-related dementia, Parkinson's disease,
amyotrophic lateral sclerosis, retinitis pigmentosa, spinal
muscular atrophy and cerebellar degeneration), myelodysplastic
syndromes, aplastic anemia, ischemic injury associated with
myocardial infarctions, stroke and reperfusion injury, arrhythmia,
atherosclerosis, toxin-induced or alcohol related liver diseases,
hematological diseases (including but not limited to chronic anemia
and aplastic anemia), degenerative diseases of the musculoskeletal
system (including but not limited to osteoporosis and arthritis)
aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple
sclerosis, kidney diseases and cancer pain.
[0277] The compounds of present invention can modulate the level of
cellular RNA and DNA synthesis. These agents are therefore useful
in the treatment of viral infections (including but not limited to
HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr
virus, Sindbis virus and adenovirus).
[0278] The compounds of the present invention are useful in the
chemoprevention of cancer. Chemoprevention is defined as inhibiting
the development of invasive cancer by either blocking the
initiating mutagenic event or by blocking the progression of
pre-malignant cells that have already suffered an insult or
inhibiting tumor relapse. The compounds are also useful in
inhibiting tumor angiogenesis and metastasis. One embodiment of the
invention is a method of inhibiting tumor angiogenesis or
metastasis in a patient in need thereof by administering an
effective amount of one or more compounds of the present
invention.
[0279] Another embodiment of the present invention is a method of
treating an immune system-related disease (e.g., an autoimmune
disease), a disease or disorder involving inflammation (e.g.,
asthma, chronic obstructive pulmonary disease, rheumatoid
arthritis, inflammatory bowel disease, glomerulonephritis,
neuroinflammatory diseases, multiple sclerosis, uveitis and
disorders of the immune system), cancer or other proliferative
disease, a hepatic disease or disorder, a renal disease or
disorder. The method includes administering an effective amount of
one or more compounds of the present invention.
[0280] Examples of immune disorders include psoriasis, rheumatoid
arthritis, vasculitis, inflammatory bowel disease, dermatitis,
osteoarthritis, asthma, inflammatory muscle disease, allergic
rhinitis, vaginitis, interstitial cystitis, scleroderma,
osteoporosis, eczema, allogeneic or xenogeneic transplantation
(organ, bone marrow, stem cells and other cells and tissues) graft
rejection, graft-versus-host disease, lupus erythematosus,
inflammatory disease, type I diabetes, pulmonary fibrosis,
dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's
and autoimmune thyroiditis), myasthenia gravis, autoimmune
hemolytic anemia, multiple sclerosis, cystic fibrosis, chronic
relapsing hepatitis, primary biliary cirrhosis, allergic
conjunctivitis and atopic dermatitis.
[0281] In one embodiment, the compounds described herein are used
as immunosuppressants to prevent transplant graft rejections,
allogeneic or xenogeneic transplantation rejection (organ, bone
marrow, stem cells, other cells and tissues), and
graft--versus--host disease. In other embodiments, transplant graft
rejections result from tissue or organ transplants. In further
embodiments, graft-versus-host disease results from bone marrow or
stem cell transplantation. One embodiment is a method of preventing
or decreasing the risk of transplant graft rejection, allogeneic or
xenogeneic transplantation rejection (organ, bone marrow, stem
cells, other cells and tissues), or graft--versus--host disease by
administering an effective amount of one or more compounds of the
present invention.
[0282] The compounds of the present invention are also useful in
combination (administered together or sequentially) with known
anti-cancer treatments such as radiation therapy or with cytostatic
or cytotoxic or anticancer agents, such as for example, but not
limited to, DNA interactive agents, such as cisplatin or
doxorubicin; topoisomerase II inhibitors, such as etoposide;
topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin
interacting agents, such as paclitaxel, docetaxel or the
epothilones (for example ixabepilone), either naturally occurring
or synthetic; hormonal agents, such as tamoxifen; thymidilate
synthase inhibitors, such as 5-fluorouracil; and anti-metabolites,
such as methotrexate, other tyrosine kinase inhibitors such as
Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF
inhibitors; CDK inhibitors; SRC inhibitors; c-Kit inhibitors;
Her1/2 inhibitors and monoclonal antibodies directed against growth
factor receptors such as erbitux (EGF) and herceptin (Her2) and
other protein kinase modulators as well.
[0283] The compounds of the present invention are also useful in
combination (administered together or sequentially) with one or
more steroidal anti-inflammatory drugs, non-steroidal
anti-inflammatory drugs (NSAIDs) or Immune Selective
Anti-Inflammatory Derivatives (ImSAIDs).
[0284] The invention further provides a pharmaceutical composition
comprising one or more compounds of the present invention (such as
a compound having formula (I), (IA) or (IA-I) together with a
pharmaceutically acceptable carrier. The pharmaceutical composition
may further comprise one or more of the active ingredients
identified above, such as other anti-cancer agents. In one
embodiment, the pharmaceutical composition includes a
therapeutically effective amount of one or more compounds of
formula (I), (IA) or (IA-I).
[0285] Yet another embodiment is a method of treating leukemia in a
patient in need thereof by administering a therapeutically
effective amount of a compound of the present invention. For
example, the compounds of the present invention are effective for
treating carcinoma of the bladder, carcinoma of the breast,
carcinoma of the colon, carcinoma of the kidney, carcinoma of the
liver, carcinoma of the lung, small cell lung cancer, esophageal
cancer, gall bladder cancer, ovarian cancer, pancreatic cancer,
stomach cancer, cervical cancer, thyroid cancer, prostate cancer,
skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer,
tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma;
tumors of the central and peripheral nervous system, astrocytoma,
neuroblastoma, glioma, schwannoma; melanoma, seminoma,
teratocarcinoma, osteosarcoma, xenoderoma pigmentosum,
keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma,
synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma,
leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma,
astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic
tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia,
acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma,
Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and
Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute
myelogenous leukemias, chronic myelogenous leukemias,
myelodysplastic syndrome, promyelocytic leukemia.
[0286] Yet another embodiment is a pharmaceutical composition
comprising one or more compounds having formula (I), (IA) or (IA-I)
together with a pharmaceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION
[0287] As used herein the following definition shall apply unless
otherwise indicated. Further many of the groups defined herein can
be optionally substituted. The listing of substituents in the
definition is exemplary and is not to be construed to limit the
substituents defined elsewhere in the specification.
[0288] The term `alkyl` refers to a straight or branched
hydrocarbon chain radical consisting solely of carbon and hydrogen
atoms, containing no unsaturation, having from one to eight carbon
atoms, and which is attached to the rest of the molecule by a
single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl
(isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl
(t-butyl).
[0289] The term substituted or unsubstituted (C.sub.1-3) alkyl
refers to an alkyl group as defined above having up to 3 carbon
atoms The term substituted or unsubstituted (C.sub.1-4) alkyl
refers to an alkyl group as defined above having up to 4 carbon
atoms, and the term substituted or unsubstituted (C.sub.1-6) alkyl
refers to an alkyl group as defined above having up to 6 carbon
atoms.
[0290] The term "alkenyl" refers to an aliphatic hydrocarbon group
containing a carbon-carbon double bond and which may be a straight
or branched or branched chain having about 2 to about 10 carbon
atoms, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl,
2-methyl-1-propenyl, 1-butenyl, and 2-butenyl.
[0291] The term substituted or unsubstituted (C.sub.1-6) alkenyl
refers to an alkenyl group as defined above having up to 4 carbon
atoms.
[0292] The term "alkynyl" refers to a straight or branched chain
hydrocarbyl radicals having at least one carbon-carbon triple bond,
and having in the range of about 2 up to 12 carbon atoms (with
radicals having in the range of about 2 up to 10 carbon atoms
presently being preferred) e.g., ethynyl, propynyl, and butnyl.
[0293] The term substituted or unsubstituted (C.sub.1-6) alkynyl
refers to an alkynyl group as defined above having up to 4 carbon
atoms.
[0294] The term "alkoxy" denotes an alkyl group as defined above
attached via an oxygen linkage to the rest of the molecule.
Representative examples of these groups are --OCH.sub.3 and
--OC.sub.2H.sub.5. The term "substituted alkoxy" refers to an
alkoxy group where the alkyl constituent is substituted (i.e.,
--O-(substituted alkyl) wherein the term "substituted alkyl" is the
same as defined above for "alkyl". For example "alkoxy" refers to
the group --O-alkyl, including from 1 to 8 carbon atoms of a
straight, branched, cyclic configuration and combinations thereof
attached to the parent structure through oxygen. Examples include
methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, and
cyclohexyloxy.
[0295] The term "C.sub.1-3 alkoxy" refers to an alkoxy group as
defined above having up to 3 atoms.
[0296] The term "cycloalkyl" denotes a non-aromatic mono or
multicyclic ring system of about 3 to 12 carbon atoms such as
cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of
multicyclic cycloalkyl groups include perhydronapththyl, adamantyl
and norbornyl groups, bridged cyclic groups, and sprirobicyclic
groups, e.g., sprio (4,4) non-2-yl.
[0297] The term "C.sub.3-8 cycloalkyl" refers to a cycloalkyl group
as defined above having up to 6 atoms.
[0298] The term "cycloalkylalkyl" refers to a cyclic
ring-containing radical containing in the range of about 3 up to 8
carbon atoms directly attached to an alkyl group which are then
attached to the main structure at any carbon from alkyl group that
results in the creation of a stable structure such as
cyclopropylmethyl, cyclobuyylethyl, and cyclopentylethyl.
[0299] The term "C.sub.3-6 cycloalkylalkyl" refers to a
cycloalkylalkyl group as defined above having up to 6 atoms.
[0300] The term "cycloalkenyl" refers to cyclic ring-containing
radicals containing in the range of about 3 up to 8 carbon atoms
with at least one carbon-carbon double bond, such as cyclopropenyl,
cyclobutenyl, and cyclopentenyl. The term "cycloalkenylalkyl"
refers to a cycloalkenyl group directly attached to an alkyl group
which are then attached to the main structure at any carbon from
alkyl group that results in the creation of a stable structure
[0301] The term "C.sub.3-6 cycloalkenyl" refers to a cycloalkenyl
group as defined above having up to 6 atoms.
[0302] The term "aryl" refers to aromatic radicals having in the
range of 6 up to 20 carbon atoms such as phenyl, naphthyl,
tetrahydronapthyl, indanyl, and biphenyl.
[0303] The term "arylalkyl" refers to an aryl group as defined
above directly bonded to an alkyl group as defined above. e.g.,
--CH.sub.2C.sub.6H.sub.5 and --C.sub.2H.sub.5C.sub.6H.sub.5.
[0304] The term "heterocyclic ring" refers to a non-aromatic 3 to
15 member ring radical which, consists of carbon atoms and at least
one heteroatom selected from the group consisting of nitrogen,
phosphorus, oxygen and sulfur. For purposes of this invention, the
heterocyclic ring radical may be a mono-, bi-, tri- or tetracyclic
ring system, which may include fused, bridged or spiro ring
systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur
atoms in the heterocyclic ring radical may be optionally oxidized
to various oxidation states. In addition, the nitrogen atom may be
optionally quaternized. The heterocyclic ring radical may be
attached to the main structure at any heteroatom or carbon atom
that results in the creation of a stable structure.
[0305] The term "heterocyclyl" refers to a heterocylic ring radical
as defined above. The heterocylcyl ring radical may be attached to
the main structure at any heteroatom or carbon atom that results in
the creation of a stable structure.
[0306] The term "heterocyclylalkyl" refers to a heterocylic ring
radical as defined above directly bonded to an alkyl group. The
heterocyclylalkyl radical may be attached to the main structure at
carbon atom in the alkyl group that results in the creation of a
stable structure. Examples of such heterocycloalkyl radicals
include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl,
decahydroisoquinolyl, imidazolinyl, imidazolidinyl,
isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl,
octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl,
4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,
thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,
thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and
1,1-dioxo-thiomorpholinyl.
[0307] The term "heteroaryl" refers to an optionally substituted 5
to 14 member aromatic ring having one or more heteroatoms selected
from N, O, and S as ring atoms. The heteroaryl may be a mono-, bi-
or tricyclic ring system. Examples of such "heterocyclic ring" or
"heteroaryl" radicals include, but are not limited to, oxazolyl,
thiazolyl, imidazolyl, pyrrolyl, furanyl, pyridinyl, pyrimidinyl,
pyrazinyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl,
carbazolyl, quinolyl, isoquinolyl, azetidinyl, acridinyl,
benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl,
dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl,
phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl,
purinyl, quinazolinyl, quinoxalinyl, tetrazoyl,
tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl,
2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl,
4-piperidonyl, pyrrolidinyl, pyridazinyl, oxazolinyl, oxazolidinyl,
triazolyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl,
thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl,
isothiazolidinyl, isoindolyl, indolinyl, isoindolinyl,
octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl,
benzimidazolyl, thiadiazolyl, benzopyranyl, tetrahydrofuryl,
tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl,
thiamorpholinyl sulfoxide, thiamorpholinyl sulfone,
dioxaphospholanyl, oxadiazolyl, chromanyl, and isochromanyl. The
heteroaryl ring radical may be attached to the main structure at
any heteroatom or carbon atom that results in the creation of a
stable structure. The term "substituted heteroaryl" also includes
ring systems substituted with one or more oxide (--O--)
substituents, such as pyridinyl N-oxides.
[0308] The term "heteroarylalkyl" refers to heteroaryl ring radical
as defined above directly bonded to an alkyl group. The
heteroarylalkyl radical may be attached to the main structure at
any carbon atom from alkyl group that results in the creation of a
stable structure.
[0309] The term "heterocyclylalkyl" refers to a heterocylic ring
radical as defined above directly bonded to an alkyl group. The
heterocyclylalkyl radical may be attached to the main structure at
carbon atom in the alkyl group that results in the creation of a
stable structure.
[0310] The term "cyclic ring" refers to a cyclic ring containing
3-10 carbon atoms.
[0311] The term "substituted" unless otherwise specified, refers to
substitution with any one or any combination of the following
substituents and may be the same or different which one or more are
selected from the groups such as hydrogen, hydroxy, halogen,
carboxyl, cyano, nitro, oxo (.dbd.O), thio (.dbd.S), substituted or
unsubstituted alkyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted
cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl,
substituted or unsubstituted heterocycyl, substituted or
unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl,
substituted or unsubstituted arylalkyl, substituted or
unsubstituted heteroaryl, substituted or unsubstituted
heteroarylalkyl, --COOR', --C(O)R', --C(S)R', --C(O)NR'R'',
--C(O)ONR'R'', --NR'R'', --NR'CONR'R'', --N(R')SOR'',
--N(R')SO.sub.2R'', --(.dbd.N--N(R')R''), --NR'C(O)OR'', --NR'R'',
--NR'C(O)R''--, --NR'C(S)R''--NR'C(S)NR''R''', --SONR'R''--,
--SO.sub.2NR'R''--, --OR', --OR'C(O)NR''R''', --OR'C(O)OR''--,
--OC(O)R', --OC(O)NR'R'', --R'NR''C(O)R''', --R'OR'', --R'C(O)OR'',
--R'C(O)NR''R''', --R'C(O)R''--R'OC(O)R'', --SR', --SOR',
--SO.sub.2R', --ONO.sub.2 wherein R', R'' and R''' in each of the
above groups can be hydrogen, hydrogen, hydroxy, halogen, carboxyl,
cyano, nitro, oxo (.dbd.O), thio (.dbd.S), imino (.dbd.NR'),
substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or
unsubstituted alkynyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted cycloalkenyl, substituted or
unsubstituted cycloalkylalkyl, substituted or unsubstituted
cycloalkenylalkyl, substituted or unsubstituted heterocycyl,
substituted or unsubstituted heterocyclcyalkyl, substituted or
unsubstituted aryl, substituted or unsubstituted arylalkyl,
substituted or unsubstituted heteroaryl, substituted or
unsubstituted heteroarylalkyl, or any two of R', R'' and R''' may
be joined to form a substituted or unsubstituted saturated or
unsaturated 3-10 membered ring, which may optionally include
heteroatoms which may be the same or different and are selected
from O, NR.sup.X or S or form oxo (.dbd.O), thio (.dbd.S) or imino
(.dbd.NR'). Substitution or the combinations of substituents
envisioned by this invention are preferably those that result in
the formation of a stable or chemically feasible compound. The term
stable as used herein refers to the compounds or the structure that
are not substantially altered when subjected to conditions to allow
for their isolation, production, detection and preferably their
recovery, purification and incorporation into a pharmaceutical
composition.
[0312] The term "halo", "halide", or, alternatively, "halogen"
means fluoro, chloro, bromo or iodo. The terms "haloalkyl,"
"haloalkenyl," "haloalkynyl" and "haloalkoxy" include alkyl,
alkenyl, alkynyl and alkoxy structures that are substituted with
one or more halo groups or with combinations thereof. For example,
the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and
haloalkoxy groups, respectively, in which the halo is fluorine.
[0313] The term "protecting group" or "PG" refers to a substituent
that is employed to block or protect a particular functionality.
Other functional groups on the compound may remain reactive. For
example, an "amino-protecting group" is a substituent attached to
an amino group that blocks or protects the amino functionality in
the compound. Suitable amino-protecting groups include, but are not
limited to, acetyl, trifluoroacetyl, tert-butoxycarbonyl (BOC),
benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc).
Similarly, a "hydroxy-protecting group" refers to a substituent of
a hydroxy group that blocks or protects the hydroxy functionality.
Suitable hydroxy-protecting groups include, but are not limited to,
acetyl and silyl. A "carboxy-protecting group" refers to a
substituent of the carboxy group that blocks or protects the
carboxy functionality. Suitable carboxy-protecting groups include,
but are not limited to, --CH.sub.2CH.sub.2SO.sub.2Ph, cyanoethyl,
2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl,
-2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl,
2-(diphenylphosphino)-ethyl, and nitroethyl. For a general
description of protecting groups and their use, see T. W. Greene,
Protective Groups in Organic Synthesis, John Wiley & Sons, New
York, 1991.
[0314] The term "stereoisomer" refers to compounds, which have
identical chemical composition, but differ with regard to
arrangement of the atoms and the groups in space. These include
enantiomers, diastereomers, geometrical isomers, atropisomer or
conformational isomers.
[0315] All the stereoisomers of compounds described herein are
within the scope of this invention. Racemic mixtures are also
encompassed within the scope of this invention. Therefore, single
stereochemical isomers as well enantiomeric, diastereoisomeric and
geometric (or conformational) mixtures of the present compounds
fall within the scope of the invention.
[0316] Certain of the compounds described herein contain one or
more asymmetric centers and can thus give rise to enantiomers,
diastereomers, and other stereoisomeric forms that can be defined,
in terms of absolute stereochemistry, as (R)- or (S)-. The present
chemical entities, pharmaceutical compositions and methods are
meant to include all such possible isomers, including racemic
mixtures, optically pure forms and intermediate mixtures. For the
instance the non-limiting example of intermediate mixtures include
a mixture of isomers in a ratio of 10:90, 13:87, 17:83, 20:80, or
22:78. Optically active (R)- and (S)-isomers can be prepared using
chiral synthons or chiral reagents, or resolved using conventional
techniques. When the compounds described herein contain olefinic
double bonds or other centers of geometric asymmetry, and unless
specified otherwise, it is intended that the compounds include both
E and Z geometric isomers.
[0317] The term "tautomers" refers to compounds, which are
characterized by relatively easy interconversion of isomeric forms
in equilibrium. These isomers are intended to be covered by this
invention. "Tautomers" are structurally distinct isomers that
interconvert by tautomerization. "Tautomerization" is a form of
isomerization and includes prototropic or proton-shift
tautomerization, which is considered a subset of acid-base
chemistry. "Prototropic tautomerization" or "proton-shift
tautomerization" involves the migration of a proton accompanied by
changes in bond order, often the interchange of a single bond with
an adjacent double bond. Where tautomerization is possible (e.g. in
solution), a chemical equilibrium of tautomers can be reached. An
example of tautomerization is keto-enol tautomerization. A specific
example of keto-enol tautomerization is the interconversion of
pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another
example of tautomerization is phenol-keto tautomerization. A
specific example of phenol-keto tautomerization is the
interconversion of pyridin-4-ol and pyridin-4(1H)-one
tautomers.
[0318] A "leaving group or atom" is any group or atom that will,
under the reaction conditions, cleave from the starting material,
thus promoting reaction at a specified site. Suitable examples of
such groups unless otherwise specified are halogen atoms and
mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups.
[0319] The term "prodrug" refers to a compound, which is an
inactive precursor of a compound, converted into its active form in
the body by normal metabolic processes. Prodrug design is discussed
generally in Hardma, et al. (Eds.), Goodman and Gilman's The
Pharmacological Basis of Therapeutics, 9th ed., pp. 11-16 (1996). A
thorough discussion is provided in Higuchi, et al., Prodrugs as
Novel Delivery Systems, Vol. 14, ASCD Symposium Series, and in
Roche (ed.), Bioreversible Carriers in Drug Design, American
Pharmaceutical Association and Pergamon Press (1987). To
illustrate, prodrugs can be converted into a pharmacologically
active form through hydrolysis of, for example, an ester or amide
linkage, thereby introducing or exposing a functional group on the
resultant product. The prodrugs can be designed to react with an
endogenous compound to form a water-soluble conjugate that further
enhances the pharmacological properties of the compound, for
example, increased circulatory half-life. Alternatively, prodrugs
can be designed to undergo covalent modification on a functional
group with, for example, glucuronic acid, sulfate, glutathione,
amino acids, or acetate. The resulting conjugate can be inactivated
and excreted in the urine, or rendered more potent than the parent
compound. High molecular weight conjugates also can be excreted
into the bile, subjected to enzymatic cleavage, and released back
into the circulation, thereby effectively increasing the biological
half-life of the originally administered compound.
[0320] The term "ester" refers to a compound, which is formed by
reaction between an acid and an alcohol with elimination of water.
An ester can be represented by the general formula RCOOR'.
[0321] These prodrugs and esters are intended to be covered within
the scope of this invention.
[0322] Additionally the instant invention also includes the
compounds which differ only in the presence of one or more
isotopically enriched atoms for example replacement of hydrogen
with deuterium or tritium, or the replacement of a carbon by
.sup.13C- or .sup.14C-enriched carbon.
[0323] The compounds of the present invention may also contain
unnatural proportions of atomic isotopes at one or more of atoms
that constitute such compounds. For example, the compounds may be
radiolabeled with radioactive isotopes, such as for example tritium
(.sup.3H), iodine-125 (.sup.125I) or carbon-14 (.sup.14C). All
isotopic variations of the compounds of the present invention,
whether radioactive or not, are encompassed within the scope of the
present invention.
[0324] Pharmaceutically acceptable salts forming part of this
invention include salts derived from inorganic bases such as Li,
Na, K, Ca, Mg, Fe, Cu, Zn, and Mn; salts of organic bases such as
N,N'-diacetylethylenediamine, glucamine, triethylamine, choline,
hydroxide, dicyclohexylamine, metformin, benzylamine,
trialkylamine, and thiamine; chiral bases such as alkylphenylamine,
glycinol, and phenyl glycinol; salts of natural amino acids such as
glycine, alanine, valine, leucine, isoleucine, norleucine,
tyrosine, cystine, cysteine, methionine, proline, hydroxy proline,
histidine, omithine, lysine, arginine, and serine; quaternary
ammonium salts of the compounds of invention with alkyl halides,
alkyl sulphates such as MeI and (Me).sub.2SO.sub.4; non-natural
amino acids such as D-isomers or substituted amino acids;
guanidine; and substituted guanidine wherein the substituents are
selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or
substituted ammonium salts and aluminum salts. Salts may include
acid addition salts where appropriate which are sulphates,
nitrates, phosphates, perchlorates, borates, hydrohalides,
acetates, tartrates, maleates, citrates, fumarates, succinates,
palmoates, methanesulphonates, benzoates, salicylates,
benzenesulfonates, ascorbates, glycerophosphates, and
ketoglutarates.
[0325] When ranges are used herein for physical properties, such as
molecular weight, or chemical properties, such as chemical
formulae, all combinations and subcombinations of ranges and
specific embodiments therein are intended to be included. The term
"about" when referring to a number or a numerical range means that
the number or numerical range referred to is an approximation
within experimental variability (or within statistical experimental
error), and thus the number or numerical range may vary from, for
example, between 1% and 15% of the stated number or numerical
range. The term "comprising" (and related terms such as "comprise"
or "comprises" or "having" or "including") includes those
embodiments, for example, an embodiment of any composition of
matter, composition, method, or process, or the like, that "consist
of" or "consist essentially of" the described features.
[0326] The following abbreviations and terms have the indicated
meanings throughout: HGFR is hepatocyte growth factor receptor;
AIDS=Acquired Immuno Deficiency Syndrome; HIV=Human
Immunodeficiency Virus; MeI=Methyl Iodide; POCI.sub.3=Phosphorous
Oxychloride; KCNS=Potassium IsoThiocyanate; TLC=Thin Layer
Chromatography; MeOH=Methanol; and CHCI.sub.3=Chloroform.
[0327] Abbreviations used herein have their conventional meaning
within the chemical and biological arts.
[0328] The term "cell proliferation" refers to a phenomenon by
which the cell number has changed as a result of division. This
term also encompasses cell growth by which the cell morphology has
changed (e.g., increased in size) consistent with a proliferative
signal.
[0329] The term "co-administration," "administered in combination
with," and their grammatical equivalents, as used herein,
encompasses administration of two or more agents to an animal so
that both agents and/or their metabolites are present in the animal
at the same time. Co-administration includes simultaneous
administration in separate compositions, administration at
different times in separate compositions, or administration in a
composition in which both agents are present.
[0330] The term "effective amount" or "therapeutically effective
amount" refers to that amount of a compound described herein that
is sufficient to effect the intended application including but not
limited to disease treatment, as defined below. The therapeutically
effective amount may vary depending upon the intended application
(in vitro or in vivo), or the subject and disease condition being
treated, e.g., the weight and age of the subject, the severity of
the disease condition, the manner of administration and the like,
which can readily be determined by one of ordinary skill in the
art. The term also applies to a dose that will induce a particular
response in target cells, e.g. reduction of platelet adhesion
and/or cell migration. The specific dose will vary depending on the
particular compounds chosen, the dosing regimen to be followed,
whether it is administered in combination with other compounds,
timing of administration, the tissue to which it is administered,
and the physical delivery system in which it is carried.
[0331] As used herein, "treatment," "treating," or "ameliorating"
are used interchangeably. These terms refers to an approach for
obtaining beneficial or desired results including but not limited
to therapeutic benefit and/or a prophylactic benefit. By
therapeutic benefit is meant eradication or amelioration of the
underlying disorder being treated. Also, a therapeutic benefit is
achieved with the eradication or amelioration of one or more of the
physiological symptoms associated with the underlying disorder such
that an improvement is observed in the patient, notwithstanding
that the patient may still be afflicted with the underlying
disorder. For prophylactic benefit, the compositions may be
administered to a patient at risk of developing a particular
disease, or to a patient reporting one or more of the physiological
symptoms of a disease, even though a diagnosis of this disease may
not have been made.
[0332] A "therapeutic effect," as that term is used herein,
encompasses a therapeutic benefit and/or a prophylactic benefit as
described above. A prophylactic effect includes delaying or
eliminating the appearance of a disease or condition, delaying or
eliminating the onset of symptoms of a disease or condition,
slowing, halting, or reversing the progression of a disease or
condition, or any combination thereof.
[0333] The term "subject" or "patient" refers to an animal, such as
a mammal, for example a human. The methods described herein can be
useful in both human therapeutics and veterinary applications. In
some embodiments, the patient is a mammal, and in some embodiments,
the patient is human.
[0334] "Radiation therapy" means exposing a patient, using routine
methods and compositions known to the practitioner, to radiation
emitters such as alpha-particle emitting radionuclides (e.g.,
actinium and thorium radionuclides), low linear energy transfer
(LET) radiation emitters (i.e. beta emitters), conversion electron
emitters (e.g. strontium-89 and samarium-153-EDTMP, or high-energy
radiation, including without limitation x-rays, gamma rays, and
neutrons.
[0335] "Signal transduction" is a process during which stimulatory
or inhibitory signals are transmitted into and within a cell to
elicit an intracellular response. A modulator of a signal
transduction pathway refers to a compound which modulates the
activity of one or more cellular proteins mapped to the same
specific signal transduction pathway. A modulator may augment
(agonist) or suppress (antagonist) the activity of a signaling
molecule.
[0336] The term "selective inhibition" or "selectively inhibit" as
applied to a biologically active agent refers to the agent's
ability to selectively reduce the target signaling activity as
compared to off-target signaling activity, via direct or indirect
interaction with the target.
[0337] The term "pharmaceutically acceptable carrier" or
"pharmaceutically acceptable excipient" includes, but is not
limited to, any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption
delaying agents, one or more suitable diluents, fillers, salts,
disintegrants, binders, lubricants, glidants, wetting agents,
controlled release matrices, colorants/flavoring, carriers,
excipients, buffers, stabilizers, solubilizers, and combinations
thereof. Except insofar as any conventional media or agent is
incompatible with the active ingredient, its use in the therapeutic
compositions of the invention is contemplated. Supplementary active
ingredients can also be incorporated into the compositions.
[0338] Inhibition of c-met kinase may be of therapeutic benefit in
treatment of various conditions, e.g., conditions characterized by
an inflammatory response including but not limited to autoimnmune
diseases, allergic diseases, and arthritic diseases.
[0339] "Inflammatory response" as used herein is characterized by
redness, heat, swelling and pain (i.e., inflammation) and typically
involves tissue injury or destruction. An inflammatory response is
usually a localized, protective response elicited by injury or
destruction of tissues, which serves to destroy, dilute or wall off
(sequester) both the injurious agent and the injured tissue.
Inflammatory responses are notably associated with the influx of
leukocytes and/or leukocyte (e.g., neutrophil) chemotaxis.
Inflammatory responses may result from infection with pathogenic
organisms and viruses, noninfectious means such as trauma or
reperfusion following myocardial infarction or stroke, immune
responses to foreign antigens, and autoimmune diseases.
Inflammatory responses amenable to treatment with the methods and
compounds according to the invention encompass conditions
associated with reactions of the specific defense system as well as
conditions associated with reactions of the non-specific defense
system.
[0340] The therapeutic methods of the invention include methods for
the amelioration of conditions associated with inflammatory cell
activation. "Inflammatory cell activation" refers to the induction
by a stimulus (including but not limited to, cytokines, antigens or
auto-antibodies) of a proliferative cellular response, the
production of soluble mediators (including but not limited to
cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive
amines), or cell surface expression of new or increased numbers of
mediators (including but not limited to, major histocompatibility
antigens or cell adhesion molecules) in inflammatory cells
(including but not limited to monocytes, macrophages, T
lymphocytes, B lymphocytes, granulocytes (polymorphonuclear
leukocytes including neutrophils, basophils, and eosinophils) mast
cells, dendritic cells, Langerhans cells, and endothelial cells).
It will be appreciated by persons skilled in the art that the
activation of one or a combination of these phenotypes in these
cells can contribute to the initiation, perpetuation, or
exacerbation of an inflammatory condition.
[0341] "Autoimmune disease" as used herein refers to any group of
disorders in which tissue injury is associated with humoral or
cell-mediated responses to the body's own constituents. "Transplant
rejection" as used herein refers-to any immune response directed
against grafted tissue (including organs or cells (e.g., bone
marrow), characterized by a loss of function of the grafted and
surrounding tissues, pain, swelling, leukocytosis, and
thrombocytopenia). "Allergic disease" as used herein refers to any
symptoms, tissue damage, or loss of tissue function resulting from
allergy. "Arthritic disease" as used herein refers to any disease
that is characterized by inflammatory lesions of the joints
attributable to a variety of etiologies. "Dermatitis" as used
herein refers to any of a large family of diseases of the skin that
are characterized by inflammation of the skin attributable to a
variety of etiologies.
[0342] The relative efficacies of compounds as inhibitors of an
enzyme activity (or other biological activity) can be established
by determining the concentrations at which each compound inhibits
the activity to a predefined extent and then comparing the results.
Typically, the preferred determination is the concentration that
inhibits 50% of the activity in a biochemical assay, i.e., the 50%
inhibitory concentration or "IC50". IC50 determinations can be
accomplished using conventional techniques known in the art. In
general, an IC50 can be determined by measuring the activity of a
given enzyme in the presence of a range of concentrations of the
inhibitor under study. The experimentally obtained values of enzyme
activity then are plotted against the inhibitor concentrations
used. The concentration of the inhibitor that shows 50% enzyme
activity (as compared to the activity in the absence of any
inhibitor) is taken as the IC50 value. Analogously, other
inhibitory concentrations can be defined through appropriate
determinations of activity. For example, in some settings it can be
desirable to establish a 90% inhibitory concentration, i.e., IC90,
etc.
[0343] Accordingly, a c-met selective inhibitor alternatively can
be understood to refer to a compound that exhibits a 50% inhibitory
concentration (IC50) with respect to c-met kinase, that is at least
10-fold, in another aspect at least 20-fold, and in another aspect
at least 30-fold, lower than the IC50 value with respect to any or
all of the other class receptor tyrosine kinase (RTK) family
members. In an alternative embodiment of the invention, the term
c-met kinase selective inhibitor can be understood to refer to a
compound that exhibits an IC50 with respect to c-met kinase that is
at least 50-fold, in another aspect at least 100-fold, in an
additional aspect at least 200-fold, and in yet another aspect at
least 500-fold, lower than the IC50 with respect to any or all of
the other RTK family members. A c-met kinase selective inhibitor is
typically administered in an amount such that it selectively
inhibits c-met activity, as described above.
[0344] The methods of the invention may be applied to cell
populations in vivo or ex vivo. "In vivo" means within a living
individual, as within an animal or human or in a subject's body. In
this context, the methods of the invention may be used
therapeutically or prophylactically in an individual. "Ex vivo" or
"In vitro" means outside of a living individual. Examples of ex
vivo cell populations include in vitro cell cultures and biological
samples including but not limited to fluid or tissue samples
obtained from individuals. Such samples may be obtained by methods
known in the art. Exemplary biological fluid samples include blood,
cerebrospinal fluid, urine, and saliva. Exemplary tissue samples
include tumors and biopsies thereof. In this context, the invention
may be used for a variety of purposes, including therapeutic and
experimental purposes. For example, the invention may be used ex
vivo or in vitro to determine the optimal schedule and/or dosing of
administration of a c-met kinase selective inhibitor for a given
indication, cell type, individual, and other parameters.
Information gleaned from such use may be used for experimental or
diagnostic purposes or in the clinic to set protocols for in vivo
treatment. Other ex vivo uses for which the invention may be suited
are described below or will become apparent to those skilled in the
art.
Pharmaceutical Compositions
[0345] The invention provides a pharmaceutical composition
comprising one or more compounds of the present invention. The
pharmaceutical composition may include one or more additional
active ingredients as described herein. The pharmaceutical
composition may be administered for any of the disorders described
herein
[0346] In some embodiments, the invention provides pharmaceutical
compositions for treating diseases or conditions related to an
undesirable, over-active, harmful or deleterious immune response in
a mammal. Such undesirable immune response can be associated with
or result in, e.g., asthma, emphysema, bronchitis, psoriasis,
allergy, anaphylaxsis, auto-immune diseases, rhuematoid arthritis,
graft versus host disease, and lupus erythematosus. The
pharmaceutical compositions of the present invention can be used to
treat other respiratory diseases including but not limited to
diseases affecting the lobes of lung, pleural cavity, bronchial
tubes, trachea, upper respiratory tract, or the nerves and muscle
for breathing.
[0347] In some embodiments, the invention provides pharmaceutical
compositions for the treatment of disorders such as
hyperproliferative disorder including but not limited to cancer
such as acute myeloid leukemia, thymus, brain, lung, squamous cell,
skin, eye, retinoblastoma, intraocular melanoma, oral cavity and
oropharyngeal, bladder, gastric, stomach, pancreatic, bladder,
breast, cervical, head, neck, renal, kidney, liver, ovarian,
prostate, colorectal, esophageal, testicular, gynecological,
thyroid, CNS, PNS, AIDS related (e.g. Lymphoma and Kaposi's
Sarcoma) or Viral-Induced cancer. In some embodiments, the
pharmaceutical composition is for the treatment of a non-cancerous
hyperproliferative disorder such as benign hyperplasia of the skin
(e. g., psoriasis), restenosis, or prostate (e. g., benign
prostatic hypertrophy (BPH)).
[0348] The invention also relates to a composition for treating a
disease related to vasculogenesis or angiogenesis in a mammal which
can manifest as tumor angiogenesis, chronic inflammatory disease
such as rheumatoid arthritis, inflammatory bowel disease,
atherosclerosis, skin diseases such as psoriasis, eczema, and
scleroderma, diabetes, diabetic retinopathy, retinopathy of
prematurity, age-related macular degeneration, hemangioma, glioma,
melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic,
prostate, colon and epidermoid cancer.
[0349] The invention also provides compositions for the treatment
of liver diseases (including diabetes), pancreatitis or kidney
disease (including proliferative glomerulonephritis and
diabetes-induced renal disease) or pain in a mammal.
[0350] The invention further provides a composition for the
prevention of blastocyte implantation in a mammal.
[0351] The subject pharmaceutical compositions are typically
formulated to provide a therapeutically effective amount of a
compound of the present invention as the active ingredient, or a
pharmaceutically acceptable salt, ester, or prodrug thereof. Where
desired, the pharmaceutical compositions contain a compound of the
present invention as the active ingredient or a pharmaceutically
acceptable salt and/or coordination complex thereof, and one or
more pharmaceutically acceptable excipients, carriers, such as
inert solid diluents and fillers, diluents, including sterile
aqueous solution and various organic solvents, permeation
enhancers, solubilizers and adjuvants.
[0352] The subject pharmaceutical compositions can be administered
alone or in combination with one or more other agents, which are
also typically administered in the form of pharmaceutical
compositions. Where desired, the subject compounds and other
agent(s) may be mixed into a preparation or both components may be
formulated into separate preparations to use them in combination
separately or at the same time.
[0353] Methods include administration of an inhibitor by itself, or
in combination as described herein, and in each case optionally
including one or more suitable diluents, fillers, salts,
disintegrants, binders, lubricants, glidants, wetting agents,
controlled release matrices, colorants/flavoring, carriers,
excipients, buffers, stabilizers, solubilizers, and combinations
thereof.
[0354] Preparations of various pharmaceutical compositions are
known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.;
Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth
Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of
Drug Action, Third Edition, Churchill Livingston, N.Y., 1990;
Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition,
McGraw Hill, 2003; Goodman and Gilman, eds., The Pharmacological
Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remingtons
Pharmaceutical Sciences, 20th Ed., Lippincott Williams &
Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second
Edition (The Pharmaceutical Press, London, 1999), all of which are
incorporated by reference herein in their entirety.
[0355] The compounds or pharmaceutical composition of the present
invention can be administered by any route that enables delivery of
the compounds to the site of action, such asoral routes,
intraduodenal routes, parenteral injection (including intravenous,
intraarterial, subcutaneous, intramuscular, intravascular,
intraperitoneal or infusion), topical administration (e.g.
transdermal application), rectal administration, via local delivery
by catheter or stent or through inhalation. The compounds can also
be administered intraadiposally or intrathecally.
[0356] The compositions can be administered in solid, semi-solid,
liquid or gaseous form, or may be in dried powder, such as
lyophilized form. The pharmaceutical compositions can be packaged
in forms convenient for delivery, including, for example, solid
dosage forms such as capsules, sachets, cachets, gelatins, papers,
tablets, capsules, suppositories, pellets, pills, troches, and
lozenges. The type of packaging will generally depend on the
desired route of administration. Implantable sustained release
formulations are also contemplated, as are transdermal
formulations.
Routes of Administration
[0357] In the methods according to the invention, the inhibitor
compounds may be administered by various routes. For example,
pharmaceutical compositions may be for injection, or for oral,
nasal, transdermal or other forms of administration, including,
e.g., by intravenous, intradermal, intramuscular, intramammary,
intraperitoneal, intrathecal, intraocular, retrobulbar,
intrapulmonary (e.g., aerosolized drugs) or subcutaneous injection
(including depot administration for long term release e.g.,
embedded-under the-splenic capsule, brain, or in the cornea); by
sublingual, anal, or vaginal administration, or by surgical
implantation, e.g., embedded under the splenic capsule, brain, or
in the cornea. The treatment may consist of a single dose or a
plurality of doses over a period of time. In general, the methods
of the invention involve administering effective amounts of a
modulator of the invention together with one or more
pharmaceutically acceptable diluents, preservatives, solubilizers,
emulsifiers, adjuvants and/or carriers, as described above.
[0358] The subject pharmaceutical composition may, for example, be
in a form suitable for oral administration as a tablet, capsule,
pill, powder, sustained release formulations, solution, suspension,
for parenteral injection as a sterile solution, suspension or
emulsion, for topical administration as an ointment or cream or for
rectal administration as a suppository. The pharmaceutical
composition may be in unit dosage forms suitable for single
administration of precise dosages. The pharmaceutical composition
will include a conventional pharmaceutical carrier or excipient and
a compound according to the invention as an active ingredient. In
addition, it may include other medicinal or pharmaceutical agents,
carriers, and adjuvants.
[0359] In one aspect, the invention provides methods for oral
administration of a pharmaceutical composition of the invention.
Oral solid dosage forms are described generally in Remington's
Pharmaceutical Sciences, supra at Chapter 89. Solid dosage forms
include tablets, capsules, pills, troches or lozenges, and cachets
or pellets. Also, liposomal or proteinoid encapsulation may be used
to formulate the compositions (as, for example, proteinoid
microspheres reported in U.S. Pat. No. 4,925,673). Liposomal
encapsulation may include liposomes that are derivatized with
various polymers (e.g., U.S. Pat. No. 5,013,556). The formulation
may include a compound of the invention and inert ingredients which
protect against degradation in the stomach and which permit release
of the biologically active material in the intestine.
[0360] Toxicity and therapeutic efficacy of the met kinase
compounds can be determined by standard pharmaceutical procedures
in cell cultures or experimental animals, e.g., for determining the
LD50 (the dose lethal to 50% of the population) and the ED50 (the
dose therapeutically effective in 50% of the population).
Additionally, this information can be determined in cell cultures
or experimental animals additionally treated with other therapies
including but not limited to radiation, chemotherapeutic agents,
photodynamic therapies, radiofrequency ablation, anti-angiogenic
agents, and combinations thereof.
[0361] The amount of the compound administered will be dependent on
the mammal being treated, the severity of the disorder or
condition, the rate of administration, the disposition of the
compound and the discretion of the prescribing physician. However,
an effective dosage is in the range of about 0.001 to about 100 mg
per kg body weight per day, preferably about 1 to about 35
mg/kg/day, in single or divided doses. For a 70 kg human, this
would amount to about 0.05 to 7 g/day, preferably about 0.05 to
about 2.5 g/day. In some instances, dosage levels below the lower
limit of the aforesaid range may be more than adequate, while in
other cases still larger doses may be employed without causing any
harmful side effect, e.g. by dividing such larger doses into
several small doses for administration throughout the day.
[0362] In some embodiments, a compound of the invention is
administered in a single dose. Typically, such administration will
be by injection, e.g., intravenous injection, in order to introduce
the agent quickly. however, other routes may be used as
appropriate. A single dose of a compound of the invention may also
be used for treatment of an acute condition.
[0363] In practice of the methods of the invention, the
pharmaceutical compositions are generally provided in doses ranging
from 1 pg compound/kg body weight to 1000 mg/kg, 0.1 mg/kg to 100
mg/kg, 0.1 mg/kg to 50 mg/kg, and 1 to 20 mg/kg, given in daily
doses or in equivalent doses at longer or shorter intervals, e.g.,
every other day, twice weekly, weekly, or twice or three times
daily. The inhibitor compositions may be administered by an initial
bolus followed by a continuous infusion to maintain therapeutic
circulating levels of drug product. Those of ordinary skill in the
art will readily optimize effective dosages and administration
regimens as determined by good medical practice and the clinical
condition of the individual to be treated. The frequency of dosing
will depend on the pharmacokinetic parameters of the agents and the
route of administration. The optimal pharmaceutical formulation
will be determined by one skilled in the art depending upon the
route of administration and desired dosage [see, for example,
Remington's Pharmaceutical Sciences, pp. 1435-1712, the disclosure
of which is hereby incorporated by reference]. Such formulations
may influence the physical state, stability, rate of in vivo
release, and rate of in vivo clearance of the administered agents.
Depending on the route of administration, a suitable dose may be
calculated according to body weight, body surface area or organ
size. Further refinement of the calculations necessary to determine
the appropriate dosage for treatment involving each of the above
mentioned formulations is routinely made by those of ordinary skill
in the art without undue experimentation, especially in light of
the dosage information and assays disclosed herein, as well as the
pharmacokinetic data observed in human clinical trials. Appropriate
dosages may be ascertained by using established assays for
determining blood level dosages in conjunction with an appropriate
physician considering various factors which modify the action of
drugs, e.g., the drug's specific activity, the severity of the
indication, and the responsiveness of the individual, the age,
condition, body weight, sex and diet of the individual, the time of
administration and other clinical factors. As studies are
conducted, further information will emerge regarding the
appropriate dosage levels and duration of treatment for various
diseases and conditions capable of being treated with the methods
of the invention.
[0364] In some embodiments, a compound of the invention is
administered in multiple doses. Dosing may be about once, twice,
three times, four times, five times, six times, or more than six
times per day. Dosing may be about once a month, once every two
weeks, once a week, or once every other day. In another embodiment
a compound of the invention and another agent are administered
together about once per day to about 6 times per day. In another
embodiment the administration of a compound of the invention and an
agent continues for less than about 7 days. In yet another
embodiment the administration continues for more than about 6, 10,
14, 28 days, two months, six months, or one year. In some cases,
continuous dosing is achieved and maintained as long as
necessary.
[0365] Administration of the agents of the invention may continue
as long as necessary. In some embodiments, an agent of the
invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or
28 days. In some embodiments, an agent of the invention is
administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In
some embodiments, an agent of the invention is administered
chronically on an ongoing basis, e.g., for the treatment of chronic
effects.
[0366] An effective amount of a compound of the invention may be
administered in either single or multiple doses by any of the
accepted modes of administration of agents having similar
utilities, including rectal, buccal, intranasal and transdermal
routes, by intra-arterial injection, intravenously,
intraperitoneally, parenterally, intramuscularly, subcutaneously,
orally, topically, or as an inhalant.
[0367] The compounds of the invention may be administered in
dosages. It is known in the art that due to intersubject
variability in compound pharmacokinetics, individualization of
dosing regimen is necessary for optimal therapy. Dosing for a
compound of the invention may be found by routine experimentation
in light of the instant disclosure.
[0368] When a compound of the invention, is administered in a
composition that comprises one or more agents, and the agent has a
shorter half-life than the compound of the invention unit dose
forms of the agent and the compound of the invention may be
adjusted accordingly.
[0369] The inhibitors of the invention may be covalently or
noncovalently associated with a carrier molecule including but not
limited to a linear polymer (e.g., polyethylene glycol, polylysine,
dextran, etc.), a branched-chain polymer (see U.S. Pat. Nos.
4,289,872 and 5,229,490; PCT Publication No. WO 93/21259), a lipid,
a cholesterol group (such as a steroid), or a carbohydrate or
oligosaccharide. Specific examples of carriers for use in the
pharmaceutical compositions of the invention include
carbohydrate-based polymers such as trehalose, mannitol, xylitol,
sucrose, lactose, sorbitol, dextrans such as cyclodextran,
cellulose, and cellulose derivatives. Also, the use of liposomes,
microcapsules or microspheres, inclusion complexes, or other types
of carriers is contemplated.
[0370] Other carriers include one or more water soluble polymer
attachments such as polyoxyethylene glycol, or polypropylene glycol
as described U.S. Pat. Nos. 4,640,835, 4,496,689, 4,301,144,
4,670,417, 4,791,192 and 4,179,337. Still other useful carrier
polymers known in the art include monomethoxy-polyethylene glycol,
poly-(N-vinyl pyrrolidone)-polyethylene glycol, propylene glycol
homopolymers, a polypropylene oxidelethylene oxide co-polymer,
polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol, as
well as mixtures of these polymers.
[0371] Derivitization with bifunctional agents is useful for
cross-linking a compound of the invention to a support matrix or to
a carrier. One such carrier is polyethylene glycol (PEG). The PEG
group may be of any convenient molecular weight and may be straight
chain or branched. The average molecular weight of the PEG can
range from about 2 kDa to about 100 kDa, in another aspect from
about 5 kDa to about 50 kDa, and in a further aspect from about 5
kDa to about 10 kDa. The PEG groups will generally be attached to
the compounds of the invention via acylation, reductive alkylation,
Michael addition, thiol alkylation or other chemoselective
conjugation/ligation methods through a reactive group on the PEG
moiety (e.g., an aldehyde, amino, ester, thiol, ci-haloacetyl,
maleimido or hydrazino group) to a reactive group on the target
inhibitor compound (e.g., an aldehyde, amino, ester, thiol,
a-haloacetyl, maleimido or hydrazino group). Cross-linking agents
can include, e.g., esters with 4-azidosalicylic acid,
homobifunctional imidoesters, including disuccinimidyl esters such
as 3,3'-dithiobis (succinimidylpropionate), and bifunctional
maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents
such as methyl-3-[(p-azidophenyl)dithiolpropioimidate yield
photoactivatable intermediates that are capable of forming
crosslinks in the presence of light. Alternatively, reactive
water-insoluble matrices such as cyanogen bromide-activated
carbohydrates and the reactive substrates described in U.S. Pat.
Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and
4,330,440 may be employed for inhibitor immobilization.
Method of Treatment
[0372] The invention also provides methods of using the compounds
or pharmaceutical compositions of the present invention to treat
disease conditions, including but not limited to diseases
associated with malfunctioning of c-met kinase and family.
[0373] The treatment methods provided herein comprise administering
to the subject a therapeutically effective amount of a compound of
the invention. In one embodiment, the present invention provides a
method of treating an inflammation disorder, including autoimmune
diseases in a mammal. The method comprises administering to said
mammal a therapeutically effective amount of a compound of the
present invention.
[0374] The disorders, diseases, or conditions treatable with a
compound provided herein, include, but are not limited to, [0375]
inflammatory or allergic diseases, including systemic anaphylaxis
and hypersensitivity disorders, atopic dermatitis, urticaria, drug
allergies, insect sting allergies, food allergies (including celiac
disease and the like), anaphylaxis, serum sickness, drug reactions,
insect venom allergies, hypersensitivity pneumonitis, angioedema,
erythema multiforme, Stevens-Johnson syndrome, atopic
keratoconjunctivitis, venereal keratoconjunctivitis, giant
papillary conjunctivitis, and mastocytosis; [0376] inflammatory
bowel diseases, including Crohn's disease, ulcerative colitis,
ileitis, enteritis, and necrotizing enterocolitis; [0377]
vasculitis, and Behcet's syndrome; [0378] psoriasis and
inflammatory dermatoses, including dermatitis, eczema, allergic
contact dermatitis, viral cutaneous pathologies including those
derived from human papillomavirus, HIV or RLV infection, bacterial,
flugal, and other parasital cutaneous pathologies, and cutaneous
lupus erythematosus; [0379] asthma and respiratory allergic
diseases, including allergic asthma, exercise induced asthma,
allergic rhinitis, otitis media, hypersensitivity lung diseases,
chronic obstructive pulmonary disease and other respiratory
problems; [0380] autoimmune diseases and inflammatory conditions,
including but are not limited to acute disseminated
encephalomyelitis (ADEM), Addison's disease, antiphospholipid
antibody syndrome (APS), aplastic anemia, autoimmune hepatitis,
coeliac disease, Crohn's disease, Diabetes mellitus (type 1),
Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome
(GBS), Reynaud's syndrome, Hashimoto's disease, lupus
erythematosus, systemic lupus erythematosus (SLE), multiple
sclerosis, myasthenia gravis, opsoclonus myoclonus syndrome (OMS),
optic neuritis, Ord's thyroiditis, oemphigus, polyarthritis,
primary biliary cirrhosis, psoriasis, rheumatoid arthritis,
psoriatic arthritis, gouty arthritis, spondylitis, reactive
arthritis, chronic or acute glomerulonephritis, lupus nephritis,
Reiter's syndrome, Takayasu's arteritis, temporal arteritis (also
known as "giant cell arteritis"), warm autoimmune hemolytic anemia,
Wegener's granulomatosis, alopecia universalis, Chagas' disease,
chronic fatigue syndrome, dysautonomia, endometriosis, hidradenitis
suppurativa, interstitial cystitis, neuromyotonia, sarcoidosis,
scleroderma, ulcerative colitis, connective tissue disease,
autoimmune pulmonary inflammation, autoimmune thyroiditis,
autoimmune inflammatory eye disease, vitiligo, and vulvodynia.
Other disorders include bone-resorption disorders and thromobsis;
[0381] tissue or organ transplant rejection disorders including but
not limited to graft rejection (including allograft rejection and
graft-v-host disease (GVHD)), e.g., skin graft rejection, solid
organ transplant rejection, bone marrow transplant rejection;
[0382] fever; [0383] cardiovascular disorders, including acute
heart failure, hypotension, hypertension, angina pectoris,
myocardial infarction, cardiomyopathy, congestive heart failure,
atherosclerosis, coronary artery disease, restenosis, and vascular
stenosis; [0384] cerebrovascular disorders, including traumatic
brain injury, stroke, ischemic reperfusion injury and aneurysm;
[0385] cancers of the breast, skin, prostate, cervix, uterus,
ovary, testes, bladder, lung, liver, larynx, oral cavity, colon and
gastrointestinal tract (e.g., esophagus, stomach, pancreas), brain,
thyroid, blood, and lymphatic system; [0386] fibrosis, connective
tissue disease, and sarcoidosis; [0387] genital and reproductive
conditions, including erectile dysfunction; [0388] gastrointestinal
disorders, including gastritis, ulcers, nausea, pancreatitis, and
vomiting; [0389] neurologic disorders, including Alzheimer's
disease; [0390] sleep disorders, including insomnia, narcolepsy,
sleep apnea syndrome, and Pickwick Syndrome; [0391] pain, myalgias
due to infection; [0392] renal disorders; [0393] ocular disorders,
including glaucoma; [0394] infectious diseases, including HIV;
[0395] sepsis; septic shock; endotoxic shock; gram negative sepsis;
gram positive sepsis; toxic shock syndrome; multiple organ injury
syndrome secondary to septicemia, trauma, or hemorrhage; [0396]
pulmonary or respiratory conditions including but not limited to
asthma, chronic bronchitis, allergic rhinitis, adult respiratory
distress syndrome (ARDS), severe acute respiratory syndrome (SARS),
chronic pulmonary inflammatory diseases (e.g., chronic obstructive
pulmonary disease), silicosis, pulmonary sarcoidosis, pleurisy,
alveolitis, vasculitis, pneumonia, bronchiectasis, hereditary
emphysema, and pulmonary oxygen toxicity; [0397]
ischemic-reperfusion injury, e.g., of the myocardium, brain, or
extremities; [0398] fibrosis including but not limited to cystic
fibrosis; keloid formation or scar tissue formation; [0399] central
or peripheral nervous system inflammatory conditions including but
not limited to meningitis (e.g., acute purulent meningitis),
encephalitis, and brain or spinal cord injury due to minor trauma;
[0400] Sjorgren's syndrome; diseases involving leukocyte
diapedesis; alcoholic hepatitis; bacterial pneumonia; community
acquired pneumonia (CAP); Pneumocystis carinii pneumonia (PCP);
antigen-antibody complex mediated diseases; hypovolemic shock;
acute and delayed hypersensitivity; disease states due to leukocyte
dyscrasia and metastasis; thermal injury; granulocyte transfusion
associated syndromes; cytokine-induced toxicity; stroke;
pancreatitis; myocardial infarction, respiratory syncytial virus
(RSV) infection; and spinal cord injury.
[0401] In certain embodiments, the cancer or cancers treatable with
the methods provided herein includes, but is or are not limited to,
[0402] leukemias, including, but not limited to, acute leukemia,
acute lymphocytic leukemia, acute myelocytic leukemias such as
myeloblasts, promyelocyte, myelomonocytic, monocytic,
erythroleukemia leukemias and myelodysplastic syndrome or a symptom
thereof (such as anemia, thrombocytopenia, neutropenia, bicytopenia
or pancytopenia), refractory anemia (RA), RA with ringed
sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in
transformation (RAEB-T), preleukemia, and chronic myelomonocytic
leukemia (CMML); [0403] chronic leukemias, including, but not
limited to, chronic myelocytic (granulocytic) leukemia, chronic
lymphocytic leukemia, and hairy cell leukemia; [0404] polycythemia
vera; [0405] lymphomas, including, but not limited to, Hodgkin's
disease and non-Hodgkin's disease; [0406] multiple myelomas,
including, but not limited to, smoldering multiple myeloma,
nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia,
solitary plasmacytoma, and extramedullary plasmacytoma; [0407]
Waldenstrom's macroglobulinemia; [0408] monoclonal gammopathy of
undetermined significance; [0409] benign monoclonal gammopathy;
[0410] heavy chain disease; [0411] bone and connective tissue
sarcomas, including, but not limited to, bone sarcoma,
osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell
tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma,
soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma,
Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma,
metastatic cancers, neurilemmoma, rhabdomyosarcoma, and synovial
sarcoma; [0412] brain tumors, including, but not limited to,
glioma, astrocytoma, brain stem glioma, ependymoma,
oligodendroglioma, nonglial tumor, acoustic neurinoma,
craniopharyngioma, medulloblastoma, meningioma, pineocytoma,
pineoblastoma, and primary brain lymphoma; [0413] breast cancer,
including, but not limited to, adenocarcinoma, lobular (small cell)
carcinoma, intraductal carcinoma, medullary breast cancer, mucinous
breast cancer, tubular breast cancer, papillary breast cancer,
primary cancers, Paget's disease, and inflammatory breast cancer;
[0414] adrenal cancer, including, but not limited to,
pheochromocytom and adrenocortical carcinoma; [0415] thyroid
cancer, including, but not limited to, papillary or follicular
thyroid cancer, medullary thyroid cancer, and anaplastic thyroid
cancer; [0416] pancreatic cancer, including, but not limited to,
insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting
tumor, and carcinoid or islet cell tumor; [0417] pituitary cancer,
including, but limited to, Cushing's disease, prolactin-secreting
tumor, acromegaly, and diabetes insipidus; [0418] eye cancer,
including, but not limited, to ocular melanoma such as iris
melanoma, choroidal melanoma, and cilliary body melanoma, and
retinoblastoma; [0419] vaginal cancer, including, but not limited
to, squamous cell carcinoma, adenocarcinoma, and melanoma; [0420]
vulvar cancer, including, but not limited to, squamous cell
carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma,
and Paget's disease; [0421] cervical cancers, including, but not
limited to, squamous cell carcinoma, and adenocarcinoma; [0422]
uterine cancer, including, but not limited to, endometrial
carcinoma and uterine sarcoma; [0423] ovarian cancer, including,
but not limited to, ovarian epithelial carcinoma, borderline tumor,
germ cell tumor, and stromal tumor; [0424] esophageal cancer,
including, but not limited to, squamous cancer, adenocarcinoma,
adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous
carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma,
and oat cell (small cell) carcinoma; [0425] stomach cancer,
including, but not limited to, adenocarcinoma, fungating
(polypoid), ulcerating, superficial spreading, diffusely spreading,
malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma;
[0426] colon cancer; [0427] rectal cancer; [0428] liver cancer,
including, but not limited to, hepatocellular carcinoma and
hepatoblastoma; [0429] gallbladder cancer, including, but not
limited to, adenocarcinoma; [0430] cholangiocarcinomas, including,
but not limited to, pappillary, nodular, and diffuse; [0431] lung
cancer, including, but not limited to, non-small cell lung cancer,
squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma,
large-cell carcinoma, and small-cell lung cancer; [0432] testicular
cancer, including, but not limited to, germinal tumor, seminoma,
anaplastic, classic (typical), spermatocytic, nonseminoma,
embryonal carcinoma, teratoma carcinoma, and choriocarcinoma
(yolk-sac tumor); [0433] prostate cancer, including, but not
limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma;
[0434] penal cancer; [0435] oral cancer, including, but not limited
to, squamous cell carcinoma; [0436] basal cancer; [0437] salivary
gland cancer, including, but not limited to, adenocarcinoma,
mucoepidermoid carcinoma, and adenoidcystic carcinoma; [0438]
pharynx cancer, including, but not limited to, squamous cell cancer
and verrucous; [0439] skin cancer, including, but not limited to,
basal cell carcinoma, squamous cell carcinoma and melanoma,
superficial spreading melanoma, nodular melanoma, lentigo malignant
melanoma, and acral lentiginous melanoma; [0440] kidney cancer,
including, but not limited to, renal cell cancer, adenocarcinoma,
[0441] hypernephroma, fibrosarcoma, and transitional cell cancer
(renal pelvis and/or uterer); [0442] Wilms' tumor; [0443] bladder
cancer, including, but not limited to, transitional cell carcinoma,
squamous cell cancer, adenocarcinoma, and carcinosarcoma; and other
cancer, including, not limited to, myxosarcoma, osteogenic sarcoma,
endotheliosarcoma, lymphangio-endotheliosarcoma, mesothelioma,
synovioma, hemangioblastoma, epithelial carcinoma,
cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma,
sebaceous gland carcinoma, papillary carcinoma, and papillary
adenocarcinomas See Fishman et al., 1985, Medicine, 2d Ed., J.B.
Lippincott Co., Philadelphia and Murphy et al., 1997, Informed
Decisions: The Complete Book of Cancer Diagnosis, Treatment, and
Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States
of America.
[0444] It will be appreciated that the treatment methods of the
invention are useful in the fields of human medicine and veterinary
medicine. Thus, the individual to be treated may be a mammal,
preferably human, or other animals. For veterinary purposes,
individuals include but are not limited to farm animals including
cows, sheep, pigs, horses, and goats; companion animals such as
dogs and cats; exotic and/or zoo animals; laboratory animals
including mice, rats, rabbits, guinea pigs, and hamsters; and
poultry such as chickens, turkeys, ducks, and geese.
[0445] In another embodiment, the compounds described herein are
used for the treatment of cancer such as acute myeloid leukemia,
thymus, brain, lung, squamous cell, skin, eye, retinoblastoma,
intraocular melanoma, oral cavity and oropharyngeal, bladder,
gastric, stomach, pancreatic, bladder, breast, cervical, head,
neck, renal, kidney, liver, ovarian, prostate, colorectal,
esophageal, testicular, gynecological, thyroid, CNS, PNS,
AIDS-related (e.g. Lymphoma and Kaposi's Sarcoma) or viral-induced
cancer. In some embodiments, said method relates to the treatment
of a non-cancerous hyperproliferative disorder such as benign
hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate
(e.g., benign prostatic hypertrophy (BPH)).
[0446] The invention also relates to a method of treating diseases
related to vasculogenesis or angiogenesis in a mammal that
comprises administering to said mammal a therapeutically effective
amount of a compound of the present invention. In some embodiments,
said method is for treating a disease selected from the group
consisting of tumor angiogenesis, chronic inflammatory disease such
as rheumatoid arthritis, atherosclerosis, inflammatory bowel
disease, skin diseases such as psoriasis, eczema, and scleroderma,
diabetes, diabetic retinopathy, retinopathy of prematurity,
age-related macular degeneration, hemangioma, glioma, melanoma,
Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate,
colon and epidermoid cancer.
[0447] Patients that can be treated with compounds of the present
invention, according to the methods of this invention include, for
example, patients that have been diagnosed as having psoriasis;
restenosis; atherosclerosis; BPH; breast cancer such as a ductal
carcinoma in duct tissue in a mammary gland, medullary carcinomas,
colloid carcinomas, tubular carcinomas, and inflammatory breast
cancer; ovarian cancer, including epithelial ovarian tumors such as
adenocarcinoma in the ovary and an adenocarcinoma that has migrated
from the ovary into the abdominal cavity; uterine cancer; cervical
cancer such as adenocarcinoma in the cervix epithelial including
squamous cell carcinoma and adenocarcinomas; prostate cancer, such
as a prostate cancer selected from the following: an adenocarcinoma
or an adenocarinoma that has migrated to the bone; pancreatic
cancer such as epitheliod carcinoma in the pancreatic duct tissue
and an adenocarcinoma in a pancreatic duct; bladder cancer such as
a transitional cell carcinoma in urinary bladder, urothelial
carcinomas (transitional cell carcinomas), tumors in the urothelial
cells that line the bladder, squamous cell carcinomas,
adenocarcinomas, and small cell cancers; leukemia such as acute
myeloid leukemia (AML), acute lymphocytic leukemia, chronic
lymphocytic leukemia, chronic myeloid leukemia, hairy cell
leukemia, myelodysplasia, myeloproliferative disorders, acute
myelogenous leukemia (AML), chronic myelogenous leukemia (CML),
mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma
(MM), and myelodysplastic syndrome (MDS); bone cancer; lung cancer
such as non-small cell lung cancer (NSCLC), which is divided into
squamous cell carcinomas, adenocarcinomas, and large cell
undifferentiated carcinomas, and small cell lung cancer; skin
cancer such as basal cell carcinoma, melanoma, squamous cell
carcinoma and actinic keratosis, which is a skin condition that
sometimes develops into squamous cell carcinoma; eye
retinoblastoma; cutaneous or intraocular (eye) melanoma; primary
liver cancer (cancer that begins in the liver); kidney cancer;
thyroid cancer such as papillary, follicular, medullary and
anaplastic; AIDS-related lymphoma such as diffuse large B-cell
lymphoma, B-cell immunoblastic lymphoma and small non-cleaved cell
lymphoma; Kaposi's Sarcoma; viral-induced cancers including
hepatitis B virus (HBV), hepatitis C virus (HCV), and
hepatocellular carcinoma; human lymphotropic virus-type 1 (HTLV-1)
and adult T-cell leukemia/lymphoma; and human papilloma virus (HPV)
and cervical cancer; central nervous system cancers (CNS) such as
primary brain tumor, which includes gliomas (astrocytoma,
anaplastic astrocytoma, or glioblastoma multiforme),
Oligodendroglioma, Ependymoma, Meningioma, Lymphoma, Schwannoma,
and Medulloblastoma; peripheral nervous system (PNS) cancers such
as acoustic neuromas and malignant peripheral nerve sheath tumor
(MPNST) including neurofibromas and schwannomas, malignant fibrous
cytoma, malignant fibrous histiocytoma, malignant meningioma,
malignant mesothelioma, and malignant mixed M{umlaut over
(.upsilon.)}llerian tumor; oral cavity and oropharyngeal cancer
such as, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal
cancer, and oropharyngeal cancer; stomach cancer such as lymphomas,
gastric stromal tumors, and carcinoid tumors; testicular cancer
such as germ cell tumors (GCTs), which include seminomas and
nonseminomas, and gonadal stromal tumors, which include Leydig cell
tumors and Sertoli cell tumors; thymus cancer such as to thymomas,
thymic carcinomas, Hodgkin disease, non-Hodgkin lymphomas
carcinoids or carcinoid tumors; rectal cancer; and colon
cancer.
[0448] The invention also relates to a method of treating diabetes
in a mammal that comprises administering to said mammal a
therapeutically effective amount of a compound of the present
invention.
[0449] In addition, the compounds described herein may be used to
treat acne.
[0450] In addition, the compounds described herein may be used for
the treatment of arteriosclerosis, including atherosclerosis.
Arteriosclerosis is a general term describing any hardening of
medium or large arteries. Atherosclerosis is a hardening of an
artery specifically due to an atheromatous plaque.
[0451] Further the compounds described herein may be used for the
treatment of glomerulonephritis. Glomerulonephritis is a primary or
secondary autoimmune renal disease characterized by inflammation of
the glomeruli. It may be asymptomatic, or present with hematuria
and/or proteinuria. There are many recognized types, divided in
acute, subacute or chronic glomerulonephritis. Causes are
infectious (bacterial, viral or parasitic pathogens), autoimmune or
paraneoplastic.
[0452] Additionally, the compounds described herein may be used for
the treatment of bursitis, lupus, acute disseminated
encephalomyelitis (ADEM), addison's disease, antiphospholipid
antibody syndrome (APS), aplastic anemia, autoimmune hepatitis,
coeliac disease, Crohn's disease, diabetes mellitus (type 1),
goodpasture's syndrome, graves' disease, guillain-barre syndrome
(GBS), hashimoto's disease, inflammatory bowel disease, lupus
erythematosus, myasthenia gravis, opsoclonus myoclonus syndrome
(OMS), optic neuritis, ord's thyroiditiSjOstheoarthritis,
uveoretinitis, pemphigus, polyarthritis, primary biliary cirrhosis,
reiter's syndrome, takayasu's arteritis, temporal arteritis, warm
autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia
universalis, chagas.sup.1 disease, chronic fatigue syndrome,
dysautonomia, endometriosis, hidradenitis suppurativa, interstitial
cystitis, neuromyotonia, sarcoidosis, scleroderma, ulcerative
colitis, vitiligo, vulvodynia, appendicitis, arteritis, arthritis,
blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis,
cholecystitis, chorioamnionitis, colitis, conjunctivitis, cystitis,
dacryoadenitis, dermatomyositis, endocarditis, endometritis,
enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis,
fibrositis, gastritis, gastroenteritis, gingivitis, hepatitis,
hidradenitis, ileitis, iritis, laryngitis, mastitis, meningitis,
myelitis, myocarditis, myositis, nephritis, omphalitis, oophoritis,
orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis,
peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis,
proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis,
sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis,
vaginitis, vasculitis, or vulvitis.
[0453] The invention also relates to a method of treating a
cardiovascular disease in a mammal that comprises administering to
said mammal a therapeutically effective amount of a compound of the
present invention. Examples of cardiovascular conditions include,
but are not limited to, atherosclerosis, restenosis, vascular
occlusion and carotid obstructive disease.
[0454] In another aspect, the present invention provides methods of
disrupting the function of a leukocyte or disrupting a function of
an osteoclast. The method includes contacting the leukocyte or the
osteoclast with a function disrupting amount of a compound of the
invention.
[0455] In another aspect of the present invention, methods are
provided for treating ophthalmic disease by administering one or
more of the subject compounds or pharmaceutical compositions to the
eye of a subject.
[0456] The invention further provides methods of modulating kinase
activity by contacting a kinase with an amount of a compound of the
invention sufficient to modulate the activity of the kinase.
Modulate can be inhibiting or activating kinase activity. In some
embodiments, the invention provides methods of inhibiting kinase
activity by contacting a kinase with an amount of a compound of the
invention sufficient to inhibit the activity of the kinase. In some
embodiments, the invention provides methods of inhibiting kinase
activity in a solution by contacting said solution with an amount
of a compound of the invention sufficient to inhibit the activity
of the kinase in said solution. In some embodiments, the invention
provides methods of inhibiting kinase activity in a cell by
contacting said cell with an amount of a compound of the invention
sufficient to inhibit the activity of the kinase in said cell. In
some embodiments, the invention provides methods of inhibiting
kinase activity in a tissue by contacting said tissue with an
amount of a compound of the invention sufficient to inhibit the
activity of the kinase in said tissue. In some embodiments, the
invention provides methods of inhibiting kinase activity in an
organism by contacting said organism with an amount of a compound
of the invention sufficient to inhibit the activity of the kinase
in said organism. In some embodiments, the invention provides
methods of inhibiting kinase activity in an animal by contacting
said animal with an amount of a compound of the invention
sufficient to inhibit the activity of the kinase in said animal. In
some embodiments, the invention provides methods of inhibiting
kinase activity in a mammal by contacting said mammal with an
amount of a compound of the invention sufficient to inhibit the
activity of the kinase in said mammal. In some embodiments, the
invention provides methods of inhibiting kinase activity in a human
by contacting said human with an amount of a compound of the
invention sufficient to inhibit the activity of the kinase in said
human. In some embodiments, the % of kinase activity after
contacting a kinase with a compound of the invention is less than
1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or 99% of the kinase
activity in the absence of said contacting step.
[0457] In some embodiments, the kinase is a pretein kinase, more
particularly a non-receptor or receptor tyrosine protein kinase. In
some embodiments, the kinase is selected from the group consisting
of C-met including mutants if any; Abl, VEGFR, Ephrin receptor B4
(EphB4); TEK receptor tyrosine kinase (HE2); FMS-related tyrosine
kinase 3 (FLT-3); Platelet derived growth factor receptor (PDGFR);
RET; ATM; ATR; hSmg-1; IIck; Src; Epidermal growth factor receptor
(EGFR); KIT; Inulsin Receptor (IR) and IGFR.
[0458] The invention further provides methods of modulating c-met
kinase activity by contacting a c-met kinase with an amount of a
compound of the invention sufficient to modulate the activity of
the c-met kinase. Modulate can be inhibiting or activating c-met
kinase activity. In some embodiments, the invention provides
methods of inhibiting c-met kinase activity by contacting a c-met
kinase with an amount of a compound of the invention sufficient to
inhibit the activity of the c-met kinase. In some embodiments, the
invention provides methods of inhibiting c-met kinase activity.
Such inhibition can take place in solution, in a cell expressing
one or more c-met kinase, in a tissue comprising a cell expressing
one or more c-met kinases, or in an organism expressing one or more
c-met kinase. In some embodiments, the invention provides methods
of inhibiting c-met kinase activity in an animal (including mammal
such as humans) by contacting said animal with an amount of a
compound of the invention sufficient to inhibit the activity of the
c-met kinase in said animal.
Combination Treatment
[0459] The present invention also provides methods for combination
therapies in which an agent known to modulate other pathways, or
other components of the same pathway, or even overlapping sets of
target enzymes are used in combination with a compound of the
present invention. In one aspect, such therapy includes but is not
limited to the combination of the subject compound with
chemotherapeutic agents, therapeutic antibodies, and radiation
treatment, to provide a synergistic or additive therapeutic
effect.
[0460] For treatment of autoimmune diseases, the subject compounds
or pharmaceutical compositions can be used in combination with
commonly prescribed drugs including but not limited to Enbrel.RTM.,
Remicade.RTM., Humira.RTM., Avonex.RTM., and Rebif.RTM.. For
treatment of respiratory diseases, the subject compounds or
pharmaceutical compositions can be administered in combination with
commonly prescribed drugs including but not limited to Xolair.RTM.,
Advair.RTM., Singulair.RTM., and Spiriva.RTM..
[0461] The compounds of the invention may be formulated or
administered in conjunction with other agents that act to relieve
the symptoms of inflammatory conditions such as encephalomyelitis,
asthma, and the other diseases described herein. These agents
include non-steroidal anti-inflammatory drugs (NSAIDs), e.g.
acetylsalicylic acid; ibuprofen; naproxen; indomethacin;
nabumetone; tolmetin; etc. Corticosteroids are used to reduce
inflammation and suppress activity of the immune system. The most
commonly prescribed drug of this type is Prednisone. Chloroquine
(Aralen) or hydroxychloroquine (Plaquenil) may also be very useful
in some individuals with lupus. They are most often prescribed for
skin and joint symptoms of lupus. Azathioprine (Imuran) and
cyclophosphamide (Cytoxan) suppress inflammation and tend to
suppress the immune system. Other agents, e.g. methotrexate and
cyclosporin are used to control the symptoms of lupus.
Anticoagulants are employed to prevent blood from clotting rapidly.
They range from aspirin at very low dose which prevents platelets
from sticking, to heparin/coumadin.
[0462] In another one aspect, this invention also relates to a
pharmaceutical composition for inhibiting abnormal cell growth in a
mammal which comprises an amount of a compound of the present
invention, in combination with an amount of an anti-cancer agent
(e.g. a chemotherapeutic agent). Many chemotherapeutics are
presently known in the art and can be used in combination with the
compounds of the invention.
[0463] In some embodiments, the chemotherapeutic is selected from
the group consisting of mitotic inhibitors, alkylating agents,
anti-metabolites, intercalating antibiotics, growth factor
inhibitors, cell cycle inhibitors, enzymes, topoisomerase
inhibitors, biological response modifiers, anti-hormones,
angiogenesis inhibitors, and anti-androgens. Non-limiting examples
are chemotherapeutic agents, cytotoxic agents, and non-peptide
small molecules such as Gleevec (Imatinib Mesylate), Velcade
(bortezomib), Iressa (gefitinib), Sprycel (Dasatinib), and
Adriamycin as well as a host of chemotherapeutic agents.
Non-limiting examples of chemotherapeutic agents include alkylating
agents such as thiotepa and cyclosphosphamide (CYTOXAN.TM.); alkyl
sulfonates such as busulfan, improsulfan and piposulfan; aziridines
such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines including altretamine,
triethylenemelamine, trietylenephosphoramide,
triethylenethiophosphaoramide and trimethylolomelamine; nitrogen
mustards such as chlorambucil, chlornaphazine, cholophosphamide,
estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide
hydrochloride, melphalan, novembichin, phenesterine, prednimustine,
trofosfamide, uracil mustard; nitrosureas such as carmustine,
chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;
antibiotics such as aclacinomysins, actinomycin, authramycin,
azaserine, bleomycins, cactinomycin, calicheamicin, carabicin,
carminomycin, carzinophilin, Casodex.TM., chromomycins,
dactinomycin, daunorubicin, detorubicin,
6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin,
idarubicin, marcellomycin, mitomycins, mycophenolic acid,
nogalamycin, olivomycins, peplomycin, p.kappa.)tfiromycin,
puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin,
tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such
as methotrexate and 5-fluorouracil (5-FU); folic acid analogues
such as denopterin, methotrexate, pteropterin, trimetrexate; purine
analogs such as fludarabine, 6-mcrcaptopurine, thiamiprine,
thioguanine; pyrimidine analogs such as ancitabine, azacitidine,
6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine,
enocitabine, floxuridine, androgens such as calusterone,
dromostanolone propionate, epitiostanol, mepitiostane,
testolactone; anti-adrenals such as aminoglutethimide, mitotane,
trilostane; folic acid replenisher such as frolinic acid;
aceglatone; aldophosphamide glycoside; aminolevulinic acid;
amsacrine; bestrabucil; bisantrene; edatraxate; defofamine;
demecolcine; diaziquone; elfomithine; elliptinium acetate;
etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine;
mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin;
phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide;
procarbazine; PSK.R.TM.-; razoxane; sizofiran; spirogermanium;
tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine;
urethan; vindesine; dacarbazine; mannomustine; mitobronitol;
mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiotepa; taxanes, e.g. paclitaxel (TAXOL.TM.,
Bristol-Myers Squibb Oncology, Princeton, N.J.) and docetaxel
(TAXOTERE.TM. Rhone-Poulenc Rorer, Antony, France); retinoic acid;
esperamicins; capecitabine; and pharmaceutically acceptable salts,
acids or derivatives of any of the above. Also included as suitable
chemotherapeutic cell conditioners are anti-hormonal agents that
act to regulate or inhibit hormone action on tumors such as
anti-estrogens including for example tamoxifen (Nolvadex.TM.),
raloxifene, aromatase inhibiting 4(5)-imidazoles,
4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone,
and toremifene (Fareston); and anti-androgens such as flutamide,
nilutamide, bicalutamide (Casodex), leuprolide, and goserelin
(Zoladex); chlorambucil; gemcitabine; 6-thioguanine;
mercaptopurine; methotrexate; platinum analogs such as cisplatin
and carboplatin; vinblastine; platinum; etoposide (VP-16);
ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine;
navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda;
ibandronate; camptothecin-11 (CPT-11); topoisomerase inhibitor RFS
2000; difluoromethylornithine (DMFO), 17.alpha.-Ethinylestradiol,
Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone,
Megestrolacetate, Methylprednisolone, Methyl-testosterone,
Prednisolone, Triamcinolone, chlorotrianisene, Hydroxyprogesterone,
Aminoglutethimide, Medroxyprogesteroneacetate, matrix
metalloproteinase inhibitors, EGFR inhibitors, Pan Her inhibitors,
VEGF inhibitors, including as anti-VEGF antibodies such as Avastin,
and small molecules such as ZD6474 and SJ6668, vatalanib,
BAY-43-9006, SU11248, CP-547632, and CEP-7055. Anti-Her2 antibodies
(such as Herceptin from Genentech) may also be utilized. Suitable
EGFR inhibitors include gefitinib, erlotinib, and cetuximab. Pan
Her inhibitors include canertinib, EKB-569, and GW-572016. Further
suitable anticancer agents include, but are not limited to, Src
inhibitors, MEK-1 kinase inhibitors, MAPK kinase inhibitors, PI3
kinase inhibitors, and PDGF inhibitors, such as imatinib. Also
included are anti-angiogenic and antivascular agents which, by
interrupting blood flow to solid tumors, render cancer cells
quiescent by depriving them of nutrition. Castration which also
renders androgen dependent carcinomas non-proliferative, may also
be utilized. Also included are IGF1R inhibitors, inhibitors of
non-receptor and receptor tyrosine kinases, and inhibitors of
integrin signalling. Additional anticancer agents include
microtubule-stabilizing agents 7-O-methylthiomethylpaclitaxel
(disclosed in U.S. Pat. No. 5,646,176),
4-desacetyl-4-methylcarbonatepaclitaxel,
3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-desacetyl-3'-dephenyl-3'-N-deb-
enzoyl-4-O-methoxycarbonyl-paclitaxel (disclosed in U.S. Ser. No.
09/712,352 filed on Nov. 14, 2000), C-4 methyl carbonate
paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D,
desoxyepothilone A, desoxyepothilone B,
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7-11-dihydroxy-8,8,10,12,16-pen-
tamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17
oxabicyclo [14.1.0]heptadecane-5,9-dione (disclosed in WO
99/02514), [1S-[1R*,3R*(E),
7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminomethyl)-4-thiazolyl]-1-methyl
ethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4-17-dioxabicyclo[14.1.0-
]-heptadecane-5,-9-dione (as disclosed in U.S. Pat. No. 6,262,094)
and derivatives thereof; and microtubule-disruptor agents. Also
suitable are CDK inhibitors, an antiproliferative cell cycle
inhibitor, epidophyllotoxin; an antineoplastic enzyme; biological
response modifiers; growth inhibitors; antihormonal therapeutic
agents; leucovorin; tegafur; and haematopoietic growth factors.
[0464] Additional cytotoxic agents include, hexamethyl melamine,
idatrexate, L-asparaginase, camptothecin, topotecan,
pyridobenzoindole derivatives, interferons, and interleukins. Where
desired, the compounds or pharmaceutical composition of the present
invention can be used in combination with commonly prescribed
anti-cancer drugs such as IIerceptin.RTM., Avastin.RTM.,
Erbitux.RTM., Rituxan.RTM., Taxol.RTM., Arimidex.RTM.,
Taxotere.RTM., and Velcade.RTM.
[0465] This invention further relates to a method for using the
compounds or pharmaceutical composition in combination with
radiation therapy in inhibiting abnormal cell growth or treating
the hyperproliferative disorder in the mammal. Techniques for
administering radiation therapy are known in the art, and these
techniques can be used in the combination therapy described herein.
The administration of the compound of the invention in this
combination therapy can be determined as described herein.
[0466] Radiation therapy can be administered through one of several
methods, or a combination of methods, including without limitation
external-beam therapy, internal radiation therapy, implant
radiation, stereotactic radiosurgery, systemic radiation therapy,
radiotherapy and permanent or temporary interstitial brachytherapy.
The term "brachytherapy," as used herein, refers to radiation
therapy delivered by a spatially confined radioactive material
inserted into the body at or near a tumor or other proliferative
tissue disease site. The term is intended without limitation to
include exposure to radioactive isotopes (e.g. At-211, 1-131,
1-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and radioactive
isotopes of Lu). Suitable radiation sources for use as a cell
conditioner of the present invention include both solids and
liquids. By way of non-limiting example, the radiation source can
be a radionuclide, such as 1-125, 1-131, Yb-169, Ir-192 as a solid
source, 1-125 as a solid source, or other radionuclides that emit
photons, beta particles, gamma radiation, or other therapeutic
rays. The radioactive material can also be a fluid made from any 5
solution of radionuclides), e.g., a solution of 1-125 or 1-131, or
a radioactive fluid can be produced using a slurry of a suitable
fluid containing small particles of solid radionuclides, such as
Au-198, Y-90. Moreover, the radionuclide(s) can be embodied in a
gel or radioactive micro spheres.
[0467] Without being limited by any theory, the compounds of the
present invention can render abnormal cells more sensitive to
treatment with radiation for purposes of killing and/or inhibiting
the growth of such cells. Accordingly, this invention further
relates to a method for sensitizing abnormal cells in a mammal to
treatment with radiation which comprises administering to the
mammal an amount of a compound of the present invention, which
amount is effective is sensitizing abnormal cells to treatment with
radiation.
[0468] The compounds or pharmaceutical compositions of the present
invention can be used in combination with an amount of one or more
substances selected from anti-angiogenesis agents, signal
transduction inhibitors, and antiproliferative agents.
[0469] Anti-angiogenesis agents, such as MMP-2
(matrix-metalloprotienase 2) inhibitors, MMP-9
(matrix-metalloprotienase 9) inhibitors, and COX--H (cyclooxygenase
11) inhibitors, can be used in conjunction with a compound of the
present invention and pharmaceutical compositions described herein.
Examples of useful COX-11 inhibitors include CELEBREX.TM.
(alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix
metalloproteinase inhibitors are described in WO 96/33172
(published Oct. 24, 1996), WO 96/27583 (published Mar. 7, 1996),
European Patent Application No. 97304971.1 (filed Jul. 8, 1997),
European Patent Application No. 99308617.2 (filed Oct. 29, 1999),
WO 98/07697 (published Feb. 26, 1998), WO 98/03516 (published Jan.
29, 1998), WO 98/34918 (published Aug. 13, 1998), WO 98/34915
(published Aug. 13, 1998), WO 98/33768 (published Aug. 6, 1998), WO
98/30566 (published Jul. 16, 1998), European Patent Publication
606,046 (published Jul. 13, 1994), European Patent Publication 931,
788 (published Jul. 28, 1999), WO 90/05719 (published May 31,
1990), WO 99/52910 (published Oct. 21, 1999), WO 99/52889
(published Oct. 21, 1999), WO 99/29667 (published Jun. 17, 1999),
PCT International Application No. PCT/IB98/01113 (filed Jul. 21,
1998), European Patent Application No. 99302232.1 (filed Mar. 25,
1999), Great Britain Patent Application No. 9912961.1 (filed Jun.
3, 1999), U.S. Provisional Application No. 60/148,464 (filed Aug.
12, 1999), U.S. Pat. No. 5,863,949 (issued Jan. 26, 1999), U.S.
Pat. No. 5,861,510 (issued Jan. 19, 1999), and European Patent
Publication 780,386 (published Jun. 25, 1997), all of which are
incorporated herein in their entireties by reference. Preferred
MMP-2 and MMP-9 inhibitors are those that have little or no
activity inhibiting MMP-1. More preferred, are those that
selectively inhibit MMP-2 and/or AMP-9 relative to the other
matrix-metalloproteinases (i. e., MAP-1, MMP-3, MMP-4, MMP-5,
MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). Some
specific examples of MMP inhibitors useful in the present invention
are AG-3340, RO 32-3555, and RS 13-0830.
[0470] The invention also relates to a method of and to a
pharmaceutical composition of treating a cardiovascular disease in
a mammal which comprises an amount of a compound of the present
invention, or an isotopically-labeled derivative thereof, and an
amount of one or more therapeutic agents use for the treatment of
cardiovascular diseases.
[0471] Examples for use in cardiovascular disease applications are
anti-thrombotic agents, e.g., prostacyclin and salicylates,
thrombolytic agents, e.g., streptokinase, urokinase, tissue
plasminogen activator (TPA) and anisoylated
plasminogen-streptokinase activator complex (APSAC), anti-platelets
agents, e.g., acetyl-salicylic acid (ASA) and clopidrogel,
vasodilating agents, e.g., nitrates, calcium channel blocking
drugs, antiproliferative agents, e.g., colchicine and alkylating
agents, intercalating agents, growth modulating factors such as
interleukins, transformation growth factor-beta and congeners of
platelet derived growth factor, monoclonal antibodies directed
against growth factors, anti-inflammatory agents, both steroidal
and non-steroidal, and other agents that can modulate vessel tone,
function, arteriosclerosis, and the healing response to vessel or
organ injury post intervention. Antibiotics can also be included in
combinations or coatings comprised by the invention. Moreover, a
coating can be used to effect therapeutic delivery focally within
the vessel wall. By incorporation of the active agent in a
swellable polymer, the active agent will be released upon swelling
of the polymer.
[0472] Other exemplary therapeutic agents useful for a combination
therapy include but are not limited to agents as described above,
radiation therapy, hormone antagonists, hormones and their
releasing factors, thyroid and antithyroid drugs, estrogens and
progestins, androgens, adrenocorticotropic hormone; adrenocortical
steroids and their synthetic analogs; inhibitors of the synthesis
and actions of adrenocortical hormones, insulin, oral hypoglycemic
agents, and the pharmacology of the endocrine pancreas, agents
affecting calcification and bone turnover: calcium, phosphate,
parathyroid hormone, vitamin D, calcitonin, vitamins such as
water-soluble vitamins, vitamin B complex, ascorbic acid,
fat-soluble vitamins, vitamins A, K, and E, growth factors,
cytokines, chemokines, muscarinic receptor agonists and
antagonists; anticholinesterase agents; agents acting at the
neuromuscular junction and/or autonomic ganglia; catecholamines,
sympathomimetic drugs, and adrenergic receptor agonists or
antagonists; and 5-hydroxytryptamine (5-HT, serotonin) receptor
agonists and antagonists.
[0473] Therapeutic agents can also include agents for pain and
inflammation such as histamine and histamine antagonists,
bradykinin and bradykinin antagonists, 5-hydroxytryptamine
(serotonin), lipid substances that are generated by
biotransformation of the products of the selective hydrolysis of
membrane phospholipids, eicosanoids, prostaglandins, thromboxanes,
leukotrienes, aspirin, nonsteroidal anti-inflammatory agents,
analgesic-antipyretic agents, agents that inhibit the synthesis of
prostaglandins and thromboxanes, selective inhibitors of the
inducible cyclooxygenase, selective inhibitors of the inducible
cyclooxygenase-2, autacoids, paracrine hormones, somatostatin,
gastrin, cytokines that mediate interactions involved in humoral
and cellular immune responses, lipid-derived autacoids,
eicosanoids, .beta.-adrenergic agonists, ipratropium,
glucocorticoids, methylxanthines, sodium channel blockers, opioid
receptor agonists, calcium channel blockers, membrane stabilizers
and leukotriene inhibitors.
[0474] Additional therapeutic agents contemplated herein include
diuretics, vasopressin, agents affecting the renal conservation of
water, rennin, angiotensin, agents useful in the treatment of
myocardial ischemia, anti-hypertensive agents, angiotensin
converting enzyme inhibitors, .beta.-adrenergic receptor
antagonists, agents for the treatment of hypercholesterolemia, and
agents for the treatment of dyslipidemia.
[0475] Other therapeutic agents contemplated include drugs used for
control of gastric acidity, agents for the treatment of peptic
ulcers, agents for the treatment of gastroesophageal reflux
disease, prokinetic agents, antiemetics, agents used in irritable
bowel syndrome, agents used for diarrhea, agents used for
constipation, agents used for inflammatory bowel disease, agents
used for biliary disease, agents used for pancreatic disease.
Therapeutic agents used to treat protozoan infections, drugs used
to treat Malaria, Amebiasis, Giardiasis, Trichomoniasis,
Trypanosomiasis, and/or Leishmaniasis, and/or drugs used in the
chemotherapy of helminthiasis. Other therapeutic agents include
antimicrobial agents, sulfonamides, trimethoprim-sulfamethoxazole
quinolones, and agents for urinary tract infections, penicillins,
cephalosporins, and other, .beta.-Lactam antibiotics, an agent
comprising an aminoglycoside, protein synthesis inhibitors, drugs
used in the chemotherapy of tuberculosis, Mycobacterium avium
complex disease, and leprosy, antifungal agents, antiviral agents
including nonretroviral agents and antiretroviral agents.
[0476] Examples of therapeutic antibodies that can be combined with
a subject compound include but are not limited to anti-receptor
tyrosine kinase antibodies (cetuximab, panitumumab, trastuzumab),
anti CD20 antibodies (rituximab, tositumomab), and other antibodies
such as alemtuzumab, bevacizumab, and gemtuzumab.
[0477] Moreover, therapeutic agents used for immunomodulation, such
as immunomodulators, immunosuppressive agents, tolerogens, and
immunostimulants are contemplated by the methods herein. In
addition, therapeutic agents acting on the blood and the
blood-forming organs, hematopoietic agents, growth factors,
minerals, and vitamins, anticoagulant, thrombolytic, and
antiplatelet drugs.
[0478] Further therapeutic agents that can be combined with a
subject compound may be found in Goodman and Gilman's "The
Pharmacological Basis of Therapeutics" Tenth Edition edited by
Hardman, Limbird and Gilman or the Physician's Desk Reference, both
of which are incorporated herein by reference in their
entirety.
[0479] The compounds described herein can be used in combination
with the agents disclosed herein or other suitable agents,
depending on the condition being treated. Hence, in some
embodiments the compounds of the invention will be co-administered
with other agents as described above. When used in combination
therapy, the compounds described herein may be administered with
the second agent simultaneously or separately. This administration
in combination can include simultaneous administration of the two
agents in the same dosage form, simultaneous administration in
separate dosage forms, and separate administration. That is, a
compound described herein and any of the agents described above can
be formulated together in the same dosage form and administered
simultaneously. Alternatively, a compound of the present invention
and any of the agents described above can be simultaneously
administered, wherein both the agents are present in separate
formulations. In another alternative, a compound of the present
invention can be administered just followed by and any of the
agents described above, or vice versa. In the separate
administration protocol, a compound of the present invention and
any of the agents described above may be administered a few minutes
apart, or a few hours apart, or a few days apart.
[0480] The methods in accordance with the invention may include
administering a c-met kinase selective inhibitor with one or more
other agents that either enhance the activity of the inhibitor or
compliment its activity or use in treatment. Such additional
factors and/or agents may produce an augmented or even synergistic
effect when administered with a c-met kinase selective inhibitor,
or minimize side effects.
[0481] In one embodiment, the methods of the invention may include
administering formulations comprising a c-met kinase selective
inhibitor of the invention with a particular cytokine, lymphokine,
other hematopoietic factor, thrombolytic or anti-thrombotic factor,
or anti-inflammatory agent before, during, or after administration
of the c-met kinase inhibitor. One of ordinary skill can easily
determine if a particular cytokine, lymphokine, hematopoietic
factor, thrombolytic of anti-thrombotic factor, and/or
anti-inflammatory agent enhances or compliments the activity or use
of the c-met kinase inhibitors in treatment.
[0482] More specifically, and without limitation, the methods of
the invention may comprise administering a c-met kinase selective
inhibitor with one or more of TNF, IL-1, IL-2, IL-3, IL4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15,
IL-16, IL-17, IL-18, IFN, G-CSF, Meg-CSF, GM-CSF, thrombopoietin,
stem cell factor, and erythropoietin. Compositions in accordance
with the invention may also include other known angiopoietins such
as Ang-2, Ang4, and Ang-Y, growth factors such as bone morphogenic
protein-i, bone morphogenic protein-2, bone morphogenic protein-3,
bone morphogenic protein-4, bone morphogenic protein-5, bone
morphogenic protein-6, bone morphogenic protein-7, bone morphogenic
protein-8, bone morphogenic protein-9, bone morphogenic protein-10,
bone morphogenic protein-11, bone morphogenic protein-12, bone
morphogenic protein-13, bone morphogenic protein-14, bone
morphogenic protein-15, bone morphogenic protein receptor IA, bone
morphogenic protein receptor TB, brain derived neurotrophic factor,
ciliary neutrophic factor, ciliary neutrophic factor receptor a,
cytokine-induced neutrophil chemotactic factor 1, cytokine-induced
neutrophil chemotactic factor 2 alpha, cytokine-induced neutrophil
chemotactic factor 2 beta, beta endothelial cell growth factor,
endothelin 1, epidermal growth factor, epithelial-derived
neutrophil attractant, fibroblast growth factor 4, fibroblast
growth factor 5, fibroblast growth factor 6, fibroblast growth
factor 7, fibroblast growth factor 8, fibroblast growth factor 8b,
fibroblast growth factor 8c, fibroblast growth factor 9, fibroblast
growth factor 10, fibroblast growth factor acidic, fibroblast
growth factor basic, glial cell line-derived neutrophic factor
receptor al, glial cell line-derived neutrophic factor receptor a2,
growth related protein, growth related protein a, growth related
protein .beta., growth related protein .gamma., heparin binding
epidermal growth factor, hepatocyte growth factor, hepatocyte
growth factor receptor, insulin-like growth factor I, insulin-like
growth factor receptor, insulin-like growth factor II, insulin-like
growth factor binding protein, keratinocyte growth factor, leukemia
inhibitory factor, leukemia inhibitory factor receptor alpha, nerve
growth factor, nerve growth factor receptor, neurotrophin-3,
neurptrophin-4, placenta growth factor, placenta growth factor 2,
platelet derived endothelial cell growth factor, platelet derived
growth factor, platelet derived growth factor A chain, platelet
derived growth factor AA, platelet derived growth factor AB,
platelet derived growth factor B chain, platelet derived growth
factor BB, platelet derived growth factor receptor a, platelet
derived growth factor receptor beta, pre-B cell growth stimulating
factor, stem cell factor, stem cell factor receptor, transforming
growth factor alpha, transforming growth factor beta, transforming
growth factor beta 1, transforming growth factor beta 1.2,
transforming growth factor beta 2, transforming growth factor beta
3, transforming growth factor beta 5, latent transforming growth
factor beta 1, transforming growth factor beta binding protein I,
transforming growth factor beta binding protein II, transforming
growth factor beta binding protein III, tumor necrosis factor
receptor type I, tumor necrosis factor receptor type II,
urokinase-type plasminogen activator receptor, and chimeric
proteins and biologically or immunologically active fragments
thereof.
[0483] The following general methodology described herein provides
the manner and process of making and using the compound of the
present invention and are illustrative rather than limiting.
Further modification of provided methodology and additionally new
methods may also be devised in order to achieve and serve the
purpose of the invention. Accordingly, it should be understood that
there may be other embodiments which fall within the spirit and
scope of the invention as defined by the specification hereto.
[0484] Representative compounds of the present invention include
those specified above in Table 1 and pharmaceutically acceptable
salts thereof. The present invention also includes the intermediate
compounds discussed in the examples and elsewhere in the
specification as well as their salts. The present invention should
not be construed to be limited to them.
General Methods of Preparation of Compounds of the Invention
[0485] The compounds of the present invention may be prepared by
the following processes. Unless otherwise indicated, the variables
(e.g. Cy.sup.1, R.sup.2, L.sub.1, L.sub.2, X, and Cy.sup.2) when
used in the below formulae are to be understood to present those
groups described above in relation to formula (I).
[0486] Scheme 1: This scheme provides a method for the preparation
of the compound of formula (IA) wherein L.sub.2 is
--CR.sup.aR.sup.b--, X is CR.sup.1 or N and the other variables
such as Cy.sup.1, R.sup.2, and Cy.sup.2 are the same as described
above in relation to formula (I).
##STR00206##
[0487] The compound of formula (1) wherein Hal represents a halogen
and R.sup.2 is the same as described above in relation to formula
(I) can be coupled with a compound of formula Cy.sup.2-L2-NH.sub.2
in the presence of a suitable base, such as sodium or potassium
carbonate, to give a compound of formula (2) wherein L.sub.2 is
--CR.sup.aR.sup.b--. The compound of formula (2) can then be
converted to a compound of formula (3) by reducing with a metal
such as iron, or a metal halide such as stannous chloride and an
acid (such as acetic acid, hydrochloric acid or ammonium chloride).
The compound of formula (3) can then be cyclised to form a compound
of formula (4) wherein X.dbd.N using nitrous acid, generated in
situ by reacting an alkali metal nitrite such as sodium nitrite
with an acid such as acetic acid or hydrochloric acid. The compound
of formula (3) can be cyclised to form a compound of formula (4)
wherein X.dbd.CR.sup.1, by heating or irradiating with microwaves
in the presence of R.sup.1COOII wherein R.sup.1 is H or a
C.sub.1-C.sub.4 alkyl group. The compound of formula (4) can be
coupled with a boronic acid of formula Cy.sup.1-B(OR).sub.2
(wherein R.dbd.H) or its ester (wherein R=alkyl) in the presence of
a transition metal catalyst such as
tetrakis(triphenylphosphine)palladium(0) and a suitable base such
as potassium carbonate to give the desired compounds of formula
(IA) wherein L.sub.2 is --CR.sup.aR.sup.b--, X is CR.sup.1 or N and
the other variables such as Cy.sup.1, R.sup.2 and Cy.sup.2 are the
same as described above in relation to formula (I)
[0488] Alternatively, the compound of formula (2) may be coupled
with a boronic acid of formula Cy.sup.1-B(OR).sub.2 (wherein
R.dbd.H) or its ester (wherein R=alkyl) in the presence of a
catalyst such as tetrakis(triphenylphosphine)palladium(0) and a
suitable base such as potassium carbonate to give a compound of
formula (5). The compound of formula (5) can then be converted to a
compound of formula (6) by reducing with a metal such as iron, or a
metal halide such as stannous chloride and an acid such as acetic
acid, hydrochloric acid or ammonium chloride. The compound of
formula (6) can then be cyclised to a compound of formula (IA)
wherein X.dbd.N, using nitrous acid, generated in situ by reacting
an alkali metal nitrite such as sodium nitrite with an acid such as
acetic acid or hydrochloric acid. The compound of formula (6) can
then be cyclised to form a compound of formula (IA) wherein
X.dbd.CR.sup.1, by heating or irradiating with microwaves in the
presence of R.sup.1COOH wherein R.sup.1 is H or a C.sub.1-C.sub.4
alkyl group.
[0489] Scheme 1A: This scheme provides a method for the preparation
of the compound of formula (IA) wherein L.sub.2 is
--CR.sup.aR.sup.b--, X is CR.sup.1 or N and the other variables
such as Cy.sup.1, R.sup.2, and Cy.sup.2 are the same as described
above in relation to formula (I).
##STR00207##
[0490] The compound of formula (1) wherein Hal represents a halogen
and R.sup.2 is the same as described above in relation to formula
(I) can be coupled with a boronic acid of formula
Cy.sup.1-B(OR).sub.2 (wherein R.dbd.H) or its ester (wherein
R=alkyl) in the presence of a transition metal catalyst such as
tetrakis(triphenylphosphine)palladium(O) and a suitable base such
as potassium carbonate to give compound of formula (1a). Compound
of formula (1a) can be converted to compound of formula (1b) using
Ammonia or rectinf compound of formula (1a) with a compound of
formula -NIIPg (wherein Pg is protecting group) under suitable
conditions. Compound of formula (1a) can then be coupled with a
compound of formula Cy.sup.2-L.sub.2-NH.sub.2 or compound of
formula (1b) can be coupled L.sub.2-NH.sub.2 in the presence of a
suitable base, such as sodium or potassium carbonate, to give a
compound of formula (5) wherein L.sub.2 is --CR.sup.aR.sup.b--. The
compound of formula (5) can then be converted to a compound of
formula (6) by reducing with a metal such as iron, or a metal
halide such as stannous chloride and an acid such as acetic acid,
hydrochloric acid or ammonium chloride. The compound of formula (6)
can then be cyclised to provide desired compound of formula (IA)
wherein X.dbd.N, using nitrous acid, generated in situ by reacting
an alkali metal nitrite such as sodium nitrite with an acid such as
acetic acid or hydrochloric acid. The compound of formula (6) can
then be cyclised to provide desired compound of formula (IA)
wherein X.dbd.CR.sup.1, by heating or irradiating with microwaves
in the presence of R.sup.1COOH wherein R.sup.1 is H or a
C.sub.1-C.sub.4 alkyl group.
##STR00208##
##STR00209##
##STR00210##
[0491] Scheme 2: This scheme provides a method for the preparation
of a compound of formula (IA-I) wherein D is substituted or
unsubstituted monocyclic aryl or substituted or unsubstituted
monocyclic heteroaryl and the other variables such as L.sub.2,
R.sup.2, X, and Cy.sup.2 are the same as described above in
relation to formula (IA-I):
##STR00211##
[0492] A compound of formula (4) can be coupled with a boronic acid
of formula (7) (wherein R.dbd.H or its ester (i.e. R=alkyl)) in the
presence of a transition metal catalyst such as
tetrakis(triphenylphosphine)palladium(0) and a suitable base such
as potassium carbonate to give compound of formula (IA-1).
[0493] Scheme 2A: This scheme provides an alternative method for
the preparation of a compound of formula (IA-I) wherein D is
substituted or unsubstituted monocyclic aryl or substituted or
unsubstituted monocyclic heteroaryl and the other variables such as
L.sub.2, R.sup.2, X, and Cy.sup.2 are the same as described above
in relation to formula (IA-I):
##STR00212##
[0494] A compound of formula (7a) wherein Lg is leaving group
(preferably Halogen or Triflate) can be coupled with a boronic acid
of formula (4a) wherein R.dbd.H or its ester (i.e. R=alkyl) in the
presence of a transition metal catalyst such as
tetrakis(triphenylphosphine)palladium(0) and a suitable base such
as potassium carbonate to give compound of formula (IA-I).
[0495] Scheme 3: This scheme provides a method for the preparation
of a compound of formula (IA-I) wherein D is phenyl substituted
with --CONH--O--(CR.sup.xR.sup.y), --OR.sup.x,
--CONH--(CR.sup.xR.sup.y).sub.p--OR.sup.x,
--CONH--(CR.sup.xR.sup.y).sub.p--NHR.sup.y Optionally the phenyl
ring is further substituted with one or more R' wherein each R' is
independently hydrogen, halogen or substituted or unsubstituted
alkyl.
##STR00213##
[0496] The compound of formula (4) can be coupled with a boronic
acid of formula (8) (wherein R.dbd.H) or its ester (wherein
R=alkyl) in the presence of a transition metal catalyst such as
tetrakis(triphenylphosphine)palladium(0) and a suitable base such
as potassium carbonate to give the compound of formula (9). The
compound of formula (9) can be hydrolysed in the presence of an
alkali metal hydroxide such as lithium hydroxide to give the
compound of formula (10). The compound of formula (10) can be
converted into a compound of formula (IA-I) by reacting it with an
amine of the formula R.sup.xR.sup.yNH in the presence of an amide
coupling reagent such as
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
(EDC.HCl), (benzotriazol-1yl)oxytris(dimethylamino)phosphonium
hexafluorophosphate (BOP) or any other amide coupling reagent known
in the art. Alternatively the conversion can be effected by
reacting the compound of formula (10) with a halogenating agent
such as thionyl chloride and subsequently reacting the resultant
acid halide with an amine of the formula
NH.sub.2--O--(CR.sup.xR.sup.y).sub.p--OR.sup.x,
NH.sub.2--(CR.sup.xR.sup.y).sub.p--OR.sup.x or
NH.sub.2--(CR.sup.xR.sup.y).sub.p--NHR.sup.y in the presence of a
suitable base such as a trialkylamine. The compounds of formula
(IA-I) can also be obtained by reacting the compound of formula (4)
with a boronic acid of formula (11) (wherein R.dbd.H) or its ester
(wherein R=alkyl).
Illustrative Example for Scheme 3
##STR00214##
[0498] Additionally, the compounds of the present invention may be
prepared by the following processes as disclosed in International
Patent Application No. PCT/IB2011/052120, filed 13 May 2011, and
U.S. patent application Ser. No. 13/108,642 filed 16 May 2011.
These methods can similarly be applied to other compounds of
formula as provided herein above with or without modification.
[0499] Similar methodologies with certain modifications as known to
those skilled in the art can be used to synthesize compounds of
formula (I), (IA) and (IA-I) wherein all the variables are to be
understood to present those groups described above in relation to
formula (I), (IA) and (IA-I) using suitable intermediates and
reagents.
EXPERIMENTAL DATA
[0500] Intermediates
Intermediate 1: Quinolin-6-ylmethanamine
[0501] Step 1: Quinoline-6-carboxylic acid: To a mixture of
4-aminobenzoic acid: (175 g, 1.28 mol), 4-nitrophenol (88.75 g,
0.64 mol) and sulphuric acid (1.2 lit.), glycerol (234.8 g, 2.55
mol) was added drop wise at 135.degree. C. After 48 h, the reaction
mixture was cooled to 0.degree. C. and the pH adjusted to 3-5 with
10% sodium hydroxide solution. The resulting precipitate was
collected by filtration and washed with water and dried under
vacuum to afford the title compound as a black solid (125 g,
56%).
[0502] Step 2: Methyl quinoline-6-carboxylate: To a solution of
quinoline-6-carboxylic acid (183 g, 1.06 mol) in methanol (1 lit.),
thionyl chloride (150.7 g, 1.2 mol) was added drop wise at
0.degree. C. and then stirred at 65.degree. C. for 12 h. The
reaction mixture was concentrated and to the residue
dichloromethane and aqueous sodium carbonate solutions were added.
The organic layer was dried with sodium sulphate and concentrated
to afford the title compound as a brown solid (150 g, 75%).
[0503] Step 3: Quinoline-6-carboxamide: To a solution of methyl
quinoline-6-carboxylate (148 g, 0.79 mol) in methanol (600 ml),
aqueous ammonia (800 ml) was added and then stirred at 45.degree.
C. for 12 h. The reaction mixture was concentrated to afford the
title compound as a dark red solid (120 g, 88%).
[0504] Step 4: Quinoline-6-carbonitrile: To a solution of
quinoline-6-carboxamide (177 g, 1.03 mol) in chloroform (1.5 lit.)
triethylamine (520.15 g, 5.15 mol) and trifluoroacetic anhydride
(540.34 g, 2.57 mol) was added drop wise below 10.degree. C. After
1.5 h, the pH was adjusted to 7 with sodium bicarbonate solution
and extracted with dichloromethane. The organic layer was dried
with sodium sulphate and concentrated to afford the title compound
as a brown solid (96 g, 59%).
[0505] Step 5: Quinolin-6-ylmethanamine: To a solution of
quinoline-6-carbonitrile (96 g, 0.62 mol) in saturated ammonia in
methanol (1 lit.), Raney-Ni (10 g) was added and the mixture was
stirred at 1 atm of H.sub.2 at RT for 16 h. The reaction mixture
was filtered and the filtrate was concentrated under vacuum to
afford the title compound as a brown oil (80 g, 82%). .sup.1H-NMR
(6 ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.83 (dd, J=4.2, 1.7 Hz,
1H), 8.29 (d, J=8.3 Hz, 1H), 7.95 (d, J=8.6 Hz, 1H), 7.85 (s, 1H),
7.75 (dd J=8.7, 1.8 Hz, 1H), 7.49 (dd, J=8.2, 4.2 Hz, 1H), 3.90 (s,
2II).
Intermediate 2: (7-fluoroquinolin-6-yl)methanamine
[0506] Step 1: 6-Bromo-7-fluoroquinoline: To a mixture of
4-bromo-2-fluoroaniline (10 g, 52.62 mmol), ferrous sulphate (3.33
g, 11.97 mmol) and glycerol (15.78 ml) con. sulphuric acid (9.15
ml) was added slowly and the reaction mixture was heated to
140.degree. C. After 12 h, the reaction mixture was cooled to
0.degree. C. and the pH adjusted to 10-12 with 10% sodium hydroxide
solution. The reaction mixture was filtered through celite, washed
with ethyl acetate and layers were separated. The organic layer was
washed with brine solution, dried over sodium sulphate and
concentrated. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the
title compound as a white solid (4.9 g, 44%). .sup.1H-NMR (.delta.
ppm, CDCl.sub.3, 400 MHz): .delta. 8.96 (dd, J=4.3, 2.7 Hz, 1H),
8.15 (m, 2H), 7.81 (d, J=9.5 Hz, 1H), 7.42 (dd, J=8.3, 4.3 Hz,
1H).
[0507] Step 2: 7-Fluoroquinoline-6-carbonitrile: To a solution of
6-bromo-7-fluoroquinoline (4.90 g, 22.12 mmol) in dimethylacetamide
(38 ml), potassium ferrocyanide (2.65 g, 4.86 mmol) and sodium
carbonate (2.34 g, 22.12 mmol). The system was purged with nitrogen
for 15 min. Palladium acetate (0.248 g, 1.10 mmol) was added under
nitrogen and heated to 120.degree. C. After 3 h, the reaction
mixture was filtered through celite, washed with ethyl acetate. The
organic layer was washed with brine solution, dried over sodium
sulphate and concentrated. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the
title compound as a white solid (3.2 g, 86%). .sup.1H-NMR (.delta.
ppm, CDCl.sub.3, 400 MHz): .delta. (dd, J=4.1, 2.9 Hz, 1H), 8.25
(m, 2H), 7.90 (d, J=10.0 Hz, 1H), 7.53 (dd, J=8.3, 4.3 Hz, 1H).
[0508] Step 3: (7-Fluoroquinolin-6-yl)methanamine: To
7-fluoroquinoline-6-carbonitrile (1.00 g, 5.813 mmol), methanol
saturated with ammonia (13.5 ml) and Raney-Ni (1.27 g) were added
and hydrogenated at 50-60 psi for 4 h. The reaction mixture was
filtered and concentrated to afford the title compound as a brown
oil (0.80 g, 78%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.85 (d, J=2.3 Hz, 1H), 8.35 (d, J=8.0 Hz, 1H), 8.06
(d, J=9.5 Hz, 1H), 7.68 (d, J=11.8 Hz, 1H), 7.49 (t, J=3.8 Hz, 1H),
3.92 (s, 2H), 1.90 (br s, 2H).
[0509] Intermediate 3:
6-Chloro-3-nitro-N-(quinolin-6-ylmethyl)pyridin-2-amine: To a
solution of 2,6-Dichloro-3-nitropyridine (1.62 g, 8.42 mmol) in
ethanol (30 ml), sodium carbonate (2.34 g, 22.12 mmol) was added at
RT and cooled to 0.degree. C. followed by the addition of
intermediate 1 (2 g, 12.64 mmol) in ethanol (20 ml) the mixture was
stirred at RT for 12 h. The reaction mixture was poured into 25 ml
of water and extracted with ethyl acetate, washed with brine
solution, dried over sodium sulphate and concentrated. The crude
product was purified by column chromatography with dichlomethane:
methanol to afford the title compound as a yellow solid (2.0 g,
50%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta.
9.35 (t, J=6.0 Hz, 11H), 8.85 (dd, J=4.0, 1.4 Hz, 11H), 8.46 (d,
J=8.5 Hz, 1H), 8.31 (d, J=7.8 Hz, 11H), 7.98 (d J=8.7 Hz, 1H), 7.88
(s, 1H), 7.79 (dd, J=8.7, 1.6 Hz, 1H), 7.50 (dd, J=8.3, 4.2 Hz,
1H), 6.80 (d, J=8.6 Hz, 1H), 4.92 (d, J=6.1 Hz, 2H).
[0510] Intermediate 4:
6-Chloro-N-((7-fluoroquinolin-6-yl)methyl)-3-nitropyridin-2-amine:
The title compound was obtained as a yellow solid (0.750 g, 50%) by
using a procedure that is similar to the one described for
intermediate 3 from 2,6-dichloro-3-nitropyridine (1.31 g, 6.81
mmol), Intermediate 2 (0.80 g, 4.54 mmol), ethanol (15 ml) and
sodium carbonate (0.838 g, 7.90 mmol). .sup.1II-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 9.27 (t, J=5.7 Hz, 1II), 8.87 (d,
J=2.8 Hz, 1H), 8.49 (d, J=8.5 Hz, 1H), 8.34 (d, J=8.0 Hz, 1H), 7.96
(d J=8.4 Hz, 1H), 7.78 (d, J=7.7 Hz, 1H), 7.49 (dd, J=8.3, 4.2 Hz,
1H), 6.83 (d, J=8.6 Hz, 1H), 4.95 (d, J=5.9 Hz, 2H).
[0511] Intermediate 5:
6-chloro-N.sup.2-(quinolin-6-ylmethyl)pyridine-2,3-diamine:
Stannous chloride (0.258 g, 1.143 mmol) and conc.HCl (3 ml) were
added intermediate 3 (0.180 g, 0.571 mmol) at RT and stirred for 1
h. After 1 h stannous chloride (0.258 g, 1.143 mmol) and conc.HCl
(2 ml) were added and maintained for 1 h. The reaction mixture was
poured into ice water and the pH was adjusted to ca. 8 with sodium
bicarbonate solution, extracted with ethyl acetate, washed with
brine, dried over anhydrous sodium sulphate and concentrated to
afford the title compound as a yellow solid (0.150 g, 92%).
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.85 (dd, J=4.2,
1.6 Hz, 1H), 8.32 (d, J=7.9 Hz, 1H), 7.98 (d, J=8.7 Hz, 1H), 7.86
(s, 1II), 7.76 (dd, J=8.7, 1.8 IIz, 1II), 7.51 (dd, J=8.3, 4.2 IIz,
1II), 6.73 (d, J=7.8 IIz, 1H), 6.59 (t, J=5.6 Hz, 1H), 6.38 (d,
J=7.7 Hz, 1H), 4.92 (s, 2H), 4.70 (s, 2H).
[0512] Intermediate 6:
6-Chloro-N2-((7-fluoroquinolin-6-yl)methyl)pyridine-2,3-diamine:
The title compound was obtained as a yellow solid (0.550 g, 74%) by
using a procedure that is similar to the one described for
intermediate 5 from intermediate 4 (0.750 g, 2.25 mmol), stannous
chloride (2.28 g, 10.14 mmol) and cone. HCl (13 ml). .sup.1H-NMR
(.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta.8.87 (d, J=3.0 Hz,
1H), 8.36 (d, J=8.2 Hz, 1H), 7.97 (d, J=8.3 Hz, 1H), 7.77 (d,
J=11.6 Hz, 1H), 7.50 (dd, J=8.2, 4.1 Hz, 1H), 6.74 (d, J=8.5 Hz,
1H), 6.54 (t, J=5.0 Hz, 1H), 6.39 (d, J=7.8 Hz, 1H), 4.94 (s, 2H),
4.72 (d, J=5.3 Hz, 2H).
[0513] Intermediate 7:
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline:
Intermediate 5 (0.220 g, 0.772 mmol) was dissolved in acetic acid
(1.3 ml) and cooled to 5.degree. C. Sodium nitrite (0.063 g, 0.927
mmol) in 0.35 ml water was added slowly followed by sulphuric acid
(0.09 ml). The reaction mixture was warmed to RT and stirred for 30
min. The reaction mixture was poured into ice water and pH adjusted
to ca. 8 with sodium bicarbonate solution, extracted with ethyl
acetate, washed with brine, dried over sodium sulphate and
concentrated to afford the title compound as a brown solid (0.220
g, 96%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.88 (s,
1H), 8.69 (d, J=8.6 Hz, 1H), 8.35 (d, J=8.1 Hz, 1H), 8.01 (d, J=8.6
Hz, 1H), 7.90 (s, 1H), 7.74 (d, J=8.5 Hz, 1H), 7.61 (d, J=8.5 Hz,
1H), 7.53 (dd, J=8.0, 4.0 Hz, 1H), 6.12 (s, 2H).
[0514] Intermediate 8:
6-((5-Chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)-7-fluoroquinol-
ine: The title compound was obtained as a brown solid (0.345 g,
62%) by using a procedure that is similar to the one described for
intermediate 7 from intermediate 6 (0.540 g, 1.78 mmol), acetic
acid (3.1 ml), sodium nitrite (0.148 g, 2.13 mmol), water (0.8 ml)
and sulphuric acid (0.2 ml). .sup.1H-NMR (.delta. ppm, CDCl.sub.3,
400 MHz): .delta. 8.91 (d, J=2.9 Hz, 1H), 8.36 (d, J=8.6 Hz, 1H),
8.08 (d, J=8.1 Hz, 1H), 7.80 (d, J=11.0 Hz, 1H), 7.70 (d, J=7.8 Hz,
1H), 7.40 (m, 2H), 6.11 (s, 2H).
[0515] Intermediate 9:
2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide:
Potassium acetate (0.627 g, 6.39 mmol) and bis(pinacolato)diboron
(0.595 g, 2.34 mmol) were added to a solution of
4-bromo-2-chlorobenzamide (0.500 g, 2.13 mmol) in dioxane 3.6 ml),
and the solution was degassed for 30 min. To this solution
[1,1'-bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH.sub.2Cl.sub.2 (0.052 g, 0.063 mmol) was added
under nitrogen atmosphere and heated to 80.degree. C. After 12 h,
the reaction mixture was filtered through celite and concentrated.
The crude product was purified by column chromatography with ethyl
acetate: petroleum ether to afford the title compound as a brown
solid (0.75 g, 69%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 7.91 (s, 1H), 7.89 (m, 1H), 7.61 (m, 2H), 7.44 (d,
J=7.6 Hz, 1H), 1.14 (s, 12H).
[0516] Intermediate 10:
3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridine-5-carbonitrile:
The title compound was obtained as a brown solid (0.400 g, 83%) by
using the procedure described for intermediate 9 from intermediate
7 (0.700 g, 2.92 mmol), zinc cyanide (0.159 g, 1.35 mmol), DMF (8
ml) and) and tetrakis(triphenylphosphine)palladium(0) (0.156 g,
0.135 mmol) under microwave irradiation (microwave power=100 W,
temperature=127.degree. C.) for 45 min. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.91 (dd, J=4.2, 1.6 Hz, 1H), 8.53
(d, J=8.4 Hz, 1H), 8.16 (d, J=8.3 Hz, 1H), 8.09 (d, J=8.8 Hz, 1H),
7.93 (s, 1H), 7.82 (dd, J=8.7, 2.0 Hz, 1H), 7.72 (d, J=8.4 Hz, 1H),
7.42 (dd, J=8.3, 4.2 Hz, 1H), 6.10 (s, 2H).
Intermediate 11:
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic
acid
[0517] Step: 1 Methyl
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate-
: To a solution of intermediate 7 (0.130 g, 0.439 mmol) and
4-methoxycarbonylphenylboronic acid (0.100 g, 0.562 mmol) in
dioxane (2.6 ml), potassium carbonate (0.202 g, 1.46 mmol) and
water (0.5 ml) were added and degassed for 30 min.
Tetrakis(triphenylphosphine)palladium(0) (0.040 g, 0.035 mmol) was
added under nitrogen at RT and the reaction mixture was refluxed
for 12 h. The solvent was evaporated completely and water was added
to the residue and extracted with ethyl acetate, dried over sodium
sulphate and concentrated under reduced pressure. The crude product
was purified by column chromatography with methanol:
dichloromethane to afford the title compound as an off-white solid
(0.100 g, 57%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz):
8.88 (dd, J=4.2, 1.8 Hz, 1H), 8.72 (d, J=8.7 Hz, 1H), 8.39 (m, 3H),
8.21 (d, J=8.8 Hz, 1H), 8.12 (d, J=8.6 Hz, 2H), 8.02 (s, 1H), 8.02
(d, J=8.8 Hz, 1H), 7.84 (dd, J=8.6, 2.0 Hz, 1H), 7.53 (dd, J=8.3,
4.2 Hz, 1H), 6.23 (s, 2H), 3.89 (s, 3H).
[0518] Step: 2
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic
acid: To a solution of intermediate 11 (0.095 g, 0.240 mmol) in
methanol (1.4 ml), lithium hydroxide (0.028 g, 1.20 mmol) in water
(0.36 ml) was added and stirred at RT. After 12 h, the pH was
adjusted to ca. 7.5 using 0.5N IICl and the solid precipitated was
filtered, washed with ethyl acetate and petroleum ether and dried
under vacuum to afford the title compound as an off-white solid
(0.070 g, 76%). M.P.: 245-247.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 13.18 (s, 1H), 8.88 (dd, J=4.1, 1.7 Hz,
1H), 8.71 (d, J=8.7 Hz, 1H), 8.39 (d, J=1.1 Hz, 1H), 8.36 (d, J=8.5
Hz, 2H), 8.21 (d, J=8.7 Hz, 1H), 8.10 (d, J=8.5 Hz, 2H), 8.03 (d,
J=9.2 Hz, 2H), 7.84 (dd, J=8.7, 2.0 Hz, 1H), 7.53 (dd, J=8.4, 4.2
Hz, 1H), 6.22 (s, 2H). MS (m/z): 381.88 (m.sup.+).
Intermediate 12:
2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)benzoic acid
[0519] Step: 1 Methyl
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)benzoate: The title compound was prepared by following the
procedure described for step 1 of Intermediate 11 using
intermediate 7 (1.00 g, 3.07 mmol),
3-chloro-4-methoxycarbonylphenylboronic acid (0.825 g, 3.84 mmol),
potassium acetate (0.976 g, 9.945 mmol), dioxan (20 ml) and
tetrakis (triphenylphosphine)palladium(0) (0.284 g, 0.246 mmol).
Reddish brown solid (1.00 g, 71%). .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 8.92 (dd, J=4.2, 1.6 Hz, 11H), 8.48 (d,
J=8.6 Hz, 11H), 8.24 (d, J=1.3 Hz, 1H), 8.17 (d, J=8.3 Hz, 11H),
8.10 (d, J=11.8 Hz, 1H), 78.04 (m, 3H), 7.87 (m, 2H), 7.43 (q,
J=4.2 Hz, 1H), 6.15 (s, 2H), 3.98 (s, 3H).
[0520] Step: 2
2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)benzoic acid: The title compound was prepared by following the
procedure described for step 2 of Intermediate 11 using step 1 of
Intermediate 12 (1.00 g, 2.18 mmol) in methanol (5 ml), lithium
hydroxide (0.856 g, 20.40 mmol), water (5 ml), THF (19 ml).
Off-white solid (0.900 g, 93%). The acid was used without further
purification in the next step.
Intermediate 13: (2-methylquinolin-6-yl)methanamine
[0521] Step 1: 2-methylquinoline-6-carboxylic acid: To
4-aminobenzoic acid (5 g, 36.45 mmol), 6N HCl (73 ml) was added and
refluxed for 2 h. Crotonaldehyde (3.06 g, 43.75 mmol) was added
dropwise over 45 min. After 12 h, the reaction mixture was cooled
to 0.degree. C. and the pH adjusted to 3-5 with aqueous ammonia
solution. The aqueous layer containing solid was washed with
dichloromethane and acidified with 2N HCl, filtered and dried under
vacuum to afford the title compound as brown solid (3.0 g,
44%).
[0522] Step 2: methyl 2-methylquinoline-6-carboxylate: To a
solution of 2-methylquinoline-6-carboxylic acid (3.0 g, 16.20 mmol)
in methanol (30 ml.), sulphuric acid (3 ml) was added dropwise at
0.degree. C. and then stirred at 65.degree. C. for 12 h. The
reaction mixture was concentrated and to the residue
dichloromethane and aqueous sodium carbonate solutions were added.
The organic layer was dried with sodium sulphate and concentrated
to afford the title compound as a brown solid (1.9 g, 59%).
[0523] Step 3: 2-methylquinoline-6-carboxamide: To a solution of
methyl 2-methylquinoline-6-carboxylate (1.9 g, 9.44 mmol) in
methanol (7.6 ml.), aqueous ammonia (10 ml) was added and then
stirred at 45.degree. C. for 12 h. The reaction mixture was
concentrated to afford the title compound as a off-white red solid
(1.0 g, 56%).
[0524] Step 4: 2-methylquinoline-6-carbonitrile: To a solution of
2-methylquinoline-6-carboxamide (1.0 g, 5.36 mmol) in chloroform (5
ml.) and triethylamine (2.71 g, 26.84 mmol), trifluoroacetic
anhydride (2.81 g, 13.42 mmol) was added dropwise below 10.degree.
C. After 1.5 h, the pH was adjusted to 7 with sodium bicarbonate
solution and extracted with dichloromethane. The organic layer was
dried with sodium sulphate and concentrated to afford the title
compound as a yellow solid (0.70 g, 77%).
[0525] Step 5: (2-methylquinolin-6-yl)methanamine: To a solution of
2-methylquinoline-6-carbonitrile (0.700 g, 4.16 mmol) in saturated
ammonia in methanol (10 ml), Raney-Ni (1.4 g) was added and the
mixture was stirred at 1 atm of H.sub.2 at RT for 16 h. The
reaction mixture was filtered and the filtrate was concentrated
under vacuum to afford the title compound as a brown oil (0.700 g,
97%). .sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.83 (dd,
J=4.2, 1.7 Hz, 1H), 8.29 (d, J=8.3 Hz, 1H), 7.95 (d, J=8.6 Hz, 1H),
7.85 (s, 1H), 7.75 (dd J=8.7, 1.8 Hz, 1H), 7.49 (dd, J=8.2, 4.2 Hz,
1H), 3.90 (s, 2H).
Intermediate 14:
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)-2-methylquinol-
ine
[0526] Step-1:
6-chloro-N-((2-methylquinolin-6-yl)methyl)-3-nitropyridin-2-amine:
The title compound was obtained as a yellow solid (0.500 g, 38%) by
using a procedure that is similar to the one described for
intermediate 3 from 2,6-dichloro-3-nitropyridine (1.17 g, 6.09
mmol), Intermediate 13 (0.700 g, 4.06 mmol), ethanol (10 ml) and
sodium carbonate (0.749 g, 7.07 mmol). .sup.1H-NMR (.delta. ppm,
CDCl.sub.3, 400 MHz): (br s, 1H), 8.38 (d, J=8.6 Hz, 1H), 8.03 (m,
2H), 7.75 (s, 1H), 7.69 (dd, J=8.7, 2.0 Hz, 1H), 7.30 (d J=8.4 Hz,
1H), 6.67 (d, J=8.6 IIz, 1II), 4.99 (d, J=5.8 IIz, 2II), 2.74 (s,
3II).
[0527] Step-2:
6-chloro-N2-((2-methylquinolin-6-yl)methyl)pyridine-2,3-diamine:
The title compound was obtained as a off-white solid (0.500 g, 95%)
by using a procedure that is similar to the one described for
intermediate 5 from Step-1 (0.500 g, 1.52 mmol), stannous chloride
(1.54 g, 6.85 mmol) and conc. HCl (5.2 ml) which is used as such in
next step.
[0528] Step-3: The title compound was obtained as a brown solid
(0.400 g, 77%) by using a procedure that is similar to the one
described for intermediate 7 from Step-2 (0.500 g, 1.67 mmol),
acetic acid (2.94 ml), sodium nitrite (0.138 g, 2.03 mmol), water
(0.8 ml) and sulphuric acid (0.2 ml) which is used as such in next
step.
Intermediate 15:
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)
benzo[d]thiazole
[0529] Step 1: tert-butyl benzo[d]thiazol-6-ylmethylcarbamate:
Triethylamine (2.92 ml, 20.82 mmol) and diphenylphosphoryl azide
(5.72 g, 20.82 mmol) were added to a solution of
benzothiazole-6-acetic acid (4.0 g, 20.82 mmol) in tert-butanol (80
ml) and refluxed for 18 h. The excess tert-butanol was distilled
out. Aq. 10% citric acid solution (20 ml) was added to the residue,
extracted with ethyl acetate, dried over sodium sulphate and
concentrated under reduced pressure to afford the title compound as
a brown gummy liquid (3.3 g, 59%) which was used as such for next
step.
[0530] Step 2: benzo[d]thiazol-6-ylmethanamine: To a solution of
tert-butyl benzo[d]thiazol-6-ylmethylcarbamate (3.3 g, 12.48 mmol)
in dioxane (33 ml), trifluoroacetic acid (8.25 ml) was added and
stirred at RT for 3 h. The reaction mixture was concentrated,
basified with sodium hydroxide solution, extracted with ethyl
acetate, the organic layers dried over sodium sulphate and
concentrated under reduced pressure to afford the title compound as
yellow solid (2.7 g) which was used as such for next step.
[0531] Step 3:
N-(benzo[d]thiazol-6-ylmethyl)-6-chloro-3-nitropyridin-2-amine: The
title compound was obtained as a yellow solid (0.460 g, 9%) by
using a procedure that is similar to the one described for
intermediate 3 from 2,6-Dichloro-3-nitropyridine (4.75 g, 24.66
mmol), benzo[d]thiazol-6-ylmethanamine (2.70 g, 16.44 mmol),
ethanol (50 ml) and sodium carbonate (3.03 g, 28.60 mmol) which was
used as such for next step.
[0532] Step: 4:
N2-(benzo[d]thiazol-6-ylmethyl)-6-chloropyridine-2,3-diamine: The
title compound was obtained as a yellow solid (0.360 g, 88%) by
using a procedure that is similar to the one described for
intermediate 5 from
N-(benzo[d]thiazol-6-ylmethyl)-6-chloro-3-nitropyridin-2-amine
(0.450 g, 1.40 mmol), stannous chloride (1.42 g, 6.31 mmol) and
conc.HCl (7.5 ml) which is used as such for next step.
[0533] Step: 5
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)
benzo[d]thiazole: The title compound was obtained as a brown solid
(0.068 g, 83%) by using a procedure that is similar to the one
described for intermediate 7 from
N2-(benzo[d]thiazol-6-ylmethyl)-6-chloropyridine-2,3-diamine (0.350
g, 0.249 mmol), acetic acid (1.75 ml), sodium nitrite (0.099 g,
1.44 mmol), water (0.8 ml) and sulphuric acid (0.4 ml). .sup.1H-NMR
(.delta. ppm, CDCl.sub.3, 400 MHz): .delta. 8.99 (s, 1H), 8.32 (d,
J=8.5 Hz, 1H), 8.11 (d, J=8.4 Hz, 1H), 8.07 (s, 1H), 7.66 (d, J=8.4
Hz, 1H), 7.36 (d, J=8.5 Hz, 1H), 6.00 (s, 2H).
Intermediate 16:
2-Chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoic acid
[0534] Step-1: Methyl
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoate: The title compound was prepared by following
the procedure described for example 1 using intermediate 8 (0.345
g, 1.091 mmol), 3-chloro-4-methoxycarbonylphenylboronic acid (0.295
g, 1.37 mmol), potassium acetate (0.359 g, 3.65 mmol), dioxane (8
ml) and tetrakis(triphenylphosphine)palladium(0) (0.101 g, 0.087
mmol). Off-white solid (0.277 g, 56%). .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 8.91 (d, J=3.3 Hz, 1II), 8.50 (d, J=8.6
IIz, 1II), 8.23 (s, 1II), 8.10 (d, J=8.2 IIz, 1II), 8.03 (d, J=6.9
IIz, 1II), 7.98 (d, J=8.1 Hz, 1H), 7.87 (m, 3H), 7.38 (dd, J=8.3,
4.2 Hz, 1H), 6.22 (s, 2H), 3.97 (s, 3H).
[0535] Step-2:
2-Chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoic acid: To a solution of Step-1 (0.185 g, 0.412
mmol) in methanol (2 ml), lithium hydroxide (0.161 g, 3.84 mmol) in
water (2 ml) and THE (4 ml) were added and stirred at RT. After 12
h, pH was adjusted to ca. 7 using 0.5N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as a pale
brown solid (0.150 g, 84%). The acid was used as such for further
steps.
Intermediate 17:
2,6-Difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)benzoic acid
[0536] Step-1: Methyl
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)benzoate: To a solution of Intermediate 7 (1.15 g, 3.91 mmol)
and 3,5-difluoro-4-methoxycarbonylphenylboronic acid (prepared
according to et. al in Eur. J. Org. Chem. 2009, 4325-4332, 1.10 g,
5.09 mmol) in dioxan (20 ml), potassium acetate (1.276 g, 13.03
mmol) was added and degassed for 30 min. Tetrakis
(triphenylphosphine)palladium(0) (0.361 g, 0.31346 mmol) was added
under nitrogen at RT and the reaction mixture was refluxed for 12
h. The solvent was evaporated completely and water was added to the
residue and extracted with ethyl acetate, dried over sodium
sulphate and concentrated under reduced pressure. The crude product
was purified by column chromatography with methanol:
dichloromethane to afford the title compound as a brown solid
(0.620 g, 37%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz):
8.91 (d, J=2.9 Hz, 1H), 8.49 (d, J=8.6 Hz, 1H), 8.17 (d, J=8.2 Hz,
1H), 8.10 (d, J=8.7 Hz, 1H), 7.97 (s, 1H), 7.86 (dd, J=8.8, 1.4 Hz,
1H), 7.81 (d, J=8.6 Hz, 1H), 7.74 (d, J=9.1 Hz, 2H), 7.43 (dd,
J=8.4, 4.2 Hz, 1H), 6.15 (s, 2H), 3.99 (s, 3H).
[0537] Step-2:
2,6-Difluoro-4-(3-(quinolin-6-ylmethyl)-3II-[1,2,3]triazolo[4,5-b]pyridin-
-5-yl) benzoic acid: To a solution of Step-1 (0.70 g, 1.62 mmol) in
methanol (3.8 ml), lithium hydroxide (0.635 g, 15.13 mmol) in water
(3.8 ml) and THE (14.3 ml) were added and stirred at RT. After 12
h, pH was adjusted to ca. 7 using 0.5N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as pale
brown solid (0.500 g, 74%). The acid was used as such for further
steps.
Intermediate 18
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)benzoic acid
[0538] Step-1: methyl
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)benzoate: The title compound was prepared by
following the procedure described for example 1 using intermediate
8 (0.750 g, 2.39 mmol), 3,5-difluoro-4-methoxycarbonylphenylboronic
acid (0.569 g, 2.63 mmol), potassium acetate (0.783 g, 7.97 mmol),
dioxane (17.2 ml) and tetrakis(triphenylphosphine)palladium(0)
(0.221 g, 0.191 mmol). Brown solid (0.78 g, 76%) which is used as
such in next step. Step-2: To a solution of Step 2 (0.780 g, 1.73
mmol) in methanol (8.4 ml), lithium hydroxide (0.678 g, 16.17 mmol)
in water (8.4 ml) and THE (17 ml) were added and stirred at RT.
After 12 h, pH was adjusted to ca. 7 using 0.5N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as a pale
brown solid (0.600 g, 80%). The acid was used as such for further
steps.
Intermediate
19:2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzoic acid
[0539] Step-1: Methyl
2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)benzoate: The title compound was prepared by following the
procedure described for example 1 using intermediate 7 (0.300 g,
1.01 mmol), 3-fluoro-4-methoxycarbonylphenylboronic acid (0.257 g,
1.29 mmol), potassium carbonate (0.466 g, 13.37 mmol), dioxan (6
ml), water (1.2 ml) and tetrakis (triphenylphosphine)palladium(0)
(0.093 g, 0.081 mmol). Brown colour solid (0.300 g, 71%).
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.88 (dd, J=4.2,
1.8 Hz, 1H), 8.74 (d, J=8.7 Hz, 1H), 8.38 (dd, J=8.4, 1.0 Hz, 1H),
8.27 (d, J=8.8 Hz, 1H), 8.24 (s, 1H), 8.22 (m, 1H), 8.07-8.00 (m,
3H), 7.83 (dd, J=8.7, 2.0 Hz, 1H), 7.63 (m, 1H), 6.24 (s, 2H), 3.89
(s, 3H).
[0540] Step-2: To a solution of Step-1 (0.230 g, 0.556 mmol) in
methanol (3.5 ml), lithium hydroxide (0.132 g, 5.56 mmol) in water
(0.9 ml) was added and stirred at RT. After 12 h, the pH was
adjusted to 7-7.5 using 0.5N HCl and the solid precipitated was
filtered, washed with ethyl acetate and petroleum ether and dried
under vacuum to afford the title compound as pale brown solid
(0.130 g, 61%). M.P.: 254-257.degree. C. .sup.1II-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MIIz):
[0541] 13.43 (s, 1H), 8.88 (dd, J=4.2, 1.7 Hz, 11H), 8.73 (d, J=8.8
Hz, 1H), 8.38 (d, J=7.5 Hz, 1H), 8.25 (d, J=8.8 Hz, 1H), 8.19 (m,
2H), 8.04 (m, 3H), 7.83 (dd, J=8.8, 2.0 Hz, 1H), 7.53 (dd, J=8.4,
4.2 Hz, 1H), 6.23 (s, 2H). MS (m/z): 400.01 (m.sup.T+1).
Intermediate 20:
2-chloro-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoic acid
[0542] Step-1: methyl
2-chloro-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoate: The title compound was prepared by following
the procedure described for Step-1 of Intermediate 17 using
intermediate 14 (0.400 g, 1.29 mmol),
3-chloro-4-methoxycarbonylphenylboronic acid (0.304 g, 1.42 mmol),
potassium acetate (0.422 g, 4.30 mmol), dioxan (8 ml) and tetrakis
(triphenylphosphine)palladium(0) (0.119 g, 0.103 mmol). Brown
colour solid (0.237 g, 41%) which is used as such in next step.
[0543] Step-2:
2-chloro-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoic acid: To a solution of Step-1 (0.237 g, 0.556
mmol) in methanol (0.5 ml), THF (2.7 ml), lithium hydroxide (0.209
g, 4.98 mmol) in water (0.5 ml) was added and stirred at RT. After
12 h, the pH was adjusted to 7-7.5 using 0.5N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as black
solid (0.200 g, 87%). which is used as such in next step.
Intermediate 21:
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2-chlorobenzoic acid
[0544] Step-1: methyl
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2-chlorobenzoate: The title compound was prepared by following the
procedure described for Step-1 of intermediate 17 using
intermediate 15 (0.400 g, 1.32 mmol),
3-chloro-4-methoxycarbonylphenylboronic acid (0.312 g, 1.45 mmol),
potassium acetate (0.433 g, 4.41 mmol), dioxan (9.5 ml) and
tetrakis (triphenylphosphine)palladium(0) (0.122 g, 0.106 mmol).
Brown colour solid (0.400 g, 69%) which is used as such in next
step.
[0545] Step-2: To a solution of Step-1 (0.400 g, 0.917 mmol) in
methanol (2.1 ml), THE (8.1 ml), lithium hydroxide (0.359 g, 8.56
mmol) in water (2.1 ml) was added and stirred at RT. After 12 h,
the pH was adjusted to 7-7.5 using 2N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as brown
solid (0.370 g, 95%). MS (m/z): 422.1 (m).
Intermediate 22:
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2,6-difluorobenzoic acid
[0546] Step-1: methyl
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2,6-difluorobenzoate: The title compound was prepared by following
the procedure described for Step-1 of intermediate 17 using
intermediate 15 (0.400 g, 1.32 mmol),
3,5-difluoro-4-methoxycarbonylphenylboronic acid (0.314 g, 1.45
mmol), potassium acetate (0.433 g, 4.41 mmol), dioxan (9.5 ml) and
tetrakis (triphenylphosphine)palladium(0) (0.122 g, 0.106 mmol).
Brown colour solid (0.380 g, 65%) which is used as such in next
step.
[0547] Step-2: To a solution of Step-1 (0.380 g, 0.868 mmol) in
methanol (1.9 ml), THE (7.6 ml), lithium hydroxide (0.340 g, 8.10
mmol) in water (1.9 ml) was added and stirred at RT. After 12 h,
the pH was adjusted to 7-7.5 using 2N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as brown
solid (0.340 g, 92%). MS (m/z): 424.2 (m.sup.++1).
Intermediate 23:
4-(3-(beno[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-
-fluorobenzoic acid
[0548] Step-1: methyl
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)--
2-fluorobenzoate: The title compound was prepared by following the
procedure described for Step-1 of intermediate 17 using
intermediate 15 (0.300 g, 0.994 mmol),
3-fluoro-4-methoxycarbonylphenylboronic acid (0.197 g, 1.09 mmol),
potassium acetate (0.324 g, 3.31 mmol), dioxan (7.1 ml) and
tetrakis (triphenylphosphine)palladium(0) (0.091 g, 0.079 mmol).
Brown colour solid (0.400 g, 95%) which is used as such in next
step.
[0549] Step-2: To a solution of Step-1 (0.400 g, 0.952 mmol) in
methanol (2.0 ml), THE (8.3 ml), lithium hydroxide (0.372 g, 8.88
mmol) in water (2.0 ml) was added and stirred at RT. After 12 h,
the pH was adjusted to 7-7.5 using 2N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as
off-white solid (0.300 g, 77%) which is used as such in next
step.
Intermediate 24
2,6-difluoro-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)benzoic acid
[0550] Step-1: methyl
2,6-difluoro-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)benzoate: The title compound was prepared by
following the procedure described for step-1 of intermediate 17
using intermediate 14 (0.500 g, 1.61 mmol),
3,5-difluoro-4-methoxycarbonylphenylboronic acid (0.383 g, 1.77
mmol), potassium acetate (0.527 g, 5.37 mmol), dioxan (11.5 ml) and
tetrakis (triphenylphosphine)palladium(0) (0.149 g, 0.129 mmol).
Brown colour solid (0.500 g, 69%) which is used as such in next
step.
[0551] Step-2: To a solution of Step-1 (0.400 g, 0.898 mmol) in
methanol (1.9 ml), THE (7.8 ml), lithium hydroxide (0.351 g, 8.37
mmol) in water (1.9 ml) was added and stirred at RT. After 12 h,
the pH was adjusted to 7-7.5 using 2N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as
off-white solid (0.200 g, 51%) which is used as such in next
step.
Intermediate 25
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic
acid
[0552] Step-1: Methyl
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate-
: The title compound was prepared by following the procedure
described Step-1 for intermediate 17 using intermediate 7 (0.130 g,
0.439 mmol), 4-methoxycarbonylphenylboronic acid (0.100 g, 0.562
mmol), potassium carbonate (0.202 g, 1.46 mmol), dioxan (2.6 ml),
water (0.5 ml) and tetrakis (triphenylphosphine)palladium(0) (0.040
g, 0.035 mmol). Off-white solid (0.100 g, 57%). .sup.1H-NMR
(.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.88 (dd, J=4.2, 1.8 Hz, 1H),
8.72 (d, J=8.7 Hz, 1H), 8.39 (m, 3H), 8.21 (d, J=8.8 Hz, 1H), 8.12
(d, J=8.6 Hz, 2H), 8.02 (s, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.84 (dd,
J=8.6, 2.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.23 (s, 2H),
3.89 (s, 3H).
[0553] Step-2: To a solution of Step-1 (0.095 g, 0.240 mmol) in
methanol (1.4 ml), lithium hydroxide (0.028 g, 1.20 mmol) in water
(0.36 ml) was added and stirred at RT. After 12 h, the pH was
adjusted to ca. 7.5 using 0.5N HCl and the solid precipitated was
filtered, washed with ethyl acetate and petroleum ether and dried
under vacuum to afford the title compound as an off-white solid
(0.070 g, 76%). M.P.: 245-247.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 13.18 (s, 1H), 8.88 (dd, J=4.1, 1.7 Hz,
1H), 8.71 (d, J=8.7 Hz, 1H), 8.39 (d, J=1.1 Hz, 1H), 8.36 (d, J=8.5
Hz, 2H), 8.21 (d, J=8.7 Hz, 1H), 8.10 (d, J=8.5 Hz, 2H), 8.03 (d,
J=9.2 Hz, 2H), 7.84 (dd, J=8.7, 2.0 Hz, 1H), 7.53 (dd, J=8.4, 4.2
Hz, 1H), 6.22 (s, 2H). MS (m/z): 381.88 (m).
Intermediate 26:
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-(trif-
luoromethyl) benzoic acid
[0554] Step-1: methyl
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-2-(trifl-
uoromethyl)benzoate: The title compound was prepared by following
the procedure described for step-1 of intermediate 17 using
intermediate 7 (0.400 g, 1.35 mmol), 3methyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)benzoa-
te (0.491 g, 1.48 mmol), potassium acetate (0.441 g, 4.50 mmol),
dioxan (9.6 ml) and tetrakis (triphenylphosphine)palladium(0)
(0.124 g, 0.108 mmol). Brown colour solid (0.400 g, 68%) which is
used as such in next step.
[0555] Step-2: To a solution of Step-1 (0.400 g, 0.863 mmol) in
methanol (4 ml), THE (8.2 ml), lithium hydroxide (0.327 g, 8.05
mmol) in water (4 ml) was added and stirred at RT. After 12 h, the
pH was adjusted to 7-7.5 using 2N HCl and the solid precipitated
was filtered, washed with ethyl acetate and petroleum ether and
dried under vacuum to afford the title compound as off-white solid
(0.250 g, 64%) which is used as such in next step.
Intermediate 27:
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-2-(trifluoromethyl)benzoic acid
[0556] Step-1: methyl
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-2-(trifluoromethyl)benzoate: The title compound was prepared by
following the procedure described for step-1 of intermediate 17
using intermediate 8 (0.400 g, 1.27 mmol), 3methyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)benzoa-
te (0.464 g, 1.40 mmol), potassium acetate (0.417 g, 4.25 mmol),
dioxan (9.6 ml) and tetrakis (triphenylphosphine)palladium(0)
(0.118 g, 0.102 mmol). Brown colour solid (0.380 g, 62%) which is
used as such in next step.
[0557] Step-2: To a solution of step-1 (0.400 g, 0.830 mmol) in
methanol (1.8 ml), THE (7.2 ml), lithium hydroxide (0.325 g, 7.75
mmol) in water (1.8 ml) was added and stirred at RT. After 12 h,
the pH was adjusted to 7-7.5 using 2N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as
off-white solid (0.300 g, 77%) which is used as such in next
step.
Intermediate 28:
2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)benzoic acid
[0558] Step-1: methyl
2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)benzoate: The title compound was prepared by following the
procedure described for step-1 of intermediate 17 using
intermediate 7 (0.290 g, 0.869 mmol), methyl
2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
(0.300 g, 1.08 mmol), potassium acetate (0.320 g, 3.26 mmol),
dioxan (7.0 ml) and tetrakis (triphenylphosphine)palladium(0)
(0.090 g, 0.078 mmol). Brown colour solid (0.250 g, 65%). which is
used as such in next step.
[0559] Step-2: To a solution of Step-1 (0.250 g, 0.640 mmol) in
methanol (5.5 ml), THE (2.5 ml), lithium hydroxide (0.250 g, 5.97
mmol) in water (2.5 ml) was added and stirred at RT. After 12 h,
the pH was adjusted to 7-7.5 using 2N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as
off-white solid (0.120 g, 48%) which is used as such in next
step.
Intermediate 29:
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-2-methylbenzoic acid
[0560] Step-1: methyl
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)-2-methylbenzoate: The title compound was prepared by following
the procedure described for step-1 of intermediate 17 using
intermediate 8 (0.303 g, 0.968 mmol), methyl
2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
(0.300 g, 1.08 mmol), potassium acetate (0.322 g, 3.28 mmol),
dioxan (7.0 ml) and tetrakis (triphenylphosphine)palladium(0)
(0.088 g, 0.077 mmol). Brown colour solid (0.250 g, 63%). which is
used as such in next step.
[0561] Step-2: To a solution of step-1 (0.250 g, 0.610 mmol) in
methanol (1.5 ml), THE (5.3 ml), lithium hydroxide (0.239 g, 5.69
mmol) in water (1.5 ml) was added and stirred at RT. After 12 h,
the pH was adjusted to 7-7.5 using 2N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as
off-white solid (0.150 g, 59%) which is used as such in next
step.
Intermediate 30:
2-Fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoic acid
[0562] Step-1: Methyl
2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoate: The title compound was prepared by following
the procedure described for step-1 of intermediate 17 using
intermediate 8 (0.350 g, 1.15 mmol),
3-fluoro-4-methoxycarbonylphenylboronic acid (0.276 g, 1.39 mmol),
potassium acetate (0.365 g, 3.71 mmol), dioxane (8 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.103 g, 0.089 mmol).
Pale brown solid (0.350 g, 70%). M.P.: 213-215.degree. C.
[0563] Step-2: To a solution of step-1 (0.240 g, 0.605 mmol) in
methanol (3 ml), lithium hydroxide (0.237 g, 5.64 mmol) in water (3
ml) and THE (6 ml) were added and stirred at RT. After 12 h, pH was
adjusted to ca. 7 using 0.5N HCl and the solid precipitated was
filtered, washed with ethyl acetate and petroleum ether and dried
under vacuum to afford the title compound as pale brown solid
(0.110 g, 44%). The acid was used as such for further steps.
Intermediate 31:
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline
1-oxide
[0564] Intermediate 7 (0.300 g, 1.01 mmol) was dissolved in
dichloromethane (3.8 ml) and metachloroperbenzoic acid (0.350 g,
2.02 mmol) was added at RT and stirred for 12 h. Sodium sulphite
solution (10 ml) and saturated potassium carbonate solution (10 ml)
were added to the reaction mixture, extracted with dichloromethane,
washed with brine, dried over sodium sulphate and concentrated. The
crude product was purified by column chromatography with methanol:
dichloromethane to afford the title compound as a pale green solid
(0.140 g, 44%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz):
.delta. 8.70 (d, J=8.6 Hz, 1H), 8.56 (d, J=6.0 Hz, 1H), 8.51 (d,
J=9.0 Hz, 1H), 7.98 (s, 1H), 7.91 (d, J=8.5 Hz, 1H), 7.77 (dd,
J=9.0, 1.5 Hz, 1H), 7.62 (d, J=8.7 Hz, 1H), 7.47 (dd, J=8.4, 1.6
Hz, 1H), 6.14 (s, 2H).
[0565] Intermediate 32:
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinolin-2(1H)--
one: Intermediate 31 (0.100 g, 0.321 mmol) was dissolved in DMF (1
ml) and trifluoacetic anhydride (0.486 g, 2.31 mmol) was added at
RT and stirred for 12 h. To the reaction mixture, sat. sodium
bicarbonate solution (10 ml) was added and the obtained solid was
filtered and washed with ethyl acetate and dried under vacuum to
afford the title compound as an off-white solid (0.060 g, 60%).
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta.
[0566] 11.74 (s, 1II), 8.66 (d, J=8.7 IIz, 1II), 7.88 (d, J=9.6
IIz, 1II), 7.65 (d, J=1.7 IIz, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.52
(dd, J=8.5, 1.9 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 6.48 (d, J=9.5 Hz,
1H), 5.93 (s, 2H).
Intermediate 33:
2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
[0567] Step: 1 4-bromo-2,6-difluorobenzaldehyde: n-BuLi (1.6M in
hexane, 38 ml, 62.16 mmol) was added drop wise to a solution of
diisopropylamine (10 ml, 77.7 mmol) in THF (28 ml) at 0.degree. C.,
maintained for 15 min. and cooled to -78.degree. C. To this
3,5-difluorobromobenzene (10 g, 51.80 mmol) in THE (56 ml) was
added, stirred at -78.degree. C. for 1 h, and N,N-dimethylformamide
(7.6 ml) was added and stirred for further 1 h. The reaction
mixture was quenched with NH.sub.4CL solution and extracted with
ethyl acetate. The organic layer was dried over sodium sulphate and
concentrated. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the
title compound as an off-white solid (5.2 g, 46%) which was used
without characterisation in the next step.
[0568] Step: 2 4-bromo-2,6-difluorobenzoic acid: To
4-bromo-2,6-difluorobenzaldehyde (4.0 g, 18.07 mmol) in DMF (80
ml), oxone (11.07 g, 18.07 mmol) was added and stirred at RT for 12
h. The reaction mixture was quenched with 2N HCl solution and
extracted with ethyl acetate. The organic layer was dried over
sodium sulphate and concentrated under vacuum to afford the title
compound as an off-white solid (3.5 g, 83%) which was used without
characterisation in the next step.
[0569] Step: 3 4-bromo-2,6-difluorobenzamide: To
4-bromo-2,6-difluorobenzoic acid (0.900 g, 3.81 mmol), thionyl
chloride (9 ml) was added and refluxed for 3 h. The excess thionyl
chloride was removed under reduced pressure and the residue was
cooled to 0.degree. C. Aqueous 25% ammonia (7 ml) was added and
stirred for 15 min. The precipitate formed was filtered and vacuum
dried to afford title compound as an off-white solid (0.700 g, 78%)
which was used without characterisation in the next step. Step: 4
2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide:
The title compound was obtained as a brown solid (0.500 g, 61%) by
using the procedure described for intermediate 9 from
4-bromo-2,6-difluorobenzamide_(0.700 g, 2.92 mmol),
bis(pinacolato)diboron (0.825 g, 3.22 mmol), potassium acetate
(0.862 g, 8.75 mmol), dioxane (5 ml) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH.sub.2Cl.sub.2 (0.071 g, 0.087 mmol). .sup.1H-NMR
(.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.12 (s, 1H), 7.86
(s, 1H), 7.26 (d, J=7.2 IIz, 1II), 1.29 (s, 12II).
[0570] Intermediate 34:
6-((5-chloro-3H-imidazo[4,5-b]pyridin-3-yl)methyl)quinoline:
Intermediate 5 (0.200 g, 0.702 mmol) was dissolved in formic acid
(1.0 ml), heated to 100.degree. C. and stirred for 12 h. The
reaction mixture was poured into ice water and pH adjusted to 7-8
with sodium bicarbonate solution, extracted with ethyl acetate,
washed with brine, dried over sodium sulphate and concentrated to
afford the title compound as yellowish brown solid (0.200 g, 97%).
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.88 (dd,
J=4.0, 1.3 Hz, 1H), 8.70 (s, 1H), 8.33 (d, J=8.2 Hz, 1H), 8.19 (d,
J=8.3 Hz, 1H), 8.01 (d, J=8.8 Hz, 1H), 7.81 (s, 1H), 7.73 (dd,
J=8.7, 1.7 Hz, 1H), 7.52 (dd, J=8.3, 2.2 Hz, 1H), 7.37 (d, J=8.4
Hz, 1H), 5.69 (s, 2H).
[0571] Intermediate 35:
6-((5-chloro-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-7-fluoroquinoline:
The title compound was obtained as a brown solid (0.400 g, 78%) by
using a procedure that is similar to the one described for
intermediate 34 from intermediate 6 (0.500 g, 1.65 mmol), and
formic acid (2.5 ml). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.92 (dd, J=4.3, 1.7 Hz, 1H), 8.16 (d, J=0.8 Hz, 1H),
8.12 (d, J=8.3 Hz, 1H), 8.04 (d, J=8.3 Hz, 1H), 7.81 (d, J=8.7 Hz,
1H), 7.78 (d, J=5.5 Hz, 1H), 7.40 (dd, J=8.4, 4.3 Hz, 1H), 7.29 (d,
J=8.3 Hz, 1H), 5.68 (s, 2H).
[0572] Intermediate 36:
6-((5-chloro-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)quinoline:
The title compound was obtained as a brown solid (0.400 g, 62%) by
using a procedure that is similar to the one described for
intermediate 34 from intermediate 5 (0.600 g, 2.10 mmol), and
acetic acid (3 ml). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.91 (dd, J=4.2, 1.3 Hz, 1H), 8.09 (d, J=9.3 Hz, 1H),
8.06 (d, J=7.5 Hz, 1H), 7.95 (d, J=8.3 Hz, 1H), 7.57 (dd, J=8.7,
2.0 Hz, 1H), 7.47 (d, J=1.2 Hz, 1H), 7.40 (dd, J=8.3, 4.0 Hz, 11H),
7.27 (d, J=8.3 Hz, 1H), 5.62 (s, 2H), 2.53 (s, 3H).
Intermediate 37:
2-chloro-N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamid-
e
[0573] Step: 1 4-bromo-2-chloro-N-methylbenzamide: To
4-bromo-2-chlorobenzoic acid (1.00 g, 4.24 mmol), thionyl chloride
(10 ml) was added and refluxed for 3 h. Excess thionyl chloride was
removed under reduced pressure and the residue was cooled to
0.degree. C. Methyl amine solution (25% in MeOH, 15 ml) was added
and stirred for 15 min. The precipitate formed was filtered and
vacuum dried to afford title compound as an off-white solid (0.900
g, 85%) which was used in the next step.
[0574] Step: 2:
2-chloro-N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamid-
e: The title compound was obtained as a brown solid (0.500 g, 46%)
by using the procedure described for intermediate 9 from
4-bromo-2-chloro-N-methylbenzamide (0.900 g, 3.62 mmol),
bis(pinacolato)diboron (1.01 g, 3.99 mmol), potassium acetate (1.18
g, 12.08 mmol), dioxane (10 ml) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH.sub.2Cl.sub.2 (0.088 g, 0.108 mmol) which was used
without characterisation in the next step.
[0575] Intermediate 38:
2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide:
The title compound was obtained as a brown solid (0.600 g, 70%) by
using the procedure described intermediate 9 from
4-bromo-2-methylbenzamide (0.700 g, 3.27 mmol),
bis(pinacolato)diboron (0.913 g, 3.59 mmol), potassium acetate
(0.96 g, 9.81 mmol), dioxane (12 ml) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II).CH.sub.2C2
(0.080 g, 0.098 mmol) which was used without characterisation in
the next step.
Intermediate 39:
6-(1-(5-chloro-3H-imidazo[4,5-b]pyridin-3-yl)ethyl)quinoline
[0576] Step: 1
6-Chloro-3-nitro-N-(1-(quinolin-6-yl)ethyl)pyridin-2-amine: The
title compound was obtained as a yellow solid (0.785 g, 50%) by
using a procedure that is similar to the one described for
intermediate 4 from 2,6-Dichloro-3-nitropyridine (0.924 g, 4.78
mmol), 1-(quinolin-6-yl)ethanamine (1.25.g, 7.25 mmol), ethanol (7
ml) and sodium carbonate (1.32 g, 12.54 mmol). .sup.1H-NMR (.delta.
ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.86 (dd, J=4.2, 1.7 Hz, 1H),
8.78 (d, J=7.5 Hz, 1H), 8.44 (d, J=8.6 Hz, 1H), 8.33 (dd, J=8.3,
1.0 Hz, 1H), 7.99 (m, 2H), 7.89 (dd J=8.8, 1.9 Hz, 1H), 7.51 (q,
J=4.2 Hz, 1H), 6.80 (d, J=7.5 Hz, 1H), 5.57 (q, J=7.1 Hz, 1H). 1.69
(d, J=7.0 Hz, 3H).
[0577] Step: 2
6-chloro-N2-(1-(quinolin-6-yl)ethyl)pyridine-2,3-diamine: The title
compound was obtained as a pale brown solid (0.600 g, 74%) by using
a procedure that is similar to the one described for intermediate 5
from 6-Chloro-3-nitro-N-(1-(quinolin-6-yl)ethyl)pyridin-2-amine
(0.900 g, 2.72 mmol), stannous chloride (2.77 g, 12.28 mmol) and
conc.HCl (1.5 ml) which is used as such for next step.
[0578] Step: 3
6-(1-(5-chloro-3H-imidazo[4,5-b]pyridin-3-yl)ethyl)quinoline: The
title compound was obtained as a brown solid (0.410 g, 80%) by
using a procedure that is similar to the one described for
intermediate 34 from
6-chloro-N2-(1-(quinolin-6-yl)ethyl)pyridine-2,3-diamine (0.500 g,
1.67 mmol), and formic acid (2.5 ml). .sup.1H-NMR (.delta. ppm,
CDCl.sub.3, 400 MHz): .delta. 8.93 (dd, J=4.2, 1.7 Hz, 1H), 8.15
(dd, J=8.3, 0.9 Hz, 1H), 8.11 (d, J=8.8 Hz, 1H), 8.08 (s, 1H), 8.03
(d, J=8.4 Hz, 1H), 7.77 (d, J=1.9 Hz, 1H), 7.68 (dd, J=8.8, 2.1 Hz,
1H), 7.44 (dd, J=8.3, 4.2 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 6.29 (q,
J=7.2 Hz, 1H), 2.11 (d, J=7.2 Hz, 3H).
Intermediate 40:
6-((5-chloro-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-5,7-difluoroquinoline
[0579] Step: 1
6-chloro-N-((5,7-difluoroquinolin-6-yl)methyl)-3-nitropyridin-2-amine:
The title compound was obtained as a yellow solid (0.050 g, 5%) by
using a procedure that is similar to the one described for
intermediate 3 from 2,6-Dichloro-3-nitropyridine (1.40 g, 7.73
mmol), (5,7-difluoroquinolin-6-yl)methanamine (1.00 g, 5.15 mmol),
ethanol (10 ml) and sodium carbonate (0.97 g, 9.22 mmol).
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 9.09 (t,
J=5.1 Hz, 1H), 8.96 (d, J=3.7 Hz, 1H), 8.49 (d, J=8.4 Hz, 1H), 8.41
(d, J=8.5 Hz, 1H), 7.68 (d, J=11.0 Hz, 1H), 7.61 (dd, J=8.4, 4.2
Hz, 1H), 6.79 (d, J=8.5 Hz, 1H), 4.97 (d, J=5.5 Hz, 2H).
[0580] Step: 2:
6-chloro-N2-((5,7-difluoroquinolin-6-yl)methyl)pyridine-2,3-diamine:
The title compound was obtained as a brown solid (0.080 g, 73%) by
using a procedure that is similar to the one described for
intermediate 5 from
6-chloro-N-((5,7-difluoroquinolin-6-yl)methyl)-3-nitropyridin-2-amine
(0.12 g, 0.342 mmol), stannous chloride (0.347 g, 1.54 mmol) and
conc.HCl (2 ml) which is used as such for next step.
[0581] Step 3:
6-((5-chloro-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-5,7-difluoroquinoline:
The title compound was obtained as a brown solid (0.150 g, 81%) by
using a procedure that is similar to the one described for
intermediate 34 from 6-chloro-N2-((5,7-difluoroquinolin-6-yl)
methyl) pyridine-2,3-diamine (0.180 g, 0.562 mmol), and formic acid
(0.9 ml). .sup.1H-NMR (6 ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.98
(dd, J=4.3, 1.6 IIz, 1II), 8.44 (dd, J=8.5, 1.1 IIz, 1H), 8.10 (s,
1H), 8.00 (d, J=8.3 Hz, 1H), 7.67 (d, J=10.6 Hz, 1H), 7.49 (dd,
J=8.5, 4.3 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 5.71 (s, 2H).
Intermediate 41:
1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
[0582] To a solution of Intermediate 7 (0.200 g, 0.676 mmol) and
1-ethoxyvinyl tri(n-butyl)stannane (0.244 g, 0.676 mmol) in
triphenylphosphine (0.0284 g, 0.054 mmol), toluene (3.8 ml), was
degassed for 30 min. To this tris(dibenzilidineacetone)
palladium(0) (0.028 g, 0.027 mmol) was added under nitrogen at RT
and the reaction mixture was refluxed for 12 h. The solvent was
evaporated completely and water was added to the residue and
extracted with ethyl acetate, dried over sodium sulphate and
concentrated under reduced pressure. Then followed by acid
hydrolysis to afford the title compound as a brown solid (0.080 g,
39%). M.P.: 165-167.degree. C. .sup.1H-NMR (.delta. ppm,
CDCl.sub.3, 400 MHz): .delta. 8.92 (d, J=3.0 Hz, 1H), 8.49 (d,
J=8.5 Hz, 1H), 8.15 (m, 1H), 7.94 (s, 1H), 7.87 (d, J=8.6 Hz, 1H),
7.43 (dd, J=8.3, 4.2 Hz, 1H), 6.15 (s, 2H), 2.82 (s, 1H).
Intermediate 42:
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)-7-fluoroquinol-
ine 1-oxide
[0583] The title compound was obtained as a brown solid (0.800 g,
76%) by using a procedure that is similar to the one described for
intermediate 31 from intermediate 8 (1.00 g, 3.18 mmol),
dichloromethane (13 ml) and metachloroperbenzoic acid (1.10 g, 6.37
mmol) which was used as such in next step.
Intermediate 43:
6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)-7-fluoroquinol-
in-2(1H)-one
[0584] Intermediate 43: The title compound was obtained as
off-white solid (0.600 g, 79%) by using a procedure that is similar
to the one described for intermediate 32 from intermediate 42
(0.800 g, 2.43 mmol), DMF (8 ml) and trifluoacetic anhydride (1.20
ml, 8.78 mmol). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz):
.delta. 11.54 (s, 1H), 8.65 (d, J=8.76 IIz, 1II), 7.87 (d, J=9.6
IIz, 1II), 7.76 (d, J=7.9 IIz, 1II), 7.60 (d, J=8.6 IIz, 1H), 7.08
(d, J=11.3 Hz, 1H), 6.44 (d, J=9.6 Hz, 1H), 5.93 (s, 2H).
Intermediate 44:
2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3-
]triazolo[4,5-b]pyridin-5-yl)benzoic acid
[0585] The title compound was prepared by following the procedure
described for step 1 of Intermediate 11 using intermediate 43
(0.100 g, 0.317 mmol), 4-borono-2-chlorobenzoic acid (0.069 g,
0.349 mmol), potassium acetate (0.103 g, 1.058 mmol), dioxan (2.30
ml), water (1.0 ml) and tetrakis (triphenylphosphine)palladium(0)
(0.029 g, 0.0254 mmol) and in microwave oven (microwave power=100
W, temperature=110.degree. C.) for 45 min. Brown solid (0.100 g,
62%). Mass: 449.6 (M.sup.+).
Intermediate 45:
2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzoic acid
[0586] The title compound was prepared by following the procedure
described for step 1 of Intermediate 11 using intermediate 32
(0.100 g, 0.320 mmol), 4-borono-2-methylbenzoic acid (0.062 g,
0.362 mmol), potassium acetate (0.104 g, 1.068 mmol), dioxan (2.30
ml), water (1.0 ml) and tetrakis (triphenylphosphine)palladium(0)
(0.029 g, 0.0254 mmol) and in microwave oven (microwave power=100
W, temperature=110.degree. C.) for 45 min. Brown solid (0.100 g,
75%) which was used as such in next step.
Intermediate 46:
2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoic
acid
[0587] Step-1: methyl
2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoat-
e: The title compound was prepared by following the procedure
described for step-1 of intermediate 17 using intermediate 34 (1.00
g, 3.36 mmol), 3-fluoro-4-methoxycarbonylphenylboronic acid (0.734
g, 3.70 mmol), potassium acetate (1.11 g, 11.22 mmol), dioxane (24
ml) and tetrakis(triphenylphosphine)palladium(0) (0.311 g, 0.269
mmol). Pale brown solid (1.00 g, 76%).
[0588] Step-2: To a solution of step-1 (1.00 g, 2.42 mmol) in
methanol (12 ml), lithium hydroxide (0.940 g, 22.62 mmol) in water
(12 ml) and THE (24 ml) were added and stirred at RT. After 12 h,
pH was adjusted to ca. 7 using 0.5N HCl and the solid precipitated
was filtered, washed with ethyl acetate and petroleum ether and
dried under vacuum to afford the title compound as off-white solid
(0.600 g, 62%). The acid was used as such for further steps.
Intermediate 47:
2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoic
acid
[0589] Step-1: methyl
2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoat-
e The title compound was prepared by following the procedure
described for step-1 of intermediate 17 using intermediate 34 (1.00
g, 3.39 mmol), 3-methyl-4-methoxycarbonylphenylboronic acid (0.716
g, 3.73 mmol), potassium acetate (1.11 g, 11.29 mmol), dioxane (24
ml) and tetrakis(triphenylphosphine)palladium(0) (0.313 g, 0.271
mmol). Pale brown solid (0.800 g, 61%).
[0590] Step-2: To a solution of step-1 (0.800 g, 1.95 mmol) in
methanol (9 ml), lithium hydroxide (0.766 g, 18.27 mmol) in water
(9 ml) and THF (18 ml) were added and stirred at RT. After 12 h, pH
was adjusted to ca. 7 using 0.5N HCl and the solid precipitated was
filtered, washed with ethyl acetate and petroleum ether and dried
under vacuum to afford the title compound as pale brown solid
(0.600 g, 83%). The acid was used as such for further steps.
Intermediate 48:
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoic
acid
[0591] Step-1: methyl
2-chloro-4-(3-(quinolin-6-ylmethyl)-3II-imidazo[4,5-b]pyridin-5-yl)benzoa-
te: The title compound was prepared by following the procedure
described for step-1 of intermediate 17 using intermediate 34 (1.00
g, 3.39 mmol), 3-chloro-4-methoxycarbonylphenylboronic acid (0.715
g, 3.37 mmol), potassium acetate (1.11 g, 11.29 mmol), dioxane (24
ml) and tetrakis(triphenylphosphine)palladium(0) (0.313 g, 0.271
mmol). Pale brown solid (0.500 g, 35%).
[0592] Step-2: To a solution of step-1 (0.500 g, 1.16 mmol) in
methanol (5.3 ml), lithium hydroxide (0.456 g, 10.86 mmol) in water
(5.3 ml) and THE (10.7 ml) were added and stirred at RT. After 12
h, pH was adjusted to ca. 7 using 0.5N HCl and the solid
precipitated was filtered, washed with ethyl acetate and petroleum
ether and dried under vacuum to afford the title compound as pale
brown solid (0.400 g, 82%). The acid was used as such for further
steps.
Intermediate 49: 4-bromo-2-(trifluoromethyl)benzamide
[0593] To 4-bromo-3-(trifluoromethyl)benzoic acid.sup.1 (1.0 g,
3.71 mmol), thionyl chloride (10 ml) was added and refluxed for 3
h. The excess thionyl chloride was removed under reduced pressure
and the residue was cooled to 0.degree. C. Aqueous 25% ammonia (7
ml) was added and stirred for 15 min. The precipitate formed was
washed with sodium bicarbonate solution and vacuum dried to afford
title compound as a brown solid (0.500 g, 50%) which is used as
such for next step. 1. Bioorg. Med. Chem. 2007, 15, 2198.
Intermediate 50:
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)benzam-
ide
[0594] The title compound was obtained as a brown solid (0.30 g,
50%) by using the procedure described in step 4 for intermediate 19
from intermediate 41 (0.500 g, 1.86 mmol), bis(pinacolato)diboron
(0.705 g, 2.77 mmol), potassium acetate (0.743 g, 7.57 mmol),
dioxane (4.6 ml) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH.sub.2Cl.sub.2 (0.061 g, 0.067 mmol) which is used
as such for next step.
Intermediate 51:
N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinamide
[0595] The title compound was obtained as a black solid (0.500 g,
53%) by using the procedure described intermediate 9 from
5-bromo-N-methylpicolinamide (0.900 g, 4.47 mmol),
bis(pinacolato)diboron (1.25 g, 4.92 mmol), potassium acetate (1.31
g, 13.43 mmol), dioxane (13 ml) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II).CH.su-
b.2C12 (0.109 g, 0.134 mmol) which was used without
characterisation in the next step.
Intermediate 52:
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
[0596] The title compound was obtained as a off-white solid (0.410
g, 84%) by using a procedure that is similar to the one described
for intermediate 9 from 5-bromoisoindolin-1-one (0.400 g, 1.88
mmol), potassium acetate (0.645 g, 6.58 mmol),
bis(pinacolato)diboron (0.520 g, 2.07 mmol) dioxane (7 ml) and
[1,1'-Bis(diphenylphosphino)ferrocene]dichloro palladium(II).
CH.sub.2Cl.sub.2 (0.076 g, 0.094 mmol). .sup.1II-NMR (.delta. ppm,
CDCl.sub.3, 400 MHz): .delta. 7.93 (m, 2H), 7.87 (d, J=7.8 Hz, 1H),
7.16 (s, 1H), 1H), 4.45 (s, 2H), 1.36 (s, 12H).
[0597] amples
Example 1
N-(2-amino-2-oxoethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,3]triazolo[4,5-b-
]pyridin-5-yl)benzamide
[0598] To a solution of intermediate 11 (0.100 g, 0.262 mmol) in
DMF (1 ml) N-ethyldiisopropylamine (0.033 g, 0.262 mmol) and IIATU
(0.099 g, 0.262 mmol) were added and stirred for 5 min.
2-aminoacetamide (0.038 g, 0.524 mmol) was added at RT and the
reaction mixture was stirred for 12 h. To the reaction mixture
water was added and extracted with ethyl acetate, dried over sodium
sulphate and concentrated under reduced pressure. The crude product
was purified by column chromatography with methanol:
dichloromethane to afford the title compound as an Off-white solid
(0.030 g, 26%). M.P.: 264-266.degree. C. .sup.1II-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.88 (dd, J=4.1, 1.6 Hz, 1H), 8.80
(t, J=5.8 Hz, 1H), 8.69 (d, J=8.8 Hz, 1H), 8.38 (s, 1H), 8.36 (d,
J=8.5 Hz, 2H), 8.22 (d, J=8.8 Hz, 1H), 8.05 (m, 4H), 7.82 (dd,
J=8.7, 1.9 Hz, 1H), 7.53 (dd, J=8.4, 4.2 Hz, 1H), 7.39 (s, 1H),
7.04 (s, 1H), 6.23 (s, 2H), 3.85 (d, J=5.8 Hz, 2H).
Example 2
N-(2-(methylamino)-2-oxoethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazo-
lo[4,5-b]pyridin-5-yl) benzamide
[0599] The title compound was prepared by following the procedure
described for example 1 using intermediate 11 (0.100 g, 0.262
mmol), DMF (1 ml), N-ethyldiisopropylamine (0.033 g, 0.262 mmol),
HATU (0.099 g, 0.262 mmol) and 3-amino-N-methylpropanamide (0.047
g, 0.524 mmol). Off-white solid (0.030 g, 25%). M.P.:
232-234.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.89 (m, 2H), 8.70 (d, J=8.7 Hz, 1H),), 8.39 (d,
J=7.6 Hz, 1H), 8.36 (d, J=8.5 Hz, 2H), 8.22 (d, J=8.8 Hz, 1H),
8.06-8.01 (m, 4H), 7.85 (m, 2H), 7.55 (dd, J=8.3, 4.2 Hz, 1H), 6.23
(s, 2H), 3.86 (d, J=5.9 Hz, 2H), 2.61 (d, J=4.6 Hz, 3H).
Example 3
N-(3-amino-3-oxopropyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5--
b]pyridin-5-yl)benzamide
[0600] The title compound was prepared by following the procedure
described for example 1 using intermediate 11 (0.100 g, 0.262
mmol), DMF (1 ml), N-ethyldiisopropylamine (0.033 g, 0.262 mmol),
HATU (0.099 g, 0.262 mmol) and 3-aminopropanamide (0.046 g, 0.524
mmol). Off-white solid (0.030 g, 25%). M.P.: 256-258.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.88 (dd,
J=4.1, 1.6 Hz, 1H),), 8.69 (d, J=8.7 Hz, 1H), 8.64 (t, J=5.4 Hz,
1H), 8.37 (d, J=7.7 Hz, 1H), 8.33 (d, J=8.4 Hz, 2H), 8.20 (d, J=8.8
Hz, 1H), 8.03 (m, 4H), 7.84 (dd, J=8.7, 1.9 Hz, 1H), 7.53 (dd,
J=8.3, 4.2 Hz, 1H), 7.35 (s, 1H), 6.82 (s, 1H), 6.22 (s, 2H), 3.49
(m, 2H), 2.39 (t, J=7.2 Hz, 2H).
Example 4
N-(3-(methylamino)-3-oxopropyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triaz-
olo[4,5-b]pyridin-5-yl)benzamide
[0601] The title compound was prepared by following the procedure
described for example 1 using intermediate 11 (0.100 g, 0.262
mmol), DMF (1 ml), N-ethyldiisopropylamine (0.033 g, 0.262 mmol),
HATU (0.099 g, 0.262 mmol) and 3-amino-N-methylpropanamide (0.055
g, 0.524 mmol). Off-white solid (0.040 g, 33%). M.P.:
226-228.degree. C. .sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.88 (dd, J=4.2, 1.7 IIz, 1II),), 8.69 (m, 2H), 8.38
(d, J=7.3 Hz, 1H), 8.33 (d, J=8.5 Hz, 2H), 8.20 (d, J=8.8 Hz, 1H),
8.03-7.97 (mm, 4H), 7.84 (dd, J=8.8, 2.0 Hz, 2H), 7.53 (dd, J=8.3,
4.2 Hz, 1H), 6.22 (s, 2H), 3.50 (m, 2H), 2.57 (d, J=4.6 Hz, 3H),
2.39 (t, J=7.2 Hz, 2H).
Example 5
2-chloro-N-(2-(pyrrolidin-1-yl)ethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,3-
]triazolo[4,5-b]pyridin-5-yl)benzamide
[0602] The title compound was prepared by following the procedure
described for example 1 using intermediate 12 (0.150 g, 0.359
mmol), DMF (1.05 ml)N-ethyldiisopropylamine (0.046 g, 0.359 mmol),
HATU (0.136 g, 0.359 mmol) and 2-(pyrrolidin-1-yl)ethanamine (0.040
g, 0.359 mmol). Yellow solid (0.040 g, 22%). M.P.: 143-145.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.88
(dd, J=4.1, 1.7 Hz, 1H), 8.70 (d, J=8.7 Hz, 1H), 8.49 (t, J=5.6 Hz,
1H), 8.37 (d, J=5.4 Hz, 1H), 8.31 (d, J=1.6 Hz, 1H), 8.25 (dd,
J=8.1, 1.7 Hz, 1H), 8.21 (d, J=8.8 Hz, 1H), 8.04 (d, J=1.6 Hz, 1H),
8.02 (d, J=8.7 Hz, 1H), 7.83 (dd, J=8.7, 2.0 Hz, 1H), 7.57 (d,
J=8.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.23 (s, 2H), 3.38 (m,
2H), 2.54 (m, 6H), 1.68 (m, 4H).
Example 6
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide
[0603] The title compound was prepared by following the procedure
described for example 1 using intermediate 12 (0.150 g, 0.360
mmol), DMF (1 ml), N-ethyldiisopropylamine (0.046 g, 0.360 mmol),
IIATU (0.136 g, 0.360 mmol) and 2-hydroxyethylhydroxylamine (0.027
g, 0.360 mmol). Yellow solid (0.049 g, 29%). M.P.: 189-191.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 10.56
(s, 1H), 8.88 (dd, J=4.1, 1.5 Hz, 1H), 8.42 (d, J=8.7 Hz, 1H), 8.16
(d, J=1.6 Hz, 1H), 8.12 (d, J=7.9 Hz, 1H), 8.04 (d, J=8.8 Hz, 1H),
8.00 (dd, J=8.1, 1.7 Hz, 1H), 7.92 (d, J=1.6 Hz, 1H), 7.81 (m, 2H),
7.60 (d, J=8.0 Hz, 1H), 7.38 (dd, J=8.3, 4.2 Hz, 1H), 6.10 (s, 2H),
4.32 (t, J=4.2 Hz, 1H), 4.08 (t, J=4.2 Hz, 2H), 3.80 (m, 2H).
Example 6a
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl) benzamide hydrochloride
[0604] The title compound was prepared by following the procedure
described for example 1 using example 6 (0.025 g, 0.052 mmol), THF
(0.5 ml) and ether-HCl (0.2 ml). Pale yellow solid (0.013 g, 49%).
M.P.: 218-220.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): .delta. 11.69 (s, 1H), 9.08 (d, J=4.3 Hz, 1H), 8.75 (d,
J=7.7 Hz, 1H), 8.72 (d, J=8.7 Hz, 1H), 8.33 (d, J=1.3 Hz, 11H),
8.26-8.17 (m, 4H), 8.02 (d, J=8.7 Hz, 1H), 7.79 (d, J=4.4 Hz, 1H),
7.63 (d, J=8.0 Hz, 1H), 6.29 (s, 2H), 3.96 (t, J=5.0 Hz, 2H), 3.66
(t, J=5.1 Hz, 2H).
Example 6b
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate
[0605] The example 6 (0.070 g. 0.147 mmol) was dissolved in THE (2
ml), para-toluenesulphonic acid (0.028 g, 0.147 mmol) was added at
0.degree. C. and stirred for 30 min. The solvent was concentrated
and dried under vacuum to afford the title compound as a yellow
solid (0.050 g, 52%). M.P.: 226-228.degree. C. .sup.1H-NMR (.delta.
ppm, DMSO-d.sub.6, 400 MHz): 11.68 (s, 1H), 9.07 (d, J=1.2 Hz, 1H),
8.73 (d, J=8.7 Hz, 2H), 8.34 (d, J=1.4 Hz, 1H), 8.27-8.19 (m, 3H),
8.13 (d, J=8.7 Hz, 1H), 8.00 (d, J=8.7 Hz, 1H), 7.78 (dd, J=8.3,
3.7 Hz, 1H), 7.64 (d, J=8.1 Hz, 1H), 7.47 (d, J=8.0 Hz, 2H), 7.10
(d, J=7.9 Hz, 2H), 6.28 (s, 2H), 3.96 (t, J=4.9 Hz, 2H), 3.66 (t,
J=4.9 Hz, 2H), 2.27 (s, 3H).
Example 6c
2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide hydrobromide
[0606] The example 6 (0.070 g. 0.147 mmol) was dissolved in THE (2
ml), HBr in ether (1.5 ml) was added at 0.degree. C. and stirred
for 30 min. The precipitate was filtered and washed with ether and
dried under vacuum to afford the title compound as a yellow solid
(0.050 g, 61%). M.P.: 222-224.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 11.68 (s, 1H), 9.07 (dd, J=4.6, 1.2 Hz,
1H), 8.73 (d, J=8.7 Hz, 2H), 8.34 (d, J=1.6 Hz, 1H), 8.27-8.19 (m,
3II), 8.13 (d, J=8.8 IIz, 1II), 8.00 (dd, J=8.7, 1.7 IIz, 1II),
7.79 (dd, J=8.4, 4.7 IIz, 1H), 7.64 (d, J=8.0 Hz, 1H), 6.29 (s,
2H), 3.96 (t, J=4.9 Hz, 2H), 3.65 (t, J=5.1 Hz, 2H).
Example 6d
sodium
(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-5-yl)benzoyl)(2-hydroxyethoxy)amide
[0607] To example 6 (0.100 g, 0.210 mmol) in isopropanol (2 ml), 3N
sodium hydroxide solution (0.076 ml) was added and stirred for 30
min. The reaction mixture was concentrated under reduced pressure.
To the residue 1 ml isopropanol was added, filtered, washed with
isopropanol, diethyl ether and dried under vacuum to afford the
title compound as a yellow solid (0.080 g, 79%). M.P.:
256-258.degree. C. .sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 8.88 (dd, J=4.2, 1.7 Hz, 1H), 8.63 (d, J=8.8 Hz, 1H), 8.38
(dd, J=8.5, 0.9 Hz, 1H), 8.15 (d, J=1.7 Hz, 1H), 8.14 (d, J=8.8 Hz,
1H), 8.07-8.00 (m, 3H), 7.83 (dd, J=8.7, 2.0 Hz, 1H), 7.53 (dd,
J=8.3, 4.2 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 6.21 (s, 2H), 5.83 (s,
1H), 3.67 (t, J=4.2 Hz, 2H), 3.54 (m, 2H).
Example 7
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyr-
idin-5-yl)-N-(2-hydroxyethoxy)benzamide
[0608] The title compound was prepared by following the procedure
described for example 6 using Intermediate 16 (0.150 g, 0.345
mmol), DMF (1.1 ml), N-ethyldiisopropylamine (0.044 g, 0.345 mmol),
HATU (0.131 g, 0.345 mmol) and 2-hydroxyethylhydroxylamine (0.053
g, 0.691 mmol). Pale green solid (0.040 g, 23%). M.P.: [0609]
195-198.degree. C. .sup.1H-NMR (b ppm, DMSO-d.sub.6, 400 MHz):
11.67 (s, 1H), 8.92 (dd, J=4.2, 1.6 Hz, 1H), 8.71 (d, J=8.7 Hz,
1H), 8.43 (d, J=7.2 Hz, 1H), 8.31 (d, J=1.5 Hz, 1H), 8.24 (m, 3H),
7.83 (d, J=11.5 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.55 (dd, J=8.5,
4.2 Hz, 1H), 6.26 (s, 2H), 4.72 (t, J=5.5 Hz, 1H), 3.96 (t, J=4.9
Hz, 2H), 3.66 (m, 2H).
Example 7a
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyr-
idin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride
[0610] The title compound was prepared by following the procedure
described for example 6a using example 7 (0.050 g, 0.101 mmol), THF
(1.0 ml) and ether-HCl (0.2 ml). Pale yellow solid (0.045 g, 84%).
M.P.: 189-191.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 11.69 (s, 1H), 8.97 (dd, J=4.4, 1.4 Hz, 1H), 8.71 (d,
J=8.7 Hz, 1H), 8.54 (d, J=8.0 Hz, 1H), 8.31 (d, J=1.5 Hz, 1H), 8.27
(m, 3H), 7.87 (d, J=11.3 Hz, 1H), 7.62 (m, 2H), 6.27 (s, 2H), 3.92
(t, J=4.9 Hz, 2H), 3.64 (m, 2H).
Example 7b
sodium
(2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4-
,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide
[0611] To example 7 (0.050 g, 0.101 mmol) in isopropanol (1.0 ml),
3N sodium hydroxide solution (0.036 ml) was added and stirred for
30 min. The reaction mixture was concentrated under reduced
pressure. To the residue 0.5 ml isopropanol was added, filtered and
washed with water (1 ml), dried under vacuum to afford the title
compound as a yellow solid (0.020 g, 37%). M.P.: 222-224.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.91 (dd, J=4.2,
1.6 Hz, 1H), 8.63 (d, J=8.8 Hz, 1H), 8.44 (dd, J=8.4, 1.0 Hz, 1H),
8.22 (d, J=8.2 Hz, 1H), 8.14 (d, J=8.6 Hz, 1H), 8.12 (s, 1H), 8.03
(dd, J=8.0, 1.7 Hz, 1H), 7.82 (d, J=11.4 Hz, 1H), 7.54 (dd, J=8.4,
4.3 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 6.24 (s, 2H), 5.79 (s, 1H),
3.67 (t, J=4.1 Hz, 2H), 3.54 (m, 2H).
Example 7c
2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]-
triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide
[0612] The title compound was prepared by following the procedure
described for example 6 using intermediate 44 (0.100 g, 0.222
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.028 g, 0.222 mmol),
HATU (0.084 g, 0.222 mmol) and 2-hydroxyethylhydroxylamine (0.034
g, 0.444 mmol). Pale green solid (0.035 g, 20%). M.P.:
211-214.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.82 (s, 1H), 11.69 (s, 1H), 8.68 (d, J=8.8 Hz, 1H), 8.32
(d, J=1.5 Hz, 1H), 8.25 (dd, J=8.1, 1.7 Hz, 1H), 8.22 (d, J=8.8 Hz,
1H), 7.94 (m, 2H), 7.64 (d, J=8.0 Hz, 1H), 7.08 (d, J=11.1 Hz, 1H),
6.46 (d, J=9.5 Hz, 1H), 6.06 (s, 2H), 4.73 (t, J=5.7 Hz, 1H), 3.95
(t, J=4.9 Hz, 2H), 3.67 (m, 2H).
Example 8
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tria-
zolo[4,5-b]pyridin-5-yl)benzamide
[0613] The title compound was prepared by following the procedure
described for example 6 using intermediate 17 (0.150 g, 0.359
mmol), DMF (1.1 ml), N-ethyldiisopropylamine (0.046 g, 0.359 mmol),
HATU (0.136 g, 0.359 mmol) and 2-hydroxyethylhydroxylamine (0.055
g, 0.718 mmol). Off-white solid (0.035 g, 20%). M.P.:
187-190.degree. C. .sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.91 (s, 1II), 8.89 (dd, J=4.2, 1.7 IIz, 1H), 8.75 (d, J=8.7
Hz, 1H), 8.37 (d, J=7.6 Hz, 1H), 8.27 (d, J=8.7 Hz, 1H), 8.12-7.99
(m, 4H), 7.83 (dd, J=8.8, 6.8 Hz, 1H), 7.54 (dd, J=8.3, 4.2 Hz,
1H), 6.24 (s, 2H), 4.74 (t, J=5.7 Hz, 1H), 3.95 (t, J=4.9 Hz, 2H),
3.65 (m, 2H).
Example 8a
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tria-
zolo[4,5-b]pyridin-5-yl)benzamide hydrochloride
[0614] The title compound was prepared by following the procedure
described for example 6a using example 8 (0.040 g, 0.083 mmol), THF
(1.0 ml) and ether-HCl (0.2 ml). Pale yellow solid (0.040 g, 95%).
M.P.: 208-210.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): [0615] 11.95 (s, 1H), 9.05 (s, 1H), 8.76 (d, J=8.7 Hz,
1H), 8.69 (br s, 1H), 8.28 (d, J=8.8 Hz, 1H), 8.19-8.09 (m, 5II),
8.00 (d, J=8.6 IIz, 1II), 7.76 (d, J=3.2 IIz, 1II), 6.29 (s, 2II),
3.95 (t, J=5.0 Hz, 2H), 3.68 (m, 2H).
Example 8b
sodium
(2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]p-
yridin-5-yl)benzoyl)(2-hydroxyethoxy)amide
[0616] To example 8 (0.080 g, 0.167 mmol) in isopropanol (2.0 ml),
3N sodium hydroxide solution (0.06 ml) was added and stirred for 30
min. The reaction mixture was concentrated under reduced pressure.
To the residue 0.5 ml isopropanol was added, filtered and washed
with water (1 ml), dried under vacuum to afford the title compound
as a off-white solid (0.060 g, 72%). M.P.: 240-242.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.88 (dd, J=4.2,
1.7 Hz, 1H), 8.66 (d, J=8.7 Hz, 1H), 8.37 (d, J=8.3 Hz, 1H), 8.19
(d, J=8.8 Hz, 1H), 8.05 (d, J=1.2 Hz, 1H), 8.02 (d, J=8.6 Hz, 1H),
7.83 (m, 3H), 7.53 (dd, J=8.4, 4.2 Hz, 1H), 6.22 (s, 2H), 5.49 (s,
1H), 3.64 (t, J=4.1 Hz, 2H), 3.51 (m, 2H).
Example 9
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b-
]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide
[0617] The title compound was prepared by following the procedure
described for example 6 using intermediate 18 (0.150 g, 0.344
mmol), DMF (1.1 ml), N-ethyldiisopropylamine (0.044 g, 0.344 mmol),
HATU (0.131 g, 0.344 mmol) and 2-hydroxyethylhydroxylamine (0.053
g, 0.689 mmol). Off-white solid (0.050 g, 29%). M.P.: [0618]
206-209.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.92 (s, 1H), 8.92 (dd, J=4.2, 1.6 Hz, 1H), 8.75 (d, J=8.7
Hz, 1H), 8.43 (d, J=7.5 Hz, 1H), 8.27 (d, J=8.8 Hz, 1H), 8.23 (d,
J=8.3 Hz, 1H), 8.07 (d, J=8.9 Hz, 2H), 7.83 (d, J=11.4 Hz, 1H),
7.55 (dd, J=8.2, 4.2 Hz, 1H), 6.27 (s, 2H), 4.74 (t, J=5.6 Hz, 1H),
3.95 (t, J=5.0 Hz, 2H), 3.65 (m, 2H).
Example 9a
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b-
]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride
[0619] The title compound was prepared by following the procedure
described for example 6a using example 9 (0.030 g, 0.060 mmol), THF
(1.0 ml) and ether-HCl (0.2 ml). Off-white solid (0.025 g, 78%).
M.P.: 193-195.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 11.95 (s, 1H), 9.01 (dd, J=4.4, 1.4 Hz, 1H), 8.77 (d,
J=8.7 Hz, 1H), 8.58 (d, J=7.8 Hz, 1H), 8.27 (m, 2H), 8.07 (d, J=8.9
Hz, 2H), 7.90 (d, J=11.2 Hz, 1H), 7.66 (dd, J=8.4, 4.5 Hz, 1H),
6.29 (s, 2H), 3.95 (t, J=4.9 Hz, 2H), 3.64 (t, J=5.1 Hz, 2H).
Example 9b
sodium
(2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazo-
lo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide
[0620] To example 9 (0.050 g, 0.182 mmol) in isopropanol (1 ml), 3N
sodium hydroxide solution (0.06 ml) was added and stirred for 30
min. The reaction mixture was concentrated under reduced pressure.
To the residue 0.5 ml isopropanol was added, filtered, dried under
vacuum to afford the title compound as a off-white solid (0.020 g,
21%). M.P.: [0621] 238-240.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 8.91 (d, J=2.9 Hz, 1H), 8.62 (d, J=8.8 Hz,
1H), 8.42 (d, J=8.0 Hz, 1H), 8.22 (d, J=8.3 Hz, 1H), 8.18 (d, J=8.8
Hz, 1H), 7.82 (m, 3H), 7.54 (dd, J=8.4, 4.2 Hz, 1H), 6.25 (s, 2H),
5.58 (s, 1H), 3.62 (t, J=5.2 Hz, 2H), 3.50 (m, 2II).
Example 10
2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide
[0622] The title compound was prepared by following the procedure
described for example 6 using intermediate 19 (0.200 g, 0.500
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.064 g, 0.500 mmol),
HATU (0.190 g, 0.500 mmol) and 2-hydroxyethythydroxylamine (0.077
g, 1.00 mmol). Off-white solid (0.040 g, 17%). M.P.: [0623]
200-203.degree. C. MS (m/z): 459.0 (m.sup.++1).
Example 11
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl acetate
[0624] The title compound was prepared by following the procedure
described for example 6 using example 6 (0.100 g, 0.210 mmol), DMF
(1.0 ml), triethylamine (0.063 g, 0.630 mmol), HOBT (0.034 g, 0.252
mmol), EDC-HCl (0.100 g, 0.525 mmol) and acetic acid (0.012 g,
0.210 mmol). Off-white solid (0.030 g, 27%). M.P.: 168-170.degree.
C. MS (m/z): 517.2 (m.sup.+).
Example 12
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridi-
n-5-yl)benzamidooxy)ethyl
2-(tert-butoxycarbonylamino)propanoate
[0625] The title compound was prepared by following the procedure
described for example 6 using example 6 (0.200 g, 0.421 mmol), DMF
(2.0 ml), triethylamine (0.128 g, 1.26 mmol), HOBT (0.068 g, 0.505
mmol), EDC-HCl (0.201 g, 1.153 mmol) and N-Boc-L-alanine (0.079 g,
0.421 mmol). Yellow solid (0.100 g, 36%) which is used as such in
next step.
Example 13
(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridi-
n-5-yl)benzamidooxy)ethyl 2-aminopropanoate
[0626] To example 12 (0.100 g, 0.154 mmol) in dichloromethane (2
ml), trifluoroacetic acid (1 ml) was added at o C and stirred at
room temperature for 12 h. The reaction mass was basified to pH
9-10 using sodium carbonate solution, extracted with
dichlromethane, dried over sodium sulphate and concentrated under
reduced pressure to afford the title compound as a off-white solid
(0.025 g, 9%). M.P.: 175-177.degree. C. MS (m/z): [0627] 546.1
(m.sup.+).
Example 14
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl pivalate
[0628] The title compound was prepared by following the procedure
described for example 6 using example 6 (0.100 g, 0.210 mmol), DMF
(1.0 ml), triethylamine (0.063 g, 0.630 mmol), HOBT (0.034 g, 0.252
mmol), EDC-HCl (0.100 g, 0.525 mmol) and pivolicc acid (0.021 g,
0.210 mmol). Off-white solid (0.060 g, 51%). M.P.: 130-133.degree.
C. MS (m/z): 558.9 (m.sup.+).
Example 15
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl isobutyrate
[0629] The title compound was prepared by following the procedure
described for example 6 using example 6 (0.100 g, 0.210 mmol), DMF
(1.0 ml), triethylamine (0.063 g, 0.630 mmol), HOBT (0.034 g, 0.252
mmol), EDC-HCl (0.100 g, 0.525 mmol) and isobutyric acid (0.018 g,
0.210 mmol). Pale yellow solid (0.030 g, 26%). M.P.:
115-118.degree. C. MS (m/z): [0630] 545.1 (m.sup.+).
Example 16
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl 2-benzamidoacetate
[0631] The title compound was prepared by following the procedure
described for example 6 using example 6 (0.100 g, 0.210 mmol), DMF
(1.0 ml), triethylamine (0.063 g, 0.630 mmol), HOBT (0.034 g, 0.252
mmol), EDC-HCl (0.100 g, 0.525 mmol) and hippuric acid (0.037 g,
0.210 mmol). Off-white solid (0.060 g, 44%). M.P.: 110-112.degree.
C. MS (m/z): [0632] 636.0 (m.sup.+).
Example 17
2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,-
3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0633] The title compound was prepared by following the procedure
described for example 7 using Intermediate 20 (0.140 g, 0.326
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.084 g, 0.652 mmol),
HATU (0.123 g, 0.326 mmol) and 2-hydroxyethylhydroxylamine (0.050
g, 0.652 mmol). Off-white solid (0.045 g, 28%). M.P.: [0634]
219-222.degree. C. MS (m/z): 489.2 (me).
Example 18
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-
-chloro-N-(2-hydroxyethoxy)benzamide
[0635] The title compound was prepared by following the procedure
described for example 6 using Intermediate 21 (0.150 g, 0.355
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.092 g, 0.711 mmol),
HATU (0.135 g, 0.355 mmol) and 2-hydroxyethylhydroxylamine (0.054
g, 0.711 mmol). Brown solid (0.014 g, 8%). M.P.: 194-196.degree. C.
MS (m/z): 481.1 (m.sup.+).
Example 19
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-
,6-difluoro-N-(2-hydroxyethoxy)benzamide
[0636] The title compound was prepared by following the procedure
described for example 6 using Intermediate 22 (0.150 g, 0.354
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.092 g, 0.708 mmol),
HATU (0.136 g, 0.354 mmol) and 2-hydroxyethylhydroxylamine (0.054
g, 0.708 mmol). Off-white solid (0.026 g, 15%). M.P.: [0637]
202-205.degree. C. MS (m/z): 483.1 (m.sup.++1).
Example 19a
sodium
(4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-
-5-yl)-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide
[0638] To example 19 (0.050 g, 0.124 mmol) in isopropanol (2 ml),
3N sodium hydroxide solution (0.067 ml) was added and stirred for
30 min. The reaction mixture was concentrated under reduced
pressure. To the residue 0.5 ml isopropanol was added, filtered,
washed with isopropanol, diethyl ether and dried under vacuum to
afford the title compound as a off-white solid (0.035 g, 67%).
M.P.: 242-244.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 9.35 (s, 1H), 8.65 (d, J=8.7 Hz, 1H), 8.29 (d, J=0.9 Hz,
1H), 8.19 (d, J=8.8 Hz, 1H), 8.07 (d, J=8.5 Hz, 1H), 7.88 (d, J=8.0
Hz, 2H), 7.65 (dd, J=8.4, 1.6 Hz, 1H), 6.17 (s, 2H), 5.52 (s, 1H),
3.63 (t, J=5.3 Hz, 2H), 3.52 (m, 2H).
Example 20
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-
-fluoro-N-(2-hydroxyethoxy)benzamide
[0639] The title compound was prepared by following the procedure
described for example 6 using Intermediate 23 (0.200 g, 0.490
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.063 g, 0.490 mmol),
HATU (0.186 g, 0.490 mmol) and 2-hydroxyethylhydroxylamine (0.075
g, 0.980 mmol). Off-white solid (0.030 g, 13%). M.P.:
164-166.degree. C. MS (m/z): 465.1 (m.sup.++1).
Example 21
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[-
1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0640] The title compound was prepared by following the procedure
described for example 6 using intermediate 24 (0.150 g, 0.346
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.089 g, 0.693 mmol),
HATU (0.131 g, 0.346 mmol) and 2-hydroxyethylhydroxylamine (0.054
g, 0.693 mmol). Off-white solid (0.040 g, 23%). M.P.: [0641]
208-210.degree. C. MS (m/z): 491.0 (m.sup.++1).
Example 21a
2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[-
1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride
[0642] The title compound was prepared by following the procedure
described for example 6a using example 21 (0.030 g, 0.061 mmol),
TIIF (2.0 ml) and ether-IICl (0.3 ml). Pale green solid (0.022 g,
68%). M.P.: 211-213.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): [0643] 11.95 (s, 1H), 8.76 (s, 1H), 8.74
(d, J=8.7 Hz, 1H), 8.28 (d, J=8.8 Hz, 1H), 8.22 (s, 1H), 8.17 (d,
J=8.8 Hz, 1H), 8.12 (d, J=8.9 Hz, 1H), 8.06 (d, J=8.7 Hz, 1H), 7.79
(d, J=7.9 Hz, 1H), 6.30 (s, 2H), 3.95 (t, J=4.9 Hz, 2H), 3.64 (m,
2H), 2.83 (s, 3H).
Example 22
N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzamide
[0644] The title compound was prepared by following the procedure
described for example 6 using intermediate 25 (0.150 g, 0.393
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.050 g, 0.393 mmol),
HATU (0.149 g, 0.393 mmol) and 2-hydroxyethylhydroxylamine (0.060
g, 0.786 mmol). Yellow solid (0.045 g, 26%). M.P.: 210-212.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.88 (s, 1H),
8.88 (dd, J=4.2, 1.7 Hz, 1H), 8.70 (d, J=8.7 Hz, 1H), 8.38 (m, 3H),
8.20 (d, J=8.7 Hz, 1H), 8.03 (m, 2H), 7.93 (d, J=8.4 Hz, 2H), 7.84
(dd, J=8.7, 2.0 Hz, 1H), 7.53 (dd, J=8.4, 4.2 Hz, 1H), 6.22 (s,
2H), 4.78 (t, J=5.7 Hz, 1H), 3.96 (t, J=4.8 Hz, 2H), 3.64 (m,
2H).
Example 23
N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)-2-(trifluoromethyl)benzamide
[0645] The title compound was prepared by following the procedure
described for example 6 using intermediate 26 (0.150 g, 0.333
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.043 g, 0.393 mmol),
HATU (0.126 g, 0.333 mmol) and 2-hydroxyethylhydroxylamine (0.051
g, 0.667 mmol). Yellow solid (0.055 g, 32%). M.P.: 240-242.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.73 (s, 1H),
8.88 (dd, J=4.1, 1.7 Hz, 1H), 8.74 (d, J=8.8 Hz, 1H), 8.58 (s, 1H),
8.56 (d, J=6.2 Hz, 1H), 8.35 (dd, J=8.4, 1.0 Hz, 1H), 8.30 (d,
J=8.0 Hz, 1H), 8.05 (d, J=1.5 Hz, 1H), 8.01 (d, J=8.7 Hz, 1H), 7.84
(dd, J=8.7, 1.9 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.54 (dd, J=8.3,
4.2 Hz, 1H), 6.24 (s, 2H), 4.75 (t, J=5.7 Hz, 1H), 3.95 (t, J=4.9
Hz, 2H), 3.65 (m, 2H).
Example 24
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide
[0646] The title compound was prepared by following the procedure
described for example 6 using Intermediate 27 (0.150 g, 0.320
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.041 g, 0.320 mmol),
IIATU (0.121 g, 0.320 mmol) and 2-hydroxyethylhydroxylamine (0.049
g, 0.640 mmol). Yellow solid (0.060 g, 35%). M.P.: 227-229.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.72 (s, 1H),
8.91 (dd, J=4.2, 1.6 Hz, 1H), 8.74 (d, J=8.7 Hz, 1H), 8.56 (m, 1H),
8.41 (dd, J=8.4, 1.0 Hz, 1H), 8.30 (d, J=8.8 Hz, 1H), 8.23 (d,
J=8.2 Hz, 1H), 7.81 (d, J=11.4 Hz, 1H), 7.74 (d, J=8.7 Hz, 1H),
7.84 (dd, J=8.7, 1.9 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.54 (dd,
J=8.3, 4.2 Hz, 1H), 6.24 (s, 2H), 4.75 (t, J=5.7 Hz, 1H), 3.95 (t,
J=4.9 Hz, 2H), 3.65 (m, 2H).
Example 24a
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide
hydrochloride
[0647] The title compound was prepared by following the procedure
described for example 6 using example 24 (0.033 g, 0.062 mmol), THF
(1.0 ml) and ether-HCl (0.1 ml). Off-white solid (0.028 g, 80%).
M.P.: 166-170.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 11.72 (s, 1H), 8.96 (dd, J=4.3, 1.5 Hz, 1H), 8.74 (d,
J=8.7 Hz, 1H), 8.56 (s, 1H), 8.53 (d, J=8.7 Hz, 1H), 8.49 (d, J=8.3
Hz, 1H), 8.30 (d, J=8.8 Hz, 11H), 8.26 (d, J=8.2 Hz, 1H), 7.85 (d,
J=11.3 Hz, 1H), 7.74 (d, J=7.9 Hz, 1H), 7.60 (dd, J=8.4, 4.4 Hz,
1H), 6.28 (s, 2H), 3.95 (t, J=4.9 Hz, 1H), 3.59 (m, 2H).
Example 25
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide
[0648] The title compound was prepared by following the procedure
described for example 6 using intermediate 28 (0.120 g, 0.303
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.039 g, 0.303 mmol),
HATU (0.115 g, 0.303 mmol) and 2-hydroxyethylhydroxylamine (0.046
g, 0.607 mmol). Yellow solid (0.025 g, 18%). M.P.: 196-198.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.50 (s, 1H),
8.88 (dd, J=4.2, 1.6 Hz, 1H), 8.67 (d, J=8.7 Hz, 1H), 8.37 (d,
J=7.6 Hz, 1H), 8.15 (d, J=8.8 Hz, 1H), 8.10 (s, 1H), 8.08 (d, J=9.2
Hz, 1H), 8.04 (d, J=1.5 Hz, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.83 (dd,
J=8.7, 2.0 Hz, 1H), 7.54 (dd, J=8.3, 4.2 Hz, 1H), 7.48 (d, J=7.8
Hz, 1H), 6.21 (s, 2H), 4.75 (t, J=5.3 Hz, 1H), 3.95 (t, J=4.8 Hz,
2H), 3.65 (m, 2H), 2.43 (s, 3H).
Example 25a
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide hydrochloride
[0649] The title compound was prepared by following the procedure
described for example 6 using example 25 (0.080 g, 0.176 mmol), THF
(2.0 ml) and ether-HCl (0.4 ml). Off-white solid (0.080 g, 93%).
M.P.: 220-222.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 11.51 (s, 1II), 8.99 (d, J=3.1 IIz, 1II), 8.68 (d, J=8.7
IIz, 1II), 8.59 (d, J=7.6 IIz, 1H), 8.16-8.08 (m, 5H), 7.93 (d,
J=8.7 Hz, 1H), 7.68 (dd, J=8.4, 4.0 Hz, 1H), 7.48 (d, J=7.8 Hz,
1H), 6.24 (s, 2H), 3.95 (t, J=5.0 Hz, 2H), 3.38 (t, J=7.0 Hz, 2H),
2.43 (s, 3H).
Example 25b
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide hydrobromide
[0650] The example 25 (0.070 g. 0.154 mmol) was dissolved in THF (2
ml), HBr in ether (1.5 ml) was added at 0.degree. C. and stirred
for 30 min. The precipitate was filtered and washed with ether and
dried under vacuum to afford the title compound as a off-white
solid (0.049 g, 59%). M.P.: 173-175.degree. C. .sup.1H-NMR (.delta.
ppm, DMSO-d.sub.6, 400 MHz): 11.51 (s, 1H), 8.99 (dd, J=4.4, 1.3
IIz, 1II), 8.68 (d, J=8.7 IIz, 1II), 8.57 (d, J=7.8 IIz, 1II),
8.16-8.06 (m, 5H), 7.92 (dd, J=8.7, 1.9 Hz, 1H), 7.67 (dd, J=8.3,
4.4 Hz, 1H), 7.48 (d, J=7.8 Hz, 1H), 6.24 (s, 2H), 3.95 (t, J=4.8
Hz, 2H), 3.64 (t, J=5.0 Hz, 2H), 2.43 (s, 3H).
Example 25c
N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo-
[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate
[0651] The example 25 (0.070 g. 0.154 mmol) was dissolved in THF (2
ml), para-toluenesulphonic acid (0.029 g, 0.154 mmol) was added at
0.degree. C. and stirred for 30 min. The solvent was concentrated
and dried under vacuum to afford the title compound as a yellow
solid (0.070 g, 70%). M.P.: 1246-126.degree. C. .sup.1H-NMR
(.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.51 (s, 1H), 9.09 (d, J=4.6
Hz, 1H), 8.77 (d, J=8.4 Hz, 1H), 8.69 (d, J=8.7 Hz, 1H), 8.20-8.08
(m, 5H), 8.02 (d, J=8.8 Hz, 1H), 7.81 (dd, J=8.1, 4.6 Hz, 1H), 7.48
(m, 3H), 7.10 (d, J=7.9 Hz, 2H), 6.27 (s, 2H), 3.95 (t, J=4.7 Hz,
2H), 3.64 (t, J=4.9 Hz, 2H), 2.43 (s, 3H), 2.27 (s, 3H).
Example 25d
N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-
-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0652] The title compound was prepared by following the procedure
described for example 6 using intermediate 45 (0.100 g, 0.242
mmol), DMF (2.0 ml), N-ethyldiisopropylamine (0.062 g, 0.484 mmol),
HATU (0.092 g, 0.242 mmol) and 2-hydroxyethylhydroxylamine (0.037
g, 0.484 mmol). Brown solid (0.007 g, 6%). M.P.: 207-209.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.75 (s, 1H),
11.52 (s, 1H), 8.65 (d, J=8.8 Hz, 1H), 8.14 (m, 3H), 7.90 (d, J=9.6
Hz, 1H), 7.78 (s, 1H), 7.63 (dd, J=8.5, 1.9 Hz, 1H), 7.49 (d, J=7.9
Hz, 1H), 7.28 (d, J=8.5 Hz, 1H), 6.48 (dd, J=9.6, 1.9 Hz, 1H), 6.02
(s, 2H), 4.76 (t, J=5.8 Hz, 1H), 3.96 (t, J=4.9 Hz, 2H), 3.65 (m,
2H), 2.45 (s, 3H).
Example 25e
6-((5-(4-(2-hydroxyethoxycarbamoyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,5-
-b]pyridin-3-yl)methyl)quinoline 1-oxide
[0653] The title compound was obtained as a pale green solid (0.020
g, 19%) by using a procedure that is similar to the one described
for intermediate 31 from example 25 (0.100 g, 0.220 mmol), DMF (2.0
ml) and metachloroperbenzoic acid (0.189 g, 1.10 mmol). M.P.:
160-162.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.52 (s, 1H), 8.68 (d, J=8.8 Hz, 1H), 8.56 (d, J=5.6 Hz,
1H), 8.52 (d, J=9.0 Hz, 1H), 8.16 (m, 4H), 7.94 (d, J=8.6 Hz, 1H),
7.86 (dd, J=8.9, 1.8 Hz, 1H), 7.47 (m, 2H), 6.23 (s, 2H), 4.76 (t,
J=5.7 Hz, 1H), 3.95 (t, J=4.8 Hz, 2H), 3.65 (m, 2H), 2.43 (s,
3H).
Example 26
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)-N-(2-hydroxyethoxy)-2-methylbenzamide
[0654] The title compound was prepared by following the procedure
described for example 6 using intermediate 29 (0.120 g, 0.361
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.046 g, 0.361 mmol),
HATU (0.137 g, 0.361 mmol) and 2-hydroxyethylhydroxylamine (0.055
g, 0.723 mmol). Yellow solid (0.060 g, 35%). M.P.: 200-203.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.51 (s, 1H),
8.92 (dd, J=4.2, 1.6 Hz, 1H), 8.67 (d, J=8.8 Hz, 11H), 8.44 (dd,
J=8.4, 1.0 Hz, 11H), 8.21 (d, J=8.2 Hz, 1H), 8.15 (d, J=8.7 Hz,
1H), 8.06 (s, 1H), 8.05 (d, J=6.3 Hz, 1H), 7.83 (d, J=11.4 Hz, 1H),
7.55 (dd, J=8.3, 4.2 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 6.24 (s, 2H),
4.76 (t, J=5.7 Hz, 1H), 3.95 (t, J=4.9 IIz, 2II), 3.65 (m, 2II),
2.41 (s, 3II).
Example 26a
4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride
[0655] The title compound was prepared by following the procedure
described for example 6 using example 26 (0.040 g, 0.084 mmol), THF
(1.0 ml) and ether-HCl (0.1 ml). Off-white solid (0.030 g, 70%).
M.P.: 146-149.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 11.51 (s, 1H), 8.96 (dd, J=4.4, 1.6 Hz, 11H), 8.67 (d,
J=8.8 Hz, 1H), 8.52 (d, J=8.3 Hz, 1H), 8.25 (d, J=8.2 Hz, 1H), 8.16
(d, J=8.7 Hz, 1H), 8.07 (m, 2H), 7.86 (d, J=11.3 Hz, 1H), 7.60 (dd,
J=8.3, 4.3 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 6.25 (s, 2H), 3.95 (t,
J=4.9 Hz, 2II), 3.64 (t, J=5.1 IIz, 2II), 2.41 (s, 3II).
Example 27
2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyr-
idin-5-yl)-N-(2-hydroxyethoxy)benzamide
[0656] The title compound was prepared by following the procedure
described for example 6 using intermediate 30 (0.150 g, 0.359
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.046 g, 0.359 mmol),
HATU (0.136 g, 0.359 mmol) and 2-hydroxyethylhydroxylamine (0.055
g, 0.718 mmol). Off-white solid (0.100 g, 58%). M.P.:
208-211.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.65 (s, 1H), 8.92 (dd, J=4.3, 1.6 Hz, 1H), 8.72 (d, J=8.7
Hz, 1H), 8.43 (dd, J=8.5, 1.0 Hz, 1H), 8.23-8.11 (m, 4H), 7.83 (d,
J=11.5 Hz, 1H), 7.76 (t, J=7.7 Hz, 1H), 7.54 (dd, J=8.4, 4.3 Hz,
1H), 6.26 (s, 2H), 4.75 (t, J=5.6 Hz, 1H), 3.95 (t, J=4.8 Hz, 2H),
3.65 (m, 2H).
Example 27a
2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyr-
idin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride
[0657] The title compound was prepared by following the procedure
described for example 6 using example 27 (0.050 g, 0.120 mmol), THF
(1.0 ml) and ether-HCl (0.3 ml). Off-white solid (0.045 g, 83%).
M.P.: 175-178.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 11.65 (s, 1II), 8.97 (dd, J=4.4, 1.4 IIz, 1II), 8.72 (d,
J=8.7 IIz, 1II), 8.52 (d, J=7.9 IIz, 1H), 8.25 (m, 2H), 8.16 (m,
2H), 7.87 (d, J=11.3 Hz, 1H), 7.76 (t, J=7.5 Hz, 1H), 7.61 (dd,
J=8.3, 4.3 Hz, 1H), 6.27 (s, 2H), 3.94 (t, J=4.8 Hz, 2H), 3.65 (m,
2H).
Example 28
2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazol-
o[4,5-b]pyridin-5-yl)benzamide
[0658] The title compound was prepared by following the procedure
described for example 6 using intermediate 12 (0.165 g, 0.399
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.154 g, 1.190 mmol),
HATU (0.151 g, 0.399 mmol) and 1-(aminooxy)propan-2-ol
hydrochloride (0.100 g, 0.786 mmol). Pale yellow solid (0.040 g,
20%). M.P.: 150-152.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 11.71 (s, 1H), 8.88 (dd, J=4.1, 1.6 Hz,
1H), 8.71 (d, J=8.7 Hz, 1H), 8.37 (d, J=8.4 Hz, 1H), 8.35 (s, 1H),
8.27 (dd, J=8.0, 1.4 Hz, 1H), 8.23 (d, J=8.8 Hz, 1H), 8.04 (d,
J=1.2 Hz, 11H), 8.02 (d, J=8.7 Hz, 1H), 7.83 (dd, J=8.7, 1.9 Hz,
1H), 7.64 (d, J=8.0 Hz, 1H), 7.54 (dd, J=8.4, 4.2 Hz, 1H), 6.23 (s,
2H), 4.81 (s, 1H), 3.94 (q, J=6.0 Hz, 1H), 3.76 (d, J=5.5 Hz, 2H),
1.10 (d, J=6.3 Hz, 3H).
Example 29
ethyl
2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyri-
din-5-yl)benzamidooxy)acetate
[0659] The title compound was prepared by following the procedure
described for example 6 using intermediate 12 (0.300 g, 0.722
mmol), DMF (2.2 ml), N-ethyldiisopropylamine (0.094 g, 0.722 mmol),
IIATU (0.274 g, 0.722 mmol) and ethyl 2-(aminooxy)acetate (0.173 g,
1.445 mmol). Off-white solid (0.090 g, 24%). M.P.: 140-142.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.98 (s, 1H),
8.88 (d, J=2.8 Hz, 1H), 8.71 (d, J=8.7 Hz, 1H), 8.37 (d, J=7.9 Hz,
1H), 8.33 (s, 1H), 8.26 (m, 2H), 8.05 (s, 1H), 8.02 (d, J=8.6 Hz,
1H), 7.83 (d, J=8.6 Hz, 1H), 7.61 (d, J=7.9 Hz, 1H), 7.54 (dd,
J=8.2, 4.1 Hz, 1H), 6.23 (s, 2H), 4.60 (s, 2H), 4.20 (q, J=6.9 Hz,
2H), 1.24 (t, J=7.1 Hz, 3H).
Example 30
2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,-
3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0660] The title compound was prepared by following the procedure
described for example 6 using intermediate 12 (0.152 g, 0.366
mmol), DMF (1.0 ml), N-ethyldiisopropylamine (0.047 g, 0.366 mmol),
HATU (0.139 g, 0.366 mmol) and 1-(aminooxy)-2-methylpropan-2-ol
(0.050 g, 0.549 mmol). Pale green solid (0.040 g, 22%). M.P.:
104-107.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.70 (s, 1H), 8.88 (dd, J=4.3, 1.6 Hz, 1H), 8.71 (d, J=8.8
Hz, 1H), 8.37 (m, 2H), 8.27 (dd, J=8.0, 1.5 Hz, 1H), 8.23 (d, J=8.7
Hz, 1H), 8.07 (d, J=8.7 Hz, 1H), 8.05 (d, J=1.4 Hz, 1H), 7.83 (dd,
J=8.7, 1.5 Hz, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2
Hz, 1H), 6.23 (s, 2H), 4.61 (s, 1H), 3.75 (s, 2II), 1.17 (s,
6II).
Example 31
(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide
[0661] The title compound was prepared by following the procedure
described for example 6 using intermediate 12 (0.165 g, 0.399
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.154 g, 1.190 mmol),
HATU (0.151 g, 0.399 mmol) and (S)-1-(aminooxy)propan-2-ol
hydrochloride (0.100 g, 0.786 mmol). Pale green solid (0.040 g,
21%). M.P.: 138-140.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 11.70 (s, 1H), 8.88 (dd, J=4.1, 1.6 Hz,
1H), 8.71 (d, J=8.8 Hz, 1H), 8.37 (d, J=8.0 Hz, 1H), 8.35 (s, 1H),
8.27 (dd, J=8.1, 1.6 Hz, 1H), 8.23 (d, J=8.7 Hz, 1H), 8.04 (d,
J=1.5 Hz, 1H), 8.02 (d, J=8.7 Hz, 11H), 7.83 (dd, J=8.7, 2.0 Hz,
1H), 7.64 (d, J=8.0 Hz, 1H), 7.54 (dd, J=8.3, 4.2 Hz, 1H), 6.23 (s,
2H), 4.80 (m, 1H),), 3.93 (q, J=5.9 Hz, 1H), 3.77 (d, J=4.8 Hz,
2H), 1.11 (d, J=6.3 Hz, 3H).
Example 32
(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide
[0662] The title compound was prepared by following the procedure
described for example 6 using intermediate 12 (0.1645 g, 0.393
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.154 g, 1.190 mmol),
HATU (0.151 g, 0.399 mmol) and (R)-1-(aminooxy)propan-2-ol
hydrochloride (0.100 g, 0.786 mmol). Pale green solid (0.050 g,
26%). M.P.: 158-160.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 11.72 (s, 1H), 8.88 (dd, J=4.2, 1.7 Hz,
1H), 8.71 (d, J=8.7 Hz, 1H), 8.37 (d, J=7.6 Hz, 1H), 8.35 (s, 1H),
8.27 (dd, J=8.0, 1.6 Hz, 11H), 8.23 (d, J=8.8 Hz, 11H), 8.04 (d,
J=1.5 Hz, 11H), 8.02 (d, J=8.7 Hz, 11H), 7.83 (dd, J=8.7, 2.0 Hz,
1H), 7.64 (d, J=8.0 Hz, 1H), 7.54 (dd, J=8.3, 4.2 Hz, 1H), 6.23 (s,
2H), 4.80 (m, 1H),), 3.92 (q, J=4.3 Hz, 1H), 3.76 (d, J=4.8 Hz,
2H), 1.11 (d, J=6.2 Hz, 3H).
Example 33
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,-
3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0663] The title compound was prepared by following the procedure
described for example 6 using Intermediate 28 (0.144 g, 0.366
mmol), DMF (1.0 ml), N-ethyldiisopropylamine (0.047 g, 0.366 mmol),
HATU (0.139 g, 0.366 mmol) and 1-(aminooxy)-2-methylpropan-2-ol
(0.050 g, 0.549 mmol). Off-white solid (0.088 g, 50%). M.P.:
145-148.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.54 (s, 1H), 8.88 (dd, J=4.2, 1.7 Hz, 1H), 8.67 (d, J=8.7
Hz, 1H), 8.38 (d, J=7.5 Hz, 1H), 8.15 (d, J=8.8 Hz, 1H), 8.13-8.00
(m, 4H), 7.83 (dd, J=8.7, 2.0 Hz, 1H), 7.54 (dd, J=8.4, 4.2 Hz,
1H), 7.47 (d, J=7.8 Hz, 1H), 6.21 (s, 2H), 4.64 (s, 1H), 3.74 (s,
2H), 2.43 (s, 3H), 1.17 (s, 6H).
Example 34
2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[-
1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0664] The title compound was prepared by following the procedure
described for example 6 using intermediate 17 (0.159 g, 0.366
mmol), DMF (1.0 ml), N-ethyldiisopropylamine (0.047 g, 0.366 mmol),
HATU (0.139 g, 0.366 mmol) and 1-(aminooxy)-2-methylpropan-2-ol
(0.040 g, 0.549 mmol). Off-white solid (0.040 g, 21%). M.P.:
171-174.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.94 (s, 1H), 8.89 (dd, J=4.2, 1.7 Hz, 1H), 8.74 (d, J=8.7
Hz, 1H), 8.37 (d, J=8.5 Hz, 1H), 8.26 (d, J=8.8 Hz, 1H), 8.10 (m,
3II), 8.01 (d, J=8.7 IIz, 1II), 7.84 (dd, J=8.2, 2.0 IIz, 1II),
7.54 (dd, J=8.3, 4.2 Hz, 1H), 6.24 (s, 2H), 4.63 (s, 1H), 3.72 (s,
2H), 1.17 (s, 6H).
Example 35
2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,-
3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0665] The title compound was prepared by following the procedure
described for example 6 using intermediate 19 (0.152 g, 0.366
mmol), DMF (1.0 ml), N-ethyldiisopropylamine (0.047 g, 0.366 mmol),
HATU (0.139 g, 0.366 mmol) and 1-(aminooxy)-2-methylpropan-2-ol
(0.040 g, 0.549 mmol). Off-white solid (0.080 g, 44%). M.P.:
148-151.degree. C. .sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.67 (s, 1II), 8.88 (dd, J=4.2, 1.7 Hz, 1H), 8.72 (d, J=8.7
Hz, 11H), 8.37 (d, J=7.5 Hz, 1H), 8.21 (d, J=7.9 Hz, 1H), 8.18 (m,
2H), 8.05 (d, J=1.6 Hz, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.84 (dd,
J=8.8, 2.0 Hz, 1H), 7.77 (t, J=8.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2
Hz, 1H), 6.23 (s, 2H), 4.65 (s, 1H), 3.73 (s, 2H), 1.17 (s,
6H).
Example 36
(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide
[0666] The title compound was prepared by following the procedure
described for example 6 using intermediate 28 (0.200 g, 0.506
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.196 g, 1.51 mmol),
HATU (0.192 g, 0.506 mmol) and (S)-1-(aminooxy)propan-2-ol
hydrochloride (0.128 g, 1.01 mmol). Off-white solid (0.100 g, 42%).
M.P.: 230-232.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 11.53 (s, 1H), 8.88 (dd, J=4.0, 1.3 Hz, 1H), 8.67 (d,
J=8.7 Hz, 1H), 8.38 (d, J=8.1 Hz, 1H), 8.15 (d, J=8.7 Hz, 1H), 8.10
(m, 4H), 7.83 (dd, J=8.7, 1.5 Hz, 1H), 7.53 (dd, J=8.3, 4.1 Hz,
1H), 7.48 (d, J=7.8 Hz, 1H), 6.21 (s, 2H), 4.85 (s, 1H), 3.92 (m,
1H), 3.75 (m, 2H), 2.43 (s, 3H), 1.10 (d, J=6.2 Hz, 3H).
Example 37
N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6--
yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0667] The title compound was prepared by following the procedure
described for example 6 using intermediate 45 (0.150 g, 0.363
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.094 g, 0.727 mmol),
HATU (0.138 g, 0.363 mmol) and 1-(aminooxy)-2-methylpropan-2-ol
(0.076 g, 0.727 mmol). Off-white solid (0.035 g, 19%). M.P.:
209-212.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.74 (s, 1H), 11.55 (s, 1H), 8.65 (d, J=8.7 Hz, 1H), 8.14
(m, 3H), 7.89 (d, J=9.6 Hz, 1H), 7.78 (d, J=1.7 Hz, 1H), 7.63 (dd,
J=8.5, 1.9 Hz, 1H), 7.48 (d, J=7.8 Hz, 1H), 7.28 (d, J=8.5 Hz, 1H),
6.48 (dd, J=9.5, 1.6 Hz, 1H), 6.02 (s, 2H), 4.65 (s, 1H), 3.74 (s,
2H), 2.45 (s, 3H), 1.18 (s, 6H).
Example 38
(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyridin-5-yl)benzamide
[0668] The title compound was prepared by following the procedure
described for example 6 using intermediate 28 (0.200 g, 0.506
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.196 g, 1.51 mmol),
HATU (0.192 g, 0.506 mmol) and (R)-1-(aminooxy)propan-2-ol
hydrochloride (0.128 g, 1.01 mmol). Off-white solid (0.034 g, 14%).
M.P.: 200-202.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): 8.88 (dd, J=4.1, 1.5 Hz, 1H), 8.62 (d, J=8.8 Hz, 1H),
8.37 (d, J=7.8 Hz, 1H), 8.10 (d, J=8.7 Hz, 1H), 8.04 (m, 4H), 7.83
(dd, J=8.7, 1.9 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 7.46 (d,
J=7.8 Hz, 1H), 6.20 (s, 2H), 3.89 (m, 1H), 3.69 (dd, J=10.6, 3.7
Hz, 1H), 3.57 (dd, J=11.5, 7.8 Hz, 1H), 2.44 (s, 3H), 1.03 (d,
J=6.4 Hz, 3H).
Example 39
N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3-
H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0669] The title compound was prepared by following the procedure
described for example 6 using intermediate 28 (0.200 g, 0.506
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.196 g, 1.51 mmol),
HATU (0.192 g, 0.506 mmol) and 2-(aminooxy)-2-methylpropan-1-ol
hydrochloride (0.142 g, 1.01 mmol). Pale yellow solid (0.034 g,
13%). M.P.: 193-195.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 11.12 (s, 1H), 8.88 (dd, J=4.2, 1.7 IIz,
1II), 8.62 (d, J=8.8 IIz, 1II), 8.38 (dd, J=8.4, 1.9 IIz, 1II),
8.16 (m, 3H), 8.05 (d, J=1.7 Hz, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.83
(dd, J=8.7, 4.7 Hz, 1H), 7.54 (m, 2H), 6.21 (s, 2H), 4.83 (t, J=6.8
Hz, 1H), 3.38 (m, 2H), 2.44 (s, 3H), 1.19 (s, 6H).
Example 40
2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)-3-
H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide
[0670] The title compound was prepared by following the procedure
described for example 6 using intermediate 12 (0.200 g, 0.480
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.186 g, 1.44 mmol),
HATU (0.182 g, 0.480 mmol) and 2-(aminooxy)-2-methylpropan-1-ol
hydrochloride (0.135 g, 0.961 mmol). Pale green solid (0.040 g,
17%). M.P.: 148-150.degree. C. Mass: 502.8 (M.sup.+).
Example 41
N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)-3-
H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide
[0671] The title compound was obtained as a off-white solid (0.040
g, 38%) by using a procedure that is similar to the one described
for intermediate 31 from example 33 (0.100 g, 0.213 mmol), DMF (2.0
ml) and metachloroperbenzoic acid (0.184 g, 1.06 mmol). M.P.:
160-162.degree. C. Mass: 498.9 (M.sup.+).
Example 42
N-Hydroxy-2-methyl-4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrid-
in-5-yl)-benzamide
[0672] The title compound was prepared by following the procedure
described for example 6 using intermediate 28 (0.200 g, 0.505
mmol), DMF (2.5 ml), triethylamine (0.352 ml, 2.52 mmol), HBTU
(0.287 g, 0.758 mmol) and hydroxylamine hydrochloride (0.069 g,
1.01 mmol). Brown solid (0.005 g, 3%). M.P.: 200-203.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz):9.16 s, 1H), 9.07
(s, 1H), 8.88 (dd, J=4.2, 1.7 Hz, 1H), 8.58 (d, J=8.8 Hz, 1H), 8.38
(dd, J=8.5, 1.0 Hz, 1H), 8.15 (s, 1H), 8.08 (m, 4H), 7.95 (d, J=8.3
Hz, 1H), 7.83 (dd, J=8.8, 2.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz,
1H), 6.18 (s, 2H), 2.31 (s, 3H).
Example 43
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl acetate
[0673] The title compound was prepared by following the procedure
described for example 6 using example 25 (0.200 g, 0.440 mmol), DMF
(2.0 ml), triethylamine (0.184 ml, 1.32 mmol), EDC-HCl (0.210 g,
1.10 mmol), HOBt (0.071 g, 0.528 mmol) and acetic acid (0.030 g,
0.440 mmol). Off-white solid (0.065 g, 29%). M.P.: 145-147.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.56 (s, 1H),
8.88 (dd, J=4.2, 1.7 Hz, 1H), 8.67 (d, J=8.7 Hz, 1H), 8.38 (dd,
J=8.3, 0.9 Hz, 1H), 8.15 (d, J=8.7 Hz, 1H), 8.10 (m, 2H), 8.04 (m,
2H), 7.83 (dd, J=8.7, 2.0 Hz, 1H), 7.54 (dd, J=8.3, 4.2 Hz, 1H),
7.48 (d, J=7.8 Hz, 1H), 6.21 (s, 2H), 4.26 (t, J=4.7 IIz, 2II),
4.13 (t, J=4.6 IIz, 2II), 2.43 (s, 3II), 2.04 (s, 3II).
Example 44
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl isobutyrate
[0674] The title compound was prepared by following the procedure
described for example 6 using example 25 (0.200 g, 0.440 mmol), DMF
(2.0 ml), triethylamine (0.184 ml, 1.32 mmol), EDC-HCl (0.210 g,
1.10 mmol), HOBt (0.071 g, 0.528 mmol) and isobutyric acid (0.038
g, 0.440 mmol). Off-white solid (0.080 g, 34%). M.P.:
157-159.degree. C. .sup.1H-NMR (6 ppm, DMSO-d.sub.6, 400 MHz):
11.42 (s, 1H), 8.88 (dd, J=4.2, 1.6 Hz, 1H), 8.64 (d, J=8.8 Hz,
1H), 8.37 (d, J=7.9 Hz, 1H), 8.12 (d, J=8.8 Hz, 1H), 8.04 (m, 4H),
7.83 (dd, J=8.7, 1.8 Hz, 11H), 7.53 (dd, J=8.3, 4.2 Hz, 11H), 7.48
(d, J=7.8 Hz, 11H), 6.20 (s, 2H), 4.26 (t, J=4.3 Hz, 2H), 4.02 (t,
J=4.2 Hz, 2H), 2.53 (m, 1H), 2.42 (s, 3H), 1.10 (d, J=7.0 Hz,
6H).
Example 45
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl pivalate
[0675] The title compound was prepared by following the procedure
described for example 6 using example 25 (0.200 g, 0.440 mmol), DMF
(2.0 ml), triethylamine (0.184 ml, 1.32 mmol), EDC-HCl (0.210 g,
1.10 mmol), HOBt (0.071 g, 0.528 mmol) and pivalic acid (0.044 g,
0.440 mmol). Off-white solid (0.070 g, 29%). M.P.: 128-130.degree.
C. .sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.57 (s,
1H), 8.91 (dd, J=4.0, 1.4 Hz, 1H), 8.68 (d, J=8.8 Hz, 1H), 8.43 (d,
J=7.9 Hz, 1H), 8.16 (d, J=8.8 Hz, 1H), 8.11 (m, 4H), 7.85 (d, J=8.8
Hz, 1H), 7.57 (dd, J=8.3, 4.2 Hz, 1H), 7.49 (d, J=7.6 Hz, 1H), 6.22
(s, 2H), 4.26 (t, J=4.5 Hz, 2H), 4.11 (t, J=4.5 Hz, 2H), 2.43 (s,
3H), 1.16 (s, 9H),
Example 46
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl benzoate
[0676] The title compound was prepared by following the procedure
described for example 6 using example 25 (0.200 g, 0.440 mmol), DMF
(2.0 ml), triethylamine (0.184 ml, 1.32 mmol), EDC-HCl (0.210 g,
1.10 mmol), HOBt (0.071 g, 0.528 mmol) and benzoic acid (0.053 g,
0.440 mmol). Off-white solid (0.020 g, 9%). M.P.: 128-130.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.62 (s, 1H),
8.88 (d, J=2.8 Hz, 1H), 8.66 (d, J=8.6 Hz, 1H), 8.37 (d, J=8.4 Hz,
1H), 8.14-8.00 (m, 7H), 7.83 (d, J=8.0 Hz, 1H), 7.65 (t, J=7.0 Hz,
1H), 7.53 (m, 4H), 6.21 (s, 2H), 4.53 (t, J=4.5 Hz, 2H), 4.26 (t,
J=4.5 Hz, 2H), 2.43 (s, 3H).
Example 47
2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5--
yl)benzamidooxy)ethyl furan-2-carboxylate
[0677] The title compound was prepared by following the procedure
described for example 6 using example 25 (0.200 g, 0.440 mmol), DMF
(2.0 ml), triethylamine (0.184 ml, 1.32 mmol), EDC-HCl (0.210 g,
1.10 mmol), HOBt (0.071 g, 0.528 mmol) and 2-furoic acid (0.049 g,
0.440 mmol). Off-white solid (0.070 g, 29%). M.P.: 146-148.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 11.61 (s,
1II), 8.88 (dd, J=4.2, 1.7 IIz, 1H), 8.67 (d, J=8.8 IIz, 1H), 8.38
(d, J=8.4 Hz, 1H), 8.15-7.98 (m, 6H), 7.83 (dd, J=8.8, 2.0 Hz, 1H),
7.54 (dd, J=8.3, 4.2 Hz, 1H), 7.49 (d, J=8.0 Hz, 1H), 7.33 (d,
J=3.3 Hz, 1H), 6.70 (d, J=1.8 Hz, 1H), 6.21 (s, 2H), 4.50 (t, J=4.8
Hz, 2H), 4.23 (t, J=4.8 Hz, 2H), 2.43 (s, 3H).
Example 48
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethanone
[0678] The title compound was prepared by following the procedure
described for intermediate 41 using intermediate 8 (2.0 g, 6.33
mmol), 1-ethoxyvinyl tri(n-butyl)stannanc (2.12 g, 6.70 mmol), DMF
(20 ml ml) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH.sub.2Cl.sub.2 (0.417 g, 0.511 mmol) in a microwave
oven (microwave power=100 W, temperature=100.degree. C.) for 45 min
and followed by acid hydrolysis. Yellow solid (1.00 g, 39%).
.sup.1H-NMR (.delta. ppm, CDCl.sub.3, 400 MHz): 6 8.92 (dd, J=4.2,
1.6 Hz, 1H), 8.50 (d, J=8.6 Hz, 1H), 8.16 (d, J=8.6 Hz, 1H), 8.09
(dd, J=8.4, 0.9 Hz, 1H), 7.83 (d, J=3.3 Hz, 1H), 7.81 (d, J=5.5 Hz,
1H), 7.39 (dd, J=8.4, 4.3 Hz, 1H), 6.21 (s, 2H), 2.78 (s, 3H).
Example 49
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyli-
dene) hydrazinecarboxamide hydrochloride
[0679] Step-1:
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyl-
idene) hydrazinecarboxamide: to a solution of intermediate 41
(0.070 g, 0.230 mmol) in ethanol (2 ml), sodium acetate (0.018 g,
0.230 mmol) and semicarbazide hydrochloride (0.026 g, 0.230 mmol)
were added and stirred at RT for 12 h. The reaction mixture was
concentrated and the residue was washed with bicarbonate solution,
dichloromethane and dried under vacuum.
[0680] Step-2:
2-(1-(3-(quinolin-6-ylmethyl)-3II-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethy-
lidene) hydrazinecarboxamide hydrochloride: the product of step-1
(0.050 g, 0.138 mmol) was dissolved in THE (1 ml), eather saturated
with HCl (0.15 ml) was added at 0.degree. C. and stirred for 15
min. The precipitate formed was washed with eather and dried under
vacuum to afford the title compound as an off-white solid (0.045 g,
82%).
[0681] M.P.: 241-243.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 9.70 (s (dd, J=4.7, 1.2 Hz, 1H),
8.85 (d, J=8.3 Hz, 1H), 8.53 (d, J=8.9 Hz, 1H), 8.46 (d, J=8.9 Hz,
1H), 8.23 (d, J=9.0 Hz, 1H), 8.20 (s, 1H), 8.05 (dd, J=8.8, 1.7 Hz,
1H), 7.86 (dd, J=8.4, 4.9 Hz, 1H), 6.73 (br s, 2H), 6.20 (s, 2H),
2.34 (s, 3H).
Example 50
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyli-
dene) hydrazinecarbothioamide
[0682] The title compound was prepared by following the procedure
described for step-1 of Example 49 using intermediate 41 (0.100 g,
0.329 mmol), ethanol (1.5 ml) and thiosemicarbazide (0.030 g, 0.329
mmol). Yellow solid (0.050 g, 40%). M.P.: 233-235.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 10.43 (s,
1H), 8.88 (dd, J=4.1, 1.5 Hz, 1H), 8.65 (d, J=8.9 Hz, 2H), 8.51 (s,
1H), 8.48 (d, J=8.9 Hz, 1H), 8.36 (d, J=7.8 Hz, 1H), 8.30 (s, 1H),
8.01 (s, 1H), 7.99 (d, J=8.9 Hz, 1H), 7.82 (dd, J=8.7, 1.9 Hz,
11H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.15 (s, 2H), 2.48 (s, 3H).
Example 51
6-((5-(1-(2-(pyridin-2-yl)hydrazono)ethyl)-3H-[1,2,3]triazolo[4,5-b]pyridi-
n-3-yl)methyl) quinoline
[0683] The title compound was prepared by following the procedure
described for step-1 of Example 49 using intermediate 41 (0.100 g,
0.329 mmol), ethanol (2 ml) and 2-hydrazinopyridine (0.036 g, 0.329
mmol), heating at 80.degree. C. for 12 h. Yellow solid (0.050 g,
39%). M.P.: 221-223.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 10.23 (s, 1H), 8.89 (dd, J=4.2, 1.7
Hz, 1H), 8.48 (d, J=8.9 Hz, 1H), 8.37 (dd, J=8.3, 1.3 Hz, 1H), 8.33
(d, J=8.9 Hz, 1H), 8.20 (dd, J=4.8, 1.0 Hz, 1H), 8.02 (s, 1H), 8.00
(d, J=9.0 Hz, 1H), 7.83 (dd, J=8.6, 2.0 Hz, 1H), 7.74 (dt, J=8.6,
1.8 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H),
6.90 (dt, J=6.5, 1.5 Hz, 1H), 6.10 (s, 2H), 2.48 (s, 3H).
Example 52
2-(amino(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)met-
hylene) hydrazinecarboxamide
[0684] The title compound was prepared by following the procedure
described for step-1 of Example 49 using intermediate 10 (0.100 g,
0.348 mmol), ethanol (3 ml), semicarbazide hydrochloride (0.050 g,
0.452 mmol), sodium acetate (0.028 mg, 0.348 mmol) and sodium
bicarbonate (0.029 mg, 0.348 mmol) heating at 80.degree. C. for 12
h. Yellow solid (0.050 g, 20%). M.P.: 194-196.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.91 (dd,
J=4.2, 1.6 IIz, 1II), 8.73 (d, J=8.6 IIz, 1II), 8.46 (s, 1II), 8.35
(d, J=7.9 IIz, 1II), 8.15 (d, J=8.4 Hz, 1H), 8.06 (s, 1H), 8.01 (d,
J=8.7 Hz, 1H), 7.89 (s, 1H), 7.86 (dd, J=8.8, 2.0 Hz, 1H), 7.53
(dd, J=8.3, 4.2 Hz, 1H), 6.23 (s, 2H).
Example 53
tert-butyl
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)ethylidene) hydrazinecarboxylate
[0685] The title compound was prepared by following the procedure
described for step-1 of Example 49 using intermediate 41 (0.200 g,
0.659 mmol), ethanol (5 ml) and tert-butyl carbazate (0.131 g,
0.989 mmol), heating at 60.degree. C. for 12 h. Off-white solid
(0.150 g, 55%). M.P.: 193-196.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 10.22 (s, 1H), 8.88 (dd, J=4.1, 1.5
IIz, 1II), 8.52 (d, J=8.9 IIz, 1II), 8.36 (d, J=7.2 IIz, 1II), 8.16
(d, J=8.9 IIz, 1II), 8.01 (m, 2H), 7.81 (dd, J=8.8, 1.8 Hz, 1H),
7.53 (dd, J=8.4, 4.2 Hz, 1H), 6.14 (s, 2H), 2.36 (s, 3H), 1.49 (s,
9H).
Example 54
(E/Z)-1-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-
ethylideneamino)imidazolidine-2,4-dione
[0686] The title compound was prepared by following the procedure
described for step-1 of Example 49 using intermediate 41 (0.100 g,
0.659 mmol), ethanol (2.2 ml), triethylamine (0.1 ml) and
1-aminohytantoin hydrochloride (0.074 g, 0.494 mmol), heating at
60.degree. C. for 12 h. Off-white solid (0.090 g, 68%). M.P.:
260-264.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 11.36 (s, 1H), 8.89 (dd, J=4.1, 1.6 Hz, 1H), 8.61 (d,
J=8.8 Hz, 1H), 8.37 (d, J=7.4 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 8.03
(d, J=1.5 Hz, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.82 (dd, J=8.7, 1.9 Hz,
1H), 7.53 (dd, J=8.3, 4.1 Hz, 1H), 6.19 (s, 2H), 4.49 (s, 2H), 2.51
(s, 3H).
Example 55
N-ethyl-2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-y-
l)ethylidene) hydrazinecarbothioamide
[0687] The title compound was prepared by following the procedure
described for step-1 of Example 49 using intermediate 41 (0.100 g,
0.329 mmol), ethanol (2 ml), N-ethylhydrazinecarbothioamide (0.078
g, 0.659 mmol) heating at 60.degree. C. for 12 h. Yellow solid
(0.050 g, 20%). M.P.: 194-196.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 10.39 (s, 1H), 8.89 (dd, J=4.2, 1.7
Hz, 1H), 8.85 (t, J=5.6 Hz, 1H), 8.62 (d, J=8.9 Hz, 1H), 8.54 (d,
J=8.9 Hz, 1H), 8.36 (d, J=7.4 Hz, 1H), 8.02 (t, J=1.7 Hz, 1H), 7.99
(d, J=9.0 Hz, 1H), 7.82 (dd, J=8.7, 2.0 Hz, 1H), 7.53 (dd, J=8.3,
4.1 Hz, 1H), 6.16 (s, 2H), 3.67 (m, 2H), 2.47 (s, 3H), 1.18 (t,
J=7.1 Hz, 3H).
Example 56
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethyli-
dene) hydrazinecarbothioamide hydrochloride
[0688] The title compound was prepared by following the procedure
described for example 49 using example 50 (0.030 g, 0.119 mmol),
THE (1.0 ml) and ether-HCl (0.5 ml). Pale yellow solid (0.030 g,
91%). M.P.: 201-2036.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 10.44 (s, 1H), 9.05 (s, 1H), 8.70
(s, 1H), 8.66 (d, J=8.9 Hz, 1H), 8.51 (s, 1H), 8.50 (d, J=8.9 Hz,
11H), 8.31 (s, 1H), 8.15 (m, 2H), 7.98 (m, 1H), 7.76 (m, 1H), 6.20
(s, 2H), 2.46 (s, 3H).
Example 57
2-(1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)ethylidene) hydrazinecarbothioamide
[0689] The title compound was prepared by following the procedure
described for step-1 of Example 49 using example 48 (0.100 g, 0.311
mmol), ethanol (2 ml) and thiosemicarbazide (0.079 g, 0.623 mmol),
heating at 60.degree. C. for 48 h. Pale yellow solid (0.090 g,
73%). M.P.: 249-253.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 10.42 (s, 1H), 8.92 (dd, J=4.2, 1.6
Hz, 11H), 8.65 (d, J=8.9 Hz, 1H), 8.51 (s, 1H), 8.48 (d, J=8.9 Hz,
11H), 8.42 (dd, J=8.3, 1.1 Hz, 1H), 8.30 (s, 1H), 8.16 (d, J=8.2
Hz, 1H), 7.82 (d, J=11.4 Hz, 1H), 7.53 (dd, J=8.3, 4.3 Hz, 1H),
6.18 (s, 2H), 2.42 (s, 3H).
Example 58
Methyl
2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethylidene) hydrazinecarboxylate
[0690] The title compound was prepared by following the procedure
described for step-1 of Example 49 using intermediate 41 (0.100 g,
0.329 mmol), methanol (2 ml) and methyl hydrazinecarboxylate (0.059
g, 0.65930 mmol), heating at 80.degree. C. for 48 h. Off-white
solid (0.080 g, 65%). M.P.: 206-208.degree. C. .sup.1H-NMR (.delta.
ppm, DMSO-d.sub.6, 400 MHz): .delta. 10.55 (s, 1H), 8.88 (dd,
J=4.0, 1.4 Hz, 1H), 8.53 (d, J=8.9 Hz, 1H), 8.36 (d, J=7.5 Hz, 1H),
8.16 (d, J=8.8 Hz, 1H), 8.01 (m, 2H), 7.81 (dd, J=8.8, 1.8 Hz, 1H),
7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.15 (s, 2H), 3.75 (s, 3H), 2.38 (s,
3H).
Example 59
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethanone oxime
[0691] To a solution of example 48 (0.100 g, 0.311 mmol) in ethanol
(2.1 ml), sodium acetate (0.025 g, 0.315 mmol) and hydroxylamine
hydrochloride (0.021 g, 0.315 mmol) were added and stirred at
60.degree. C. for 12 h. The reaction mixture was concentrated and
the residue was washed with water, dichloromethane, ethyl acetate
and dried under vacuum to afford the title compound as an off-white
solid as a mixture of two diastereomers (approx. 9:1) (0.070 g,
67%). M.P.: 244-247.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 11.92 (s, 0.9H), 11.27 (s, 1H),
8.92 (dd, J=4.2, 1.6 Hz, 1H), 8.75 (d, J=8.6 Hz, 0.1H), 8.60 (d,
J=8.7 Hz, 0.1H), 8.52 (d, J=8.8 Hz, 0.9H), 8.41 (d, J=7.3 Hz,
0.9H), 8.16 (d, J=8.3 Hz, 1H), 8.02 (d, J=8.6 Hz, 1H), 7.82 (d,
J=11.5 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.27 (s, 0.2H), 6.18
(s, 1.8H), 2.25 (s, 2.7H), 2.19 (s, 0.3H).
Example 60
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethanone O-methyl oxime
[0692] To a solution of example 48 (0.100 g, 0.311 mmol) in ethanol
(2.1 ml), sodium acetate (0.025 g, 0.315 mmol) and methoxylamine
hydrochloride (0.026 g, 0.315 mmol) were added and stirred at
60.degree. C. for 12 h. The reaction mixture was concentrated and
the residue was washed with water, dichloromethane, ethyl acetate
and dried under vacuum to afford the title compound as an off-white
solid as a mixture of two diastereomers (approx. 9:1) (0.050 g,
45%). M.P.: 169-172.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 6 8.90 (dd, J=4.2, 1.6 Hz, 1H), 8.38 (d,
J=8.8 Hz, 0.1H), 8.31 (d, J=8.8 Hz, 0.9H), 8.12 (d, J=8.8 Hz, 1H),
8.06 (dd, J=8.4, 1.0 Hz, 1H), 7.80 (d, J=11.1 Hz, 1H), 7.75 (d,
J=7.9 Hz, 1H), 7.37 (dd, J=8.3, 4.3 Hz, 1H), 6.15 (s, 2H), 2.36 (s,
2.7H), 2.33 (s, 0.3H).
Example 61
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethanone O-2-hydroxyethyl oxime
[0693] The title compound was prepared by following the procedure
described for step-i of Example 49 using example 48 (0.100 g, 0.311
mmol), ethanol (2 ml) and 2-hydroxyethythydroxytamine (0.047 g,
0.623 mmol) heating at 60.degree. C. for 12 h. Pate green solid
(0.055 g, 46%). M.P.: 142-145.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.92 (dd, J=4.2, 1.7 IIz, 1II),
8.54 (d, J=8.8 IIz, 1II), 8.42 (dd, J=8.4, 1.0 IIz, 1II), 8.16 (d,
J=8.3 IIz, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.82 (d, J=11.4 Hz, 1H),
7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.19 (s, 2H), 4.74 (t, J=5.6 Hz, 1H),
4.25 (t, J=5.0 Hz, 2H), 3.69 (t, J=5.0 Hz, 2H), 2.29 (s, 3H).
Example 62
1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
O-2-hydroxyethyl oxime
[0694] 2-Hydroxyethylhydroxylamine was prepared according to
Shiow-Jyi et al. J. Med. Chem. 2007, 50 (25), 6367-6382. The title
compound was prepared by following the procedure described for
step-1 of Example 49 using intermediate 41 (0.196 g, 0.646 mmol),
ethanol (5 ml) and 2-hydroxyethylhydroxylamine (0.100 g, 1.29 mmol)
heating at 60.degree. C. for 12 h. Pale green solid (0.090 g, 38%).
M.P.: 165-168.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): .delta. 8.88 (dd, J=4.1, 1.9 Hz, 1H), 8.55 (d, J=8.8 Hz,
1H), 8.36 (d, J=7.4 Hz, 1H), 8.02 (m, 3H), 7.81 (dd, J=8.7, 1.9 Hz,
1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.16 (s, 2H), 4.75 (t, J=5.6 Hz,
1H), 4.26 (t, J=5.3 Hz, 2H), 3.71 (m, 2H), 2.35 (s, 3H).
Example 63
1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone
O-2-aminoethyl oxime
[0695] To example 62 (0.300 g, 0.827 mmol) in dichloromethane (3
ml), triethylamine (0.251 g, 2.41 mmol) was added and cooled to
0.degree. C. Methenesulphonyl chloride (0.189 g, 1.65 mmol) was
added and stirred at RT for 2 h. The reaction mixture was basified
with sodium bicarbonate solution, extracted with dichloromethane,
dried and concentrated to afford brown coloured mesylate (0.350 g).
The mesylate was dissolved in DMF (1.7 ml) and sodium azide (0.103
g, 1.584 mmol) was added and heated at 80.degree. C. for 12 h. The
reaction mixture was quenched with water, extracted with ethyl
acetate, dried with sodium sulphate and concentrated to afford
brown coloured azide (0.260 g). To the azide dissolved in THE (4.7
ml), triphenylphosphine (0.108 g, 0.413 mmol) and aqueous ammonia
solution (0.23 ml) were added and refluxed for 3 h. The reaction
mixture was quenched with water, extracted with ethyl acetate,
dried with sodium sulphate and concentrated. The crude product was
column chromatographed with methanol: dichloromethane to afford the
title compound as a pale green solid (0.110 g, 37%). M.P.:
122-125.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.88 (dd, J=4.2, 1.7 IIz, 1II), 8.54 (d, J=8.8 IIz,
1II), 8.36 (dd, J=7.9, 1.3 IIz, 1II), 8.02 (m, 3H), 7.81 (dd,
J=8.8, 2.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 6.16 (s, 2H),
4.20 (t, J=5.8 Hz, 2H), 2.86 (t, J=5.9 Hz, 2H), 2.31 (s, 3H), 1.58
(s, 2H).
Example 64
1-(2-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)
ethylideneaminooxy)ethyl)urea
[0696] To example 63 (0.050 g, 0.137 mmol) in dichloromethane (17
ml), trimethylsilylisocyanate (0.064 g, 0.556 mmol) was added and
stirred at RT for 12 h. The reaction mixture was concentrated
completely under vacuum, the residue was washed with water,
filtered and dried under vacuum to afford the title compound as an
off-white solid (0.030 g, 54%). M.P.: 207-210.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.89 (dd,
J=4.2, 1.7 Hz, 1H), 8.55 (d, J=8.8 Hz, 1H), 8.36 (d, J=8.3 Hz, 1H),
8.04 (m, 3H), 7.81 (dd, J=8.8, 1.8 Hz, 1H), 7.53 (dd, J=8.3, 4.2
Hz, 1H), 6.16 (s, 2H), 6.04 (t, J=5.6 Hz, 1H), 5.47 (s, 2H), 4.22
(t, J=5.6 Hz, 2H), 3.34 (m, 2H), 2.35 (s, 3H).
Example 65
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethanone O-methyl oxime hydrochloride
[0697] The title compound was prepared by following the procedure
described for example 49 using example 60 (0.030 g, 0.085 mmol),
TIIF (1.0 ml) and ether-IICl (0.2 ml). Off-white solid (0.030 g,
90%). M.P.: 200-204.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.99 (d, J=4.3 Hz, 1H), 8.55 (d,
J=8.8 Hz, 2H), 8.23 (d, J=8.1 Hz, 1H), 8.01 (d, J=8.7 Hz, 1H), 7.88
(d, J=11.2 Hz, 1H), 7.63 (dd, J=8.3, 4.4 Hz, 1H), 6.20 (s, 2H),
4.01 (s, 3H), 2.27 (s, 3H).
Example 66
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethanone oxime hydrochloride
[0698] The title compound was prepared by following the procedure
described for example 49 using example 59 (0.025 g, 0.074 mmol),
THE (1.0 ml) and ether-HCl (0.3 ml). Off-white solid (0.025 g,
90%). M.P.: 243-246.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 11.93 (s, 1H), 8.99 (dd, J=4.3, 1.4
Hz, 1H), 8.76 (d, J=8.6 Hz, 0.1H), 8.61 (d, J=8.3 Hz, 0.1H), 8.55
(d, J=8.3 Hz, 0.9H), 8.52 (d, J=8.8 Hz, 0.9H), 8.23 (d, J=8.1 Hz,
1H), 8.02 (d, J=8.8 Hz, 1H), 7.88 (d, J=11.2 Hz, 1H), 7.63 (dd,
J=8.4, 4.5 Hz, 1H), 6.28 (s, 0.2H), 6.20 (s, 2.7H), 2.25 (s, 2.7H),
2.21 (s, 0.3H).
Example 67
1-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl-
)ethanone O-2-hydroxyethyl oxime hydrochloride
[0699] The title compound was prepared by following the procedure
described for example 49 using example 61 (0.020 g, 0.052 mmol),
THE (0.5 ml) and ether-HCl (0.2 ml). Pale green solid (0.020 g,
91%). M.P.: 193-196.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.97 (dd, J=4.3, 1.5 Hz, 1H), 8.55
(d, J=8.8 Hz, 1H), 8.52 (d, J=8.4 Hz, 1H), 8.21 (d, J=8.1 IIz,
1II), 8.02 (d, J=8.8 IIz, 1II), 7.86 (d, J=11.3 IIz, 1II), 7.61
(dd, J=8.3, 4.4 IIz, 1H), 6.20 (s, 2H), 4.25 (t, J=5.0 Hz, 2H),
3.69 (t, J=5.2 Hz, 2H), 2.29 (s, 3H).
Example 68
N-(3-Dimethylamino-propyl)-4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-
-b]pyridin-5-yl)-benzamide dihdrochloride
[0700] The title compound was prepared by following the procedure
described for example 49 using
N-(2-(dimethylamino)ethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,3]triazolo[-
4,5-b]pyridin-5-yl)benzamideyl)phenyl)methanone (0.100 g, 0.215
mmol), THF (2.0 ml) and ether-HCl (2 ml). Yellow solid (0.100 g,
92%). M.P.: 110-112.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 10.06 (br s, 1H), 9.05 (br s, 1H), 8.81 (br
s, 1H), 8.71 (d, J=8.8 Hz, 2H), 8.34 (d, J=8.4 Hz, 2H), 8.22 (m,
3H), 8.04 (m, 3H), 7.76 (br s, 1H), 6.27 (s, 2H), 3.39 (m, 2H),
3.12 (m, 2H), 2.75 (s, 3H), 2.74 (s, 3H), 1.95 (m, 2H).
Example 101
2-chloro-N-(2-(dimethylamino)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[-
4,5-b]pyridin-5-yl)benzamide
[0701] To a solution of example 1012 ((0.100 g, 0.250 mmol) in DMF
(0.7 ml)N-ethyldiisopropylamine (0.032 g, 0.250 mmol) and HATU
(0.095 g, 0.250 mmol) were added and stirred for 5 min.
(2-dimethylaminoethylamine (0.033 g, 0.375 mmo was added at RT and
the reaction mixture was stirred for 12 h. To the reaction mixture
water was added and extracted with ethyl acetate, dried over sodium
sulphate and concentrated under reduced pressure. The crude product
was purified by column chromatography with methanol:
dichloromethane to afford the title compound as a Grey solid (0.023
g, 16%). M.P.: 110-112.sup.00.1.sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 400 MHz): J=4.1, 1.6 Hz, 1H), 8.72
(s, 1H), 8.41 (s, 1H), 8.34 (d, J=8.2 Hz, 1H), 8.20 (s, 1H), 8.18
(d, J=8.3 Hz, 1H), 8.14 (dd, J=8.0, 1.6 Hz, 1H), 8.01 (s, 1H), 7.98
(d, J=2.8 Hz, 1H), 7.96 (s, 1H), 7.84 (dd, J=8.7, 1.9 Hz, 1H), 7.53
(m, 2H), 5.78 (s, 2H), 3.36 (m, 2H), 2.52 (m, 2H), 2.27 (s,
6H).
Example 102
2-chloro-N-(3-(dimethylamino)propyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo-
[4,5-b]pyridin-5-yl)benzamide
[0702] The title compound was prepared by following the procedure
described for example 101 using example 1012 (0.100 g, 0.250 mmol),
DMF (0.7 ml), N-ethyldiisopropylamine (0.032 g, 0.250 mmol), HATU
(0.095 g, 0.250 mmol) and 3-dimethylaminopropylamine (0.038 g,
0.375 mmol). Grey solid (0.011 g, 9%). M.P.: 80-84.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.87 (dd,
J=4.1, 1.5 Hz, 1H), 8.72 (s, 1H), 8.45 (t, J=5.6 Hz, 1H), 8.34 (d,
J=8.1 Hz, 1H), 8.20 (s, 1H), 8.18 (d, J=8.3 Hz, 1H), 8.14 (dd,
J=8.1, 1.4 Hz, 1H), 8.01 (s, 1H), 7.98 (d, J=3.5 Hz, 1H), 7.95 (s,
1H), 7.84 (dd, J=8.7, 1.8 Hz, 1H), 7.53 (m, 2H), 5.78 (s, 2H), 3.27
(m, 2H), 2.29 (t, J=7.0 Hz, 2H), 2.13 (s, 6H), 1.65 (m, 2H).
Example 103
2-chloro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-y-
l)benzamide
[0703] The title compound was prepared by following the procedure
described for example 101 using example 1012 (0.100 g, 0.250 mmol),
DMF (0.7 ml), N-ethyldiisopropylamine (0.097 g, 0.750 mmol), HATU
(0.095 g, 0.250 mmol) and methoxylamine hydrochloride (0.041 g,
0.500 mmol). Grey solid (0.025 g, 23%). M.P.: 72-75.degree. C.
.sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 11.63
(s, 1H), (dd, J=4.2, 1.7 IIz, 1H), 8.73 (s, 1H), 8.34 (d, J=7.2 Hz,
1H), 8.24 (d, J=1.5 Hz, 1H), 8.21 (d, J=8.4 Hz, 1H), 8.19 (dd,
J=8.7, 1.7 Hz, 11H), 8.01 (m, 3H), 7.84 (dd, J=8.7, 1.9 Hz, 1H),
7.56 (d, J=8.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 5.78 (s, 2H),
3.73 (s, 3H).
Example 104
N-(2-(dimethylamino)ethyl)-2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imid-
azo[4,5-b]pyridin-5-yl)benzamide
[0704] The title compound was prepared by following the procedure
described for example 101 using example 1015 (0.100 g, 0.239 mmol),
DMF (1 ml), N-ethyldiisopropylamine (0.062 g, 0.478 mmol), HATU
(0.090 g, 0.239 mmol) and 2-dimethylaminoethylamine (0.021 g, 0.239
mmol). Pale green solid (0.030 g, 26%). M.P.: 145-147.degree. 0.1
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 400 MHz): J=4.2,
1.7 Hz, 1H), 8.75 (s, 1H), 8.74 (t, J=5.6 Hz, 1H), 8.33 (d, J=7.4
Hz, 1H), 8.22 (d, J=8.4 Hz, 1H), 8.03 (m, 3H), 7.94 (d, J=9.1 Hz,
2H), 7.83 (dd, J=8.7, 2.0 Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H),
5.79 (s, 2H), 3.40 (m, 2H), 2.53 (m, 2H), 2.29 (s, 6H).
Example 105
2,6-difluoro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-
-5-yl) benzamide
[0705] The title compound was prepared by following the procedure
described for example 101 using example 1015 (0.100 g, 0.239 mmol),
DMF (1 ml), N-ethyldiisopropylamine (0.092 g, 0.717 mmol), HATU
(0.090 g, 0.239 mmol) and methoxylamine hydrochloride (0.039 g,
0.478 mmol). Pale green solid (0.040 g, 38%). M.P.: 158-160.degree.
0.1.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 400
MHz): J=4.2, 1.7 Hz, 1H), 8.76 (s, 1H), 8.33 (d, J=8.4 Hz, 1H),
8.23 (d, J=8.4 Hz, 1H), 8.05-7.96 (m, 5H), 7.83 (dd, =J 8.7, 2.0
Hz, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 5.79 (s, 2H), 3.73 (s,
3H).
Example 106
1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethanone
[0706] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (1.0 g, 3.39
mmol), 1-ethoxyvinyl tri(n-butyl)stannane (1.12 g, 3.56 mmol), DMF
(10 ml) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH.sub.2Cl.sub.2 (0.221 g, 0.271 mmol) in a microwave
oven (microwave power=100 W, temperature=100.degree. C.) for 45
min. and followed by acid hydrolysis. Off-white solid (0.500 g,
49%). .sup.1H-NMR (.delta. ppm, CDCl.sub.3, 400 MHz): .delta. 8.94
(dd, J=4.2, 1.7 Hz, 1H), 8.27 (s, 1H), 8.19 (d, J=8.4 Hz, 1H), 8.12
(m, 3H), 7.78 (d, J=1.8 Hz, 1H), 7.73 (dd, J=8.7, 2.0 Hz, 1H), 7.45
(dd, J=8.2, 4.2 Hz, 1H), 5.72 (s, 2H), 2.79 (s, 3H).
Example 107
2-(1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethylidene)
hydrazinecarboxamide
[0707] To a solution of example 106 (0.100 g, 0.330 mmol) in
ethanol (2 ml), sodium acetate (0.027 g, 0.330 mmol) and
semicarbazide hydrochloride (0.036 g, 0.330 mmol) were added and
stirred at RT for 12 h. The reaction mixture was concentrated and
the residue was washed with bicarbonate solution, dichloromethane
and dried under vacuum to afford the title compound as an off white
solid (0.060 g, 51%). M.P.: 228-231.degree. C. .sup.1H-NMR (.delta.
ppm, DMSO-d.sub.6, 400 MHz): .delta. 9.40 (s, 1H), 8.88 (dd, J=4.2,
1.7 Hz, 1H), 8.66 (s, 1H), 8.34 (d, J=7.4 Hz, 1H), 8.26 (d, J=8.6
Hz, 1H), 8.02 (d, J=8.5 Hz, 1H), 7.98 (s, 2H), 7.84 (dd, J=8.7, 2.0
Hz, 1H), 7.53 (dd, J=8.2, 4.2 Hz, 1H), 6.58 (s, 2H), 5.71 (s, 2H),
2.32 (s, 3H).
Example 108
2-(1-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)ethylidene)
hydrazinecarbothioamide
[0708] The title compound was prepared by following the procedure
described for example 107 using example 106 (0.100 g, 0.330 mmol),
ethanol (2 ml) and thiosemicarbazide (0.042 g, 0.330 mmol), heating
at 60.degree. C. for 12 h. Off-white solid (0.075 g, 59%). M.P.:
218-221.degree. fo.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz):
.delta. 400 MHz): J=4.1, 1.6 Hz, 1H), 8.69 (s, 1H), 8.40 (d, J=8.5
Hz, 1H), 8.37 (s, 1H), 8.33 (d, J=8.8 Hz, 1H), 8.10 (s, 1H),
8.04-7.98 (m, 3H), 7.83 (dd, J=8.7, 1.9 Hz, 1H), 7.52 (dd, J=8.3,
4.1 Hz, 1H), 5.72 (s, 2H), 2.45 (s, 3H).
Example 109
(R)-2-fluoro-N-(2-hydroxypropyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-
-b]pyridin-5-yl)benzamide
[0709] The title compound was prepared by following the procedure
described for example 6 using intermediate 46 (0.200 g, 0.503
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.130 g, 1.00 mmol),
HATU (0.191 g, 0.503 mmol) and (R)-1-aminopropan-2-ol (0.056 g,
0.755 mmol). Off-white solid (0.080 g, 35%). M.P.: 151-158.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.87 (dd,
J=4.2, 1.6 Hz, 1H), 8.73 (s, 1H), 8.34 (dd, J=8.4, 1.1 Hz, 1H),
8.21 (m, 2H), 8.07 (m, 5H), 7.84 (dd, J=8.8, 1.9 Hz, 1H), 7.76 (t,
J=7.9 Hz, 1H), 7.52 (dd, J=8.3, 4.2 Hz, 1H), 5.78 (s, 2H), 4.76 (d,
J=4.8 Hz, 1H), 3.79 (m, 1H), 3.23 (m, 2H), 1.09 (d, J=6.2 Hz, 3H).
Mass: 456.4 (M.sup.++1).
Example 110
(S)-2-fluoro-N-(2-hydroxypropyl)-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-
-b]pyridin-5-yl)benzamide
[0710] The title compound was prepared by following the procedure
described for example 6 using intermediate 46 (0.200 g, 0.503
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.130 g, 1.00 mmol),
HATU (0.191 g, 0.503 mmol) and (S)-1-aminopropan-2-ol (0.056 g,
0.755 mmol). Off-white solid (0.050 g, 22%). M.P.: 166-169.degree.
C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.87 (dd,
J=4.2, 1.7 Hz, 1H), 8.73 (s, 1H), 8.35 (dd, J=8.4, 1.3 Hz, 1H),
8.21 (m, 2H), 8.07 (m, 5H), 7.85 (dd, J=8.8, 1.9 Hz, 1H), 7.76 (t,
J=7.9 IIz, 1II), 7.52 (dd, J=8.3, 4.2 IIz, 1II), 5.74 (s, 2II),
4.49 (br s, 1II), 3.79 (m, 1II), 3.23 (m, 2H), 1.09 (d, J=6.2 Hz,
3H). Mass: 456.4 (M.sup.++1).
Example 111
N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]py-
ridin-5-yl)-benzamide
[0711] The title compound was prepared by following the procedure
described for example 6 using intermediate 47 (0.200 g, 0.507
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.131 g, 1.01 mmol),
HATU (0.192 g, 0.507 mmol) and 2-hydroxyethylhydroxylamine (0.078
g, 1.01 mmol). Off-white solid (0.075 g, 32%). M.P.:
223-225.degree. C. .sup.1II-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.45 (s, 1II), 8.87 (dd, J=4.2, 1.7 IIz, 1H), 8.70 (s, 1H),
8.35 (d, J=8.2 Hz, 1H), 8.18 (d, J=8.4 Hz, 1H), 8.01 (m, 4H), 7.92
(d, J=8.4 Hz, 1H), 7.84 (dd, J=8.7, 2.0 Hz, 1H), 7.53 (dd, J=8.3,
4.2 Hz, 1H), 7.42 (d, J=7.8 Hz, 1H), 5.77 (s, 2H), 4.76 (t, J=5.6
Hz, 1H), 3.98 (t, J=4.7 Hz, 2H), 3.64 (m, 2H), 2.41 (s, 3H).
Example 112
N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidaz-
o[4,5-b]pyridin-5-yl)-benzamide
[0712] The title compound was prepared by following the procedure
described for example 6 using intermediate 47 (0.200 g, 0.507
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.131 g, 1.01 mmol),
HATU (0.192 g, 0.507 mmol) and 1-(aminooxy)-2-methylpropan-2-ol
(0.106 g, 1.01 mmol). Off-white solid (0.053 g, 21%). M.P.:
176-178.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.48 (s, 1H), 8.87 (d, J=2.7 Hz, 1H), 8.69 (s, 1H), 8.34 (d,
J=8.1 Hz, 1H), 8.18 (d, J=8.4 Hz, 1H), 8.01 (m, 4H), 7.91 (d, J=8.5
Hz, 1H), 7.84 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.2, 4.3 Hz, 1H), 7.41
(d, J=7.7 Hz, 1H), 5.77 (s, 2H), 4.64 (s, 1H), 3.73 (s, 2H), 2.41
(s, 3H), 1.17 (s, 6H).
Example 113
2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]py-
ridin-5-yl)-benzamide
[0713] The title compound was prepared by following the procedure
described for example 6 using intermediate 48 (0.150 g, 0.361
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.093 g, 0.722 mmol),
HATU (0.137 g, 0.361 mmol) and 2-hydroxyethylhydroxylamine (0.055
g, 0.722 mmol). Pale green solid (0.035 g, 20%). M.P.:
198-200.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.63 (s, 1H), 8.87 (dd, J=4.2, 1.7 Hz, 1H), 8.73 (s, 1H),
8.35 (d, J=8.4 Hz, 1H), 8.23-8.14 (m, 3H), 8.00 (m, 3H), 7.84 (dd,
J=8.6, 1.9 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.53 (dd, J=8.3, 4.2
Hz, 1H), 5.78 (s, 2H), 4.73 (d, J=5.7 Hz, 1H), 3.95 (t, J=5.0 Hz,
2H), 3.66 (m, 2H).
Example 114
2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imidaz-
o[4,5-b]pyridin-5-yl)-benzamide
[0714] The title compound was prepared by following the procedure
described for example 6 using intermediate 48 (0.150 g, 0.361
mmol), DMF (1.5 ml), N-ethyldiisopropylamine (0.093 g, 0.722 mmol),
HATU (0.137 g, 0.361 mmol) and 1-(aminooxy)-2-methylpropan-2-ol
(0.075 g, 0.722 mmol). Pale yellow solid (0.050 g, 27%). M.P.:
146-148.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 11.65 (s, 1H), 8.87 (dd, J=4.1, 1.6 Hz, 1H), 8.73 (s, 1H),
8.34 (d, J=7.5 Hz, 1H), 8.23 (d, J=1.4 Hz, 1H), 8.21 (d, J=8.4 Hz,
1H), 8.16 (dd, J=8.4, 1.4 Hz, 1H), 8.01 (m, 3H), 7.84 (dd, J=8.7,
1.9 Hz, 1H), 7.56 (d, J=8.1 Hz, 1H), 7.53 (dd, J=8.4, 4.2 Hz, 1H),
5.78 (s, 2H), 4.62 (s, 1H), 3.74 (s, 2H), 1.17 (s, 6H).
Example 1001
6-((5-(4-carbamoyl-3,5-difluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3--
yl)methyl) quinoline 1-oxide
[0715] Step-1: Methyl
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)benzoate: To a solution of Intermediate 7 (1.15 g, 3.91 mmol)
and 3,5-difluoro-4-methoxycarbonylphenylboronic acid (1.10 g, 5.09
mmol) in dioxane (20 ml), potassium acetate (1.276 g, 13.03 mmol)
was added and degassed for 30 min. To this tetrakis
(triphenylphosphine)palladium(0) (0.361 g, 0.31346 mmol) was added
under nitrogen at RT and the reaction mixture was refluxed for 12
h. The solvent was evaporated completely and water was added to the
residue and extracted with ethyl acetate, dried over sodium
sulphate and concentrated under reduced pressure to afford the
title compound as an brown solid (0.620 g, 37%). .sup.1H-NMR
(.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.91 (d, J=2.9 Hz,
1H), 8.49 (d, J=8.6 Hz, 1H), 8.17 (d, J=8.2 Hz, 1H), 8.10 (d, J=8.7
Hz, 1H), 7.97 (s, 1H), 7.86 (dd, J=8.8, 1.4 Hz, 1H), 7.81 (d, J=8.6
Hz, 1H), 7.74 (d, J=9.1 Hz, 2H), 7.43 (dd, J=8.4, 4.2 Hz, 11H),
6.15 (s, 2H), 3.99 (s, 3H).
[0716] Step-2:
2,6-Difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)benzoic acid: To a solution of step-1 of example 1001 (0.70 g,
1.62 mmol) in methanol (3.8 ml), lithium hydroxide (0.635 g, 15.13
mmol) in water (3.8 ml) and THF (14.3 ml) were added and stirred at
RT. After 12 h, pH was adjusted to ca. 7 using 0.5N HCl and the
solid precipitated was filtered, washed with ethyl acetate and
petroleum ether and dried under vacuum to afford the title compound
as pale brown solid (0.500 g, 74%). The acid was used as such for
further steps.
[0717] Step-3:
2,6-Difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin--
5-yl)benzamide: To step-2 of example 1001 (0.500 g, 1.19 mmol),
thionyl chloride (10 ml) was added and refluxed for 3 h. The excess
thionyl chloride was removed under reduced pressure and the residue
was cooled to 0.degree. C. Aqueous 25% ammonia (7 ml) was added and
stirred for 15 min. The precipitate formed was washed with sodium
bicarbonate solution and vacuum dried to afford title compound as
an off-white solid (0.400 g, 81%). M.P.: 272-275.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.88 (dd,
J=3.9 Hz, 1H), 8.74 (d, J=8.8 Hz, 1H), 8.37 (d, J=7.8 Hz, 1H), 8.25
(d, J=8.9 Hz, 1H), 8.20 (s, 1H), 8.07 (m, 3H), 8.01 (d, J=8.5 Hz,
1H), 7.93 (s, 1H), 7.83 (d, J=6.8 Hz, 1H), 7.53 (dd, J=8.6, 4.4 Hz,
1H), 6.24 (s, 2H).
[0718] Step-4:
6-((5-(4-carbamoyl-3,5-difluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-
-yl)methyl) quinoline 1-oxide: To step-3 of example 1001 (0.100 g,
0.240 mmol) in acetone (1.5 ml) and water (1.5 ml), oxone (1.47 g,
2.40 mmol) was added and stirred at RT for 12 h. To the reaction
mixture sodium bicarbonate solution (5 ml) was added and extracted
with dichloromethane, dried over sodium sulphate and concentrated
under reduced pressure. The crude product was purified by column
chromatography with methanol: dichloromethane to afford the title
compound as a pale-yellow solid (0.010 g, 10%). M.P.:
234-236.degree. C. .sup.1H-NMR (b ppm, DMSO-d.sub.6, 400 MHz):
.delta. 8.74 (d, J=8.8 Hz, 1H), 8.55 (d, J=7.9 Hz, 1H), 8.52 (d,
J=9.0 Hz, 1H), 8.26 (d, J=8.8 Hz, 1H), 8.19 (s, 1H), 8.14 (s, 1H),
8.05 (d, J=8.8 Hz, 2H), 7.92 (d, J=8.2 Hz, 2H), 7.87 (dd, J=9.0,
1.6 Hz, 1H), 7.47 (dd, J=8.5, 4.1 Hz, 1H), 6.25 (s, 2H).
Example 1002
6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)m-
ethyl)-7-fluoroquinoline 1-oxide
[0719] Step-1: Methyl
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoate: The title compound was prepared by following
the procedure described for step-1 of example 1001 using
intermediate 8 (0.345 g, 1.091 mmol),
3-chloro-4-methoxycarbonylphenylboronic acid (0.295 g, 1.37 mmol),
potassium acetate (0.359 g, 3.65 mmol), dioxane (8 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.101 g, 0.087 mmol).
Off-white solid (0.277 g, 56%). .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.91 (d, J=3.3 Hz, 1H), 8.50 (d,
J=8.6 Hz, 1H), 8.23 (s, 1H), 8.10 (d, J=8.2 Hz, 1H), 8.03 (d, J=6.9
Hz, 1H), 7.98 (d, J=8.1 Hz, 1H), 7.87 (m, 3H), 7.38 (dd, J=8.3, 4.2
Hz, 1H), 6.22 (s, 2H), 3.97 (s, 3H).
[0720] Step-2:
2-Chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzoic acid: To a solution of step-1 of example 1002
(0.185 g, 0.412 mmol) in methanol (2 ml), lithium hydroxide (0.161
g, 3.84 mmol) in water (2 ml) and THE (4 ml) were added and stirred
at RT. After 12 h, pH was adjusted to ca. 7 using 0.5N HCl and the
solid precipitated was filtered, washed with ethyl acetate and
petroleum ether and dried under vacuum to afford the title compound
as a pale brown solid (0.150 g, 84%). The acid was used as such for
further steps.
[0721] Step-3:
2-Chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]py-
ridin-5-yl)benzamide: The title compound was prepared by following
the procedure described for step-3 of example 1001 using step-2 of
example 2 (0.050 g, 0.115 mmol), thionyl chloride (2 ml) and
aqueous 25% ammonia (2 ml). Brown solid (0.015 g, 30%). M.P.:
202-204.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.92 (d, J=4.1 Hz, 1H), 8.70 (d, J=8.6 Hz, 1H), 8.44
(d, J=8.0 Hz, 1H), 8.27 (s, 1H), 8.22 (m, 3H), 7.96 (s, 1H), 7.83
(d, J=11.5 Hz, 1H), 7.68 (s, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.55 (dd,
J=8.4, 4.3 Hz, 1H), 6.26 (s, 2H).
[0722]
Step-4:6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[1,2,3]triazolo[4,5-b]-
pyridin-3-yl)methyl)-7-fluoroquinoline 1-oxide: The title compound
was prepared by following the procedure described for step-4 of
example 1001 using step-3 of Example 1002 (0.100 g, 0.231 mmol),
acetone (1.5 ml), water (1.5 ml) and oxone (1.42 g, 2.31 mmol).
Pale yellow solid (0.010 g, 9%). M.P.: 176-178.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.71 (d,
J=8.7 Hz, 1H), 8.62 (d, J=6.0 Hz, 1H), 8.34 (d, J=7.6 Hz, 1H),
8.27-8.19 (m, 4H), 8.00 (d, J=8.7 Hz, 1H), 7.95 (s, 1H), 7.67 (s,
1H), 7.60 (d, J=8.0 Hz, 1H), 7.49 (dd, J=8.5, 6.1 Hz, 1H), 6.20 (s,
2H).
Example 1003
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-
-yl)benzamide 2,2,2-trifluoroacetate
[0723] To step-3 of Example 1001 (0.100 g, 0.240 mmol), 2 ml of 2%
Trifluoroacetic acid in acetonitrile: water (1:1) was added and
stirred for 10 min. The clear solution obtained, was concentrated
under reduced pressure to afford the title compound as a brown
solid (0.57 g, 44%). M.P.: 203-206.degree. C. .sup.1H-NMR (.delta.
ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.98 (d, J=4.2 Hz, 1H), 8.74
(d, J=8.7 Hz, 1H), 8.56 (d, J=8.1 Hz, 1H), 8.25 (d, J=8.7 Hz, 1H),
8.18 (s, 1H), 8.13 (s, 1H), 8.07 (m, 3H), 7.92 (s, 1H), 7.91 (d,
J=6.7 Hz, 1H), 7.67 (dd, J=8.0, 4.3 Hz, 1H), 6.27 (s, 2H).
Example 1004
2-chloro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[-
4,5-b]pyridin-5-yl)benzamide
[0724] To a solution of Intermediate 32 (0.060 g, 0.202 mmol) and
intermediate 9 (0.072 g, 0.253 mmol) in dioxane (1.8 ml), potassium
carbonate (0.093 g, 0.675 mmol) was added and degassed for 30 min.
To this tetrakis (triphenylphosphine)palladium(0) (0.018 g, 0.016
mmol) was added under nitrogen at RT and the reaction mixture was
refluxed for 12 h. The solvent was evaporated completely and water
was added to the residue and extracted with ethyl acetate, dried
over sodium sulphate and concentrated under reduced pressure. The
crude product was purified by column chromatography with methanol:
dichloromethane to afford the title compound as an off-white solid
(0.040 g, 46%). M.P.: >300.degree. C. .sup.1H-NMR (6 ppm,
DMSO-d.sub.6, 400 MHz): .delta. 11.74 (s 8.67 (d, J=8.7 Hz, 1H),
8.31 (d, J=1.5 Hz, 1H), 8.25 (dd, J=8.0, 1.5 Hz, 1H), 8.20 (d,
J=8.8 Hz, 1H), 7.95 (s, 1H), 7.89 (d, J=9.5 Hz, 1H), 7.78 (s, 1H),
7.68 (s, 1H), 7.62 (d, J=8.1 Hz, 2H), 7.28 (d, J=8.4 Hz, 1H), 6.48
(d, J=8.2 Hz, 1H), 6.03 (s, 2H).
Example 1005
2,6-difluoro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triaz-
olo[4,5-b]pyridin-5-yl)benzamide
[0725] The title compound was prepared by following the procedure
described for example 1004 using intermediate 32 (0.150 g, 0.507
mmol), intermediate 33 (0.176 g, 0.634 mmol), potassium carbonate
(0.233 g, 1.689 mmol), dioxane (4 ml), water (2 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.046 g, 0.040 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 30 min. Off-white solid (0.050 g,
23%). M.P.: 275-278.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta.11.74 (s, 1H), 8.70 (d, J=8.6 Hz,
1H), 8.23 (m, 2H), 8.07 (d, J=8.6 Hz, 2H), 7.93 (s, 1H), 7.88 (d,
J=9.6 Hz, 1H), 7.79 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.28 (d, J=8.3
Hz, 1H), 6.48 (d, J=9.5 Hz, 1H), 6.04 (s, 2H).
Example 1006
4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-
,6-difluorobenzamide
[0726] The title compound was prepared by following the procedure
described for example 1004 using intermediate 15 (0.120 g, 0.397
mmol), intermediate 33 (0.110 g, 0.496 mmol), potassium carbonate
(0.182 g, 1.32 mmol), dioxane (2.5 ml), water (1 ml) and tetrakis
(triphenylphosphine)palladium(0) (0.036 g, 0.031 mmol) under
microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Yellow solid (0.050 g,
30%). M.P.: 255-258.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 9.37 (s, 1H), 8.72 (d, J=8.7 Hz,
1H), 8.30 (d, J=1.2 Hz, 1H), 8.25 (d, J=8.8 Hz, 1H), 8.20 (s, 1H),
8.07 (d, J=8.7 Hz, 2H), 8.05 (s, 1H), 7.92 (s, 1H), 7.65 (dd,
J=8.4, 1.6 Hz, 1H), 6.19 (s, 2H).
Example 1007
2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b-
]pyridin-5-yl) benzamide
[0727] The title compound was prepared by following the procedure
described for example 4 using intermediate 8 (0.100 g, 0.319 mmol),
intermediate 33 (0.111 g, 0.399 mmol), potassium carbonate (0.147
g, 1.06 mmol), dioxane (2 ml), water (0.8 ml) and tetrakis
(triphenylphosphine)palladium(0) (0.029 g, 0.025 mmol) under
microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Off-white solid (0.075 g,
54%). M.P.: 244-247.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.92 (dd, J=4.3, 1.6 Hz, 1H), 8.73
(d, J=8.8 Hz, 1H), 8.42 (d, J=7.4 Hz, 1H), 8.25 (d, J=8.8 Hz, 1H),
8.21 (s, 1H), 8.19 (s, 1H), 8.01 (d, J=8.8 Hz, 2H), 7.92 (s, 1H),
7.82 (d, J=11.4 Hz, 1H), 7.55 (dd, J=8.3, 4.2 Hz, 1H), 6.27 (s,
2H).
Example 1008
2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamid-
e
[0728] To a solution of Intermediate 34 (0.150 g, 0.508 mmol) and
intermediate 9 (0.179 g, 0.636 mmol), in dioxane (3 ml), potassium
carbonate (1.276 g, 13.03 mmol), water (1 ml) and tetrakis
(triphenylphosphine)palladium(0) (0.047 g, 0.040 mmol) was added
under nitrogen at RT and the reaction mixture was kept under
microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min The solvent was evaporated
completely and water was added to the residue and extracted with
ethyl acetate, dried over sodium sulphate and concentrated under
reduced pressure. The crude product was purified by column
chromatography with methanol: dichloromethane to afford the title
compound as an off-white solid (0.095 g, 45%). M.P.:
212-214.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): .delta. 8.87 (dd, J=4.1, 2.8 Hz, 1H), 8.73 (s, 1H), 8.35 (d,
J=8.5 Hz, 1H), 8.20 (s, 1H), 8.18 (d, J=7.6 Hz, 1H), 8.13 (d, J=8.1
Hz, 1H), 8.01 (m, 3H), 7.90 (s, 1H), 7.83 (d, J=8.7 Hz, 1H), 7.62
(s, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.53 (dd, J=8.6, 4.5 Hz, 1H), 5.78
(s, 2H).
Example 1009
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamid-
e hydrochloride
[0729] The example 1008 (0.050 g, 0.119 mmol), was dissolved in THE
(1.5 ml), ether saturated with HCl (0.15 ml) was added at 0.degree.
C. and stirred for 15 min. The precipitate formed was washed with
ether and dried under vacuum to afford the title compound as an
off-white solid (0.040 g, 75%). M.P.: 244-246.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 9.19 (d,
J=4.0 Hz, 1H), 9.11 (s, 1H), 8.99 (d, J=8.2 Hz, 1H), 8.34-8.27 (m,
3H), 8.19-8.06 (m, 4H), 7.97 (dd, J=8.3, 5.0 Hz, 1H), 7.90 (s, 1H),
7.62 (s, 1H), 7.55 (d, J=8.0 Hz, 1H), 5.92 (s, 2H).
Example 1010
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benz-
amide
[0730] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (0.100 g, 0.339
mmol), intermediate 33 (0.117 g, 0.424 mmol), potassium carbonate
(0.156 g, 1.12 mmol), dioxane (2 ml), water (0.8 ml) and tetrakis
(triphenylphosphine)palladium(0) (0.032 g, 0.027 mmol) under
microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Off-white solid (0.080 g,
57%). M.P.: 242-245.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.87 (dd, J=4.1, 1.6 Hz, 1H), 8.75
(s, 1H), 8.33 (d, J=7.6 Hz, 1H), 8.22 (d, J=8.4 Hz, 1H), 8.13 (s,
1H), 8.03 (m, 3H), 7.93 (d, J=9.0 Hz, 2H), 7.86 (s, 1H), 7.83 (dd,
J=8.7, 1.8 Hz, 1H), 7.53 (dd, J=8.3, 4.1 Hz, 1H), 5.79 (s, 2H).
Example 1011
Methyl
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)b-
enzoate
[0731] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (2.5 g, 8.48
mmol), 3-chloro-4-methoxycarbonylphenylboronic acid (2.0 g, 9.32
mmol), potassium acetate (2.77 g, 28.24 mmol), dioxane (50 ml) and
tetrakis (triphenylphosphine)palladium(0) (0.784 g, 0.678 mmol).
Brown solid (crude) (4.0 g) which is used as such for next
step.
Example 1012
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzoic
acid
[0732] To a solution of Example 1011 (4.00 g, 9.38 mmol) in
methanol (43 ml), lithium hydroxide (3.65 g, 87.12 mmol) in water
(43 ml) and THE (86 ml) were added and stirred at RT. After 12 h,
pH was adjusted to 7-7.5 using 0.5N HCl and the solid precipitated
was filtered, washed with ethyl acetate and petroleum ether and
dried under vacuum to afford the title compound as an black solid
(1.2 g, 31%). .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz):
.delta. 8.87 (dd, J=4.1, 1.4 Hz, 1H), 8.71 (s, 1H), 8.34 (d, J=7.4
Hz, 1H), 8.18 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 8.09 (d, J=8.0 Hz,
1H), 8.02 (s, 1H), 8.01 (d, J=8.1 Hz, 1H), 7.96 (d, J=8.4 Hz, 1H),
7.84 (dd, J=8.8, 1.7 Hz, 1H), 7.72 (d, J=8.3 Hz, 1H), 7.52 (d,
J=8.3, 4.1 Hz, 1H), 5.78 (s, 2H).
Example 1013
2-chloro-N-ethyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)-
benzamide
[0733] The title compound was prepared by following the procedure
described for example 101 using example 1012 (0.100 g, 0.251 mmol),
DMF (0.7 ml), N-ethyldiisopropylamine (0.064 g, 0.500 mmol), HATU
(0.095 g, 0.250 mmol) and ethylamine hydrochloride (0.040 g, 0.500
mmol). Pale green solid (0.035 g, 32%). M.P.: 185-187.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): .delta. 8.87 (dd,
J=4.2, 1.6 Hz, 1H), 8.73 (s, 1H), 8.44 (t, J=5.5 Hz, 1H), 8.34 (d,
J=8.3 Hz, 1H), 8.20 (d, J=1.6 Hz, 1H), 8.18 (s, 1H), 8.14 (dd,
J=8.0, 1.6 Hz, 1H), 8.01 (d, J=9.4 Hz, 2H), 7.96 (s, 1H), 7.84 (dd,
J=8.7, 1.6 Hz, 1H), 7.53 (m, 2H), 5.78 (s, 2H), 3.29 (m, 2H), 1.09
(t, J=7.0 Hz, 3H).
Example 1014
Methyl
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5--
yl)benzoate
[0734] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (1.5 g, 5.08
mmol), 3,5-difluoro-4-methoxycarbonylphenylboronic acid (1.20 g,
5.59 mmol), potassium acetate (1.66 g, 16.94 mmol), dioxane (30 ml)
and tetrakis (triphenylphosphine)palladium(0) (0.470 g, 0.407
mmol). Brown solid (1.7 g, 77%). .sup.1H-NMR (.delta. ppm,
CDCl.sub.3, 400 MHz): .delta. 8.93 (dd, J=4.3, 1.7 IIz, 1II), 8.19
(d, J=8.4 IIz, 1II), 8.18 (s, 1II), 8.14 (m, 2H), 7.80 (d, J=1.5
IIz, 1II), 7.75 (m, 4H), 7.44 (dd, J=8.3, 4.2 Hz, 1H), 5.72 (s,
2H), 3.97 (s, 3H).
Example 1015
2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benz-
oic acid
[0735] To a solution of Example 1014 (1.7 g, 3.94 mmol) in methanol
(18 ml), lithium hydroxide (1.54 g, 36.81 mmol) in water (18 ml)
and THE (36 ml) were added and stirred at RT. After 12 h, pH was
adjusted to 7-7.5 using 0.5N HCl and the solid precipitated was
filtered, washed with ethyl acetate and petroleum ether and dried
under vacuum to afford the title compound as an off-white solid
(1.0 g, 61%) which is used as such for next step.
Example 1016
N-ethyl-2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-
-yl) benzamide
[0736] The title compound was prepared by following the procedure
described for example 101 using example 1015 (0.100 g, 0.239 mmol),
DMF (1 ml), N-ethyldiisopropylamine (0.092 g, 0.717 mmol), HATU
(0.090 g, 0.239 mmol) and ethylamine hydrochloride (0.038 g, 0.478
mmol). Pale green solid (0.020 g, 19%). M.P.: 174-176.degree. C.
.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400 MHz): 8.87 (dd, J=4.1,
1.6 IIz, 1II), 8.75 (s, 1II), 8.71 (t, J=5.5 IIz, 1II), 8.33 (d,
J=7.4 Hz, 1H), 8.22 (d, J=8.4 Hz, 1H), 8.03 (d, J=8.5 Hz, 2H), 8.00
(d, J=8.7 Hz, 1H), 7.93 (d, J=9.1 Hz, 2H), 7.83 (dd, J=8.7, 1.9 Hz,
1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 5.79 (s, 2H), 3.28 (m, 2H), 1.12
(t, J=7.2 Hz, 3H).
Example 1017
2-chloro-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl-
) benzamide
[0737] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (0.100 g, 0.339
mmol), intermediate 37 (0.175 g, 0.424 mmol), potassium carbonate
(0.156 g, 1.12 mmol), dioxane (2 ml), water (0.5 ml) and tetrakis
(triphenylphosphine)palladium(0) (0.031 g, 0.027 mmol) under
microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Pale green solid (0.030 g,
21%). M.P.: 169-171.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.87 (d, J=2.8 Hz, 1H), 8.72 (s,
1H), 8.37 (m, 2H), 8.20 (s, 1H), 8.18 (d, J=8.0 Hz, 1H), 8.14 (dd,
J=8.0, 1.2 Hz, 1H), 8.01 (m, 3H), 7.84 (d, J=8.3 Hz, 1H), 7.53 (m,
2H), 5.78 (s, 2H), 2.77 (d, J=4.6 Hz, 3H).
Example 1018
2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamid-
e
[0738] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (0.100 g, 0.339
mmol), intermediate 38 (0.110 g, 0.424 mmol), potassium carbonate
(0.156 g, 1.12 mmol), dioxane (2 ml), water (0.8 ml) and tetrakis
(triphenylphosphine)palladium(0) (0.031 g, 0.027 mmol) under
microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Pale green solid (0.070 g,
52%). M.P.: 135-138.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.87 (dd, J=4.1, 1.6 Hz, 1H), 8.68
(s, 1H), 8.34 (d, J=7.0 Hz, 1H), 8.17 (d, J=8.4 Hz, 1H), 8.01-7.95
(m, 4H), 7.90 (d, J=8.4 Hz, 1H), 7.84 (dd, J=8.6, 1.9 Hz, 1H), 7.72
(s, 1H), 7.53 (dd, J=8.3, 4.2 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 7.36
(s, 1H), 5.77 (s, 2H), 2.44 (s, 3H).
Example 1019
2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamid-
e 2,2,2-trifluoroacetate
[0739] To Example 1008 (0.060 g, 0.144 mmol), 1 ml of 2%
Trifluoroacetic acid in acetonitrile: water (1:1) was added and
stirred for 20 min. The clear solution obtained was concentrated
under reduced pressure to afford the title compound as a brown
solid (0.50 g, 65%). M.P.: 158-160.degree. (0..sup.1H-NMR (.delta.
ppm, DMSO-d.sub.6, 400 MHz): 400 MHz): J=4.6, 1.6 Hz, 1H), 8.86 (s,
1H), 8.69 (d, J=8.3 Hz, 1H), 8.23 (d, J=8.4 Hz, 1H), 8.17 (d, J=1.5
Hz, 2H), 8.12 (m, 2H), 8.01 (m, 2H), 7.89 (s, 1H), 7.70 (dd, J=8.4,
4.7 Hz, 1H), 7.62 (s, 1H), 7.56 (d, J=8.0 Hz, 1H), 5.85 (s,
2H).
Example 1020
2-chloro-4-(2-methyl-3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl-
) benzamide
[0740] The title compound was prepared by following the procedure
described for example 1008 using intermediate 36 (0.100 g, 0.323
mmol), intermediate 9 (0.113 g, 0.404 mmol), potassium carbonate
(0.149 g, 1.078 mmol), dioxane (2.0 ml), water (0.5 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.029 g, 0.025 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Off-white solid (0.030 g,
22%). M.P.: 207-2090) f.sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 400 MHz): J=4.2, 1.7 Hz, 1H), 8.33 (d, J=7.4 Hz, 1H), 8.20
(d, J=1.6 Hz, 1H), J=8.1, 1.7 IIz, 1II), 8.08 (d, J=8.3 IIz, 1II),
8.00 (d, J=8.8 IIz, 1II), 7.95 (d, J=8.3 IIz, 1II), 7.87 (s, 1H),
7.83 (s, 1H), 7.71 (dd, J=8.7, 1.9 Hz, 1H), 7.60 (s, 1H), 7.54 (d,
J=8.0 Hz, 1H), 7.51 (dd, J=8.3, 4.2 Hz, 1H), 5.77 (s, 2H), 2.59 (s,
3H).
Example 1021
2-chloro-4-(3-(1-(quinolin-6-yl)ethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benza-
mide
[0741] The title compound was prepared by following the procedure
described for example 1008 using intermediate 39 (0.100 g, 0.323
mmol), intermediate 9 (0.113 g, 0.404 mmol), potassium carbonate
(0.149 g, 1.078 mmol), dioxane (2.0 ml), water (0.5 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.029 g, 0.025 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Grey solid (0.060 g, 43%).
M.P.: 157-159.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6,
400 MHz): .delta. 8.86 (dd, J=4.2, 1.6 Hz, 1H), 8.84 (s, 1H), 8.36
(d, J=7.4 Hz, 1H), 8.18 (d, J=8.4 Hz, 1H), 8.14 (d, J=1.6 Hz, 1H),
8.09 (m, 2H), 7.99 (d, J=8.8 Hz, 1H), 7.94 (d, J=8.4 Hz, 1H), 7.88
(s, 1H), 7.85 (dd, J=8.9, 1.8 Hz, 1H), 7.61 (s, 1H), 7.54 (d, J=7.9
Hz, 1H), 7.52 (dd, J=7.5, 4.2 Hz, 11H), 6.32 (q, J=7.0 Hz, 1H),
2.14 (d, J=7.1 Hz, 3H).
Example 1022
2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-imidazo[4,5-b]pyridin-5-y-
l)benzamide
[0742] The title compound was prepared by following the procedure
described for example 1008 using intermediate 35 (0.100 g, 0.319
mmol), intermediate 9 (0.112 g, 0.399 mmol), potassium carbonate
(0.146 g, 1.062 mmol), dioxane (2.0 ml), water (0.5 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.029 g, 0.025 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Off-white solid (0.100 g,
73%). M.P.: 230-232.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.89 (d, J=2.8 Hz, 1H), 8.68 (s,
1H), 8.40 (d, J=8.0 Hz, 1H), 8.20 (m, 2H), 8.13 (d, J=8.1 Hz, i H),
8.10 (dd, J=8.0, 1.6 Hz, 1H), 7.97 (d, J=8.4 Hz, 1H), 7.88 (s, 1H),
7.82 (d, J=11.6 Hz, 1H), 7.60 (s, 1H), 7.53 (d, J=8.4 Hz, 1H), 7.51
(dd, J=7.7, 4.2 Hz, 1H), 5.83 (s, 2H).
Example 1023
2-chloro-4-(3-((5,7-difluoroquinolin-6-yl)methyl)-3H-imidazo[4,5-b]pyridin-
-5-yl) benzamide
[0743] The title compound was prepared by following the procedure
described for example 1008 using intermediate 40 (0.100 g, 0.303
mmol), intermediate 9 (0.106 g, 0.378 mmol), potassium carbonate
(0.139 g, 1.008 mmol), dioxane (2.0 ml), water (0.8 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.028 g, 0.024 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Off-white solid (0.100 g,
73%). M.P.: 220-224.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): .delta. 8.98 (dd, J=4.1, 2.7 Hz, 1H), 8.71
(s, 1H), 8.58 (d, J=8.0 Hz, 1H), 8.19 (d, J=1.4 Hz, 1H), 8.15 (d,
J=8.4 Hz, 1H), 8.06 (dd, J=8.0, 1.5 Hz, 1H), 7.95 (d, J=8.4 Hz,
1H), 7.89 (s, 1H), 7.73 (d, J=11.1 Hz, 1H), 7.66 (dd, J=8.5, 4.3
Hz, 1H), 7.61 (s, 1H), 7.52 (d, J=8.0 Hz, 1H), 5.83 (s, 2H).
Example 1024
4-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-2-trifluoromethyl--
benzamide
[0744] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (0.150 g, 0.508
mmol), intermediate 50 (0.208 g, 0.661 mmol), potassium carbonate
(0.234 g, 1.69 mmol), dioxane (2.9 ml), water (0.8 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.047 g, 0.040 mmol) at
100.degree. C. for 12 h. Off-white solid (0.017 g, 7%). M.P.:
243-245.degree. C. Mass: 448.9 (M.sup.++1).
Example 1025
4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-methy-
l-benzamide
[0745] The title compound was prepared by following the procedure
described for example 1008 using intermediate 35 (0.150 g, 0.479
mmol), intermediate 38 (0.162 g, 0.623 mmol), potassium carbonate
(0.220 g, 1.59 mmol), dioxane (2.8 ml), water (0.7 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.044 g, 0.038 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 50 min. Off-white solid (0.020 g,
10%). M.P.: 206-208.degree. C. Mass: 448.9 (M.sup.++1).
Example 1026
4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-trifl-
uoromethyl-benzamide
[0746] The title compound was prepared by following the procedure
described for example 1008 using intermediate 35 (0.100 g, 0.319
mmol), intermediate 50 (0.139 g, 0.415 mmol), potassium carbonate
(0.156 g, 1.12 mmol), dioxane (2.0 ml), water (0.5 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.031 g, 0.027 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 50 min. Off-white solid (0.040 g,
27%). M.P.: 239-241.degree. C. Mass: 465.9 (M.sup.+).
Example 1027
4-[3-(5,7-Difluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-m-
ethyl-benzamide
[0747] The title compound was prepared by following the procedure
described for example 1008 using intermediate 40 (0.100 g, 0.303
mmol), intermediate 38 (0.102 g, 0.393 mmol), potassium carbonate
(0.139 g, 1.00 mmol), dioxane (2.0 ml), water (0.8 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.028 g, 0.024 mmol) at
100.degree. C. for 12 h. Pale green solid (0.017 g, 10%). M.P.:
158-160.degree. C. Mass: 430.1 (M.sup.++1).
Example 1028
4-[3-(5,7-Difluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-t-
rifluoromethyl-benzamide
[0748] The title compound was prepared by following the procedure
described for example 1008 using intermediate 40 (0.150 g, 0.454
mmol), intermediate 50 (0.186 g, 0.596 mmol), potassium carbonate
(0.209 g, 1.51 mmol), dioxane (2.9 ml), water (1.2 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.041 g, 0.036 mmol) at
100.degree. C. for 12 h. Off-white solid (0.017 g, 7%). M.P.:
252-254.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 8.97 (d, J=3.2 Hz, 1H), 8.74 (s, 1H), 8.56 (s, 1H), 8.50 (d,
J=8.6 Hz, 1H), 8.36 (d, J=7.7 Hz, 11H), 8.18 (d, J=8.4 Hz, 1H),
8.01 (d, J=8.4 Hz, 1H), 7.97 (s, 1H), 7.70-7.59 (m, 4H), 5.84 (s,
2H).
Example 1029
4-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl]-2-methy-
l-benzamide hydrochloride
[0749] The example 1025 (0.060 g, 0.145 mmol), was dissolved in THF
(2.0 ml), ether saturated with HCl (0.50 ml) was added at 0.degree.
C. and stirred for 15 min. The precipitate formed was washed with
ether and dried under vacuum to afford the title compound as pale
green solid (0.050 g, 76%). M.P.: 250-252.degree. C. .sup.1H-NMR
(.delta. ppm, DMSO-d.sub.6, 400 MHz): 9.19 (s, 1H0, 9.07 (dd,
J=4.6, 1.4 Hz, 1H), 8.71 (d, J=8.1 Hz, 1H), 8.35 (d, J=8.0 Hz, 1H),
8.28 (d, J=8.5 Hz, 1H), 8.05 (d, J=8.5 Hz, 1H), 8.01 (d, J=11.0 Hz,
1H), 7.98 (m, 2H), 7.75 (m, 2II), 7.47 (d, J=8.5 IIz, 1II), 7.40
(s, 1II), 5.93 (s, 2II), 2.43 (s, 3II).
Example 1030
2,N-Dimethyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benza-
mide
[0750] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (0.100 g, 0.339
mmol), intermediate 37 (0.121 g, 0.441 mmol), potassium carbonate
(0.156 g, 1.12 mmol), dioxane (2.0 ml), water (0.5 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.031 g, 0.027 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Off-white solid (0.012 g,
9%). M.P.: 118-120.degree. C. Mass: 408.4 (M.sup.++1).
Example 1031
5-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-pyridine-2-carboxy-
lic acid methylamide
[0751] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (0.100 g, 0.339
mmol), intermediate 51 (0.115 g, 0.441 mmol), potassium carbonate
(0.156 g, 1.12 mmol), dioxane (2.0 ml), water (0.5 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.031 g, 0.027 mmol) at
100.degree. C. for 12 h. Off-white solid (0.070 g, 52%). M.P.:
219-221.degree. C. Mass: 395.4 (M.sup.++1).
Example 1032
5-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,3-dihydr-
o-isoindol-1-one
[0752] The title compound was prepared by following the procedure
described for example 1008 using intermediate 7 (0.150 g, 0.507
mmol), intermediate 52 (0.163 g, 0.634 mmol), potassium carbonate
(0.233 g, 1.68 mmol), dioxane (2.0 ml), water (0.5 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.046 g, 0.040 mmol)
under microwave irradiation (microwave power=100 W,
temperature=100.degree. C.) for 45 min. Off-white solid (0.010 g,
5%). M.P.: 237-239.degree. C. .sup.1H-NMR (.delta. ppm,
DMSO-d.sub.6, 400 MHz): 8.88 (dd, J=4.2, 1.7 Hz, 1H), 8.71 (d,
J=8.7 Hz, 1H), 8.69 (s, 1H), 8.41 (m, 3H), 8.21 (d, J=8.7 Hz, 1H),
8.01 (m, 2H), 7.83 (d, J=7.6 IIz, 2II), 7.54 (dd, J=8.3, 4.1 IIz,
1II), 6.23 (s, 2II), 4.48 (s, 2II).
Example 1033
5-(3-Quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-2,3-dihydro-isoind-
ol-1-one
[0753] The title compound was prepared by following the procedure
described for example 1008 using intermediate 34 (0.150 g, 0.508
mmol), intermediate 52 (0.164 g, 0.636 mmol), potassium carbonate
(0.234 g, 1.69 mmol), dioxane (2.5 ml), water (1.0 ml) and
tetrakis(triphenylphosphine)palladium(0) (0.047 g, 0.040 mmol) at
100.degree. C. for 12 h. Off-white solid (0.080 g, 40%). M.P.:
267-269.degree. C. .sup.1H-NMR (.delta. ppm, DMSO-d.sub.6, 400
MHz): 8.87 (dd, J=4.2, 1.7 Hz, 1H), 8.71 (s, 1H), 8.59 (s, 1H),
8.36 (dd, J=8.5, 1.2 Hz, 1H), 8.30 (s, 1H), 8.26 (dd, J=8.1, 1.3
Hz, 1H), 8.21 (d, J=8.4 Hz, 1H), 8.01 (m, 3H), 7.84 (dd, J=8.7, 2.0
Hz, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.53 (dd, J=8.3, 4.1 Hz, 1H), 5.79
(s, 2H), 4.45 (s, 2H).
Biological Assay
[0754] The pharmacological properties of the compounds of this
invention may be confirmed by a number of pharmacological assays.
The pharmacological assays which can be been carried out with the
compounds according to the invention and/or their pharmaceutically
acceptable salts are exemplified below.
1. MET Kinase Assay Protocol:
[0755] Colorimetric Determination of c-Met Kinase Activity
[0756] The receptor tyrosine kinase c-Met is a heterodimeric
transmembrane glycoprotein involved in several cellular processes
that aid in tumor progression. Phosphorylation of the tyrosine
residues in the c-Met kinase domain is critical for its activity
and the resulting down-stream effects. The colorimetric assay
allows detection of the phosphorylated form of a biotinylated
peptide upon activation of human recombinant Met kinase.
MET Kinase Assay Protocol:
[0757] c-Met Kinase activity shall be determined using an
HTScan.RTM. Met Kinase Assay Kit (Cell Signalling Technology,
Beverly, Mass.) with modifications. All incubations are carried out
at room temperature. Briefly, 12.5 .mu.l of a 4.times. reaction
cocktail (DTT/Kinase buffer containing appropriate quantity of
human Met kinase) is added to each well of a 96-well plate
containing 12.5 .mu.l pre-diluted compound of interest and
incubated for 5 minutes. After the initial incubation, 25
.mu.l/well of 2.times.ATP/biotinylated peptide is added and
incubated for an additional 30 minutes. The reaction is terminated
by the addition of 50 .mu.l/well stop buffer (50 mM EDTA, pH 8.0).
The reaction mixture (25 l/well) is then transferred to a
streptavidin coated plate (Perkin Elmer, Cat #4009-0010) containing
75 .mu.l dH.sub.2O and incubated for 60 minutes. The plate is
washed with 200 .mu.l/well wash buffer (1.times.PBS, 0.05%
Tween-20). After washing, 100 .mu.l/well phospho-tyrosine mAb
(1:1000 in wash buffer containing 1% BSA) is added and incubated
for 60 minutes. After another round of washes, 100 .mu.l/well
europium labelled anti-mouse IgG (1:500 in wash buffer containing
1% BSA) is added and incubated for an additional 30 minutes.
Following additional washes, 100 .mu.l/well Delfia.RTM. enhancement
solution (Perkin Elmer, Cat #1244-105) is added and incubated for
45 minutes. Florescence is measured on a microplate reader (BMG
Labtech., Germany) at 340 nm (excitation) and 615 nm (emission) for
calculating % inhibition. Data generated can be analyzed further
using Graphpad Prism (Graphpad software, San Diego Calif.) for
determination of IC.sub.50.
[0758] Results: The results are as given below in Table 4A, 4B and
4C as % Inhibition or IC50 of c-Met
TABLE-US-00004 TABLE 4A c-Met Enzyme MKN45 % inhibition IC50 %
inhibition GI50 Example No @ 100 nM nM @ 100 nM nM Example 1 A -- 0
-- Example 2 A* -- -- ++ Example 3 B* -- -- ++ Example 4 A* -- -- +
Example 5 A* ++++ A ++++ Example 6 A* ++++ A ++++ Example 6a -- --
-- -- Example 6b -- -- -- -- Example 6c -- -- -- -- Example 6d --
-- -- -- Example 7 A ++++ A ++++ Example 7a -- -- A ++++ Example 7b
-- -- -- -- Example 7c -- -- -- -- Example 8 A ++++ C +++ Example
8a -- -- C +++ Example 8b -- -- -- -- Example 9 A ++++ A +++
Example 9a -- -- A ++++ Example 9b -- -- -- -- Example 10 A ++++ A
++++ Example 11 A -- -- -- Example 12 -- -- -- -- Example 13 A --
-- -- Example 14 A -- -- -- Example 15 A -- -- -- Example 16 A --
-- -- Example 17 D -- -- -- Example 18 B ++++ C +++ Example 19 A
++++ C +++ Example 19a -- -- -- -- Example 20 A ++++ A +++ Example
21 A ++++ D -- Example 21a A -- -- -- Example 22 A -- B +++ Example
23 A -- A +++ Example 24 A -- A ++++ Example 24a -- -- -- --
Example 25 A ++++ A ++++ Example 25a -- -- B ++++ Example 25b -- --
-- -- Example 25c -- -- -- -- Example 25d D -- -- -- Example 25e --
-- -- -- Example 26 A -- A ++++ Example 26a -- -- Example 27 A -- A
++++ Example 27a -- -- Example 28 A -- A ++++ Example 29 A -- D ++
Example 30 A ++++ A ++++ Example 31 B B ++++ Example 32 A ++++ A
++++ Example 33 A -- -- -- Example 34 A -- A ++++ Example 35 A -- A
++++ Example 36 A -- -- -- Example 37 B -- -- -- Example 38 A -- A
-- Example 39 A -- A -- Example 40 A -- -- -- Example 41 -- -- --
-- Example 42 A -- -- -- Example 43 A -- -- -- Example 44 A -- --
-- Example 45 A -- -- Example 46 A -- -- -- Example 47 A -- -- --
Example 48 -- -- -- -- Example 49 -- -- -- -- Example 50 A* ++++ A
++++ Example 51 D* -- D -- Example 52 D* -- -- -- Example 53 D* --
D -- Example 54 C* -- -- -- Example 55 D* -- -- -- Example 56 -- --
-- -- Example 57 A* ++++ B ++++ Example 58 D* -- C -- Example 59 A*
++++ -- ++++ Example 60 A* ++++ -- +++ Example 61 A* ++++ -- +++
Example 62 D* -- D -- Example 63 A* ++++ D + Example 64 B -- -- --
Example 65 -- -- -- -- Example 66 -- -- -- -- Example 67 -- -- --
-- Example 68 A -- -- --
TABLE-US-00005 TABLE 4B c-Met Enzyme MKN45 % inhibition IC50 %
inhibition GI50 Example No @ 100 nM nM @ 100 nM nM Example 101 D*
-- -- -- Example 102 D* -- -- -- Example 103 C* -- -- -- Example
104 B* ++ D -- Example 105 C* -- D -- Example 106 -- -- -- --
Example 107 A* ++ D + Example 108 D* -- D -- Example 109 A -- -- --
Example 110 A -- -- -- Example 111 A -- D -- Example 112 A -- D --
Example 113 A -- -- -- Example 114 A -- -- -- D = <25%, C =
.gtoreq.25-<50%, B = .gtoreq.50-<75%, A = .gtoreq.75 to 100%
+++++ = <25 nM; ++++ = 25 to .ltoreq.50 Mm; +++ = >50 to
.ltoreq.100 nM; ++ = >100-.ltoreq.250 nM and + =
>251-.ltoreq.1000 nM *tested @ 300 nM
TABLE-US-00006 TABLE 4C c-Met Enzyme MKN45 % inhibition IC50 %
inhibition GI50 Example No @ 100 nM nM @ 100 nM nM Example 1001 D
-- -- -- Example 1002 D -- -- -- Example 1003 A* +++++ -- --
Example 1004 D* -- -- -- Example 1005 D -- -- -- Example 1006 A*
++++ A ++++ Example 1007 A* +++++ A +++++ Example 1008 A* +++ C ++
Example 1009 -- -- -- -- Example 1010 D* -- -- -- Example 1011 --
-- -- -- Example 1012 -- -- -- -- Example 1013 D* -- -- -- Example
1014 -- -- -- -- Example 1015 -- -- -- -- Example 1016 C* -- D --
Example 1017 C* -- D -- Example 1018 B* -- C -- Example 1019 -- --
-- -- Example 1020 D* -- B -- Example 1021 D* -- C -- Example 1022
A* +++++ B +++ Example 1023 A* +++++ B +++++ Example 1024 A +++++
-- ++ Example 1025 A +++++ -- +++ Example 1026 C -- -- -- Example
1027 A -- A -- Example 1028 A -- A -- Example 1029 -- -- -- --
Example 1030 D -- -- -- Example 1031 D -- -- -- Example 1032 A --
-- -- Example 1033 D -- -- -- D = <25%, C = .gtoreq.25-<50%,
B = .gtoreq.50-<75%, A = .gtoreq.75 to 100% +++++ = <25 nM;
++++ = 25 to .ltoreq.50 Mm; +++ = >50 to .ltoreq.100 nM; ++ =
>100-.ltoreq.250 nM and + = >251-.ltoreq.1000 nM *tested @
300 nM
3. Inhibition of MKN-45 Proliferation:
[0759] Cell proliferation assays were carried out using the high
Met expressing human gastric adenocarcinoma cell line, MKN-45,
according to the following schedule: [0760] Day 1: Cells were
plated in 96-well plates in complete growth medium. [0761] Day 2:
Compounds at desired concentrations were added. [0762] Day 5: Cell
viability was determined using the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
dye reduction test.
[0763] Results: The results are as given as % Inhibition of MKN-45
proliferation at 100 nM and G150 values in Table 4A to 4C
above.
4. Inhibition of c-Met Kinase Phosphorylation in MKN-45 Cells:
[0764] MKN45 cells are a prototype of "c-Met addicted" cells having
constitutively activated c-Met kinase similar to that observed in
sub-sects of gastric or hepatocellular cancer patients with
dysregulated c-Met kinase activity. Inhibition of Met
phosphorylation was determined using a cell based ELISA assay
according to the following schedule: [0765] Day 1: MKN-45 cells
were plated in 96-well plates in complete growth medium. [0766] Day
2: Inhibitors at the desired concentration were added to the plates
and incubated for 1 h and lysed subsequently.
[0767] Lysates were transferred to NUNC Maxisorp plates coated with
anti-cMet receptor antibody. Phopho-tyrosine mAb and IIRP-lined
anti-mouse IgG were used as primary and secondary antibodies
respectively. Optical density was measured on a microplate reader
(BMG Labtech., Germany) at 450 nM. Inhibition of c-Met
phosphorylation in this cell line indicates a therapeutic potential
for test compounds in patients diagnosed with cancers caused by
aberrant c-Met kinase signalling.
[0768] Results: The results are provided above in Table 4D as IC50
values.
TABLE-US-00007 TABLE 4D Example No IC 50 Example 6 +++ Example 7 +
Example 8 ++++ Example 9 +++ Example 25 +++ Example 30 +++ Example
31 + Example 32 + Example 33 ++ Example 1006 +++ + = .ltoreq.10;
++' = >10 to .ltoreq.25; +++ = >25-.ltoreq.50 and +++ =
>50-.ltoreq.500 in nM
5. Inhibition of c-Met Kinase Phosphorylation in NCI-H441
Cells:
[0769] Inhibition of Met phosphorylation was determined using a
cell based ELISA assay according to the following schedule:
[0770] Day 1: NCI-H441 cells were plated in 96-well plates in
complete growth medium.
[0771] Day 2: Inhibitors at the desired concentration were added to
the plates, incubated for 1 h and lysed subsequently. Lysates were
transferred to NUNC Maxisorp plates coated with anti-cMet receptor
antibody. Phopho-tyrosine mAb and HRP-lined anti-mouse IgG were
used as primary and secondary antibodies respectively. Optical
density was measured on a microplate reader (BMG Labtech., Germany)
at 450 nM. The compounds potently inhibited c-Met kinase
phosphorylation in NCI-H441, a non-small cell lung cancer derived
cell line indicating a therapeutic potential in lung cancer
patients with mutant kras.
[0772] Results: The results are given below in Table 5 as IC50
values.
TABLE-US-00008 TABLE 5 Example No IC 50 Example 6 + Example 7 +
Example 8 +++ Example 9 ++ Example 25 + Example 30 ++ Example 33 +
Example 1006 + + = .ltoreq.10; ++' = >10 to .ltoreq.25; +++ =
>25-.ltoreq.50 and +++ = >50-.ltoreq.500 in nM
6. Inhibition of Akt Phosphorylation in MKN-45 or NCI-H441
Cells:
[0773] Akt is a serine-threonine kinase and a downstream marker
regulated by c-Met kinase via the PI3K pathway. Once
phosphorylated, Akt regulates several end processes including cell
survival and growth. Cells were treated with 0-1000 nM of test
compounds, lysed, and the proteins separated on a 10% SDS-PAGE.
Following separation, proteins were transferred onto a
nitrocellulose membrane and detected by chemiluminescence after
incubation with pAkt 5473 mAb (primary) and rabbit anti-mouse Ab
(secondary). Intensity of the bands was determined using ImageJ
1.42q (NIH, USA) and normalized to Actin (loading control).
[0774] Results: The results are provided below as IC50 values in
Table 6.
TABLE-US-00009 TABLE 6 Example No MKN-45 NCI-H441 Example 6 ++ +
Example 7 + + Example 8 ++++ + Example 9 ++++ ++ Example 25 ++ +
Example 30 +++ + Example 33 +++ + Example 1006 +++ + + =
.ltoreq.10; ++' = >10 to .ltoreq.25; +++ = >25-.ltoreq.50 and
+++ = >50-.ltoreq.250 in nM
7. Induction of Apoptosis in MKN-45 Cells: I
[0775] Induction of Caspase 3 was measured fluorimetrically. Cells
were incubated with desired concentrations of the compound for 24
h. After incubation, cells were harvested and counted. An equal
number of viable cells per well (0.3.times.10.sup.6 cells) were
used for determination of caspase-3 activity. Increase in apoptosis
manifested by an elevation in caspase-3 levels was determined using
a Caspase-3 kit from Millipore. Data are expressed as a percent of
the maximum response (100%). Compounds of the invention
dose-dependently induced apoptosis in MKN-45 cells manifested by an
increase in caspase-3 activity.
[0776] Results: The results are provided below as percentage
induction @ 3 .mu.M in Table 7.
TABLE-US-00010 TABLE 5 Example No % inhibition Example 6 B Example
7 A Example 8 C Example 9 A Example 25 B Example 30 B Example 33 A
Example 1006 B A is .gtoreq.75; B is <75 and .gtoreq.50; C is
<50 and .gtoreq.25 and D is <25. in %
8. Inhibition of HGF-Induced Met Phosphorylation in MDA-MB-231
Cells:
[0777] MDA-MB-231 is a breast cancer cell line having a high level
of c-Met expression. Activation of Met kinase in these cells occurs
only after the addition of its natural ligand, Hepatocyte Growth
Factor (HGF). Upon binding to the extracellular domain of the
enzyme, it triggers phosphorylation of tyrosine residues and
regulates several downstream events such as cell proliferation.
Cell proliferation assays were carried out using the high Met
expressing cell line (MDA-MB-231) according to the following
schedule: [0778] Day 1: Cells were plated in 96-well plates in
complete growth medium. [0779] Day 2: Media was replaced with
starvation medium containing 0.04% BSA. [0780] Day 3: Inhibitors at
the desired concentrations and HGF (50 ng/ml) were added. [0781]
Day 5: Cell viability was determined using the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
dye reduction test.
[0782] The compounds of the present invention tested potently
inhibited HGF-induced Met phosphorylation in MDA-MB-231 cells
thereby implicating their role in the modulation of the HGF/Met
axis in breast cancer.
[0783] Results: The results are provided below in Table 8 as IC50
values.
TABLE-US-00011 TABLE 8 Example No IC 50 Example 6 + Example 25 +
Example 30 + Example 33 ++ Example 1006 ++ + = .ltoreq.10; ++ =
>10 to .ltoreq.50; in nM
9. Hepatocyte Growth Factor (HGF) Induced Cell Scatter:
[0784] Human prostate cancer (PC3), human breast cancer (MDAMB231),
Human lung adenocarcinoma (NCIH-441) cells were individually
allowed to grow in small colonies by plating them in low density
(20,000 cells/well) in growth media supplemented with 10% foetal
bovine serum and incubated overnight at 37.degree. C. and 5%
CO.sub.2. The next day each of these cells were placed in
starvation media, i.e. serum-free growth media and incubated
overnight at 37.degree. C. and 5% CO.sub.2. Test compounds were
added at required concentrations in complete growth media
supplemented with foetal bovine serum and allowed an incubation of
2 hours. Cells were stimulated by replacing the test compounds with
complete growth media containing 40 ng/ml HGF and incubated for 48
hrs. Cell scatter was observed as dissemination of the cells under
effect of HGF in comparison to unstimulated cells growing in small
colonies.
[0785] Results: Exemplary compounds of the invention potently
inhibited IIGF-induced PC3, MDAMB231 and NCIH-441 cell scatter when
tested @ 1 to 1000 nM thereby indicating their potential effect and
therapeutic utility in metastasis.
10. Hepatocyte Growth Factor (HGF) Induced Scratch Wound Assay for
Cell Motility:
[0786] Individually 60,000 cells/well each of Human prostate cancer
(PC3), human breast cancer (MDAMB231), Human lung adenocarcinoma
(NCIH-441) were plated in growth media supplemented with 10% foetal
bovine serum and incubated at 37.degree. C. and 5% CO.sub.2, grown
to confluency. A channel was introduced between cells using a 200
.mu.l tip and fresh serum containing media was added along with
inhibitors and HGF (50 ng/ml). Cells were incubated overnight at
37.degree. C. and 5% CO.sub.2 and cell motility was observed under
microscope as migration of cells into the artificially created
space.
[0787] Results: Exemplary compounds of the invention potently
inhibited HGF-induced PC3, MDAMB231 and NCIH-441 cell migration
when tested @ 1 to 1000 nM thereby indicating their potential
effect and therapeutic utility in metastasis.
[0788] Although the invention herein has been described with
reference to particular embodiments, it is to be understood that
these embodiments are merely illustrative of the principles and
applications of the present invention. It is therefore to be
understood that numerous modifications may be made to the
illustrative embodiments and that other arrangements may be devised
without departing from the spirit and scope of the present
invention as described above and the claims.
[0789] All publications and patent and/or patent applications cited
in this application are herein incorporated by reference to the
same extent as if each individual publication or patent application
was specifically and individually indicated to be incorporated
herein by reference.
* * * * *
References